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   1	  
1	  Summary	  
	  
Receptor	  stimulation	  by	  IL-­‐1β	  and	  LPS	  initiates	  the	  interaction	  of	  the	  E3	  Ligase	  TRAF6	  and	  the	  
E2-­‐conjugating	  enzyme	  Ubc13,	  which	  is	  required	  to	  mediate	  signal	  progression	  towards	  NF-­‐κB	  
activation.	  Interfering	  with	  the	  TRAF6-­‐Ubc13	  complex	  formation	  by	  small	  molecules	  could	  help	  
to	   relieve	   symptoms	   of	   diseases	   associated	   with	   elevated	   NF-­‐κB	   activation	   including	  
autoimmune	  diseases,	  metabolic	  disorders	  and	  cancer.	  To	  identify	  specific	  inhibitors	  of	  TRAF6-­‐
Ubc13	   interaction,	   a	   High-­‐Throughput-­‐Screening	   involving	   the	   ALPHAScreen	   technology	   was	  
established.	  Screening	  of	  small	  molecule	   libraries	  consisting	  of	  ~25,000	  compounds	   led	  to	  the	  
identification	   of	   several	   selective	   inhibitors	   of	   TRAF6-­‐Ubc13	   interaction.	   Two	   of	   the	   most	  
potent	  compounds	  (C27	  and	  C25)	  were	  selected	  for	  further	  studies	  of	  their	  effects	  on	  TRAF6-­‐
Ubc13	  in	  vitro	  and	  on	  TRAF6	  function	  and	  NF-­‐κB	  signaling	  in	  cells.	  Both	  compounds	  are	  directly	  
binding	  to	  TRAF6	  and	  are	  capable	  of	  disrupting	  TRAF6	  binding	  to	  Ubc13	   in	  a	  dose	  dependent	  
manner.	   Cell	   based	   assays	   revealed	   a	   strong	   but	   non-­‐pathway	   selective	   effect	   on	   NF-­‐κB	  
signaling	   after	   C27	   treatment.	   In	   contrast,	   C25	   led	   to	   a	   milder,	   but	   IL-­‐1β	  /TLR	   specific	  
impairment	   of	   NF-­‐κB	   activation	   in	   EMSA	   as	   well	   as	   target	   gene	   experiments.	   Studies	   of	   the	  
structure	  activity	  relationships	  of	  C25	  highlighted	  the	  analog	  C25-­‐0140	  as	  a	  compound	  with	  a	  
strongly	  enhanced	  inhibitory	  potential	  in	  cells.	  Biochemical	  experiments	  proved	  that	  C25-­‐0140	  
is	   directly	   binding	   to	   the	   RING-­‐Zincfinger1	   domain	   of	   TRAF6	   and	   inhibits	   the	   TRAF6-­‐Ubc13	  
interaction	  with	  an	  IC50	  of	  ~	  2.6µM.	  In	  cells,	  C25-­‐0140	  diminished	  TRAF6	  auto-­‐ubiquitination	  as	  
well	   as	   the	  activity	  of	   the	   IKK	  complex	  after	   IL-­‐1β	  stimulation	  and	   it	   thereby	  exhibited	   strong	  
effects	  on	  NF-­‐κB	  activation.	  However,	  despite	  the	  augmented	  effectiveness	  of	  compound	  C25-­‐
0140,	  the	  selectivity	  of	  the	  compound	  was	  decreased.	  Besides	  affecting	  TRAF6-­‐dependent	  IL-­‐1β	  
and	   LPS	   pathways,	   TNFα-­‐induced	   NF-­‐κB	   activation	   was	   impaired	   as	   well.	   Based	   on	   studies	  
describing	   the	   pharmacological	   disposition	   of	   C25-­‐0140,	   the	   compound	  was	   tested	   in	   a	   diet-­‐
induced	   obesity	   (DIO)	  mouse	  model	   that	   is	   characterized	   by	   low-­‐grade	   chronic	   inflammation	  
leading	  to	  increased	  glucose	  intolerance.	  Indeed,	  C25-­‐0140	  administration	  reduced	  the	  weight	  
gain	  without	  affecting	  food	  uptake	  of	  the	  animals,	  but	  did	  not	  improve	  glucose	  tolerance.	  There	  
was	   a	   tendency	   for	   a	   slight	   relieve	   of	   the	   chronic	   inflammatory	   symptoms	   in	   the	   animals	  
indicating	   that	   the	   compound	   affects	   innate	   immune	   signaling	   in	   vivo.	   Taken	   together,	   the	  
identification	  of	  the	  first	  small	  molecules	  specifically	  inhibiting	  the	  TRAF6-­‐Ubc13	  interaction	   in	  
vitro	  by	  directly	  targeting	  the	  TRAF6	  RING-­‐Zincfinger1	  domain	  provides	  a	  proof	  of	  concept	  for	  
the	   feasibility	   of	   small	  molecule	   targeting	   of	   an	   E2-­‐E3	   interaction.	   The	   identified	   compounds	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inhibit	  TRAF6	  activity	  and	  NF-­‐κB	  signaling	   in	  cells	  and	   first	   in	  vivo	  data	   indicate	  an	  effect	   in	  a	  
TRAF6-­‐dependent	  mouse	  model	  of	  diet-­‐induced	  obesity.	  However,	  cellular	  studies	  indicate	  that	  
the	   identified	   small	   molecules	   are	   not	   highly	   selective	   for	   TRAF6-­‐Ubc13	   inhibition.	   Further	  
investigations	  will	   be	   necessary	   to	   unravel	   the	   exact	  mode	   of	   action	   and	   to	   further	   improve	  
effectiveness	  and	  selectivity	  of	  the	  compounds.	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2	  Introduction	  
	  
2.1	  The	  Ubiquitin	  Proteasome	  System	  	  
The	   ubiquitin	   proteasome	   system	   (UPS)	   is	   a	   key	   regulator	   of	   cellular	   functions	   in	   eukaryotes	  
ranging	   from	   proteasome-­‐dependent	   proteolysis	   to	   modulation	   of	   protein	   function	   in	   cell	  
signaling,	  autophagy	  and	  DNA	  damage	  response	  as	  well	  as	  structure	  assembly	  and	  localization	  
of	   cellular	   proteins	   (Deshaies	   and	   Joazeiro,	   2009).	   Ubiquitination	   is	   a	   posttranslational	  
modification	   that	   covalently	   attaches	   ubiquitin	   molecules	   to	   substrates.	   Ubiquitin	   is	   a	   small	  
(8.5kDa)	  regulatory	  protein	  consisting	  of	  76	  amino	  acids	  forming	  a	  compact	  globular	  structure	  
with	  an	  exposed	  C-­‐terminal	  tail	  that	  can	  be	  covalently	  linked	  to	  another	  ubiquitin	  molecule	  or	  
to	   other	   substrate	   proteins	   (Husnjak	   and	   Dikic,	   2012).	   In	   the	   human	   ubiquitin-­‐modified	  
proteome	  more	  than	  4,000	  to	  5,000	  proteins	  are	  shown	  to	  be	  modified	  by	  ubiquitin	  (Husnjak	  
and	  Dikic,	  2012).	  Ubiquitin	  substrates	  can	  be	  modified	  by	  either	  monoubiquitination	  at	  one	  or	  
multiple	  sites	  or	  polyubiquitination	  with	  the	  different	  linkage	  types	  of	  ubiquitin	  chains	  leading	  
to	  various	  functional	  consequences	  (Komander	  and	  Rape,	  2012).	  
	  
2.1.1	  The	  ubiquitination	  cascade	  	  
Within	  the	  ubiquitination	  cascade,	  ubiquitin	  is	  covalently	  bound	  to	  substrate	  lysines	  in	  a	  three-­‐
enzyme	  cascade	  involving	  E1,	  E2	  and	  E3	  enzymes.	  The	  process	  of	  ubiquitination	  is	  displayed	  in	  
Figure	  2.2.	  In	  the	  humane	  proteome	  two	  E1	  enzymes,	  approximately	  40	  E2	  and	  around	  600	  E3	  
enzymes	  are	  described	  (Husnjak	  and	  Dikic,	  2012).	  E1	  enzymes	  are	  ubiquitin-­‐activating	  proteins	  
and	   catalyze	   the	   activation	   of	   an	   ubiquitin	   molecule,	   which	   is	   the	   first	   step	   within	   the	  
ubiquitination	  process.	  E2s	  are	  ubiquitin-­‐conjugating	  enzymes.	  Their	  active-­‐site	  cysteine	  forms	  
a	  thioester	  linkage	  with	  the	  C-­‐terminus	  of	  the	  ubiquitin	  molecule	  (Deshaies	  and	  Joazeiro,	  2009).	  
E3	  ubiquitin	  ligases	  bind	  E2	  and	  substrate	  and	  mediate	  the	  transfer	  of	  ubiquitin	  from	  the	  E2	  to	  
the	   substrate	   (Deshaies	   and	   Joazeiro,	   2009).	   The	   ubiquitination	   cascade	   begins	   with	   ATP-­‐
dependent	   charging	   of	   the	   ubiquitin-­‐activating	   enzyme	   E1	   resulting	   in	   the	   formation	   of	   a	  
thioester	  bond	  between	  the	  C-­‐terminus	  of	  the	  ubiquitin	  and	  the	  active	  site	  cysteine	  of	  the	  E1	  
enzyme.	   In	   a	   transthioesterification	   reaction,	   ubiquitin	   is	   then	   transferred	   to	   the	   active	   site	  
cysteine	   of	   the	   ubiquitin-­‐conjugating	   enzyme	   E2.	   Next,	   an	   E3	   ubiquitin	   ligase	   catalyzes	   the	  
transfer	  of	  the	  ubiquitin	  from	  the	  E2	  to	  the	  substrate	  resulting	  in	  an	  isopeptide	  linkage	  between	  
the	   C-­‐terminus	   of	   the	   ubiquitin	   molecule	   and	   the	   ε-­‐aminogroup	   of	   the	   substrate	   lysine	   or	  
methionine	  (Berndsen	  and	  Wolberger,	  2014).	  Deubiquitinating	  enzymes	  (DUBs)	  can	  remove	  the	  
ubiquitin	  from	  the	  substrate	  to	  recycle	  the	  ubiquitin	  molecules.	  Multiple	  ubiquitination	  cycles	  
lead	  to	  polyubiquitination	  of	  the	  substrates.	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Figure	  2.1:	  The	  ubiquitination	  process.	  Schematic	  overview	  of	  the	  ubiquitination	  process.	  First,	  ubiquitin	  (grey)	  is	  
activated	   in	   an	   ATP-­‐dependent	   manner	   and	   bound	   to	   the	   E1	   activating	   enzyme	   (purple).	   After	   transfer	   of	   the	  
ubiquitin	  to	  the	  E2	  conjugating	  enzyme	  (red),	  E3	  ligases	  (blue)	  remove	  the	  ubiquitin	  from	  the	  E2	  and	  attach	  it	  to	  
the	  substrate.	  Thereby,	  RING	  E3	   ligases	  use	  a	  one-­‐step	  reaction	  whereas	  HECT	  and	  RBR	  E3	   ligases	  operate	  via	  a	  
two-­‐step	  reaction	  to	  transfer	  the	  ubiquitin	  to	  the	  substrate.	  In	  the	  end,	  deubiquitinating	  enzymes	  (green)	  remove	  
the	  ubiquitin	  molecules.	  	  
	  
2.1.2	  Types	  and	  functions	  of	  ubiquitination	  
Ubiquitin	   is	  primarily	  attached	  to	   lysine	  residues,	  but	   it	  can	  also	  bind	  to	  the	  ε-­‐amino	  group	  at	  
the	  N-­‐terminus	  of	  the	  substrate	  as	  well	  as	  to	  cysteine,	  serine	  and	  threonine	  residues	  of	  target	  
proteins	   (Husnjak	   and	   Dikic,	   2012).	   Attaching	   of	   single	   (monoubiquitination)	   or	   several	  
independent	  ubiquitin	  molecules	  (multiple	  monoubiquitination)	  to	  target	  proteins	  are	  shown	  to	  
regulate	  signaling,	  endocytosis	  and	  DNA	  repair	  (Husnjak	  and	  Dikic,	  2012).	  Polyubiquitin	  chains	  
can	   be	   formed	   on	   methionine	   1	   and	   all	   seven	   internal	   lysine	   residues	   within	   an	   ubiquitin	  
molecule	  (Lys6,	  Lys11,	  Lys	  27,	  Lys29,	  Lys33,	  Lys48	  and	  Lys63).	  Homotypic	  ubiquitin	  chains	  that	  
contain	  only	  one	  linkage	  type	  per	  polymer	  or	  heterotypic	  ubiquitin	  chains	  that	  include	  multiple	  
linkage	   types	   per	   polymer	   can	   be	   generated	   (Husnjak	   and	   Dikic,	   2012;	   Komander	   and	   Rape,	  
2012).	   Depending	   on	   the	   type	   of	   linkage,	   polyubiquitination	   leads	   to	   a	   variety	   of	   functions.	  
Whereas	   Lys48-­‐linked	   chains	   are	   well	   known	   to	   target	   the	   substrate	   for	   proteasomal	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variety	  of	  non-­‐proteolytic	  functions	   like	  trafficking,	  DNA	  damage	  response	  as	  well	  as	  signaling	  
for	  NF-­‐κB	  activation	  in	  innate	  and	  adaptive	  immunity	  (Haglund	  and	  Dikic,	  2005).	  Up	  to	  now,	  the	  
roles	   of	   the	   other	   linkages	   have	   not	   been	   studied	   in	   great	   detail	   but	   these	   “atypical”	  
polyubiquitin	  chains	  become	  more	  and	  more	  subject	  of	  investigation.	  For	  example,	  Lys11	  chains	  
are	   known	   to	   promote	   proteasomal	   degradation	   of	   substrate	   proteins	   during	   cell	   cycle	  
progression	   (Jin	   et	   al.,	   2008)	   as	   well	   as	   regulating	   the	   endoplasmatic	   reticulum-­‐associated	  
degradation	   (ERAD)	   (Xu	   et	   al.,	   2009).	   Even	   a	   regulatory	   function	   of	   Lys11	   chains	   in	   NEMO-­‐
dependent	  NF-­‐κB	   activation	   upon	   TNFα	   stimulation	   is	   described	   (Dynek	   et	   al.,	   2010).	  During	  
stress	  response	  Lys27	  and	  Lys33	  polyubiquitin	  chains	  are	  assembled	  (Hatakeyama	  et	  al.,	  2001).	  	  
Lys29-­‐linked	   chains	  appear	   to	   function	   in	  ubiquitin	   fusion	  degradation	   (Johnson	  et	   al.,	   1995).	  
Ubiquitin	  molecules	  can	  also	  be	   linked	  head	  to	   tail	   forming	  Met1-­‐linked	   (linear)	  polyubiquitin	  
chains.	   To	   date,	   only	   one	   E3	   ligase	   complex,	   LUBAC	   (linear	   ubiquitin	   assembly	   complex)	   has	  
been	   shown	   to	   assemble	   such	   chains	   (Kirisako	   et	   al.,	   2006)	   and	  plays	   a	   crucial	   role	   in	  NF-­‐κB	  
signaling	   (Rahighi	   et	   al.,	   2009).	   The	   existence	   of	   heterotypic	   ubiquitin	   chains	   has	   been	  
demonstrated	  in	  vitro,	  but	  their	  role	  in	  vivo	  is	  not	  clear,	  yet	  (Kulathu	  and	  Komander,	  2012).	  
	  
2.1.3	  E3	  Ubiquitin	  ligases	  
E3	  ubiquitin	   ligases	   are	  divided	   into	   three	   classes	  each	   characterized	  by	   conserved	   structural	  
domains	   and	   the	   distinct	  mechanism	   to	   transfer	   ubiquitin	   from	   the	   E2	   to	   the	   substrate:	   the	  
RING,	   the	   HECT	   and	   the	   RBR	   E3	   ligases.	   The	   RING	   (really	   interesting	   new	   gene)	   E3	   ligases	  
contain	   a	   RING	   domain	   that	  mediates	   both	   binding	   of	   the	   ubiquitin	   charged	   E2	   conjugating	  
enzyme	  as	  well	  as	  the	  ubiquitin	  transfer	  from	  the	  E2	  to	  the	  substrate	  (Lorick	  et	  al.,	  1999)	  (see	  
Figure	  2.1).	  Representative	  RING	  E3	  ligases	  involved	  in	  TLR/IL-­‐1R	  and	  TNFR	  signaling	  are	  TRAF2,	  
TRAF5,	   TRAF6	   and	   cIAP1/2	   (Deshaies	   and	   Joazeiro,	   2009).	   Their	   RING	   domain	   folds	   into	   a	  
conserved	  cross-­‐brace	  structure	  and	  incorporates	  two	  zinc	  ions.	  The	  basic	  sequence	  expression	  
of	  the	  canonical	  RING	  domain	  is	  Cys-­‐X2-­‐Cys-­‐X(9-­‐39)-­‐Cys-­‐X(1-­‐3)-­‐His-­‐X(2-­‐3)-­‐Cys-­‐X2-­‐Cys-­‐X(4-­‐48)-­‐Cys-­‐X2-­‐Cys	  
(where	  X	   is	  any	  amino	  acid).	  The	  conserved	  cysteine	  and	  histidine	   residues	  are	  buried	  within	  
the	   domains	   core	   in	   order	   to	  maintain	   the	   overall	   structure	   through	   binding	   of	   the	   two	   zinc	  
atoms	   (Deshaies	   and	   Joazeiro,	   2009).	   The	   E2-­‐E3	   interaction	   appears	   to	   be	   transient	   and	   to	  
compete	  with	  binding	  of	  the	  E1	  enzyme	  to	  E2	  depending	  on	  the	  presence	  or	  absence	  of	  an	  E2-­‐
bound	   ubiquitin	   (Elektr	   et	   al.,	   2005).	   Most	   RING	   E3	   ligases	   contain	   a	   domain	   to	   recruit	   the	  
substrate	   for	   ubiquitin	   conjugation	   in	   addition	   to	   the	   E2-­‐binding	  RING	  domain	   (Deshaies	   and	  
Joazeiro,	   2009).	   However,	   a	   subset	   of	   RING	   E3	   ligases	   known	   as	   cullin	   E3s	   are	  multi-­‐subunit	  
complexes	  and	  use	  three	  proteins	  to	   facilitate	  E2-­‐Ubiquitin	  and	  substrate	  binding	   (Lydeard	  et	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al.,	   2013;	   Skaar	   et	   al.,	   2013):	   the	   cullin	   protein	   presents	   the	   scaffold	   protein,	   the	   RING-­‐box	  
protein	   that	   is	   similar	   to	   the	   RING	   domain	   found	   in	   single-­‐polypeptide	   E3	   ligases,	   and	   the	  
bridging	  F-­‐box	  protein	   that	   facilitates	  binding	  of	  substrates	   (Lydeard	  et	  al.,	  2013;	  Skaar	  et	  al.,	  
2013).	   The	   need	   to	   specifically	   target	   a	   broad	   variety	   of	   substrates	   accounts	   for	   the	   great	  
diversity	  among	  the	  estimated	  600	  human	  E3	  ligases.	  E3	  ligases	  need	  to	  modify	  specific	  lysine	  
residue	   of	   ubiquitin.	   As	   E3	   ligases	   harboring	   a	   RING	   can	   synthesize	   different	   chain	   types	  
depending	  on	  the	  E2,	  the	  linkage	  specificity	   is	  determined	  by	  the	  E2	  (Kim	  et	  al.,	  2007;	  Ye	  and	  
Rape,	  2009).	  Therefore,	  RING	  E3s	  that	  interact	  with	  a	  single	  E2	  generally	  display	  the	  specificity	  
of	  this	  particular	  E2	  enzyme.	  	  
The	  HECT	  (homology	  to	  E6AP	  C	  terminus)	  and	  the	  RING-­‐between-­‐RING	  (RBR)	  ubiquitin	   ligases	  
use	  a	  two-­‐step	  reaction	  to	  first	  transfer	  ubiquitin	  from	  the	  E2	  to	  an	  active	  site	  cysteine	  within	  
the	  E3	  and	  then	  from	  the	  E3	  to	  the	  substrate	  (Berndsen	  and	  Wolberger,	  2014)	  (see	  Figure	  2.1).	  
For	   that,	   HECT	   and	   RBR	   E3	   ligases	   contain	   an	   intrinsic	   catalytic	   cysteine	   (Rotin	   and	   Kumar,	  
2009).	  The	  E2	  enzyme	  charges	  this	  cysteine	  with	  ubiquitin	  before	  it	  is	  used	  for	  modification.	  In	  
this	  case,	  the	  linkage	  specificity	  is	  not	  determined	  by	  the	  E2	  but	  by	  the	  HECT	  and	  RBR	  E3	  ligases.	  
HECT	   E3	   ligases	   consist	   of	   a	   C-­‐terminal	   HECT	   domain	   and	   a	   N-­‐terminal	   domain	   that	   harbors	  
binding	  sites	  for	  the	  E2	  enzyme	  and	  as	  well	  the	  catalytic	  cysteine	  residue	  (Huang	  et	  al.,	  1999;	  
Kee	  et	  al.,	  2007).	  	  
Unlike	   RING	   or	   HECT	   E3	   ligases,	   the	   RBR	   E3	   ligase	   group	   consists	   of	   complex	   multidomain	  
proteins	  and	  share	  a	  common	  structure	  of	  three	  domains:	  RING1,	  In-­‐Between-­‐RING	  and	  RING2	  
(Marin	  and	  Ferrus,	  2002).	  The	  RING2	  domain	  possesses	  a	  single	  cysteine	  residue	  for	  binding	  an	  
ubiquitin	  molecule	  from	  the	  E2,	  forming	  a	  thioester	  linkage	  with	  ubiquitin	  and	  transferring	  it	  to	  
the	  substrate	  (Spratt	  et	  al.,	  2014).	  The	  domain	  between	  the	  RING	  domains	  folds	  as	  the	  RING2	  
domain	   but	   lacks	   the	   catalytic	   cysteine	   residue	   as	   well	   as	   ubiquitination	   activity.	   The	   RING1	  
domain	  also	  contains	  multiple	  cysteine	  residues	  to	  coordinate	  zinc	   ions	  and	  shows	  similarities	  
to	  the	  RING	  E3	  ligase	  consensus	  sequence	  (Marin	  and	  Ferrus,	  2002).	  These	  three	  domains	  are	  
invariable	   found	   in	   that	   specific	   order	   indicating	   that	   all	   three	   domains	   are	   required	   for	  
ubiquitination	   (Marin	  and	  Ferrus,	  2002;	  Marin	  et	  al.,	  2004).	  The	  proteins	  HOIL-­‐1	  and	  HOIP	  of	  
the	  LUBAC	  complex	  represent	  two	  members	  of	  the	  RBR	  E3	  ligases	  (Tokunaga	  et	  al.,	  2011).	  	  
	  
2.1.4	  Deubiquitinases	  
Deubiquitinases	  (DUBs)	  are	  a	  family	  of	  around	  100	  enzymes	  that	  counteract	  ubiquitination	  and	  
play	  a	  critical	  role	   in	  regulating	  the	  majority	  of	  the	  ubiquitin-­‐dependent	  processes	  (Komander	  
and	  Rape,	   2012;	  Clague	  et	   al.,	   2012).	   Besides	  processing	   the	  ubiquitin	  precursor	  protein	   into	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monoubiquitin,	  DUBs	  are	  also	  responsible	  for	  recycling	  ubiquitin	  molecules	  as	  well	  as	  reversing	  
ubiquitination	  of	  ubiquitin	  modification	  of	  target	  proteins	  (Reyes-­‐Turcu	  et	  al.,	  2009).	  DUBs	  are	  
subdivided	   into	   five	   families	   according	   to	   the	   architecture	   of	   their	   catalytic	   domains:	  
JAB1/MPN/MOV34	   family	   (JAMMs),	   Josephins,	   ovarian	   tumor	   proteases	   (OTUs),	   ubiquitin	  
COOH-­‐terminal	  hydrolases	  (UCHs)	  and	  ubiquitin	  specific	  proteases	  (USPs)	  (Clague	  et	  al.,	  2013).	  
Whereas	   UCHs,	   USPs,	   OTUs	   and	   Josephins	   function	   as	   cysteine	   proteases,	   JAMMs	   are	   zinc-­‐
dependent	  metalloproteases	   (Harhaj	   and	  Dixit,	   2012).	  Most	  DUBs	  are	   covalently	  modified	  by	  
phosphorylation,	  ubiquitination	  or	  sumoylation	  to	  regulate	  their	  activity,	  localization	  or	  half-­‐life	  
(Reyes-­‐Turcu	   et	   al.,	   2009).	   The	   extent	   of	   linkage	   specificity	   varies	   among	   the	   DUB	   families.	  
While	  Ubiquitin-­‐specific	  protease	  (USP)	  family	  DUBs	  do	  not	  exhibit	  linkage	  specificity	  (Faesen	  et	  
al.,	  2011),	  most	  human	  OTU	  enzymes	  reveal	   linkage	  specificity	  for	  a	  defined	  subset	  of	   linkage	  
subtypes	   (Mevissen	   et	   al.,	   2013).	   OTUB1	   prefers	   K48-­‐linked	   polyubiquitin	   chains	   in	   DNA	  
damage	   response	   (Edelmann	   et	   al.,	   2009),	   whereas	   OTULIN	   shows	  Met1	   specificity	   in	   TNFα	  
signaling	  (Keusekotten	  et	  al.,	  2013).	  This	  specificity	  is	  mediated	  by	  the	  selectivity	  of	  the	  catalytic	  
core,	  the	  ubiquitin-­‐binding	  domains	  of	  the	  DUBs	  or	  adaptor	  proteins.	  	  
	  
2.2	  NF-­‐κB	  signaling	  
The	  eukaryotic	   transcription	   factor	  nuclear	   factor	  “kappa-­‐light-­‐chain-­‐enhancer”	  of	  activated	  B	  
cells	  (NF-­‐κB)	  plays	  a	  critical	  role	  in	  regulating	  the	  expression	  of	  a	  large	  variety	  of	  genes	  that	  are	  
involved	   in	   several	   cellular	   processes	   including	   innate	   and	   adaptive	   immune	   response,	   cell	  
growth	   as	   well	   as	   cell	   development	   (Napetschnig	   and	   Wu,	   2013).	   Several	   signals	   including	  
cytokines,	   pathogens,	   injuries	   and	   other	   stress	   conditions	   induce	   activation	   of	   the	   NF-­‐κB	  
transcription	  factors	  that	  are	  tightly	  regulated	  (Napetschnig	  and	  Wu,	  2013).	  Inappropriate	  NF-­‐
κB	   signaling	   is	   described	   to	   cause	   autoimmunity,	   chronic	   inflammation	   and	   various	   cancers	  
(Toubi	  et	  al.,	  2004,	  Bassères	  et	  al.,	  2006).	  NF-­‐κB	  signaling	  can	  be	  divided	  in	  the	  canonical	  and	  
noncanonical	   NF-­‐κB	   pathway	   depending	   on	   the	   stimulus.	   The	   canonical	   NF-­‐κB	   signaling	   is	  
induced	  by	  most	  physiological	  NF-­‐κB	  stimuli	  whereas	   the	  noncanonical	  NF-­‐κB	  signaling	  arises	  
only	  from	  certain	  ligands	  (Figure	  2.2)	  (Oeckinghaus	  et	  al.,	  2011).	  
	  
2.2.1	  The	  NF-­‐κB	  transcription	  factor	  family	  
NF-­‐κB	   is	  a	  heterodimeric	  protein	  composed	  of	  different	  combinations	  of	  members	  of	   the	  Rel	  
family	   transcription	   factors	   including	  RelA	   (p65),	  RelB,	  c-­‐Rel,	  p50	   (p105	  precursor),	  p52	   (p100	  
precursor)	   and	   Relish	   (Gilmore,	   2006).	   All	   members	   share	   a	   conserved	   DNA-­‐binding	   and	  
dimerization	   domain	   termed	   Rel	   homology	   region	   (RHR)	   that	   is	   responsible	   for	   homo-­‐	   or	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heterodimerization	  among	  the	  Rel	  proteins	  (Hoffmann	  et	  al.,	  2006).	  Whereas	  RelA,	  RelB	  and	  c-­‐
Rel	   contain	   a	   C-­‐terminal	   transactivation	   domain	   (TAD)	   to	   activate	   gene	   expression,	   p50,	   p52	  
and	  Relish	  harbor	  a	  long,	  ankyrin	  repeat-­‐containing	  domain	  (ARD)	  and	  are	  therefore	  not	  able	  to	  
activate	  target	  gene	  expression	  as	  a	  homodimer	  (Vallabhapurapu	  and	  Karin,	  2009;	  Oeckinghaus	  
et	  al.,	  2011).	  NF-­‐κB	  proteins	  bind	  as	  a	  homo-­‐	  or	  heterodimer	  to	  a	  specific	  DNA	  target	  sequence	  
requiring	  the	  C-­‐terminal	  domain	  for	  dimerization	  as	  well	  as	  for	  making	  phosphate	  contact	  with	  
the	  DNA	  (Chen	  and	  Ghosh,	  1999).	  
In	  unstimulated	  cells,	  NF-­‐κB	  is	  either	  retained	  in	  the	  cytoplasm	  by	  the	  inhibitors	  of	  the	  κB	  (IκB)	  
family	   that	  mask	   the	   nuclear	   localization	   signal	   (NLS)	   of	   NF-­‐κB	   and	   therefore	   prevent	  NF-­‐κB	  
from	   binding	   to	   DNA	   (canonical	   NF-­‐κB	   signaling)	   or	   it	   is	   sequestered	   like	   in	   the	   case	   of	   the	  
inactive	  precursor	  p100	  (noncanonical	  NF-­‐κB	  signaling)	  (Figure	  2.2)	  (Vallabhapurapu	  and	  Karin,	  




The	   family	   of	   IκB	   consists	   of	   the	   classical	   IκB	   proteins	   (IκBα,	   IκBβ	   and	   IκBε),	   the	   NF-­‐κB	  
precursor	   proteins	   p100	   and	  p105	   as	  well	   as	   the	  nuclear	   IκBs	   (IκBζ,	   Bcl-­‐3	   and	   IκBNS).	   These	  
proteins	   serve	   as	   inhibitors	   and	   regulators	   of	   NF-­‐κB	   activity.	   The	   cytosolic	   IκBα	   protein	  
regulates	  the	  activation	  and	  inactivation	  of	  NF-­‐κB	  whereby	  its	  transcription	  in	  turn	  is	  regulated	  






















































Figure	   2.2:	   Canonical	   and	   noncanonical	  
signaling	   to	  NF-­‐κB.	  Schematic	  illustration	  of	  
the	   pathways	   activating	   NF-­‐κB	   signaling.	  
Canonical	  NF-­‐κB	  signaling	   is	  induced	  by	  TLR,	  
IL-­‐1R,	  TNFR	  and	  antigen	  receptors	  leading	  to	  
the	  activation	  of	  the	  TAK1	  complex	  followed	  
by	   IKK	   signaling	   to	   activate	   NF-­‐κB.	   In	  
noncanonical	  NF-­‐κB	  signaling,	  stimulation	  of	  
cell-­‐type	   specific	   receptors	   including	   CD40	  
and	  RANK	  initiate	  NIK	  activation	  resulting	   in	  
phosphorylation	   of	   IKKα	   and	   processing	   of	  
p100	  to	  p52	  to	  allow	  NF-­‐κB	  activation.	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for	  NF-­‐κB	  dimers	   containing	  a	  p65	  or	   c-­‐Rel	   subunit	  whereas	   the	  nuclear	   IκBs	  prefer	  p50	  and	  
p52	  homodimers	  (Huxford	  and	  Ghosh,	  2009;	  Ohno	  et	  al.,	  1990).	  	  
The	   transcription	   factor	   NF-­‐κB	   regulates	   a	   broad	   spectrum	   of	   target	   genes	   due	   to	   its	  
involvement	   in	  a	  variety	  of	  cellular	  processes.	   Immune	  regulatory	  proteins	   including	  adhesion	  
molecules	   (Intracellular	   Adhesion	   Molecule	   1	   (ICAM-­‐1)	   and	   Vascular	   Adhesion	   Molecule	  
(VCAM)),	  cytokines	  (TNFα,	  IL-­‐1β,	  IL-­‐6),	  regulators	  of	  apoptosis	  (Bcl-­‐XL	  and	  IAP),	  cyclins,	  growth	  
factors	  that	  are	  responsible	  for	  proliferation	  and	  regulators	  of	  NF-­‐κB	  (IκBα,	  c-­‐Rel	  and	  p105)	  are	  
coordinated	  in	  a	  NF-­‐κB	  dependent	  manner	  (Oeckinghaus	  and	  Ghosh,	  2009).	  These	  NF-­‐κB	  target	  
genes	   enable	   the	   organism	   to	   respond	   effectively	   to	   external	   stimuli	   including	   infections,	  
cytokines	  and	  genotoxic	  stress	  (Oeckinghaus	  and	  Ghosh,	  2009).	  	  
The	  biological	  function	  of	  NF-­‐κB	  involves	  crosstalk	  between	  the	  canonical	  and	  noncanonical	  NF-­‐
κB	   pathways	   at	   different	   levels	   including	   upstream	   signaling	   crosstalk	   as	   well	   as	   nuclear	  
interactions	  (Sun,	  2012).	  The	  positive	  and	  negative	  interplays	  between	  the	  two	  NF-­‐κB	  signaling	  
pathways	  may	  control	  the	  kinetics	  and	  magnitude	  of	  the	  expression	  of	  NF-­‐κB	  regulated	  target	  
genes	  (Sun,	  2012).	  
	  
2.2.2	  Canonical	  NF-­‐κB	  signaling	  
2.2.2.1	  Activation	  of	  the	  transcription	  factor	  NF-­‐κB	  
In	   canonical	   NF-­‐κB	   signaling,	   proinflammatory	   stimuli	   like	   tumor	   necrosis	   factor	   a	   (TNFα),	  
Interleukin	   (IL-­‐1),	   lipopolysaccharide	   (LPS)	   or	   antigens	   lead	   to	   stimulation	   of	   a	   variety	   of	  
receptors	  such	  as	  TNF	  receptor	  (TNFR1),	  Interleukin-­‐1	  receptors	  (IL-­‐1R),	  Toll-­‐like	  receptor	  (TLR)	  
as	  well	  as	  antigen	  receptors	  including	  B	  cell	  receptor	  (BCR)	  and	  T	  cell	  receptor	  (TCR).	  Figure	  2.3	  
illustrates	  the	  schematic	  process	  of	  canonical	  NF-­‐κB	  signaling.	  Upon	  receptor	  stimulation,	  the	  
TAK1	   complex	   consisting	   of	   the	   kinase	   TAK1	   (TGFβ-­‐activated	   kinase	   1)	   and	   the	   TAK1	  binding	  
proteins	  TAB1,	  TAB2	  and	  TAB3	  is	  activated	  (Landström	  et	  al.,	  2010).	  TAK	  1	  is	  a	  member	  of	  the	  
MAPKKK	  family	  and	  requires	  the	  TAB	  proteins	  for	  its	  kinase	  activity	  (Kishimoto	  et	  al.,	  2000).	  The	  
Zincfinger	  domains	  of	  TAB2	  and	  TAB3	  specifically	  recognize	  K63-­‐linked	  polyubiquitin	  chains	  that	  
are	   either	   unanchored	   or	   attached	   to	   substrate	   proteins	   including	   TRAF6,	   RIP1	   and	   NEMO	  
(Wang	  et	  al.,	  2001).	  Recruitment	  of	  multiple	  TAK1	  complexes	  brings	  the	  kinase	  domains	  of	  TAK1	  
proteins	   close	   to	   each	   other	   resulting	   in	   auto-­‐phosphorylation	   and	   activation	   of	   the	   TAK1	  
kinase,	  which	  in	  turn	  can	  activate	  the	  IKK	  complex.	  The	  IKK	  complex	  consists	  of	  the	  two	  catalytic	  
subunits	   IKKα,	   IKKβ	   and	   the	   regulatory	   subunit	   IKKγ	   also	   called	   NEMO	   (NF-­‐κB	   essential	  
modifier)	   (Karin,	   1999).	   Two	  NEMO	  molecules	   assemble	   a	   dimer	   and	   associate	  with	   the	   one	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IKKα	   and	  one	   IKKβ	  molecule.	  Binding	  of	  NEMO	  to	  polyubiquitin	   is	   crucial	   for	   IKK	   recruitment	  
and	  subsequent	  NF-­‐κB	  activation	  (Napetschnig	  and	  Wu,	  2013).	  These	  polyubiquitin	  chains	  serve	  
as	   extended	   scaffolds	   for	   recruitment	   of	   signaling	   molecules	   and	   enhance	   higher-­‐order	  
oligomerization	  (Ferrao	  et	  al.,	  2012).	  Whereas	  the	  N-­‐terminus	  of	  NEMO	  is	  required	  for	  binding	  
the	   catalytic	   IKK	   subunits,	   its	   C-­‐terminal	   region	   is	   responsible	   for	   ubiquitin	   chain	   recognition	  
(Hadian	  et	  al.,	  2011;	  Xu	  et	  al.,	  2011).	  The	  NEMO	  dimer	  preferentially	  binds	  linear	  (Met1-­‐linked)	  
ubiquitin	   chains	   with	   the	   highest	   affinity	   and	   shows	  modest	   binding	   to	   K63-­‐linked	   ubiquitin	  




Linear	  ubiquitin	  chains	  that	  are	  bound	  by	  NEMO	  are	  generated	  by	  the	  linear	  ubiquitin	  assembly	  
complex	   (LUBAC)	   (Kirisako	   et	   al.,	   2006).	   This	   complex	   consists	   of	   three	   components:	   Heme-­‐
Oxidized	   IRP2	   ubiquitin	   ligase	   1	   (HOIL-­‐1),	   HOIL-­‐1	   interacting	   protein	   (HOIP)	   (the	   catalytic	  
subunit)	   and	   Sharpin	   (Tokunaga	   et	   al.,	   2011).	   LUBAC	  mediates	   ubiquitination	   of	   NEMO	  with	  
linear	   ubiquitin	   chains,	   which	   is	   required	   for	   IL-­‐1β,	   LPS	   and	   TNFα	   induced	   NF-­‐κB	   activation	  
(Tokunaga	  et	  al.,	  2011;	  Emmerich	  et	  al.,	  2013).	  UbcH5	  and	  UbcH7	  are	  E2	  enzymes	  that	  support	  
the	  ubiquitin	  ligase	  activity	  of	  LUBAC	  (Gerlach	  et	  al.,	  2011;	  Ikeda	  et	  al.,	  2011;	  Tokunaga	  et	  al.,	  
2011).	   In	  IL-­‐1β	  stimulated	  cells,	  the	  formation	  of	  K63-­‐linked/linear	  polyubiquitin	  hybrid	  chains	  
































Figure	   2.3:	   Canonical	   NF-­‐κB	   signaling.	   Upon	   receptor	  
stimulation,	  polyubiquitin	  chains	  are	  generated	  to	  serve	  
as	   platforms	   for	   complex	   assembly	   for	   the	   TAK1	  
complex	   as	   well	   as	   the	   LUBAC	   complex.	   TAK1	   induces	  
phosphorylation-­‐dependent	   IKKβ	   activation	   whereas	  
LUBAC	   attaches	   linear	   ubiquitin	   chains	   to	   IKKγ.	   The	  
active	   IKK	   complex	   phosphorylates	   IκBα	   followed	   by	  
K48-­‐linked	   polyubiquitination	   and	   proteasomal	  
degradation	   of	   IκBα.	   The	   released	  NF-­‐κB	   transcription	  
factor	   translocates	   into	   the	   nucleus	   to	   induce	  
transcription	  of	  target	  genes.	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chains	   resulting	   in	   the	   TAK1-­‐catalyzed	   phosphorylation	   and	   activation	   of	   the	   IKK	   complex	  
(Emmerich	  et	  al.,	  2013).	  	  
The	  active	  IKK	  complex	  catalyzes	  phosphorylation	  of	  two	  serine	  residues	  (Ser32	  and	  Ser36)	  of	  
IκBα.	   This	   phosphorylation	   in	   turn	   leads	   to	   K48-­‐linked	   ubiquitination	   that	   targets	   IκBα	   for	  
proteasomal	  degradation.	  NF-­‐κB	  is	  then	  released	  from	  its	   inhibitory	  complex	  and	  translocates	  
into	  the	  nucleus	  to	  bind	  its	  target	  sequences	  to	  activate	  gene	  transcription.	  	  
	  
2.2.2.2	  Membrane	  proximal	  interactions	  
Proinflammatory	   cytokines	   initiate	   a	   signaling	   cascade	   leading	   to	   the	   activation	   of	   the	   IKK	  
complex.	   Several	   receptor-­‐induced	   activation	   pathways	   of	   IKK	   are	   described	   for	   the	   Toll-­‐like	  
receptor/Interleukin-­‐1	   receptor	   (TLR/IL-­‐1R)	   superfamily	   as	   well	   as	   the	   tumor	   necrosis	   factor	  
receptor	  (TNFR)	  superfamily	  (Napetschnig	  and	  Wu,	  2013).	  	  	  
	  
2.2.2.2.1	  Signaling	  cascades	  triggered	  by	  the	  TLR/IL-­‐1R	  superfamily	  
The	   TLR/IL-­‐1R	   superfamily	   belongs	   to	   the	   pattern	   recognition	   receptors.	   Each	   of	   the	   TLRs	  
recognized	   a	   specific	   PAMP	   (pathogen	   associated	  molecular	   pattern)	   with	   their	   extracellular	  
domain.	  PAMPs	  are	  lipopolysaccharide	  (LPS)	  of	  gram-­‐negative	  bacteria	  as	  well	  as	  peptidoglycan	  
and	   lipoteichoic	  acid	  of	  gram-­‐positive	  bacteria,	  RNAs	  of	  selected	  viruses	  and	  various	   forms	  of	  
stress	   signals	   (O´Neill	   et	   al.,	   2013).	   13	   mammalian	   TLRs	   have	   been	   identified	   so	   far.	   Their	  
structure	   consists	   of	   three	  domains:	   an	  N-­‐terminal	   extracellular	   leucine-­‐rich	   repeat	   region	   to	  
sense	  extracellular	  pathogens	  and	  signals	  during	  tissue	  injury,	  a	  transmembrane	  domain	  as	  well	  
as	   a	   C-­‐terminal	   intracellular	   Toll/IL-­‐1R	   (TIR)	   domain	   (O`Neill	   and	   Bowie,	   2007).	   Each	   of	   the	  
different	  ligands	  is	  bound	  to	  distinct	  surfaces	  of	  the	  TLR	  dimers.	  Upon	  sensing	  these	  molecules,	  
TLR	  signaling	  induces	  the	  production	  of	  various	  proinflammatory	  cytokines	  including	  TNFα,	   IL-­‐
1β,	   IL-­‐6	   and	   IL-­‐12	   as	  well	   as	   the	   type	   I	   interferons	   IFNα	   and	   IFNγ,	   chemokines,	   antimicrobial	  
enzymes	   and	   other	   inflammatory	   mediators	   (Xie,	   2013).	   These	   molecules	   stimulate	   acute	  
inflammatory	  responses	  as	  well	  as	  phagocytosis	  and	  autophagy,	  which	  present	  the	  mechanisms	  
of	  innate	  immunity	  against	  many	  pathogens	  (Into	  et	  al.,	  2012;	  O`Neill	  and	  Bowie,	  2007;	  Sanjuan	  
et	   al.,	   2009).	   Furthermore,	   TLR	   signaling	   serves	   to	   prime	   the	   adaptive	   immune	   response	   via	  
upregulation	  of	  adhesion	  molecules	  including	  ICAM-­‐1	  and	  VCAM	  and	  co-­‐stimulatory	  molecules	  
such	  as	  CD40,	  CD80	  and	  CD86	  on	  antigen	  presenting	  cells	  (Suhir	  et	  al.,	  2010;	  Kawai	  et	  al,	  2008).	  
TLRs	   that	   sense	   lipids	  or	   proteins	   are	   located	  on	   the	   cell	  membrane	  and	   include	  TLR1,	   TRL2,	  
TLR4,	   TLR5,	   TLR6	   and	   TLR10	   (Ostuni	   et	   al.,	   2010).	   In	   contrast,	   TLR3,	   TLR7,	   TLR8	   and	   TLR9	  
recognize	   microbial	   and	   host-­‐derived	   nucleic	   acids	   including	   double	   (dsRNA)	   and	   single	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stranded	   RNA	   (ssRNA)	   as	   well	   as	   CpG	   DNA	   and	   therefore	   reside	   in	   intracellular	   endosomes	  
(Ostuni	   et	   al.,	   2010;	   O´Neill	   et	   al.,	   2013).	   Except	   TLR3,	   all	   TLRs	   use	   the	   MyD88	   dependent	  
pathway	  including	  TRAF6	  to	  activate	  NF-­‐κB	  signaling	  (O´Neill	  et	  al.,	  2013).	  	  An	  overview	  of	  TLR	  




Receptors	  of	  the	  IL-­‐1R	  family	  contain	  three	  immunoglobulin-­‐like	  domains	  in	  their	  extracellular	  
domain	  that	  are	  brought	  in	  close	  proximity	  upon	  dimerization	  (Wang	  et	  al.,	  2010;	  Thomas	  et	  al.,	  
2012).	   TLRs	   and	   IL-­‐1R	   family	   members	   all	   share	   a	   common	   cytoplasmic	   TIR	   domain	   and	  
consequently	   involve	   overlapping	   components	   for	   downstream	   signaling	   (Wertz	   and	   Dixit,	  
2012).	  Upon	  ligand-­‐induced	  activation,	  TRLs	  and	  IL-­‐1Rs	  form	  dimers	  for	  signal	  progression	  (Latz	  
et	  al.,	  2007;	  Tsukamoto	  et	  al.,	  2010).	  Higher-­‐order	  oligomers	  of	  receptors	  might	  be	  required	  for	  
intracellular	  signal	  initiation	  (Motshwene	  et	  al.,	  2009).	  It	  is	  thought	  that	  upon	  ligand	  binding	  to	  
the	   extracellular	   domains,	   the	   intracellular	   TIR	   domains	   oligomerize	   creating	   a	   platform	  
allowing	   TIR-­‐domain	   containing	   adaptor	   molecules	   to	   nucleate	   (O`Neill	   and	   Bowie,	   2007).	  
MyD88	   (myeloid	   differentiation	   primary-­‐response	   gene	   88)	   is	   the	   primary	   signaling	   adaptor	  
protein	   for	   IL-­‐1β	   and	   TLR	   signaling	   (O`Neill	   and	   Bowie,	   2007).	   Upon	   receptor	   stimulation,	  
several	  MyD88	  proteins	  oligomerize	  via	  their	  TIR	  domains	  at	  the	  receptor	  proximal	  membrane.	  
They	   form	   a	   platform	   for	   other	   TIR-­‐domain	   containing	   adaptor	   molecules	   to	   assemble	   and	  
oligomerize	  (O`Neill	  and	  Bowie,	  2007).	  MyD88	  associates	  with	  members	  of	  the	  IL-­‐1R-­‐associated	  

























Figure	   2.4:	   TLR	   signaling	   pathways.	   Figure	  
adopted	   from	   O´Neill	   et	   al.,	   2013.	   Whereas	  
TLR4,	   TLR5,	   TLR1,	   TLR2	   and	   TLR6	   sense	   their	  
respective	   ligands	   at	   the	   cell	   surface,	   TLR3,	  
TLR7,	  TLR8	  and	  TLR9	   localize	   in	  the	  endosome	  
and	   recognize	   microbial	   and	   host-­‐derived	  
nucleic	   acids.	   After	   dimerization	   of	   the	   TLRs	  
(except	   TLR3),	   MyD88-­‐dependent	   signaling	  
activates	   TRAF6	   leading	   to	   NF-­‐κB	   activation.	  
TLR3	   signals	   through	  and	  MyD88-­‐independent	  
pathway	  to	  activate	  NF-­‐κB.	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complex	   termed	   the	   Myddosome	   (Motshwene	   et	   al.,	   2009).	   Besides	   MyD88	   proteins,	   this	  
complex	  consists	  of	  IRAK1,	  IRAK2	  and	  IRAK4	  building	  four	  layers	  within	  the	  Myddosome.	  Upon	  
binding	  of	   the	   ligand	  to	   the	  receptor,	   two	  top	   layers	  of	  MyD88	  are	   formed	  and	  recruit	   IRAK4	  
proteins	   to	   the	  complex.	  After	   four	   IRAK4	  molecules	  have	  assembled	   the	  middle	   layer	  of	   the	  
Myddosome,	   IRAK2	   and	   IRAK1	  molecules	   form	   the	  bottom	   layer	   of	   this	   complex	   (Figure	   2.5)	  
(Lin	  et	  al.,	  2010).	  The	  Myddosome	  serves	  as	  a	  scaffold	  for	  phosphorylation	  of	  IRAK1	  and	  IRAK2	  
initiated	  by	  IRAK4	  to	  recruit	  TRAF6	  to	  the	  membrane	  (Ye	  et	  al.,	  2002).	  	  
TRAF6	  is	  an	  E3	  ubiquitin	  ligase	  crucial	  for	  TLR	  and	  IL-­‐1R	  induced	  NF-­‐κB	  signaling	  pathway	  (Wu	  
and	   Arron,	   2003).	   TRAF6,	   in	   conjunction	  with	   the	   E2	   complex	   Ubc13/Uev1a,	   generates	   K63-­‐
linked	  polyubiquitin	  chains	  required	  for	  TRAF6	  auto-­‐ubiquitination	  as	  well	  as	  ubiquitination	  of	  
substrate	  proteins	   including	   IRAK1	   (Conze	  et	  al.,	  2008).	  These	  K63-­‐linked	  polyubiquitin	  chains	  
provide	   a	   platform	   for	   the	   assembly	   of	   signaling	   molecules	   including	   the	   TAK	   complex	   and	  
LUBAC	  (Schmukle	  and	  Walczak,	  2012).	  The	  receptor	  proximal	  signaling	  upon	  TLR/IL-­‐1R	  signaling	  
towards	  NF-­‐κB	  signaling	  is	  depicted	  in	  Figure	  2.5.	  
	  



























































Figure	  2.5:	  TLR/IL-­‐1R	  and	  TNFR	  induced	  NF-­‐κB	  
signaling.	   Upon	   receptor	   stimulation,	   adaptor	  
proteins	  are	  recruited	  to	  the	  receptor	  proximal	  
membrane	  to	  attract	  E3	  ligases	  for	  synthesis	  of	  
polyubiquitin	   chains.	   TLR/IL-­‐1R	   ligand	   binding	  
induces	   formation	   of	   the	   Myddosome	   at	   the	  
receptor	   followed	   by	   TRAF6	   recruitment.	  
Activation	   of	   TRAF6	   leads	   to	   auto-­‐
ubiquitination	  and	  polyubiquitination	  of	  IRAK2.	  
These	  chains	  serve	  as	  a	  scaffold	  for	  binding	  of	  
the	   TAK1	   complex	   and	   LUBAC.	   TNFα	   triggers	  
the	   assembly	   of	   TRAF2/TRAF5	   and	   cIAP1/2	  
followed	  by	  polyubiquitination	  of	   cIAP1/2	   and	  
RIP1	   to	   enable	   TAK1	   complex	   and	   LUBAC	  
binding	  for	  signaling	  towards	  NF-­‐κB	  activation.	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2.2.2.2.2	  Signaling	  via	  the	  TNF	  receptor	  superfamily	  
Stimulation	  of	  the	  Tumor	  Necrosis	  Factor	  Receptor	  (TNFR)	  superfamily	  results	   in	  either	  NF-­‐κB	  
activation	  or	  apoptosis	  depending	  on	  the	  proteins	  that	  are	  recruited	  to	  the	  intracellular	  domain	  
of	   the	   TNFRs	   (Bianchi	   and	   Meier,	   2009).	   Upon	   ligand	   binding,	   TNFRs	   trimerize	   and	   TNFR-­‐
associated	  factors	  (TRAFs)	  are	  recruited	  to	  the	  respective	  receptor	  either	  directly	  or	  via	  adaptor	  
proteins.	   For	   instance,	  binding	  of	   trimeric	  TNFα	   to	  TNFR1	   induces	   receptor	   trimerization	  and	  
subsequently	   recruitment	  of	   the	  TNFR1-­‐associated	  death	  domain	  proteins	   (TRADD)	   to	   form	  a	  
platform	   in	   order	   to	   attract	   additional	   signaling	  mediators.	   These	  mediators	   include	   the	   Fas-­‐
associated	  death	  domain	  protein	  (FADD),	  TRAF2	  and	  the	  Receptor-­‐Interacting	  Protein	  1	  (RIP1).	  
TRAF2	  recruits	  the	  cellular	  inhibitor	  apoptosis	  proteins	  1	  and	  2	  (cIAP1/2)	  forming	  an	  active	  E3	  
ligase	  complex	   (Mahoney	  et	  al.,	  2008).	  An	  overview	  of	  TNFα	  membrane	  proximal	   signaling	   is	  
illustrated	   in	   Figure	   2.5.	   It	   is	   thought,	   that	   cIAP1/2	   facilitate	   K63-­‐linked	   auto-­‐ubiquitination	  
followed	   by	   K63-­‐linked	   polyubiquitination	   of	   TRAF2	   and	   RIP1	   (Mahoney	   at	   el.,	   2008).	  
Ubiquitinated	  RIP1	  then	  might	  serve	  as	  a	  scaffold	  for	  the	  assembly	  of	  the	  TAK1	  complex	  as	  well	  
as	  LUBAC	  (Haas	  et	  al.,	  2009).	  LUBAC	  activity	  results	  in	  linear	  ubiquitination	  of	  RIP1	  and	  NEMO	  
(Gerlach	  et	  al.,	  2011).	  For	  optimal	  IKK	  activation,	  the	  interaction	  of	  NEMO	  with	  both	  linear	  and	  
K63-­‐linked	   polyubiquitin	   chains	   is	   required	   (Hadian	   et	   al.,	   2011).	   Furthermore,	   K11-­‐linked	  
polyubiquitination	  of	  RIP1	  mediated	  by	  cIAP1	  and	  UbcH5	  is	  reported	  (Dynek	  et	  al.,	  2010).	  	  
 
2.2.2.3	  Regulation	  of	  NF-­‐κB	  by	  Deubiquitinases	  
The	   removal	   of	   polyubiquitin	   chains	   by	   DUBs	   is	   necessary	   to	   terminate	   NF-­‐κB	   activity	  
(Napetschnig	  and	  Wu,	  2013).	  Selected	  DUBs	  involved	  in	  regulating	  the	  NF-­‐κB	  pathway	  are	  A20,	  
Cezanne,	   OTULIN	   and	   CYLD	   (Düwel	   et	   al.,	   2009;	   Harhaj	   and	   Dixit,	   2012;	   Keusekotten	   et	   al.,	  
2013).	   All	   listed	   DUBs	   differ	   in	   their	   temporal	   activation	   and	   ubiquitin	   linkage	   specificity	  
ensuring	  tight	  regulation	  of	  terminating	  NF-­‐κB	  activity.	  Whereas	  Cezanne	  prefers	  K11	  linkages	  
to	   regulate	   RIP1	   ubiquitination	   (Enesa	   et	   al.,	   2008),	   OTULIN	   (OTU	   DUB	   with	   linear	   linkage	  
specificity)	   is	  Met1	  specific	  and	   is	  shown	  to	  counteract	  LUBAC-­‐mediated	  signaling	  to	  NF-­‐κB	  in	  
response	  to	  TNFα	  stimulation	  (Keusekotten	  et	  al.,	  2013).	  Several	  DUBs	  including	  A20	  and	  CYLD	  
have	   been	   demonstrated	   to	   deconjugate	   K63-­‐linked	   ubiquitin	   chains	   and	   negatively	   regulate	  
NF-­‐κB	  signaling	  (Wertz	  et	  al.,	  2004;	  Kovalenko	  et	  al.,	  2003).	  	  	  
A20	   (TNFAIP3,	   tumor	  necrosis	   factor	   alpha	   induced	  protein	   3)	   is	   an	  ubiquitin-­‐editing	   enzyme	  
and	   belongs	   to	   the	   ovarian	   tumor	   superfamily	   of	   DUBs	   (Makarova	   et	   al.,	   2000).	   It	  mediates	  
deubiquitination	  of	  K63-­‐linked	  polyubiquitin	  but	  at	  the	  same	  time	  is	  also	  able	  to	  generate	  K48-­‐
linked	  polyubiquitin	  chains	  due	  to	  its	  E3	  ligase	  activity.	  Both	  functions	  are	  necessary	  for	  NF-­‐κB	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inhibition	   (Heyninck	   and	   Beyaert,	   2005).	   A20	   can	   deubiquitinate	   several	   NF-­‐κB	   regulatory	  
proteins	  including	  TRAF6,	  RIP1	  and	  NEMO	  (Boone	  et	  al.,	  2004;	  Wertz	  et	  al.,	  2004).	  A20-­‐deficient	  
mice	   develop	   severe	   inflammatory	   responses	   in	   multiple	   organs	   due	   to	   the	   enhanced	   and	  
prolonged	  activation	  of	  NF-­‐κB	  after	  stimulation	  (Lee	  et	  al.,	  2000).	  A20	  is	  also	  shown	  to	  play	  a	  
critical	   role	   in	   regulating	   NF-­‐κB	   signaling	   in	   T	   cells	   by	   counteracting	   K63-­‐linked	  
polyubiquitination	   of	  Malt1	   (Düwel	   et	   al.,	   2009).	   CYLD,	   as	  USP	   deubiquitinase,	  was	   originally	  
identified	   as	   a	   tumor	   suppressor	   and	   that	   mutations	   in	   this	   gene	   caused	   familial	  
cylindromatosis,	  a	  predisposition	  of	  benign	   tumors	  of	  hair	   follicles	   (Bignell	  et	  al.,	  2000).	  CYLD	  
physically	   interacts	  with	  and	  deubiquitinates	  NEMO.	  Furthermore,	  CYLD	  downregulates	  NF-­‐κB	  
signaling	  by	  removing	  attached	  ubiquitin	  molecules	  from	  TRAF2,	  TRAF6,	  TRAF7,	  RIP1	  and	  NEMO	  
(Trompouki	   et	   al.,	   2003;	   Kovalenko	   et	   al.,	   2003;	   Brummelkamp	   et	   al.,	   2003;	   Yoshida	   et	   al.,	  
2005).	  	  
	  
2.2.3	  Noncanonical	  NF-­‐κB	  signaling	  
As	   most	   members	   of	   the	   TNFR	   family	   can	   activate	   both	   NF-­‐κB	   signaling	   pathways,	   some	  
primarily	  activate	  the	  noncanonical	  path	  including	  CD40	  and	  BAFF-­‐R	  on	  B	  cells	  as	  well	  as	  RANK	  
on	   osteoclasts	   (Sun,	   2012).	   The	   noncanonical	   NF-­‐κB	   pathway	   therefore	   responds	   to	   non-­‐
inflammatory	   stimuli	   and	   plays	   a	   critical	   role	   in	   development	   and	   differentiation	   processes	  
including	  lymphoid	  organogenesis	  and	  architecture	  organization,	  B-­‐cell	  maturation	  and	  survival,	  
maturation	  of	  dendritic	  cells,	  T-­‐cell	  differentiation	  and	  bone	  metabolism	  (Sun,	  2012).	  Compared	  
to	   the	   canonical	  NF-­‐κB	   signaling,	   the	   noncanonical	   pathway	   involves	   slower	   p100	  processing	  
providing	   a	   delayed,	   but	   long-­‐lasting	   NF-­‐κB	   activation	   (Hoffmann	   and	   Baltimore,	   2006).	  
Noncanonical	  NF-­‐κB	  signaling	  predominantly	  targets	  activation	  of	  the	  RelB/	  p52	  NF-­‐κB	  complex	  
and	  does	  not	  depend	  on	  IKKγ	  but	  requires	  IKKα	  and	  NIK	  (NF-­‐κB	  inducing	  kinase)	  to	  activate	  NF-­‐
κB	  signaling	  (Sun,	  2012).	  A	  schematic	  overview	  of	  the	  noncanonical	  NF-­‐κB	  signaling	  pathway	  is	  
illustrated	   in	   Figure	   2.2.	   One	   essential	   element	   in	   noncanonical	   NF-­‐κB	   signaling	   is	   the	  
proteasomal	  processing	  of	  p100	  to	  p52	  to	  allow	  formation	  of	  an	  active	  NF-­‐κB	  heterodimer	  to	  
enter	  the	  nucleus	  and	  to	  promote	  transcription	  of	  target	  genes.	  This	  processing	  is	   initiated	  by	  
phosphorylation	  of	  IKKα,	  which	  is	  in	  turn	  triggered	  by	  NIK.	  Usually,	  NIK	  levels	  in	  the	  cytosol	  are	  
kept	   low	   caused	   by	   its	   degradation	   via	   the	   UPS	   (Vallabhapurapu	   and	   Karin,	   2009).	   In	  
unstimulated	   cells,	   NIK	   is	   constitutively	   bound	   to	   TRAF2	   and	   TRAF3	   that	   are	   thought	   to	  
contribute	  to	  NIK	  degradation	  by	  generating	  K63-­‐linked	  polyubiquitin	  chains	  to	  link	  cIAP1/2	  to	  
NIK	   (Zarnegar	   et	   al.,	   2008).	   cIAP1/2	   then	   assemble	   degradative	   polyubiquitin	   chains	   on	   NIK	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causing	   its	   proteasomal	   degradation.	   Upon	   receptor	   ligation,	   the	   cIAP1/2,	   TRAF2	   and	   TRAF3	  
proteins	   are	   proteasomal	   degraded	   leading	   to	   NIK	   stabilization	   and	   subsequent	  
phosphorylation	   and	   activation	   of	   IKKα	   (Vallabhapurapu	   et	   al.,	   2008).	   This	   permits	   p100	  
processing	   and	   noncanonical	   NF-­‐κB	   activation	   resulting	   in	   the	   upregulation	   of	   anti-­‐apoptotic	  
proteins	  of	  the	  Bcl-­‐2	  family	  (such	  as	  Bcl-­‐2,	  Bcl-­‐xl	  and	  Mcl-­‐1)	  to	  induce	  cell	  survival	  (Wallach	  and	  
Kovalenko,	  2008;	  Rickert	  et	  al.,	  2011).	  	  
 
2.2.4	  NF-­‐κB	  signaling	  in	  diseases	  
2.2.4.1	  NF-­‐κB	  signaling	  in	  inflammatory	  disorders	  and	  cancer	  
NF-­‐κB	   transcription	   factors	   regulate	   a	  number	  of	   important	  physiological	   processes	   including	  
inflammation	   and	   immune	   response	   as	   well	   as	   cell	   growth	   and	   survival.	   In	   several	   human	  
diseases	  such	  as	  chronic	  inflammatory	  diseases	  and	  cancers	  activation	  of	  NF-­‐κB	  is	  elevated	  and	  
contributes	  to	  the	  pathology.	  
In	  chronic	   inflammation,	  the	  persistent	  existence	  of	  NF-­‐κB	  activating	  stimuli	  seems	  to	  surpass	  
the	  inhibitory	  feedback	  loop	  leading	  to	  an	  elevated	  constitutive	  activation	  of	  NF-­‐κB	  (Hoesel	  and	  
Schmid,	  2013).	  As	  a	   result,	  chronic	   inflammation	  perpetuates	  and	  amplifies	   itself	   through	  the	  
diverse	   autocrine	   and	   paracrine	   loops	   of	   cytokines	   (Makarov,	   2001).	   For	   example,	   patients	  
suffering	   from	   rheumatoid	   arthritis	   (RA),	   a	   chronic	   inflammatory	   disease	   leading	   to	   joint	  
destruction	  and	  disability,	  exhibit	  elevated	  levels	  of	  activation	  of	  the	  canonical	  NF-­‐κB	  pathway	  
resulting	   in	  an	   inflammatory	  phenotype	  marked	  by	  excessive	  cytokine	  signaling	  and	  recruited	  
immune	   cells	   in	   the	   inflamed	   pannus	   (Simmonds	   and	   Foxwell,	   2008).	   Furthermore,	   NF-­‐κB	   is	  
also	   shown	   to	   have	   important	   roles	   in	   the	   pathogenesis	   of	   inflammatory	   bowel	   disease	   and	  
chronic	  obstructive	  pulmonary	  disease	  (Lawrence,	  2009).	  	  
In	   cancer,	   NF-­‐κB	   is	   recognized	   in	  many	   steps	   of	   cancer	   initiation	   and	   prolongation.	   NF-­‐κB	   is	  
constitutively	  activated	   in	  many	  types	  of	  cancer	   including	   leukemia,	   lymphoma,	  colon	  cancer,	  
lung	   cancer	   and	  breast	   cancer	   (Staudt,	   2010).	  NF-­‐κB	  activation	   results	   in	   the	  upregulation	  of	  
anti-­‐apoptotic	  genes	  providing	  cell	  survival	  mechanism	  leading	  to	  cell	  proliferation	  and	  causes	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2.2.4.2	  NF-­‐κB	  signaling	  in	  metabolic	  diseases	  	  
Metabolic	  disorders	   including	  obesity,	   type	  2	  diabetes	  and	  atherosclerosis	  have	  been	  thought	  
as	   lipid	   disorders	   causes	   by	   overnutrition.	   Nowadays,	   it	   is	   known	   that	   chronic	   low-­‐grade	  
inflammation	  plays	  a	  central	  role	   in	  the	  initiation,	  propagation	  and	  development	  of	  metabolic	  
diseases	  as	  well	  (Baker	  et	  al.,	  2011).	  Consistent	  with	  its	  central	  role	  in	  regulating	  inflammatory	  
responses,	  various	  recent	  studies	  revealed	  the	  implication	  of	  NF-­‐κB	  in	  the	  development	  of	  such	  
diseases	   contributing	   to	   the	   chronic	   inflammation.	   Although	   the	   exact	   mechanistic	  
understanding	   of	   how	   inflammatory	   signaling	   induces	   metabolic	   disorders	   is	   not	   clear	   yet,	  
recent	  findings	  give	  first	  insights	  into	  this	  correlation.	  Upon	  nutrient	  excess,	  resident	  tissue	  cells	  
activate	   NF-­‐κB	   (Baker	   et	   al.,	   2011).	   Oxidized	   lipoproteins	   in	   the	   bloodstream	   trigger	   the	  
secretion	   of	   specific	   chemokines	   by	   the	   vascular	   endothelia	   and	   lead	   to	   the	   recruitment	   of	  
leukocytes	  to	  the	  site	  of	   inflammation	  (Weisberg	  et	  al.,	  2006).	   Invasion	  of	  these	   leukocytes	   is	  
mediated	   by	   the	   adhesion	  molecules	   ICAM-­‐1	   and	   VCAM	   induced	   by	   NF-­‐κB	   (Bosanska	   et	   al.,	  
2010).	   Furthermore,	   hepatocytes	   as	   well	   as	   adipocytes	   induce	   NF-­‐κB	   in	   response	   to	  
overnutrition.	  TLR4	  signaling	  in	  adipocytes	  and	  macrophages	  induced	  by	  nutritional	  fatty	  acids,	  
whose	  circulating	   levels	  are	  often	   increased	   in	  obesity,	   causes	   the	  activation	  of	   inflammatory	  
pathways	   and	   plays	   an	   important	   role	   in	   obesity-­‐associated	   insulin	   resistance	   as	   depicted	   in	  
Figure	  2.6	  (Shi	  et	  al.,	  2006).	  TLR4	  is	  found	  to	  be	  upregulated	  in	  adipocytes	  of	  diet-­‐induced	  obese	  
mice.	  Although	  TLR4-­‐deficient	  mice	  have	  increased	  obesity,	  they	  are	  partially	  protected	  against	  
HFD-­‐induced	   insulin	   resistance	   (Shi	   et	   al.,	   2006).	   Further	   research	   of	   the	   inflammatory	  
pathways	   in	   obese	   and	   diabetic	  mice	   confirmed	   that	  MyD88	   and	   NF-­‐κB	   protein	   levels	   were	  
elevated	  in	  adipose	  tissue	  and	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  taken	  from	  type	  2	  
diabetes	  mellitus	  (T2DM)	  subjects	  (Creely	  et	  al.,	  2007;	  Ahmad	  et	  al.,	  2012).	  Also,	  the	  levels	  of	  
circulating	  proinflammatory	  cytokines	   like	  TNFα	  and	   IL-­‐6	  are	   increased	   in	  T2DM	  subjects	  as	  a	  
consequence	   of	   elevated	   NF-­‐κB	   signaling	   (Creely	   et	   al.,	   2007;	   Ahmad	   et	   al.,	   2012).	   Obesity	  
induced	   inflammation	   is	   mediated,	   at	   least	   in	   part,	   by	   circulating	   saturated	   free	   fatty	   acids	  
(FFAs)	   that	   stimulate	   intracellular	   proinflammatory	   pathways	   in	   a	   TLR4-­‐dependent	   manner	  
(Heinrichsdorff	  and	  Olefsky,	  2012).	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For	  a	   long	  time	  the	  connection	  of	  FFA	  and	  TLR4	  has	  been	  controversial,	  but	   in	  2012	  Pal	  et	  al.	  
identified	  Fetuin-­‐A	  as	  an	  endogenous	  ligand	  for	  TLR4	  that	  directly	  links	  FFA	  to	  TLR4	  activation	  
(Pal	   et	   al.,	   2012).	   Fetuin-­‐A	   (FetA)	   is	   a	   64kDa	   glycoprotein	   that	   is	   secreted	   from	   the	   liver	   and	  
adipose	   tissue.	   Knockdown	   of	   FetA	   in	  mice	   with	   insulin	   resistance	   caused	   by	   a	   high-­‐fat-­‐diet	  
resulted	  in	  decreased	  TLR4	  signaling	  in	  adipose	  tissue	  (Pal	  et	  al.,	  2012).	  Administration	  of	  FetA	  
caused	  inflammatory	  signaling	  and	  insulin	  resistance.	  Removing	  either	  FetA	  or	  TLR4	  prevented	  
FFA-­‐induced	   insulin	   resistance	   and	   therefore	   proves	   that	   the	   FFA-­‐FetA	   binding	   to	   TLR4	  
stimulates	  lipid	  induced	  insulin	  resistance	  (Pal	  et	  al.,	  2012).	  Elevated	  circulating	  FetA	  levels	  are	  
detected	  in	  obesity	  and	  related	  disorders	  including	  type	  2	  diabetes	  mellitus	  and	  are	  associated	  
with	   impaired	   insulin	   sensitivity	   and	   glucose	   tolerance	   (Trepanowski	   et	   al.,	   2014).	   As	   NF-­‐κB	  
inflammatory	   pathways	   promote	   metabolic	   diseases,	   therapeutic	   strategies	   might	   directly	  
target	   NF-­‐κB	   target	   genes.	   Therefore,	   blocking	   the	   action	   of	   inflammatory	   mediators	   is	  



































Figure	  2.6:	  NF-­‐κB	  and	  TRAF6	  in	  obesity	  and	  insulin	  
resistance	   (adopted	   from	   Heinrichsdorff	   and	  
Olefsky,	   2012).	   In	   obesity,	   free-­‐fatty-­‐acid	   (FFA)	  
levels	   are	   elevated.	   FFAs	   are	   bound	   by	   the	   liver	  
secretory	   protein	   FetuinA	   (FetA)	   and	   present	  
ligands	  for	  TLR4.	  Activated	  TLR4	  signaling	  results	  in	  
TRAF6-­‐dependent	   NF-­‐κB	   activation	   and	  
transcription	   of	   proinflammatory	   genes.	   Constant	  
secretion	  of	  inflammatory	  cytokines	  causes	  chronic	  
inflammation	   leading	   to	  worsening	   of	   obesity	   and	  
insulin	  resistance.	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2.3	  TRAF6	  in	  cellular	  signaling	  
2.3.1	  The	  TRAF	  protein	  family	  
TNFR-­‐associated	  factor	  (TRAF)	  proteins	  serve	  as	  adapter	  molecules	  for	  a	  variety	  of	  cell	  surface	  
receptors	  and	  regulate	  diverse	  cellular	  responses.	  TRAFs	  were	  originally	   identified	  as	  signaling	  
adaptors	   that	   directly	   bind	   to	   the	   cytoplasmic	   region	   of	   receptors	   of	   the	   TNFR	   superfamily	  
(Inoue	   et	   al.,	   2000).	   However,	   over	   the	   past	   decade	   the	   number	   of	   receptor	   families	   that	  
involve	  TRAFs	  for	  signaling	  has	  expanded	  rapidly.	  These	   include	  Toll-­‐like	  receptors	  (TLRs),	   IL-­‐1	  
receptor	   family,	   NOD-­‐like	   receptors	   (NLRs),	   RIG-­‐I-­‐like	   receptors	   (RLRs),	   T	   cell	   receptor,	   IL-­‐17	  
receptors,	  IFN	  receptors	  and	  TGFβ	  receptors	  (Xie	  et	  al.,	  2013).	  The	  TRAF	  protein	  family	  includes	  
seven	  members:	  TRAF1,	  TRAF2,	  TRAF3,	  TRAF4,	  TRAF5,	  TRAF6	  and	  TRAF7	  (Zotti	  et	  al.,	  2012).	  
In	   general,	   TRAF	   proteins	   share	   a	   characteristic	   modular	   structure	   of	   conserved	   domains	   to	  
mediate	   signals	   from	   different	   receptors	   to	   various	   cellular	   outcomes	   (Arch	   et	   al.,	   1998).	   At	  
their	   C-­‐terminus	   TRAF	   proteins	   possess	   a	   TRAF	   domain	   that	   consists	   of	   a	   coiled-­‐coil	   and	   the	  
MATH	  domain.	  This	  terminus	  allows	  oligomerization	  of	  TRAF	  proteins	  as	  well	  as	  interaction	  with	  
receptor	   proteins	   and	   other	   cytoplasmic	   factors	   (Takeuchi	   et	   al.,	   1996).	   Minor	   structural	  
differences	  in	  this	  domain	  among	  TRAFs	  define	  the	  specificity	  of	  each	  TRAF	  protein	  binding	  to	  
various	   receptors	   (Chung	   et	   al.,	   2007;	   Ely	   et	   al.,	   2007).	   This	   defines	   a	  main	   role	   of	   TRAFs	   to	  
serve	   as	   adaptor	   proteins	   in	   the	   assembly	   of	   receptor-­‐associated	   signaling	   complexes	   and	  
thereby	   linking	   upstream	   receptors	   to	   downstream	   effector	   enzymes.	   Genetically	   modified	  
murine	   strains	  carrying	  a	  deletion	   in	   the	   loci	  encoding	   for	  each	   individual	  TRAF	  protein	   show	  
that	  each	  TRAF	  proteins	  plays	  a	  unique	  and	  well	  defined	  role	  in	  the	  biology	  of	  the	  cell	  and	  the	  
organism	  (Zotti	  et	  al.,	  2012).	  Although	  the	  N-­‐terminal	  region	  of	  TRAF	  proteins	  is	  less	  conserved,	  
all	  TRAFs,	  except	  for	  TRAF1,	  contain	  a	  conserved	  RING	  domain	  connected	  to	  a	  variable	  number	  
of	   Zincfinger	   domains	   (Ha	   et	   al.,	   2009).	   The	   RING	   domain	   is	   found	   in	   a	   large	   number	   of	   E3	  
ubiquitin	  ligases	  and	  holds	  the	  core	  of	  the	  ubiquitin	  ligase	  catalytic	  domain.	  The	  RING	  domains	  
of	   TRAF3,	   6	   and	   7	   are	   capable	   of	   promoting	   ubiquitination	   to	   activate	   their	   downstream	  
pathways	   revealing	   that	   TRAFs	   can	   facilitate	   adaptor	  protein	   and	  E3	  ubiquitin	   ligase	   function	  
(Deng	  et	  al.,	  2000;	  Bouwmeester	  et	  al.,	  2004;	  Kayagaki	  et	  al.,	  2007;	  Alvarez	  et	  al.,	  2010).	  	  
In	   addition	   to	   the	   cytoplasmic	   domain	   of	   receptors,	   TRAF	   proteins	   also	   interact	  with	   various	  
intercellular	  factors	  including	  kinases,	  regulators	  of	  signaling	  pathways,	  structural	  proteins	  and	  
adaptor	  molecules	  to	  mediate	  cellular	  function	  (Zotti	  et	  al.,	  2012).	  Whereas	  TRAF2,	  TRAF3	  and	  
TRAF5	   seem	   to	   signal	   within	   the	   TNF	   receptor	   superfamily,	   TRAF6	   is	   more	   pleiotropic	   in	  
participating	  in	  the	  signal	  transduction	  of	  many	  receptor	  systems	  like	  IL-­‐1β	  and	  LPS	  signaling	  as	  
well	  as	   in	  T	  cell	  receptor	  and	  CD40	  signaling	  (Oeckinghaus	  et	  al.,	  2007;	  Ye	  et	  al.,	  2002).	  TRAF-­‐
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Introduction	  
	   20	  
dependent	   signaling	   pathways	   typically	   lead	   to	   the	   activation	   of	   NF-­‐κB	   or	  mitogen-­‐activated	  
protein	   kinases	   (MAPKs).	   Either	   acting	   alone	   or	   in	   combination,	   TRAFs	   mediate	   a	   variety	   of	  
cellular	   processes	   including	   survival,	   proliferation,	   differentiation,	   activation,	   cytokine	  
production	  and	  autophagy	  (Xie,	  2013).	  Alterations	  in	  TRAFs	  may	  contribute	  to	  the	  pathogenesis	  
of	   human	   diseases	   including	   cancers,	   autoimmune	   diseases	   and	   immunodeficiencies	  
(Hildebrand	  et	  al.,	  2011;	  Namjou	  et	  al.,	  2012;	  Netea	  et	  al.,	  2012).	  
	  
2.3.2	  TRAF6	  
2.3.2.1	  Structure	  of	  the	  TRAF6	  protein	  	  
TRAF6	  is	  a	  member	  of	  the	  TRAF	  protein	  family	  and	  functions	  as	  an	  adaptor	  protein	  as	  well	  as	  an	  
E3	  ubiquitin	  ligase	  to	  mediate	  cytokine	  signaling	  after	  activation	  of	  the	  transcription	  factor	  NF-­‐
κB.	   The	   TRAF6	   coding	   sequence	   is	   located	   on	   Chromosome	   11p12.	   Two	   alternatively	   spliced	  
transcript	   variants	   encoding	   an	   identical	   protein	   have	   been	   reported.	   The	   ubiquitously	  
expressed	   TRAF6	   protein	   exhibits	   522	   amino	   acids	   and	   a	   size	   of	   60kDa.	   TRAF6	   is	   generally	  
located	  in	  the	  cytoplasm	  but	  is	  also	  found	  in	  the	  nucleus	  of	  some	  aggressive	  B	  cell	  lymphoma	  as	  
well	  as	  in	  resting	  and	  activated	  T	  and	  B	  cells	  (Pham	  et	  al.,	  2008).	  TRAF6	  exhibits	  a	  RING	  domain	  
and	  4	  Zincfingers	  at	  its	  N-­‐terminus	  whereas	  the	  C-­‐terminal	  TRAF	  domain	  contains	  a	  Coiled-­‐Coil	  
domain	  and	  a	  conserved	  MATH	  domain	  (Figure	  2.7)	  (Yin	  et	  al.,	  2009).	  
	  	  	   	  
Figure	   2.7:	   Structure	   und	   domain	   functions	   of	   TRAF6.	   Schematic	   illustration	  of	   the	   structure	   of	   TRAF6.	   The	  N-­‐
terminus	   consists	   of	   a	   RING	   finger	   connected	   to	   four	   Zincfinger	   domains,	  whereas	   the	   C-­‐terminal	   region	   (TRAF	  
domain)	  harbors	  the	  Coiled-­‐Coil	  and	  the	  MATH	  domain.	  In	  addition	  to	  dimerization,	  the	  RING-­‐Zincfinger1	  domain	  
mediates	  binding	  to	  E2	  enzymes	  to	  carry	  out	  the	  E3	  ligase	  activity	  (via	  the	  C70	  residue)	  leading	  to	  K63-­‐linked	  auto-­‐
ubiquitination	  of	  TRAF6	  at	  K124.	  TRAF6	  can	  be	  sumoylated	  at	  K124,	  K142	  and	  K453.	  The	  TRAF	  domain	  facilitates	  
trimerization	  and	  binding	  to	  substrates,	  receptors	  and	  adapter	  proteins.	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The	  TRAF	  domain	  forms	  a	  mushroom-­‐shaped	  trimeric	  structure	  with	  the	  MATH	  domain	  as	  the	  
head	  for	  sequence	  specific	  interaction	  with	  receptors	  like	  TLR4	  and	  IL-­‐1R	  and	  adaptor	  proteins	  
including	  IRAK1	  and	  MyD88	  whereas	  the	  coiled	  coil	  domain	  presents	  the	  stalk	  for	  trimerization	  
(Ye	   et	   al.,	   2002).	   The	   N-­‐terminal	   structure	   of	   TRAF6	   can	   be	   described	   as	   a	   golf-­‐club-­‐like	  
formation	  with	  the	  Zincfinger	  domains	  forming	  the	  shaft	  and	  the	  RING	  domain	  building	  the	  club	  
head	  (Yin	  et	  al.,	  2009).	  The	  RING	  domain	  folds	   into	  a	  canonical	  cross-­‐brace	  fold	  containing	  an	  
aspartate	  residue.	  Stacked	  aromatic	  and	  aliphatic	  side	  chains	  that	  are	  conserved	  among	  TRAF	  
proteins	   form	   the	   hydrophobic	   dimer	   interface	   whereas	   the	   Zincfinger	   domains	   structure	   a	  
canonical	  β-­‐β-­‐α-­‐fold	   (Yin	  et	  al.,	  2009).	  The	  N-­‐terminal	   region	  of	  TRAF6	  mediates	  dimerization	  
(Yin	  et	  al.,	  2009).	  Furthermore,	   this	  domain	   functions	  as	  an	  E3	  ubiquitin	   ligase	   for	  K63-­‐linked	  
polyubiquitination	  harboring	  the	  active	  cysteine	  site	  C70	  and	  is	  responsible	  for	  the	  interaction	  
with	   E2	   enzymes	   in	   order	   to	   facilitate	   ubiquitination	   (Yin	   et	   al.,	   2009).	   The	   alternating	  
dimerization	   of	   the	   N-­‐terminus	   and	   trimerization	   of	   the	   C-­‐terminus	   results	   in	   infinite	   TRAF6	  
aggregation.	   These	   higher-­‐order	   assemblies	   are	   required	   for	   TRAF6-­‐mediated	  
polyubiquitination	   and	   NF-­‐κB	   activation	   (Yin	   et	   al.,	   2009).	   The	   TRAF6	   protein	   can	   be	  
posttranslational	  modified	  by	  SUMO1	  at	  K124,	  K142	  and	  K453	  in	  the	  nucleus	  (Pham	  et	  al.,	  2008)	  
as	   well	   as	   K63-­‐linked	   poly-­‐ubiquitinated	   at	   K124	   in	   the	   cytoplasm	   after	   cell	   stimulation	  
(Lamothe	  et	  al.,	  2007).	  	  
	  
2.3.2.2	  Functions	  of	  TRAF6	  in	  signaling	  pathways	  
TRAF6	   mainly	   mediates	   signaling	   from	   members	   of	   the	   TLR/IL-­‐1R	   family	   (Xie,	   2013).	   By	  
functioning	  as	  adaptor	  protein	  on	  the	  one	  hand	  and	  as	  E3	  ubiquitin	   ligase	  on	  the	  other	  hand,	  
this	  protein	  serves	  as	  a	  signal	  transducer	  in	  the	  NF-­‐κB	  pathway	  to	  activate	  the	  IKK	  complex	  in	  
response	   to	   various	   environmental	   stimuli	   including	   proinflammatory	   cytokines.	   In	   TLR/IL-­‐1R	  
signaling,	   TRAF6	  mediates	   the	  MyD88-­‐dependent	   pathway	   (all	   TLRs	   except	   TLR3)	   in	   order	   to	  
activate	  NF-­‐κB	  signaling	  (Xie,	  2013).	   In	  MyD88-­‐dependent	  signaling,	  TRAF6,	  together	  with	  the	  
E2	   complex	   Ubc13/UeV1a,	  mediates	   the	   attachment	   of	   K63-­‐linked	   polyubiquitin	   chains	   onto	  
substrates	  (Keating	  and	  Bowie,	  2009).	  Besides	  its	  requirement	  in	  TLR	  and	  IL-­‐1R	  signaling,	  TRAF6	  
also	  is	  involved	  in	  several	  additional	  pathways	  such	  as	  TNFR,	  T	  cell	  receptor	  and	  IL-­‐17	  receptor	  
signaling	  as	  well	  as	  in	  DNA	  damage	  response	  (Xie,	  2013).	  The	  involvement	  of	  TRAF6	  in	  various	  
signaling	  pathways	  is	  summarized	  in	  Figure	  2.8.	  	  
TNFR	   signaling	   includes	  CD40	  and	  RANK	   signaling.	  Upon	  CD40	   stimulation,	   TRAF6	  and	  Ubc13	  
together	   with	   many	   other	   signaling	   proteins	   including	   TRAF1,	   TRAF2,	   TRAF3	   and	   TRAF5	   are	  
recruited	  to	  the	  cytoplasmic	  domain	  of	  the	  receptor	   inducing	  the	  K63-­‐specific	  ubiquitin	   ligase	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activity	   of	   TRAF6	   (Xie,	   2013).	   Upon	   formation	   of	   signaling	   complexes,	   MEKK1	   and	   TAK1	   are	  
phosphorylated	   and	   in	   turn	   activated	   to	   promote	   MAPK1	   and	   NF-­‐κB	   signaling	   to	   mediate	  
effector	  functions	  of	  CD40	  (Bishop	  et	  al.,	  2007).	  Signaling	  through	  Receptor	  Activator	  of	  NF-­‐κB	  
(RANK)	  is	  critical	  for	  the	  differentiation	  and	  activation	  of	  osteoclasts,	  cells	  that	  are	  responsible	  
for	   bone	   resorption.	   The	   structural	   and	  metabolic	   integrity	   of	   bone	   is	   regulated	   through	   the	  
dynamic	   process	   of	   bone	   remodeling	   mediated	   by	   bone	   resorption	   through	   osteoclasts	   and	  
formation	  of	  new	  bone	  by	  osteoblasts	  (Phan	  et	  al.,	  2004).	  The	  interaction	  of	  RANK	  with	  TRAF6	  
is	   required	   for	   appropriate	   formation	   of	   cytoskeletal	   structures	   and	   functional	   resorptive	  
activity	  of	  obsteoclasts	   (Armstrong	  et	  al.,	  2002).	  TRAF6	  binds	  RANK	   in	  a	  unique	  motif	   located	  
within	   the	   membrane	   proximal	   region	   to	   induce	   IKK	   activation	   as	   well	   as	   osteoclast	  
differentiation	  (Darnay	  et	  al.,	  1999;	  Lamothe	  et	  al.,	  2007).	  	  	  
	  
	  	  	  	  	  	  	   	  
Figure	  2.8:	  Involvement	  of	  TRAF6	  in	  various	  signaling	  pathways	  to	  activate	  NF-­‐κB	  signaling.	  Schematic	  overview	  
of	   the	  variety	  of	   signaling	  pathways	   that	  are	  dependent	  on	  TRAF6	   function	   to	  activate	  NF-­‐κB.	  Besides	  TLR/IL-­‐1R	  
signaling,	  TRAF6	  is	  a	  critical	  key	  part	  of	  CD40	  signaling	  along	  with	  other	  TRAF	  proteins.	  RANK	  signaling	  stimulates	  
NF-­‐κB	  activation	  in	  a	  TRAF6-­‐dependent	  manner.	  Upon	  T	  cell	  stimulation	  by	  antigen	  presenting	  cells	  (APC),	  TRAF6	  is	  
recruited	   to	   the	  CARMA1-­‐BCL10-­‐MALT1	   complex	   for	   signal	   progress.	   IL-­‐17	   signaling	   stimulates	   TRAF	  proteins	   to	  
operate	   together	  with	  Act-­‐1	   to	   induce	  NF-­‐κB	  activation.	  Genotoxic	   stress	   results	   in	  complex	   formation	   including	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TRAF6	   also	   plays	   a	   major	   role	   in	   T	   cell	   receptor	   (TCR)	   signaling	   as	   it	   is	   recruited	   into	   the	  
CARMA1-­‐BCL10-­‐MALT1	   complex	   via	   its	   interaction	   with	   the	   paracaspase	   MALT1	   (Sun	   et	   al.,	  
2004;	  Bidere	  et	  al.,	  2006;	  Oeckinghaus	  et	  al.,	  2007).	  TRAF6	  activity	  is	  required	  for	  the	  K63-­‐linked	  
poylubiquitination	  of	  MALT1,	  which	  in	  turn	  is	  a	  prerequisite	  for	  signal	  progression	  towards	  NF-­‐
κB	  (Oeckinghaus	  et	  al.,	  2007).	  	  
In	  IL-­‐17	  signaling,	  the	  heterodimeric	  IL-­‐17A	  and	  IL-­‐17C	  receptor	  recruits	  a	  novel	  adaptor	  protein	  
Act1.	  Act1	   is	  a	  E3	   ligase	  that	   further	  recruits	  TRAF6	  along	  with	  TRAF2	  and	  TRAF5	  to	  the	   IL-­‐17	  
receptor	   complex.	   In	   cooperation	  with	   the	   E2	   enzyme	   complex	  Ubc13/Uev1a,	   Act1	   catalyzes	  
K63-­‐linked	  polyubiquitination	   that	   in	   turn	   facilitates	  ubiquitination	  of	   IL-­‐17A	   to	   induce	  NF-­‐κB	  
signaling	   through	  TAK1	  and	   IKK	  activation	   (Gaffen,	   2009;	   Zepp	  et	   al.,	   2011).	   IL-­‐17	   signaling	   is	  
responsible	   in	  host	  defense	  against	  bacterial,	   fungal	  and	  helminthic	  parasite	   infections	  and	   is	  
mediated	   by	   the	   T	   helper	   cell	   population	   Th17	   (Chang	   and	   Dong,	   2011).	   In	   DNA	   damage	  
response,	  TRAF6	  induces	  NF-­‐κB	  signaling	  after	  activation	  of	  the	  DNA	  strand	  break	  sensor	  ATM	  
(Ataxia	   telangiectasia	   mutated)	   (Hinz	   et	   al.,	   2010).	   Upon	   DNA	   damage,	   activated	   ATM	  
translocates	   into	   the	   cytoplasm	   to	   interact	   with	   TRAF6	   resulting	   in	   K63-­‐linked	  
polyubiquitination	   of	   TRAF6	   followed	   by	   recruitment	   of	   cIAP1	   (Hinz	   et	   al.,	   2010).	   The	   ATM-­‐
TRAF6-­‐cIAP1	   complex	   then	   stimulates	   the	   phosphorylation	   of	   TAK1,	   followed	   by	   cIAP1	  
catalyzed	  monoubiquitination	  of	  NEMO	  at	  Lys285,	  a	  prerequisite	  for	  genotoxic	  NF-­‐κB	  activation	  
and	  DNA	  damage	  response	  (Hinz	  et	  al.,	  2010).	  	  
Engagement	  of	  TRAF6	  in	  other	  signaling	  pathways	  upon	  stimulation	  of	  NOD,	  RIG-­‐I,	  IFN,	  TGF-­‐β,	  
IL-­‐2	  and	  C-­‐type	  lectin	  receptors	  has	  been	  describes	  as	  well	  (Xie,	  2013).	  	  
	  
2.3.2.3	  Counteracting	  TRAF6	  activity	  by	  DUBs	  
TLR	   and	   IL-­‐1R	   induce	   immune	   responses	   that	   rely	   on	   the	   activity	   of	   downstream	   TRAF6	  
signaling.	   Therefore,	   TRAF6	   activation	   needs	   to	   be	   tightly	   controlled	   and	   is	   shown	   to	   be	  
negatively	   regulated	   by	   several	   deubiquitinating	   enzymes	   including	   A20,	   CYLD,	   USP20	   and	  
Cezanne.	  	  
A20	   is	   induced	   in	   IL-­‐1β/LPS	   and	   T	   cell	   receptor	   signaling	   and	  was	   suggested	   to	   remove	   K63-­‐
linked	   polyubiquitin	   chains	   from	   TRAF6	   to	   terminate	   NF-­‐κB	   activation	   (Boone	   et	   al.,	   2004;	  
Heyninck	  and	  Beyaert,	  1999;	  Düwel	  et	  al.,	  2009).	  However,	  A20-­‐OTU	  knockin-­‐mice	  that	  lack	  the	  
deubiquitinase	  domain	  of	  A20	  do	  not	  show	  signs	  of	   inflammation	  and	  responded	  normally	   to	  
LPS	  and	  undergo	  normal	  NF-­‐κB	  activation	  indicating	  that	  the	  deubiquitinase	  function	  of	  A20	  is	  
dispensable	   for	  NF-­‐κB	   signaling	   (De	   et	   al.,	   2014).	   It	   is	   proposed	   that	  A20	   rather	   functions	   to	  
disrupt	   the	   interaction	   of	   TRAF6	   and	   Ubc13	   than	   promoting	   the	   degradation	   of	   TRAF6	   and	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instead	   targets	   Ubc13	   with	   K48-­‐linked	   polyubiquitin	   chains	   for	   proteasomal	   degradation	  
(Shembade	  et	  al.,	  2010).	  	  
Another	   cysteine	   protease	   DUB	   that	   regulates	   TRAF6	   activation	   is	   the	   tumor	   suppressor	  
Cylindromatosis	  (CYLD)	  that	  directly	  interacts	  with	  TRAF6	  after	  IL-­‐1β	  stimulation	  (Kovalenko	  et	  
al.,	  2003).	  CYLD	  negatively	  modulates	  TRAF6-­‐mediated	  activation	  of	  IKK	  by	  cleaving	  off	  the	  K63-­‐
linked	  polyubiquitin	  chains	  of	  TRAF6	  (Kovalenko	  et	  al.,	  2003).	  CYLD	  deficiency	  in	  mice	  does	  not	  
only	  cause	  aberrant	  immune	  and	  inflammatory	  responses,	  but	  also	  leads	  to	  impaired	  osteoclast	  
differentiation	   and	   severe	   osteoporosis	   (Jin	   et	   al.,	   2008).	   CYLD	   therefore	   not	   only	   regulates	  
TRAF6	  activity	  in	  IL-­‐1β,	  but	  also	  in	  RANK	  signaling	  by	  deubiquitinating	  TRAF6	  (Jin	  et	  al.,	  2008).	  
Additional	  DUBs	  controlling	  TRAF6	  activity	  are	  the	  ubiquitin-­‐specific	  peptidase	  USP20	  and	  the	  
OTU	  domain	  DUB	  Cezanne	  (Cellular	  Zincfinger	  Anti-­‐NF-­‐κB)	  (Yasunaga	  et	  al.,	  2012;	  Luong	  et	  al.,	  
2103).	   While	   USP20	   deubiquitinates	   TRAF6	   in	   IL-­‐1β	   induced	   NF-­‐κB	   activation,	   Cezanne	  
suppresses	  NF-­‐κB	   signaling	   in	   response	   to	   hypoxia-­‐reoxygenation	   by	   reducing	   the	   K63-­‐linked	  
polyubiquitination	  of	  TRAF6	  (Yasunaga	  et	  al.,	  2012;	  Luong	  et	  al.,	  2103).	  	  
Altogether,	   considering	   that	   TRAF6	   is	   so	   tightly	   negatively	   regulated	   in	   a	   variety	   of	   different	  
circumstances	  and	  that	  A20	  and	  CYLD	  knock	  out	  mice	  develop	  severe	  inflammatory	  syndromes,	  
the	  negative	  regulation	  of	  TRAF6	  signaling	  is	  necessary	  to	  prevent	  harmful	   immune	  responses	  
and	  inflammatory	  diseases.	  	  
	  
2.3.2.4	  TRAF6	  in	  diseases	  
Due	   to	   the	   key	   role	   of	   TRAF6	   in	   innate	   and	   adaptive	   immune	   response	   as	   well	   as	   in	   bone	  
formation	  and	  resorption,	  alterations	   in	  TRAF6	  expression	  cause	  severe	  consequences.	  TRAF6	  
deficient	  mice	  exhibit	  perinatal	  death	  with	  multiple	  organ	  abnormalities	  indicating	  that	  TRAF6	  is	  
indispensable	  for	  early	  development.	  The	  mice	  die	  of	  severe	  osteopetrosis,	  splenomegaly	  and	  
thymic	   atrophy	   (Lomaga	   et	   al.,	   1999;	   Naito	   et	   al.,	   1999).	   Furthermore,	   these	   mice	   feature	  
systemic	  inflammation	  as	  well	  as	  impaired	  IL-­‐1β	  and	  TLR	  signaling	  (Zotti	  et	  al.,	  2012).	  	  
Overexpression	   of	   TRAF6	   leads	   to	   chronic	   immune	   stimulation	   causing	   a	   broad	   variety	   of	  
disorders	   including	  autoimmune	  diseases,	  carcinoma	  and	  metabolic	  diseases.	   Individual	  single	  
nucleotide	  polymorphisms	  (SNPs)	   in	  the	  TRAF6	  gene	  locus	  are	  linked	  to	  autoimmune	  diseases	  
including	   rheumatoid	   arthritis	   and	   systemic	   lupus	   erythematodes	   (Namjou	   et	   al.,	   2012).	  
Overexpression	  and	  amplification	  of	  TRAF6	  has	  been	  reported	  in	  several	  human	  carcinomas.	  In	  
colon	  cancer,	  TRAF6	  is	  found	  to	  be	  upregulated	  and	  to	  promote	  proliferation	  (Sun	  et	  al.,	  2014).	  
Furthermore,	  amplifications	  of	  the	  TRAF6	  sequence	  have	  been	  reported	  to	  cause	  lung	  cancer	  as	  
well	  as	  osteosarcoma	  (Starczynowski	  et	  al.,	  2011;	  Meng	  et	  al.,	  2012).	  Downregulation	  of	  TRAF6	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in	   human	   lung	   cancers	   and	   osteosarcoma	   cells	   results	   in	   suppressed	   NF-­‐κB	   activation	   along	  
with	   diminished	   tumor	   formation	   and	   invasion	   suggesting	   that	   TRAF6	   overexpression	   may	  
promote	  the	  tumorigenesis	  and	  invasion	  of	  lung	  cancer	  and	  osteosarcoma	  cells	  (Starczynowski	  
et	  al.,	  2011;	  Meng	  et	  al.,	  2012).	  	  
	  
2.3.2.4.1	  TRAF6	  in	  obesity	  and	  insulin	  resistance	  
Inflammation	  displays	  a	  major	  role	  in	  the	  pathogenesis	  of	  metabolic	  disorders	  associated	  with	  
obesity.	  Diet-­‐induced	  obesity	  can	  cause	  low-­‐level	  inflammation	  and	  insulin	  resistance	  involving	  
IL-­‐1β	   as	   one	   of	   the	   key	   inflammatory	   cytokines	   (Tack	   et	   al.,	   2012).	   In	   monocytes	   of	   obese	  
patients	  TRAF6	  levels	  are	  increased	  linking	  TRAF6	  to	  metabolic	  disorders	  (Hulsman	  et	  al.,	  2012).	  
The	  protein	  levels	  of	  TRAF6,	  a	  critical	  key	  player	  in	  IL-­‐1β	  induced	  NF-­‐κB	  signaling,	  are	  increased	  
in	  adipose	  tissue	  samples	  of	  obese	  and	  type	  2	  diabetic	  mice	   in	  association	  with	  TLR4,	  MyD88	  
and	  NF-­‐κB	  upregulation	  (Creely	  et	  al.,	  2007).	  Gene	  expression	  profiles	  of	  monocytes	  of	  obese	  
subjects	  revealed	  elevated	   levels	  of	  TRAF6	  (Hulsmans	  et	  al.,	  2012).	  Further	  research	  detected	  
decreased	  expression	  of	  miR-­‐146b-­‐5p	  in	  monocytes	  during	  obesity.	  MiR-­‐146b-­‐5p	  is	  a	  microRNA	  
that	  diminishes	  the	  expression	  of	  TNFα,	  IL-­‐1β	  and	  IL-­‐6	  in	  monocytes	  by	  the	  targeted	  repression	  
of	  IRAK1	  and	  TRAF6	  (Hulsmans	  et	  al.,	  2012).	  	  
Mice	   deficient	   in	   CD40-­‐TRAF6	   signaling	   exhibit	   protection	   against	   weight	   gain	   and	   insulin	  
resistance	   in	   a	   high-­‐fat-­‐diet	   model	   (Chatzigeorgiou	   et	   al.,	   2014).	   Furthermore,	   these	   mice	  
showed	   a	   reduction	   in	   both	   adipose	   tissue	   inflammation	   and	   hepatosteatosis	   in	   diabetes-­‐
induced-­‐obesity	   (Chatzigeorgiou	  et	  al.	  2014).	  Besides,	   treatment	  of	  mice	  on	  high-­‐fat-­‐diet	  with	  
the	   small	   inhibitor	   SMI	   6860766,	   a	   CD40-­‐TRAF6	   interaction	   inhibitor,	   improves	   glucose	  
tolerance	  and	  ameliorates	  adipose	  tissue	  inflammation	  (Van	  den	  Berg	  et	  al.,	  2014).	  	  
	  
2.4	  The	  TRAF6	  -­‐	  Ubc13	  interaction	  in	  NF-­‐κB	  signaling	  
2.4.1	  The	  ubiquitin-­‐conjugating	  enzyme	  Ubc13	  
The	   Ubc13	   protein	   is	   encoded	   by	   the	   UBE2N	   gene	   located	   on	   Chromosome	   12q22	   and	  
composes	   of	   152	   amino	   acids.	   It	   is	   a	   17kDa	   E2	   ubiquitin-­‐conjugating	   enzyme	   involved	   in	   the	  
ubiquitination	  process.	   In	  order	   to	  accomplish	   its	   function	  of	   catalyzing	   the	   synthesis	  of	  K63-­‐
linked	   polyubiquitin	   chains	   it	   forms	   a	   heterodimer	   with	   the	   ubiquitin-­‐conjugating	   E2	   variant	  
Uev1a	  (McKenna	  et	  al.,	  2003).	  Uev1a	  is	  a	  UBC-­‐E2	  variant	  that	  has	  lost	  its	  catalytic	  cysteine	  but	  is	  
still	   capable	   of	   non-­‐covalently	   binding	   of	   ubiquitin	   (Eddins	   et	   al.,	   2006).	   The	   selection	   of	   the	  
appropriate	   lysine	   used	   for	   chain	   formation	   requires	   the	   recognition	   of	   a	   specific	   acceptor	  
ubiquitin	   surface	   by	   the	   E2	   donor	   ubiquitin	   complex	   (Berndsen	   and	   Wolberger,	   2014).	   To	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enable	  K63-­‐linked	  specificity,	  Ubc13	  uses	  the	  auxiliary	  subunit	  Uev1a	  (Deng	  et	  al.,	  2000).	  This	  
interaction	  places	  the	  acceptor	  ubiquitin	  in	  a	  way	  that	  the	  lysine	  63	  faces	  the	  active	  site	  of	  the	  
charged	  Ubc13.	   The	   residues	   72-­‐83	   of	   Ubc13	   are	   responsible	   for	   the	   interaction	  with	  Uev1a	  
(VanDemark	  et	  al.,	  2001).	  Proximal	  to	  this	  binding	  site,	  the	  active	  site	  cysteine	  87	  of	  Ubc13	  is	  
located	  (VanDemark	  et	  al.,	  2001).	  Together	  with	  the	  respective	  E3	  ubiquitin	  ligase,	  for	  example	  
TRAF6,	   it	  mediates	  K63-­‐linked	  ubiquitination	  of	  the	  E3	  ligase	   itself	  as	  well	  as	  of	  substrates	  for	  
signal	  progression	  (Deng	  et	  al.,	  2000).	  Ubc13	  was	  first	  described	  to	  regulate	  TNFR1	  signaling	  as	  
a	  dominant	  negative	  version	  of	  Ubc13	  blocked	  TNFα	  and	  TRAF2	  induced	  NF-­‐κB	  signaling	  (Deng	  
et	  al.,	  2000).	  Ubc13	  is	  also	  involved	  in	  TLR	  (Akira	  and	  Takeda,	  2004),	  IL-­‐1R	  signaling	  (Yin	  et	  al.,	  
2009)	   and	   in	   B-­‐cell	   and	   T-­‐cell-­‐receptor	   signaling	   (Yamamoto	   et	   al.,	   2006).	   Ubc13	   genetic	  
ablation	  studies	   revealed	   that	  homozygous	  Ubc13	  deletion	   is	  embryonic	   lethal	   (Fukushima	  et	  
al.,	  2007;	  Yamamoto	  et	  al.,	  2006).	  A	  hemizygous	  Ubc13+/-­‐	  mouse	  strain	  features	  impaired	  TRAF6	  
ubiquitination	   and	   TRAF6-­‐dependent	   LPS	   signaling	   (Fukushima	   et	   al.,	   2007).	   Conditional	  	  	  
Ubc13-­‐/-­‐	  mice	  generated	  by	  Yamamoto	  et	   al.	   showed	   impaired	  B	   cell	   development	  as	  well	   as	  
reduced	  B	   cell	   and	  bone	  marrow	  macrophage	  activation	   in	   response	   to	   LPS	  and	   IL-­‐1β	   stimuli	  
(Yamamoto	  et	  al.,	  2006).	  Ubc13	  is	  also	  required	  for	  IL-­‐1β	  induced	  but	  not	  for	  TNFα	  induced	  IKK	  
activation	  (Xu	  et	  al.,	  2009).	  Structural	  studies	  revealed	  that	  TRAF2	  and	  TRAF5,	  both	  involved	  in	  
TNFα	  signaling,	  are	  not	  capable	  of	  interacting	  with	  the	  E2	  conjugating	  enzyme	  Ubc13	  (Yin	  et	  al.,	  
2009).	  Furthermore,	  TRAF2	  and	  TRAF5	  fail	  to	  generate	  polyubiquitin	  chains	  in	  the	  presence	  of	  
several	   tested	   E2	   enzymes	   (Yin	   et	   al.,	   2009).	   However,	   cIAP1	   and	   cIAP2	   undergo	   auto-­‐
ubiquitination	  in	  the	  presence	  of	  the	  Ubc13/Uev1a	  dimer	  (Yin	  et	  al.,	  2009)	  and	  therefore	  may	  
exhibit	  the	  E3	  ubiquitin	  ligases	  critical	  for	  TNFα	  induced	  NF-­‐κB	  signaling.	  However,	  it	  might	  be	  
possible	   that	   other	   E2	   family	   members,	   such	   as	   UbcH5,	   which	   also	   mediates	   K63-­‐linked	  
polyubiquitin	   chain	   synthesis	   compensate	   for	   Ubc13	   in	   TNFα	   signaling	   (Varfolomeev	   et	   al.,	  
2008;	  Xu	  et	  al.,	  2009).	   
In	   Ubc13+/-­‐	   mice	   that	   were	   fed	   a	   high-­‐fat-­‐diet,	   lower	   levels	   of	   blood	   glucose	   were	   detected	  
while	   body	  weight	   was	   not	   significantly	   altered	   (Joo	   et	   al.,	   2013).	   Reduced	   insulin	   secretion	  
coupled	   with	   increased	   insulin	   sensitivity	   were	   obtained	   indicating	   that	   Ubc13	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2.4.2	  The	  direct	  interaction	  of	  TRAF6	  and	  Ubc13	  	  
Structural	   studies	   demonstrate	   that	   Ubc13	   is	   able	   to	   directly	   interact	   with	   TRAF6.	   The	  
Ubc13/Uev1a/TRAF6	   complex	   mediates	   TRAF6	   K63-­‐linked	   auto-­‐ubiquitination	   as	   well	   as	  
assembly	  of	  polyubiquitin	  chains	  to	  activate	  TAK1	  (Lamothe	  et	  al.,	  2007;	  Yin	  et	  al.,	  2009).	  While	  
Ubc13	  directly	   interacts	  with	   TRAF6,	  Uev1a	  provides	   the	   linkage	   specificity	   (Yin	   et	   al.,	   2009).	  
Already	  in	  2004,	  Yeast-­‐Two-­‐Hybrid	  assays	  revealed	  that	  the	  TRAF6	  RING	  domain	  interacts	  with	  
the	   E2	   complex	   through	   its	   direct	   binding	   to	   Ubc13	   (Wooff	   et	   al.,	   2004).	   In	   2009,	   Yin	   et	   al.	  
confirmed	  the	  necessity	  of	  the	  TRAF6	  RING	  domain	  for	  the	  interaction	  with	  Ubc13.	  Surprisingly,	  
gel	  filtration	  chromatography	  analysis	  of	  the	  complex	  formation	  showed	  that	  the	  RING	  domain	  
alone	  was	   not	   sufficient	   for	   Ubc13	   interaction.	   Instead,	   the	   RING	   and	   Zincfinger1	   domain	   of	  
TRAF6	  together	  mediate	  complex	  formation	  with	  Ubc13.	  However,	  the	  interaction	  involves	  only	  
direct	  contacts	  of	  the	  RING	  and	  the	  preceding	  residues	  to	  Ubc13	  while	  the	  Zincfinger1	  domain	  
plays	   a	   structural	   role	   (Yin	   et	   al.,	   2009).	   In	   this	   complex,	   several	   residues	   within	   the	   RING	  
domain	  of	  TRAF6	  form	  the	  major	  contact	  site	  with	  Ubc13:	  Q54,	  D57,	  E69,	  P21,	  I72,	  L74,	  Met75,	  
A101	  and	  P106.	  Figure	  2.9	  presents	  the	  ribbon	  diagram	  of	  the	  TRAF6-­‐Ubc13	  complex	  with	  the	  
corresponding	  residues	  for	  binding.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2.9:	  The	  interaction	  of	  TRAF6	  and	  Ubc13	  in	  crystal	  structures	  (Yin	  et	  al.,	  2009).	  (A)	  Ribbon	  diagram	  of	  the	  
TRAF6-­‐Ubc13	   complex.	   The	  RING-­‐Zincfinger1	  domain	  of	   TRAF6	  depicted	   in	  magenta	   facilitates	  binding	  of	  Ubc13	  
(orange).	  Thereby,	  the	  RING	  domain	  mediates	  direct	  contacts	  to	  Ubc13	  whereas	  the	  Zincfinger1	  (Z1)	  is	  critical	  for	  
maintaining	  the	  structure	  of	  the	  RING	  domain.	  (B)	  Detailed	  illustration	  of	  the	  residues	  mediating	  the	  direct	  contact	  
of	  TRAF6	  and	  Ubc13.	  TRAF6	  is	  shown	  in	  magenta,	  Ubc13	  in	  orange.	  (C)	  A	  dimeric	  complex	  of	  TRAF6-­‐Ubc13-­‐Uev2.	  
The	  marked	  Lys124	  residues	  of	  TRAF6	  present	  the	  auto-­‐ubiquitination	  sites.	  Active	  site	  cysteine	  residues	  of	  Ubc13	  
are	  shown	  in	  orange.	  
A B
C
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In	   cells,	   the	   interaction	   of	   TRAF6	   and	  Ubc13	   is	   critical	   for	   both	   TRAF6	   auto-­‐ubiquitination	   as	  
well	   as	   activation	  of	  NF-­‐κB	  upon	   receptor	   stimulation	   such	  as	   IL-­‐1β	   and	   LPS	   (Lamothe	  et	   al.,	  
2007;	   Lamothe	   et	   al.,	   2008).	   Retroviral	   transfection	   of	   TRAF6-­‐deficient	   MEFs	   with	   wildtype	  
TRAF6	   rescued	   auto-­‐ubiquitination	   as	   well	   as	   NF-­‐κB	   activation	   upon	   stimulation	   (Yin	   et	   al.,	  
2009).	   In	   contrast,	   TRAF6	   harboring	   mutations	   disrupting	   the	   Ubc13	   interaction	   like	   C70A,	  
D57K,	  I72D	  and	  I74H	  failed	  to	  induce	  TRAF6	  auto-­‐ubiquitination	  in	  response	  to	  IL-­‐1β	  stimulation	  
(Yin	  et	  al.,	  2009).	   Importantly,	  only	  TRAF6	  wildtype	  reconstitution	   led	  to	  the	  activation	  of	  the	  
IKK	  complex	  whereas	  the	  Ubc13-­‐binding	  mutants	  did	  not	  exhibit	  IKK	  activity	  (Yin	  et	  al.,	  2009).	  
Extended	  studies	  revealed	  that	  the	  Zincfinger	  domains	  2-­‐4	  of	  TRAF6	  are	  dispensable	  for	  TRAF6	  
auto-­‐ubiquitination	   as	   well	   as	   IKK	   activation	   and	   that	   TRAF6	   auto-­‐ubiquitination	   and	   Ubc13	  
binding	  are	  dependent	  on	  the	  Zincfinger1	  domain	  and	  an	  intact	  RING	  domain	  only	  (Lamothe	  et	  
al.,	  2008).	  These	  data	  support	  the	  crucial	  role	  of	  the	  interaction	  of	  the	  TRAF6	  RING-­‐Zincfinger1	  
(RZ1)	  domain	  and	  Ubc13	   in	  cells	  not	  only	  for	  TRAF6	  auto-­‐ubiquitination	  but	  also	  activation	  of	  
NF-­‐κB	  upon	  stimulation.	  	  
In	  Ubc13,	  TRAF6	  binds	  the	  N-­‐terminal	  helix	  including	  the	  M64	  residue	  displaying	  one	  important	  
contact	  for	  TRAF6	  binding	  as	  a	  M64A	  mutant	  did	  not	  interact	  with	  TRAF6	  in	  Yeast-­‐Two-­‐Hybrid	  
assays	  (Zheng	  et	  al.,	  2000;	  Wooff	  et	  al.,	  2004).	  Other	  residues	  involved	  in	  TRAF6	  binding	  are	  R6,	  
R7,	   K10,	   R14,	   as	  well	   as	   S96,	   P97	   and	  A98	   (Yin	   et	   al.,	   2009).	  However,	   the	   impact	   of	   TRAF6-­‐
binding	  mutants	  in	  Ubc13	  on	  NF-­‐κB	  activation	  are	  not	  analyzed,	  yet.	  
Altogether,	  the	  interaction	  of	  TRAF6-­‐Ubc13	  exhibits	  several	  unique	  features:	   i)	  the	  interaction	  
surface	  of	   around	  1000	  Å2	   is	   relatively	   small	   for	   protein-­‐protein-­‐binding,	   ii)	   residues	   that	   are	  
involved	  in	  binding	  are	  absolutely	  critical	  as	  mutating	  a	  single	  residue	  leads	  to	  the	  disruption	  of	  
the	  complex,	  iii)	  the	  majority	  of	  the	  residue	  involved	  in	  binding	  are	  exposed	  on	  the	  interaction	  
surface	  and	  are	  available	  for	  hydrophobic	  interactions,	  iv)	  the	  involved	  residues	  are	  specific	  for	  
the	  interaction	  of	  TRAF6	  and	  E2	  enzymes	  (Ubc13	  and	  UbcH5),	  v)	  the	  interaction	  is	  a	  transient	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2.5	  Protein-­‐protein-­‐interactions	  and	  the	  UPS	  in	  drug	  discovery	  	  
The	   identification	   of	   small	   molecules	   influencing	   protein	   function	   and	   the	   process	   of	  
transforming	   these	   molecules	   into	   lead	   series	   are	   main	   goals	   in	   modern	   drug	   discovery	  
(Bleicher	   et	   al.,	   2003).	   High-­‐Throughput-­‐Screening	   (HTS)	   is	   a	   screening	   of	   large	   chemical	  
libraries,	  mostly	   performed	   in	   vitro,	   to	   identify	   hits	   that	   are	   active	   against	   biological	   targets	  
using	  automation,	  miniaturized	  assays	  and	  large-­‐scale	  data	  analysis	  (Keseru	  and	  Makara,	  2006).	  	  
Up	   to	   date,	   there	   are	   3,000	   to	   10,000	   known	   disease	   modifying	   proteins	   but	   only	   a	   minor	  
portion	  of	   around	  400	  proteins	   are	  explored	   for	   therapeutic	  development	   (Overington	  et	   al.,	  
2006;	  Jin	  et	  al.,	  2013).	  The	  majority	  of	  these	  400	  protein	  targets	  fall	  into	  a	  few	  families	  including	  
G	  protein-­‐coupled	  receptors,	  nuclear	  receptors,	  ion	  channels	  or	  enzymes	  (for	  example	  kinases,	  
proteases,	   deacetylases)	   (Makley	   and	   Gestwicki,	   2013).	   Many	   of	   these	   targets	   contain	   deep	  
grooves	   that	  are	  accessible	   to	  bind	   low	  molecular	  weight	  molecules.	   In	  contrast,	   the	  modern	  
shift	   in	   HTS	   includes	   other	   types	   of	   targets	   like	   non-­‐enzymes	   that	   act	   as	   adapter	   proteins.	  
Similar	  to	  enzymes,	  these	  adapter	  molecules	  regulate	  a	  majority	  of	  the	  human	  proteome	  and	  
they	  include	  proteins	  involved	  in	  organizing	  signaling	  pathways,	  maintaining	  structural	  integrity,	  
assembly	   and	   disassembly	   of	   protein	   complexes,	   chaperon	   function,	   subcellular	   transport,	  
transcription,	  translation	  and	  other	  critical	   functions	  (Makley	  and	  Gestwicki,	  2013).	   Instead	  of	  
using	  enzymatic	  activity	   to	   carry	  out	   their	  biological	   functions,	  most	  adapter	  proteins	   involve	  
either	   transient	   or	   stable	   protein-­‐protein	   interactions	   (PPIs).	   PPIs	   mediate	   critical	   regulatory	  
events	   in	   physiology	   and	   pathology	   and	   therefore	   may	   represent	   important	   targets	   for	  
pharmaceutical	   intervention.	   Targeting	   PPIs	  with	   small	  molecules	   faces	   two	  main	   challenges.	  
First,	  PPI	  usually	   involves	  a	   large	  number	  of	  polar	  and	  hydrophobic	   interactions	  across	  a	   large	  
interface	   of	   1,500	   -­‐	   3,000	   Å2.	   Second,	   the	   interaction	   interfaces	   are	   usually	   planar	   and	   lack	  
binding	   pockets	   (Jin	   et	   al.,	   2014).	   However,	   within	   the	   interface	   region	   not	   all	   residues	   are	  
equally	  important	  and	  it	  is	  possible	  to	  define	  hotspots.	  Hotspots	  are	  a	  small	  subset	  of	  residues	  
of	  a	  binding	  interface	  that	  are	  critical	  for	  the	  interaction.	  Furthermore,	  PPIs	  can	  be	  divided	  into	  
permanent	   and	   transient	   interactions.	   Transient	   interactions	   are	   easier	   to	   target	   than	  
permanent	  interactions	  (Villoutreix	  et	  al.,	  2014).	  	  
The	  ubiquitin	   system	  plays	   an	   important	   role	   in	   the	   regulation	  of	  most	   cellular	   pathways.	   Its	  
deregulation	   has	   been	   implicated	   in	   a	   wide	   range	   of	   human	   diseases	   including	   cancer,	  
neurodegenerative	  and	  immunological	  disorders	  as	  well	  as	  viral	  infections.	  Therefore,	  targeting	  
the	  UPS	  by	  small	  molecules	  provides	  an	  opportunity	   for	   the	  development	  of	   therapeutics	   for	  
the	  treatment	  of	  several	  diseases.	  Due	  to	  the	  complexity	  of	  the	  ubiquitination	  reaction	  and	  its	  
outcome,	  inhibitors	  targeting	  the	  UPS	  are	  rather	  underexplored.	  However,	  significant	  advances	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in	  understanding	   the	  molecular	  nature	  of	   the	  ubiquitination	  process	  and	   its	   regulation	  of	   the	  
cellular	   signals	  have	  been	  made.	  Also,	   improvement	  of	   screening	  methods	  already	   led	   to	   the	  
discovery	  of	   the	   first	   compounds	   targeting	   the	   components	  of	   the	  UPS	  and	  promises	   further	  
success.	   In	   2003,	   the	   FDA	   approved	   the	   proteasome	   inhibitor	   Bortezomib	   for	   treatment	   of	  
hematologic	  malignancies	  and	  thereby	  became	  the	  first	  drug	  targeting	  the	  UPS	  in	  clinics	  (Kane	  
et	   al.,	   2003).	   Upstream	   from	   the	   proteasome,	   the	   UPS	   provides	  many	   additional	   targets	   for	  
small	  molecules	  such	  as	  E3	  ubiquitin	   ligases.	   In	  contrast	   to	  proteasome,	  E1	  and	  E2	   inhibitors,	  
targeting	  E3	   ligases	  might	   specifically	   impair	  only	  a	   limited	  set	  of	   substrates	  and	  might	  cause	  
fewer	  toxic	  side	  effects.	  Examples	  for	  targeting	  E3	  ligase-­‐protein	  interactions	  within	  the	  UPS	  are	  
small	  molecule	   inhibitors	   of	   the	  MDM2-­‐p53	   PPI.	   Development	   of	   these	   compounds	   aims	   for	  
their	   administration	   in	   cancer	   therapy	   to	   reactivate	   the	   p53	   tumor	   suppressor	   function.	  
Different	  strategies	  succeeded	  in	  targeting	  this	  interaction.	  The	  MDM2	  inhibitor	  nutlin	  interacts	  
with	   the	   p53-­‐binding	   pocket	   to	   inhibit	   p53	   degradation	   whereas	   the	   small	   molecule	   RITA	  
directly	  binds	  p53	  to	  interfere	  with	  the	  p53/MDM2	  interaction	  (Vassilev	  et	  al.,	  2004;	  Issaeva	  et	  
al.,	  2004).	  RG7112,	  a	  derivate	  of	  nutlin,	   is	  currently	  undergoing	  phase	   I	  clinical	   trials	   (Khoo	  et	  
al.,	  2014).	  Further	  examples	  for	  interfering	  with	  PPIs	  are	  IAP	  (inhibitor	  of	  apoptosis)	  inhibitors.	  
IAPs	  are	  usually	   targeted	  by	   Smac,	   a	  mitochondrial	   protein	  and	  negative	   regulator	  of	   IAPs.	   It	  
enhances	   apoptosis	   by	   binding	   to	   IAPs	   to	   prevent	   their	   interaction	   with	   caspases.	   The	  
observation	  that	  a	  short	  IAP-­‐binding	  motif	  (IBM)	  of	  smac	  binds	  IAPs	  and	  blocks	  the	  interaction	  
of	   IAPs	   and	   caspases	   led	   to	   the	   development	   of	   small	   molecules	   that	   target	   this	   IBM	   of	  
numerous	   IAPs	   including	   XIAP,	   cIAP1	   and	   cIAP2	   (Gyrd-­‐Hansen	   and	   Meier,	   2010).	   These	  
compounds	   induce	  degradation	  of	   IAPs	  and	   lead	  to	  caspase	  activation	  resulting	   in	  a	  decrease	  
viability	  of	  cancer	  cells.	  The	  first	  compound	  targeting	  this	  class	  of	  proteins	  is	  GDC-­‐0152	  and	  is	  
currently	  tested	  in	  clinical	  trials	  (Flygare	  et	  al.,	  2012).	  
However,	  no	  small	  molecules	  targeting	  the	  interface	  of	  an	  E3	  ligase	  -­‐	  E2	  enzyme	  are	  known	  yet.	  
Due	  to	  the	  unique	  features	  of	  the	  binding	  of	  TRAF6	  to	  Ubc13	  (described	  in	  2.4.2)	  this	  protein-­‐
protein	   interaction	   is	   considered	   to	   be	   druggable.	   Small	   molecules	   targeting	   this	   interface	  
would	  not	  only	  abrogate	  the	  interaction	  of	  TRAF	  and	  Ubc13,	  but	  would	  also	  cause	  inhibition	  of	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3	  Aim	  of	  this	  thesis	  
The	   E3	   ubiquitin	   ligase	   TRAF6	   is	   a	   critical	   contributor	   to	  NF-­‐κB	   signaling.	   It	   is	  well	   known	   to	  
regulate	  pathways	  in	  innate	  as	  well	  as	  in	  adaptive	  immune	  response.	  Elevated	  levels	  of	  NF-­‐κB	  
and	   TRAF6	   cause	   a	   variety	   of	   diseases	   including	   autoimmune	   diseases,	   carcinomas	   and	  
metabolic	   disorders.	   Therefore,	   targeting	   TRAF6	   offers	   a	   potential	   novel	   strategy	   for	  
therapeutic	   intervention	   of	  multiple	   diseases.	   In	   TRAF6-­‐dependent	   signaling,	   TRAF6	   interacts	  
with	   the	   E2	   complex	   Ubc13/Uev1a	   to	   facilitate	   its	   auto-­‐ubiquitination	   and	   subsequent	   K63-­‐
linked	   polyubiquitination	   of	   substrates	   to	   mediate	   signal	   transduction	   towards	   NF-­‐κB	  
activation.	  The	  N-­‐terminal	  RING-­‐Zincfinger1	  domain	  of	  TRAF6	  is	  responsible	  for	  Ubc13	  binding	  
and	   was	   therefore	   selected	   to	   be	   targeted	   by	   small	   molecules.	   The	   aim	   was	   to	   establish	   a	  
suitable	  a	  High-­‐Throughput-­‐Screening	  assay	  and	  to	  perform	  the	  HTS	  campaign.	  Hits	  have	  to	  be	  
validated	  and	  optimized	  in	  vitro	  as	  well	  as	  in	  cell-­‐based	  assays.	  After	  analog	  screening,	  the	  anti-­‐
inflammatory	   potency	   of	   the	   best	   hit	   should	   be	   analyzed	   in	   a	   high-­‐fat-­‐diet	   induced	   obesity	  
mouse	  model	   that	   is	  marked	   by	   glucose	   intolerance	   and	   low-­‐grade	   chronic	   inflammation.	   In	  
2014,	   a	   TRAF6	   inhibitor	   targeting	   the	   MATH	   domain	   of	   TRAF6	   was	   shown	   to	   improve	   the	  
chronic	   inflammation	   and	   glucose	   tolerance	   in	   an	   obese	  mouse	  model	   (Van	   den	   Berg	   et	   al.,	  
2014).	  This	  should	  enable	  comparison	  of	  the	  efficiency	  of	  the	  best	  compound	  identified	  in	  this	  
work	   in	  ameliorating	  the	  symptoms	  as	  well	  as	  the	  effects	  of	  targeting	  the	  different	  termini	  of	  
TRAF6.	  	  




4.1	  Establishment	  of	  a	  TRAF6-­‐Ubc13	  interaction	  assay	  for	  High-­‐Throughput-­‐Screening	  
4.1.1	  Biochemical	  validation	  of	  the	  TRAF6-­‐Ubc13	  interaction	  
For	  the	  identification	  of	  small	  molecules	  targeting	  the	  RING-­‐Zincfinger1	  (RZ1)	  domain	  of	  TRAF6	  
to	   prevent	   its	   binding	   to	   Ubc13	   as	   well	   as	   its	   auto-­‐ubiquitination,	   a	   suitable	   in	   vitro	   High-­‐
Throughput-­‐Screening	   (HTS)	   setting	   had	   to	   be	   established.	   It	   is	   proposed	   that	   only	   the	   N-­‐
terminal	  RZ1	  domain	  of	  TRAF6	  directly	  interacts	  with	  Ubc13	  (Wooff	  et	  al.,	  2004;	  Yin	  et	  al.,	  2009;	  
Lamothe	  et	  al.,	  2008).	  To	  confirm	  these	  data,	  a	  Yeast-­‐Two-­‐Hybrid	  assay	  was	  performed	  before	  
starting	  the	  purification	  of	  recombinant	  proteins.	  First,	  selected	  TRAF6	  constructs	  were	  cloned	  
into	  the	  pGAD	  vector	   fusing	  TRAF6	  to	  the	  activation	  domain	  of	   the	  transcription	  factor	  GAL4.	  
Ubc13	  fulllength	  was	  cloned	  into	  the	  pGBD	  vector	  marking	  it	  with	  the	  DNA	  binding	  domain	  of	  
GAL4.	  Growth	  of	   the	   transformed	  yeast	   strain	  on	  a	   selective	  medium	   lacking	  histidine	   is	  only	  
obtained	  after	  the	  reconstitution	  of	  a	  functional	  transcription	  factor	  GAL4	  upon	  interaction	  of	  
TRAF6	   and	  Ubc13.	   The	   binding	   of	   fulllength	   TRAF6	   to	  Ubc13	   could	   be	   confirmed	  with	   a	   fast	  
growing	   yeast	   spot	   (Fig.	   4.1).	   Also,	   yeast	   colonies	  were	   obtained	   after	   transformation	   of	   the	  
TRAF6	  RZ1	  domain	  and	  Ubc13.	  In	  contrast,	  yeast	  colonies	  carrying	  single	  point	  mutations	  in	  the	  
Ubc13	   binding	  motif	   (C70A,	   D57K	   or	   I72F)	   within	   the	   TRAF6	   RZ1	   domain	   did	   not	   survive	   on	  
selective	  medium.	  In	  agreement	  with	  these	  findings,	  yeast	  transformed	  with	  TRAF6	  constructs	  
missing	  the	  RZ1	  domain	  but	  containing	  the	  Coiled-­‐Coil	  or	  Coiled-­‐Coil	  and	  MATH	  domain	  did	  not	  
grow	  on	  the	  selection	  medium	  either	  (Fig.	  4.1).	  
	  



























Figure	   4.1:	   Confirmation	   of	   TRAF6	   binding	   to	  
Ubc13	   via	   the	   N-­‐terminal	   RING-­‐Zincfinger1	  
domain.	   In	   a	   Yeast-­‐Two-­‐Hybrid	   assay	   only	   TRAF6	  
fulllength	   and	   the	   TRAF6	  RING-­‐Zincfinger1	  domain	  
interact	   with	   Ubc13.	   Ubc13-­‐binding	   mutations	  
(C70A,	   D57K	   and	   I72F)	   or	   lack	   of	   the	   RING-­‐
Zincfinger1	   domain	   do	   not	   lead	   to	   yeast	   cell	  
growth.	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After	  confirming	  that	  only	  the	  RZ1	  domain	  of	  TRAF6	  is	  required	  for	  Ubc13	  binding,	  the	  TRAF6	  
RZ1	  wildtype	  as	  well	  as	  the	  single	  point	  mutations	  (C70A,	  D57K	  and	  I72F)	  were	  cloned	  into	  the	  
pASK-­‐IBA-­‐3+	  vector	  fusing	  the	  protein	  to	  a	  C-­‐terminal	  StrepII-­‐tag	  (TRAF6StrepII).	  Ubc13	  and	  a	  C-­‐
terminal	   Flag-­‐His-­‐tag	   were	   cloned	   into	   the	   pGex-­‐4T1	   vector	   (Ubc13FH).	   The	   Coomassie	   Blue	  
staining	  of	  the	  purified	  proteins	   is	  shown	   in	  Figure	  4.2A	  and	  revealed	  clean	  protein	  solutions.	  
Before	   establishing	   an	   in	   vitro	   HTS	   assay	   with	   these	   proteins,	   a	   gel-­‐filtration	   assay	   was	  
performed	   with	   equimolar	   concentrations	   of	   TRAF6	   and	   Ubc13	   to	   confirm	   binding	   of	   the	  
purified	   proteins.	   Incubating	   both	   proteins	   caused	   a	   peak	   shift	   clearly	   indicating,	   that	  





4.1.2	  Establishment	  of	  the	  ALPHAScreen	  TRAF6-­‐Ubc13	  binding	  assay	  for	  HTS	  
For	   establishing	   a	   suitable	   in	   vitro	   HTS	   system	   the	   ALPHAScreen	   system	   (Amplified	  
Luminescence	   Proximity	   Homogeneous	   Assay)	   provided	   by	   Perkin	   Elmer	   was	   used.	   For	   the	  
establishment	   of	   a	   functional	   ALPHAScreen	   system	   Strep-­‐Tactin	   Donor	   beads	   binding	   to	  
TRAF6StrepII	   and	   Nickel	   Chelate	   Acceptor	   beads	   targeting	   Ubc13FH	   were	   applied	   to	   the	  
reaction	   mix.	   The	   first	   step	   in	   establishing	   this	   assay	   was	   to	   determine	   optimal	   protein	  
concentrations.	   Cross-­‐titrations	   of	   TRAF6WTStrepII-­‐Ubc13FH	   and	   TRAF6C70AStrepII-­‐Ubc13FH	   to	  
define	   the	   best	   conditions	   for	   a	   suitable	   screening	   were	   performed	   (Fig.	   4.3A	   and	   data	   not	  
shown).	  The	  optimal	  protein	  amounts	  were	   set	   to	  a	   concentration	   that	   still	  was	   in	   the	   linear	  
range	  but	  also	  provided	  feasible	  production	  of	  protein	  amounts.	  Accordingly,	  the	  ideal	  protein	  
concentration	   of	   TRAF6StrepII	   was	   100nM,	   whereas	   for	   Ubc13FH	   75nM	   was	   assessed	   (Fig.	  






















































B Figure	   4.2:	   Proof	   of	  
purity	   and	   activity	   of	  
recombinant	   purified	  
proteins.	   (A)	  
Recombinant	   purified	  
proteins	   appear	   clean	   in	  
a	   Coomassie	   Blue	  
staining.	   (B)	  
Recombinantly	   purified	  
TRAF6WTStrepII	   and	  
Ubc13FH	   proteins	  
directly	   interact	   in	  a	  gel-­‐
filtration	  assay.	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remained	   in	  the	  upper	  range	  of	  the	   linear	  scale,	  whereas	  the	  TRAF6C70AStrepII-­‐Ubc13FH	  assay	  
exhibited	  only	  background	  signals	   (Fig.	  4.3A).	  Next,	  the	  amount	  of	  Donor	  and	  Acceptor	  beads	  
was	  titrated	  to	  yield	  a	  high	  ratio	  of	  TRAF6WT	  to	  TRAF6mutant.	  Out	  of	  7	  tested	  concentrations	  (20	  -­‐	  
2µg/mL)	  4µg/mL	  beads	  still	  revealed	  a	  ratio	  of	  TRAF6WT	  to	  TRAF6mutant	  with	  more	  than	  100	  fold	  
induction	  (Fig.	  4.3B)	  and	  therefore	  was	  determined	  to	  be	  sufficient	  for	  the	  screening	  assay.	  In	  a	  
mutant	   screen	  with	   the	   screening	   conditions	   defined	   thus	   far,	   TRAF6D57KStrepII	  was	   the	   best	  
control	   mutant	   with	   a	   193	   fold	   ratio	   compared	   to	   the	   wildtype	   TRAF6WTStrepII	   (Fig.	   4.3C).	  
Hence,	  the	  TRAF6D57KStrepII	  protein	  was	  selected	  as	  a	  reference	  for	  the	  intensity	  of	  maximum	  
inhibition	   during	   screening	   procedure.	   Including	   the	   TRAF6D57KStrepII	   mutant	   in	   every	  
performed	  screen	  was	  necessary	  to	  determine	  the	  highest	  level	  of	  inhibition	  as	  the	  signal	  units	  
did	  vary	  from	  assay	  to	  assay	  depending	  on	  the	  efficacy	  of	  the	  bead	  batches	  (Figures	  4.3A	  and	  
4.3B).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  4.3:	  Benchtop	  establishment	  of	   the	  ALPHAScreen	  assay.	  (A)	  Cross-­‐titrations	  of	  protein	  amounts	  revealed	  
100nM	  TRAF6StrepII	  and	  75nM	  Ubc13FH	  as	  the	  optimal	  protein	  concentration	  combination.	  (B)	  Cross-­‐titrations	  of	  
bead	  amounts	  illustrated	  4µg/mL	  of	  Donor	  and	  Acceptor	  beads	  as	  the	  most	  reasonable	  concentration.	  (C)	  TRAF6	  
mutant	  screen	  highlighted	  TRAF6D57K	  as	  the	  best	  mutant.	  Mean	  and	  standard	  deviation	  are	  depicted.	  	  
	  
For	   the	   final	   settings	   presented	   in	   Figure	   4.4A,	   all	   conditions	  were	   tested	   in	   the	   presence	  of	  
0.5%	   DMSO	   that	   was	   used	   for	   dissolving	   the	   compounds.	   TRAF6WTStrepII	   and	   Ubc13FH	  
incubated	  with	   Donor	   and	   Acceptor	   beads	   featured	   high	   signal	   units,	  which	  were	   abrogated	  
A
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when	   replacing	   TRAF6WT	   by	   the	   TRAF6	   D57Kmutant	   (Fig.	   4.4A).	   Background	   signals	   were	   also	  
obtained	   in	   the	   absence	   of	   one	   of	   the	   two	  beads	   as	  well	   as	   beads	  without	   any	   protein	   (Fig.	  
4.4A).	  This	  confirmed	  that	  the	   interaction	  of	  TRAF6WTStrepII	  and	  Ubc13FH	  is	  highly	  specific	  as	  
well	  as	  direct	  and	   that	   the	   requirements	   for	  converting	   this	  benchtop	  assay	   in	  an	  automated	  
HTS	  assay	  are	  met.	  
	  
	  
Figure	   4.4:	   Converting	   the	   ALPHAScreen	   method	   from	   a	   benchtop	   into	   an	   automated	   assay.	   (A)	   Established	  
ALPHAScreen	   conditions	   for	   benchtop	   use	   including	   all	   controls	   confirm	   a	   specific	   assay	   for	   High-­‐Throughput-­‐
Screening.	   (B)	   Calculated	   statistical	   computations	   of	   an	   inter-­‐plate	   test	   in	   automated	   ALPHAScreen	   settings	  
revealing	  excellent	  assay	  conditions	  for	  High-­‐Throughput-­‐Screening.	  Mean	  and	  standard	  deviation	  are	  depicted.	  	  
	  
For	  the	  automation	  of	  the	  ALPHAScreen	  assay	  both	  protein	  solutions	  as	  well	  as	  the	  beads	  were	  
pipetted	   automatically.	   To	   imitate	   compound	   transfer,	   DMSO	   was	   applied	   to	   the	   solutions	  
automatically	  as	  well.	   In	  Figure	  4.4B,	  results	  of	  an	  inter-­‐plate	  test	  of	  an	  automated	  screen	  are	  
listed.	   In	   order	   to	   determine	   the	   quality,	   several	   statistical	   parameters	   were	   calculated:	   the	  
average	   of	   the	   positive	   and	   negative	   controls	   as	   well	   the	   standard	   deviations	   (StDEV),	  
coefficient	  of	  variation	  (CV),	  the	  Z´	  factor	  and	  the	  signal	  window	  (SW)	  (for	  a	  detailed	  description	  
of	  the	  parameters	  see	  7.2.3.10).	  All	  CV	  values	  for	  the	  positive	  as	  well	  as	  the	  negative	  controls	  
did	  not	   exceed	  20%	  and	   therefore	   referred	   to	   an	  optimal	   assay	   (Fig.	   4.4B).	   The	   calculated	   Z´	  
factors	  reaching	  from	  0.72	  to	  0.84	  displayed	  values	  for	  an	  excellent	  assay	  (Zhang	  et	  al.,	  1999).	  
Furthermore,	   all	   plates	  met	   the	   criterion	  of	   a	   recommended	  SW	  higher	   than	  2.	   The	   required	  
acceptance	  criteria	  of	  CV	  <	  20%,	  Z´	  factor	  >	  0.5	  and	  SW	  >	  2	  (Iversen	  et	  al.,	  2012)	  plus	  the	  DMSO	  
compatibility	  were	  all	  met	  and	  therefore,	  the	  established	  ALPHAScreen	  assay	  settings	  qualified	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4.2	  HTS,	  Hit	  identification	  and	  Hit	  verification	  	  
4.2.1	  HTS	  –	  Hit	  identification	  
For	  the	  identification	  of	  small	  molecules	  impairing	  the	  TRAF6-­‐Ubc13	  interaction,	  three	  in-­‐house	  
chemical	   diverse	   libraries	   were	   available:	   ChemDIV	   (10,000	   compounds),	   Enamine	   (10,000	  
compounds)	   and	   ChemBridge	   (5,000	   compounds).	   In	   the	   screening	   process	   each	   compound	  
was	  screened	  with	  a	   final	  concentration	  of	  10µM.	  All	  80	  screening	  plates	  met	   the	  criteria	   for	  
the	   Z´	   factor	   (between	   0.5	   and	   0.9;	   data	   not	   showns).	   For	   the	   CV,	   only	   7	   out	   of	   80	   plates	  
showed	  a	  value	  slightly	  higher	  than	  20%	  whereas	  73	  plates	  met	  the	  criteria	  for	  CV	  <	  20%	  (data	  
not	  shown).	  The	  results	  for	  all	  three	  library	  screenings	  are	  summarized	  in	  Figure	  4.5A.	  In	  dark	  
grey	   compounds	   not	   affecting	   the	   TRAF6-­‐Ubc13	   interaction	   in	   this	   ALPHAScreen	   assay	   are	  
displayed.	   Small	   molecules	   interfering	   with	   the	   ALPHAScreen	   technology	   are	   shown	   in	   light	  
grey.	  Compounds	  specifically	  inhibiting	  TRAF6-­‐Ubc13	  binding	  are	  presented	  in	  red.	  Figure	  4.5B	  
presents	  the	  scheme	  of	  selecting	  hit	  compounds	  out	  of	  the	  performed	  HTS.	  In	  total	  520	  out	  of	  
25,000	  tested	  compounds	  showed	  an	  inhibition	  of	  TRAF6-­‐Ubc13	  binding	  with	  more	  than	  25%	  at	  
10µM	   compound	   concentration.	   This	   corresponds	   to	   a	   primary	   hit	   rate	   of	   2.08%.	   These	   520	  
compounds	  were	  analyzed	  being	  for	  frequent	  hitters.	  Frequent	  hitters	  are	  compounds	  acting	  by	  
non-­‐specific	  mechanisms	  and	  either	   interfere	  with	  the	  ALPHAScreen	  chemistry	  or	  prevent	  the	  
binding	  of	  Nickel	  Chelate	  beads	  to	  the	  His-­‐tag	  moiety	  of	  the	  proteins	  (Schorpp	  et	  al.,	  2014).	  In	  
parallel	  with	   the	  TRAF6-­‐Ubc13	  screen,	  3	  additional	  HTS	  campaigns	  were	  performed	  using	   the	  
ALPHAScreen	  technology	  as	  well	  but	  involving	  different	  tag-­‐combinations	  (GST-­‐His,	  His-­‐Myc	  and	  
Biotin-­‐His).	   Several	   compounds	   appeared	   to	   inhibit	   all	   analyzed	   protein-­‐protein	   interactions	  
and	   were	   identified	   as	   frequent	   hitters	   (Schorpp	   et	   al.,	   2014).	   Altogether	   137	   compounds	  
referred	  to	  frequent	  hitters	  at	  a	  10µM	  concentration	  and	  therefore	  were	  eliminated	  from	  the	  
hit	  list.	  Furthermore,	  in	  parallel	  with	  the	  TRAF6-­‐Ubc13	  screen	  another	  HTS	  campaign	  involving	  
GST-­‐OTUB1-­‐Ubc13FH	  was	  conducted.	  OTUB1	  is	  a	  deubiquinating	  enzyme	  targeting	  an	  interface	  
of	  Ubc13	  that	  overlapps	  with	  the	  TRAF6	  binding	  site	  (Wiener	  et	  al.,	  2012).	  In	  order	  to	  identify	  
compounds	  specifically	   targeting	  TRAF6	  rather	   than	  Ubc13,	   the	  screenings	  of	  TRAF6WTStrepII-­‐
Ubc13FH	  and	  GST-­‐OTUB1-­‐Ubc13FH	  were	  compared	  for	  compounds	  impairing	  both	  interactions	  
at	   a	   concentration	   of	   10µM.	   In	   the	   end,	   205	   small	   molecules	   hitting	   both	   assay	   had	   to	   be	  
eliminated	  referring	  to	  178	  compounds	  remaining	  for	  hit	  picking	  (Fig.	  4.5B).	  This	  led	  to	  a	  hit	  rate	  
of	   0,712%	   out	   of	   25,000	   screened	   compounds	   that	   specifically	   inhibit	   the	   TRAF6-­‐Ubc13	  
interaction	  and	  thereby	  most	  likely	  target	  TRAF6.	  	  
Summarizing	  the	  HTS	  campaign,	  out	  of	  25,000	  compounds	  178	  hit	  molecules	  were	  obtain	  after	  
exclusion	  of	  frequent	  hitters	  and	  small	  molecules	  most	  likely	  targeting	  Ubc13FH.	  




Figure	  4.5:	  High-­‐Throughput-­‐Screening	  campaign	  and	  subsequent	  hit	  verification.	  (A)	  Overview	  of	  the	  activity	  of	  
compounds	   of	   three	   in-­‐house	   small	   molecule	   libraries.	   In	   red,	   all	   specific	   hits	   are	   displayed.	   Specific	   hits	   are	  
classified	  as	  molecules	  that	  do	  not	  interfere	  with	  the	  ALPHAScreen	  technology	  (frequent	  hitters	  and	  His	  frequent	  
hitters	   are	   excluded)	   and	   do	   not	   target	   Ubc13.	   (B)	   Scheme	   for	   selecting	   compounds	   including	   the	   compound	  
numbers	  as	  well	  as	  the	  conditions	  for	  exclusion.	  (C)	  Summary	  of	  biochemical	  hit	  verification	  assay	  of	  178	  primary	  
hit	   compounds	   and	   exemplary	   data	   for	   each	   type	   of	   possible	   effects.	   The	  majority	   of	   the	   retested	   compounds	  
show	  no	  effect	  (53236510).	  34	  compounds	  demonstrate	  a	  specific	  serial	  dilution	  effect	  with	  either	  strong	  (Z087-­‐
0166)	  or	  weak	  (G827-­‐0171)	  inhibitory	  potential.	  Mean	  and	  standard	  deviation	  are	  shown.	  	  
	  
4.2.2	  HTS	  –	  Hit	  verification	  
Next,	  a	  hit	  picking	  campaign	  was	  completed	  to	  verify	  the	  178	  small	  molecules	  out	  of	  the	  HTS	  
campaign	  for	  specific	  and	  dose-­‐dependent	  effects.	  Therefore,	   five-­‐point	  serial	  dilutions	  of	  the	  
178	   small	   molecules	   ranging	   from	   2.5µM	   to	   40µM	   final	   compound	   concentration	   were	  
prepared.	  These	  dilutions	  were	  applied	  to	  the	  TRAF6WTStrepII-­‐Ubc13FH	  ALPHAScreen	  assay	  and	  
in	  parallel	   to	   the	  GST-­‐OTUB1-­‐Ubc13FH	  ALPHAScreen	  assay.	   In	   Figure	  4.5C,	   a	   summary	  of	   the	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results	   is	   illustrated.	  All	   in	   all,	   144	   compounds	  did	  not	   show	   inhibitory	  effects	   in	  both	   tested	  
assays	   implying	   their	   false	  positive	  nature	   in	   the	   initial	  HTS	   campaign.	  One	  example	   for	   false	  
positive	   hits	   (compound	   53236510)	   is	   displayed	   in	   the	   first	   diagram	   of	   Figure	   4.5C.	   34	  
compounds	   demonstrated	   inhibitory	   serial	   dilution	   effects	   on	   TRAF6WTStrepII-­‐Ubc13FH	  
interaction,	   but	   at	   the	   same	   time	   did	   not	   affect	   the	   binding	   of	   GST-­‐OTUB1	   to	   Ubc13FH	   in	  
ALPHAScreen	   assay.	   However,	   not	   all	   compounds	   reached	   an	   IC50	   value	   below	   40µM	   (Figure	  
4.6A).	  Exemplary,	  the	  second	  and	  the	  third	  diagram	  in	  Figure	  4.5C	  present	  two	  out	  of	  these	  34	  
compounds	  with	  a	  strong	  (Z087-­‐0166)	  or	  a	  moderate	  (G827-­‐0171)	  inhibitory	  effect.	  	  
The	  results	  obtained	  from	  the	  HTS	  campaign	  and	  the	  hit	  verification	  demonstrate	  that	  34	  out	  of	  
25,000	   small	   molecules	   exhibited	   a	   specific	   and	   dose-­‐dependent	   inhibition	   of	   the	  
TRAF6WTStrepII-­‐Ubc13FH	  interaction.	  	  
	  
4.3	  Biochemical	  and	  cell-­‐based	  Hit	  validation	  
In	  order	  to	  validate	  the	  34	  verified	  hits,	  all	  compounds	  were	  reordered	  from	  the	  corresponding	  
companies.	  Unfortunately,	  only	  27	  compounds	  were	  available	  by	  that	  time.	  Thus,	  biochemical	  
as	  well	  as	   cell-­‐based	  assays	  were	  performed	  with	   the	  27	   reordered	  compound	   to	  verify	   their	  
inhibitory	  potential.	  	  
	  
4.3.1	  Biochemical	  hit	  validation	  
In	   order	   to	   prove	   the	   specificity	   of	   the	   27	   selected	   compounds	   in	   binding	   to	   TRAF6,	  
ALPHAScreen	  assays	   including	  the	  protein-­‐protein	   interactions	  of	  TRAF6StrepII-­‐Ubc13FH,	  GST-­‐
OTUB1-­‐Ubc13FH	  and	  GST-­‐RNF8-­‐Ubc13FH	  were	  conducted	  in	  parallel.	  RNF8	  (RING	  finger	  8)	  is	  an	  
E3	   ubiquitin	   ligase	   carrying	   a	   RING-­‐motif	   responsible	   for	   the	   interaction	   to	   Ubc13	   and	   is	  
involved	   in	  DNA	  damage	   response	   (Campbell	   et	   al.,	   2012).	   Since	   the	  RING	  domains	  of	  TRAF6	  
and	   RNF8	   display	   a	   significantly	   structural	   similarity	   (supplement	   10.11),	   this	   interaction	  was	  
included	   in	   the	   hit	   validation	   process	   to	   exclude	   general	   RING	   domain	   binding	   compounds.	  
Serial	  dilution	  experiments	  were	  performed	  assaying	  all	  three	  different	  ALPHAScreen	  assays	  in	  
parallel.	  Out	  of	  the	  27	  reordered	  small	  molecules	  only	  compound	  20	  did	  not	  affect	  TRAF6Strep-­‐
Ubc13FH	   binding	   (Figure	   4.6A	   and	   B).	   All	   other	   molecules	   showed	   reduced	   TRAF6-­‐Ubc13	  
interaction.	   In	   total,	  13	  out	  of	  27	  compounds	  showed	  strong	  effects	   (IC50	  <	  10µM)	  on	  TRAF6-­‐
Ubc13	  binding	  while	  not	  impairing	  either	  OTUB1-­‐Ubc13	  or	  RNF8-­‐Ubc13	  interaction.	  Exemplary,	  
compound	   18	   is	   shown	   in	   Figure	   4.6B.	   Graphs	   of	   all	   27	   compounds	   are	   shown	   in	   the	  
supplement	   10.1-­‐4.	   In	   a	   range	   of	   an	   IC50	   between	   11µM	   and	   50µM	   eight	   small	   molecules	  
inhibited	  the	  binding	  of	  TRAF6	  to	  Ubc13	  but	  at	  the	  same	  time	  did	  not	  affect	  OTUB1-­‐Ubc13	  or	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RNF8-­‐Ubc13	  interaction.	  Finally,	  five	  compounds	  only	  had	  little	  effects	  on	  TRAF6-­‐Ubc13	  binding	  
(IC50	   from	   51	   to	   100µM).	   In	   some	   cases	   IC50	   values	   of	   the	   primary	   hit	   compounds	   and	   the	  
reordered	  compounds	  differed	  pointing	  out	  the	  batch-­‐to-­‐batch	  variability	  (Figure	  4.6A).	  Hence,	  
in	   biochemical	   hit	   validation	   experiments,	   only	   one	   compound	   (C20)	   did	   not	   display	   an	  
inhibitory	   potential.	   All	   other	   compounds	   still	   revealed	   specific	   impairment	   of	   TRAF6-­‐Ubc13	  
binding	  without	  affecting	  OTUB1-­‐Ubc13	  or	  RNF8-­‐Ubc13	  interaction.	  	  
	  
	  
Figure	  4.6:	  Biochemical	  hit	  validation	  of	  27	  reordered	  compounds	  using	  the	  ALPHAScreen	  system.	  (A)	  Summary	  
of	   the	  analyzed	  hit	  compounds	   in	  ALPHAscreen	  assays	   in	   the	  High-­‐Throughput-­‐Screening,	  hit	  verification	  and	  hit	  
validation	  experiments	  with	  reordered	  compounds.	  Except	  compound	  20,	  all	  compounds	  specifically	  reduced	  the	  
interaction	   of	   TRAF6-­‐Ubc13.	   (B)	   Exemplary	   data	   of	   two	   reordered	   compounds	   in	   titration	   assays	   in	   the	   hit	  
validation	  process.	  Compound	  18	  impairs	  TRAF6-­‐Ubc13	  binding	  specifically	  whereas	  compound	  20	  does	  not.	  Mean	  
and	  standard	  deviation	  are	  depicted.	  	  
	  
4.3.2	  Cell-­‐based	  hit	  validation	  
For	   accomplishing	   the	   validation	   of	   the	   27	   hits	   in	   cells,	   cell	   toxicity	   of	   each	   compound	   was	  
analyzed	  in	  a	  CellTiter-­‐Blue	  viability	  assay	  which	  is	  a	  homogeneous	  and	  fluorometric	  method	  to	  
estimate	  the	  number	  of	  viable	  cells	  in	  a	  multiwell	  plate	  format.	  This	  approach	  is	  based	  on	  the	  
ability	   of	   living	   cells	   to	   convert	   the	   redox	   dye	   resazurin	   into	   resofurin,	   a	   fluorescent	   end	  
product.	  The	  fluorescence	  signal	  is	  proportional	  to	  the	  number	  of	  viable	  cells.	  The	  compounds	  
were	   applied	   to	   human	   hepatoma	   cells	   (HepG2)	   and	   to	  mouse	   embryonic	   fibroblasts	   (MEF).	  






























1 4 <	  2,5 0,25 >100
2 6 20,91 19,37
3 6 23,38 0,94
4 10 30,11 15,46
5 12 32,13 9,73
6 13 32,42 41,66
7 14 >	  40 48,43
8 20 39,96 68,39
9 41 >	  40 53,09
10 41 >	  40 23,71
11 52 >	  40 74,10
12 62 >	  40 80,00
13 57 >	  40 49,19
14 16 19,22 30,56
15 3 <	  2,5 <	  0.1
16 32 >	  40 74,75
17 14 38,83 18,32
18 4 24,15 4,33
19 2 9,95 0,97
20 24 20,29 >100
21 18 16,67 0,44
22 56 24,13 4,49
23 25 24,77 2,55
24 63 24,43 0,90
25 9 21,51 1,10
26 2 <	  2,5 <	  0.1
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primarily	  metabolized	  in	  the	  liver.	  Administering	  the	  cytotoxicity	  of	  the	  compounds	  in	  MEF	  cells	  
was	   required	   because	   following	   analyses	   were	   conducted	   in	   these	   cells.	   A	   summary	   of	   all	  
compounds	   in	   HepG2	   and	  MEF	   cells	   at	   a	   concentration	   of	   50µM,	   which	   will	   be	   the	   highest	  
working	   concentration	   in	   later	   experiments,	   is	   presented	   in	   Figure	   4.7A.	   A	   compound	   was	  
considered	   to	   be	   non-­‐cell	   toxic	   when	   the	   cell	   viability	   obtained	   after	   24hours	   of	   compound	  
treatment	  was	  still	  higher	  than	  75%.	  Only	  compounds	  C5,	  C11,	  C20	  and	  C24	  showed	  less	  than	  
75%	  viable	  cells	  in	  both	  cell	  lines	  although	  C5,	  C11	  and	  C24	  almost	  reached	  the	  75%	  cell	  viability	  
limit	  (Fig.	  4.7A).	  C20,	  however,	  exhibited	  the	  most	  prominent	  cytotoxicity	  with	  less	  than	  40%	  of	  
living	  cells	  in	  both	  cell	  lines	  and	  therefore	  is	  indeed	  considered	  to	  be	  cell	  toxic.	  Compounds	  C8,	  
C19	  and	  C22	  decreased	  cell	  viability	  under	  75%	  only	  in	  HepG2	  cells,	  but	  remained	  non-­‐cell	  toxic	  
in	  MEF	  cells.	  Compound	  C10	  and	  C4	  are	  the	  only	  molecules,	  which	  displayed	  a	  higher	  toxicity	  on	  
MEF	  cells	  compared	  to	  HepG2.	  This	  observation	  needs	  to	  be	  considered	  for	  hit	  validation	  in	  the	  
following	  cell-­‐based	  assays	  in	  MEF	  cells.	  
Next,	   the	   compounds	  were	   analyzed	   for	   their	   effects	   on	   NF-­‐κB	   activation	   in	   Electrophoretic	  
Mobility	   Shift	   Assay	   (EMSA).	   Compounds	   were	   tested	   in	   IL-­‐1β	   and	   TNFα	   stimulation	  
experiments	   to	   determine	   selectivity	   of	   the	   compounds.	   The	   TRAF6	   dependency	   of	   IL-­‐1β	  
induced	  NF-­‐κB	  signaling	  was	  verified	  in	  TRAF6-­‐/-­‐	  MEF	  cells	  that	  were	  not	  able	  to	  activate	  NF-­‐κB	  
signaling	  (Lamothe	  et	  al.,	  2008	  and	  Figure	  4.7B).	  NF-­‐κB	  activation	  upon	  TNFα	  stimulation	  was	  
not	   impaired	   in	   these	   cells	   (Yamamoto	   et	   al.,	   2006	   and	   Figure	   4.7B).	   In	   the	   first	   round	   of	  
experiments,	   MEF	   cells	   were	   treated	   with	   30µM	   and	   50µM	   compound	   for	   six	   hours,	  
subsequently	   stimulated	  with	   IL-­‐1β,	   lysed	   and	   then	   analyzed	   in	   EMSA.	   In	   the	   second	   round,	  
compounds	  were	  tested	  after	  IL-­‐1β	  and	  TNFα	  stimulation	  side	  by	  side.	  Figure	  4.7C	  represents	  
one	   experiment	   of	   the	   second	   round.	   For	   the	   exact	   quantification	   of	   NF-­‐κB	   activation	   after	  
stimulation,	  the	  levels	  of	  NF-­‐κB	  were	  normalized	  to	  Oct1	  amounts,	  which	  are	  commonly	  used	  
as	   a	   loading	   control	   for	   EMSA.	   NF-­‐κB	   activation	   was	   then	   quantified	   using	   the	   LabImage1D	  
software	  to	  compare	  the	  efficiencies	  of	  the	  tested	  compounds.	  Compound	  C26	  did	  not	  show	  an	  
effect.	   Compound	   C22	   showed	   an	   IL-­‐1β	   specific,	   but	   very	   mild	   effect	   on	   NF-­‐κB	   activation	  
whereas	   C24	   and	   C25	   led	   to	   a	   stronger	   IL-­‐1β	   specific	   impaired	  NF-­‐κB	   signaling	   compared	   to	  
TNFα.	   Compounds	   C23	   and	   C27	   exhibited	   strong	   effects	   after	   IL-­‐1β	   stimulation	   but	   reduced	  
TNFα	   induced	  NF-­‐κB	  activation	  to	  the	  same	  extent	   (Figure	  4.7C).	  Figure	  4.7D	  summarizes	  the	  
quantifications	   for	   each	   compound	   at	   a	   concentration	   of	   50µM	   after	   IL-­‐1β	   as	   well	   as	   TNFα	  
stimulation.	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Figure	   4.7:	   Cytotoxicity	   assays	   and	   cell-­‐based	   hit	   validation	   of	   27	   compounds	   using	   EMSA	   technology.	   (A)	  
CellTiter-­‐Blue	  assays	  of	  27	  compounds	  for	  cell	  toxicity	  tests	   in	  HepG2	  and	  MEF	  cells	  after	  24	  hours	  of	  compound	  




















5 C8 C7 C6 C2















































5 C8 C7 C6 C2





















































































































































































ƐƟŵƵůĂƟŽŶ -­‐ +-­‐ + -­‐ +-­‐ +
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	  
 42	  
reduction	  in	  cell	  viability	  whereas	  all	  other	  compounds	  show	  no	  cell	  toxic	  effects.	  Mean	  and	  standard	  deviation	  are	  
depicted.	  (B)	  EMSA	  experiments	  upon	  IL-­‐1β	  and	  TNFα	  stimulation	  experiments	  in	  wildtype	  MEF	  and	  TRAF6-­‐/-­‐	  MEF	  
cells	  revealed	  the	  TRAF6-­‐dependency	  of	  IL-­‐1β	   induced	  NF-­‐κB	  activation	  whereas	  TNFα	  signaling	  does	  not	  rely	  on	  
TRAF6.	   (C)	   Exemplary	   data	   for	   the	   quantification	   of	   EMSA	   experiments	   derived	   from	   compound	   treated	   cells	  
(50µM)	   after	   IL-­‐1β	   and	   TNFα	   stimulation.	   C23	   and	   C27	   treatment	   cause	   a	   strong	   reduction	   in	  NF-­‐κB	   activation	  
after	   IL-­‐1β	   and	   TNFα stimulation.	   C25	   reduces	   NF-­‐κB	   activation	   selectively	   after	   IL-­‐1β	   stimulation	  whereas	   C26	  
does	  not	  show	  inhibitory	  potential.	  (D)	  Summary	  of	  quantified	  NF-­‐κB	  activition	  for	  27	  compounds	  out	  of	  the	  EMSA	  
experiments	   at	   a	   concentration	  of	   50µM.	   IL-­‐1β	   data	  were	   generated	  out	  of	   two	  experiments;	   TNFα	   stimulation	  
experiments	  were	  performed	  only	  once.	  C25,	  C1,	  C13,	  C14	  and	  C24	  are	  the	  only	  compounds	  that	  showed	  an	  IL-­‐1β	  
selective	  inhibition	  of	  NF-­‐κB	  activation.	  	  
	  
Small	  molecules	  were	  considered	  to	  be	  a	  specific	  hit	  compound	  by	  meeting	  the	  following	  two	  
criteria:	   i)	  NF-­‐κB	   activation	   after	   IL-­‐1β	   stimulation	  was	   reduced	   in	   both	   test	   rounds	   by	  more	  
than	   25%	   at	   50µM	   compound	   concentration	   (quantification	   of	   each	   single	   experiment	   is	  
depicted	   in	   supplement	  10.5)	  and	   ii)	  TNFα	   induced	  NF-­‐κB	  activation	  must	  not	  be	   reduced	  by	  
more	   than	   25%	   at	   a	   concentration	   of	   50µM.	   Whereas	   6	   compounds	   did	   not	   impair	   NF-­‐κB	  
activation,	   19	   compounds	   reduced	   activation	  of	  NF-­‐κB	  after	   IL-­‐1β	   stimulation	   in	   at	   least	   one	  
round.	   8	   out	   of	   these	   19	   molecules	   decreased	   IL-­‐1β	   induced	   NF-­‐κB	   activation	   in	   both	   test	  
rounds	  (C1,	  C4,	  C10,	  C13,	  C14,	  C24,	  C25	  and	  C27).	  Nevertheless,	  C4,	  C10	  and	  C27	  did	  not	  meet	  
the	   second	   criteria	   of	   not	   inhibiting	   TNFα	   induced	   NF-­‐κB	   activation	   by	   more	   than	   25%.	  
Furthermore,	   it	  cannot	  be	  excluded	  that	  C4	  and	  C10	  diminished	  NF-­‐κB	  activation	  due	  to	  their	  
slightly	  cytotoxic	  effects	  obtained	  in	  MEF	  cells	  in	  CellTiter-­‐Blue	  assays	  (Figure	  4.7A).	  In	  the	  end,	  
5	  out	  of	  27	  tested	  compounds	  met	  the	  criteria	  for	  presenting	  selective	  hit	  compounds	  in	  these	  
hit	  validation	  settings:	  C1,	  C13,	  C14,	  C24,	  C25	  whereas	  C25	  was	  the	  most	  effective	  compound	  
after	  IL-­‐1β	  stimulation	  while	  not	  impairing	  TNFα	  induced	  NF-­‐κB	  activation.	  
	  
4.4	  Validation	  of	  C27	  in	  biochemical	  and	  cell-­‐based	  assays	  
C27	   is	  a	  compound	   from	  the	  ChemDIV	   library	  and	   its	  chemical	   structure	   is	  depicted	   in	  Figure	  
4.8A.	  It	  meets	  the	  Lipinski´s	  rule	  of	  five	  (Figure	  4.8B)	  and	  therefore	  is	  considered	  to	  be	  a	  drug-­‐
like	  and	  potentially	  orally	  available	  compound	  (Lesson,	  2012).	  The	  criteria	  for	  the	  Lipinski´s	  rule	  
of	   five	  are	  depicted	   in	  7.1.13.	  C27	  showed	  a	  strong	  effect	   in	  specifically	   impairing	  the	  TRAF6-­‐
Ubc13	  interaction	  in	  vitro	  in	  ALPHAScreen	  assays	  as	  well	  as	  decreasing	  activation	  of	  NF-­‐κB	  after	  
IL-­‐1β	  stimulation	  in	  MEF	  cells.	  Treatment	  of	  MEF	  cells	  with	  C27	  showed	  that	   it	  also	   interferes	  
with	   TNFα	   induced	   NF-­‐κB	   activation.	   Although	   this	   compound	   did	   not	   display	   pathway	  
selectivity,	   it	  was	   the	  strongest	  acting	  compound	   in	  NF-­‐κB	  activation	  experiments.	  To	   further	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examine	   the	   effectiveness	   and	   selectivity	   of	   this	   small	  molecule,	   biochemical	   as	  well	   as	   cell-­‐
based	  studies	  were	  performed.	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   4.8:	   Biochemical	   validation	   of	   C27.	   (A)	   Compound	   structure,	   chemical	   formula	   and	   name	   of	   C27.	   (B)	  
Molecular	   properties	   of	   C27	   that	  meet	   the	   criteria	   of	   the	   Lipinski´s	   rule	   of	   five.	   (C)	   ALPHAScreen	   assays	   testing	  
increasing	   concentrations	   of	   C27.	   C27	   impairs	   TRAF6WTStrepII-­‐Ubc13FH	   interaction	   dose-­‐dependently	   while	  
binding	  of	  GST-­‐OTUB1	  and	  GST-­‐RNF8	  to	  Ubc13FH	  remain	  unaffected.	  Mean	  and	  standard	  deviation	  are	  shown.	  (D)	  
NMR	  studies	  of	  TRAF6WT	  and	  C27	  revealing	  that	  C27	  directly	  targets	  TRAF6	  (NMR	  experiments	  were	  performed	  by	  
Dr.	  Grzegorz	  Popowicz	  from	  the	  Institute	  of	  Structural	  Biology	  at	  the	  Helmholtz	  Zentrum	  München).	  
	  
4.4.1	  Biochemical	  validation	  of	  C27	  
To	   specify	   the	   IC50	   for	   C27,	   dose-­‐response	   ALPHAScreen	   assays	   in	   a	   lower	   range	   were	  
performed	   (0.02	   -­‐	   10µM).	   C27	   showed	   a	   strong	   inhibitory	   effect	   on	   TRAF6WTStrepII-­‐Ubc13FH	  
interaction	   with	   an	   IC50	   of	   0.29µM	   ±	   0.02µM	   while	   GST-­‐OTUB1	   and	   GST-­‐RNF8	   binding	   to	  
















































































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	  
 44	  
(Figure	   4.8C).	   To	   confirm	   the	   direct	   binding	   of	   C27	   to	   TRAF6,	   15N-­‐labeled	   TRAF6WT	   protein	  
without	  carrying	  tags	  was	  recombinantly	  purified	  and	  analyzed	  in	  nuclear	  magnetic	  resonance	  
(NMR)	   experiments.	   NMR	   experiments	   were	   performed	   by	   Dr.	   Grzegorz	   Popowicz	   at	   the	  
Institute	   of	   Structural	   Biology	   at	   the	  Helmholtz	   Zentrum	  München.	  NMR	   spectra	   of	   TRAF6WT	  
only	  (blue)	  and	  TRAF6WT	  incubated	  with	  C27	  (red)	  at	  a	  ratio	  of	  1:5	  are	  depicted	  in	  Figure	  4.8D.	  
Multiple	  peaks	  were	  shifting	  or	  disappearing	  upon	  C27	   treatment	   indicating	   that	  C27	  directly	  
targets	  the	  TRAF6	  RZ1	  domain.	  Arrows	  highlight	  peaks	  that	  are	  strongly	  affected	  by	  C27.	  
As	   C27	   directly	   targets	   the	   RING-­‐Zincfinger1	   domain	   of	   TRAF6,	   further	   investigations	   of	   C27	  
were	  carried	  out	  in	  cell-­‐based	  assays.	  	  
	  
4.4.2	  Cell-­‐based	  validation	  of	  C27	  
Before	  investigating	  the	  influence	  of	  C27	  in	  NF-­‐κB	  signaling	  after	  various	  stimuli,	  a	  more	  precise	  
cell	   toxicity	   study	   was	   performed.	   Besides	   CellTiter-­‐Blue	   experiments,	   Hoechst33342	   and	  
Mitotracker	   stainings	   in	   living	   cells	   were	   conducted.	   Hoechst33342	   is	   a	   cell-­‐permeable	   blue	  
fluorescent	  dye	   that	   intercalates	   into	  DNA	  and	   is	   used	   to	  determine	   the	  nucleus	   area	   in	   this	  
experiment.	  Mitotracker	   is	  a	  red	  fluorescent	  dye	  that	   incorporates	   into	  mitochondria	  of	   living	  
cells	  and	  is	  used	  to	  analyze	  the	  mitochondrial	  mass.	  In	  CellTiter-­‐Blue	  experiments,	  C27	  was	  well	  
tolerated	   in	   HepG2	   and	   MEF	   cells	   up	   to	   the	   tested	   concentration	   of	   100µM	   (Figure	   4.9A).	  
Moreover,	   in	   both	   cell	   lines	   the	   nucleus	   area	   and	   the	   overall	   mitochondrial	   mass	   were	   not	  
markedly	  altered	  (Figure	  4.9A).	  	  
To	   verify	   the	   EMSA	  data	   from	   the	  hit	   validation	   assays,	   time-­‐dependent	   experiments	   in	  MEF	  
cells	  were	   conducted	   to	   analyze	   the	  phosphorylation	   status	  of	   IκBα,	   its	   degradation	   and	   the	  
resulting	   NF-­‐κB	   DNA	   binding	   after	   various	   stimuli.	   In	   previous	   EMSA	   experiments	   NF-­‐κB	  
activation	  was	  drastically	  reduced	  to	  10%	  when	  treating	  cells	  with	  30µM	  C27	  (Figure	  4.7D	  and	  
supplement	  10.5).	  Therefore,	  time-­‐dependent	  experiments	  were	  performed	  with	  applying	  only	  
5µM	  C27	  to	  the	  cells.	  After	  DMSO	  or	  compound	  treatment	  for	  six	  hours,	  cells	  were	  stimulated	  
with	   IL-­‐1β,	   LPS	   or	   TNFα	   for	   the	   indicated	   time	   points	   (Figure	   4.9B).	   In	   IL-­‐1β	   stimulation	  
experiments,	   the	   induced	   phosphorylation	   of	   IκBα	   was	   delayed	   after	   C27	   treatment	   and	  
consistent	  with	  that	  degradation	  of	  IκBα	  was	  reduced	  after	  20	  min	  stimulation	  as	  well.	  In	  line	  
with	  this,	  NF-­‐κB	  activation	  was	  diminished	  for	  all	  indicated	  time	  points	  compared	  to	  the	  DMSO	  
treated	  cells.	  These	  data	  indicate	  that	  5µM	  C27	  were	  still	  sufficient	  to	  impair	  NF-­‐κB	  activation.	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Figure	  4.9:	  Cytotoxicity	  tests	  and	  cell-­‐based	  verification	  of	  C27	  after	   IL-­‐1β ,	  LPS	  and	  TNFα 	   stimulation	   in	  EMSA	  
experiments.	  (A)	  Cytotoxicity	  tests	  of	  C27	  in	  HepG2	  and	  MEF	  cells.	  C27	  is	  well	  tolerated	  by	  HepG2	  and	  MEF	  cells.	  
Means	  and	  standard	  deviation	  are	  depicted.	  (B)	  Time-­‐dependent	  NF-­‐κB	  EMSA	  and	  Western	  Blot	  data	  of	  MEF	  cells	  
treated	   with	   5µM	   C27	   and	   stimulation	   with	   IL-­‐1β,	   LPS	   or	   TNFα.	   C27	   impairs	   activation	   of	   NF-­‐κB	   in	   all	   three	  
signaling	  pathways.	  
	  
As	   expected,	   5µM	   of	   compound	   27	   inhibited	   LPS	   induced	   NF-­‐κB	   activation	   resulting	   from	  
diminished	   phosphorylation	   of	   IκBα	   as	   well.	   It	   appears	   that	   C27	   influenced	   LPS	   signaling	  
stronger	   than	   IL-­‐1β	   signaling	   in	   EMSA	   experiments	   but	   this	   might	   result	   from	   a	   weaker	  
induction	   of	   NF-­‐κB	   activation	   upon	   LPS	   stimulation	   that	   is	   also	   visible	   in	   the	   degradation	   of	  
IκBα.	  Upon	  TNFα	  stimulation,	  phosphorylation	  and	  degradation	  of	  IκBα	  as	  well	  as	  activation	  of	  
NF-­‐κB	  were	  reduced	  similar	  to	  IL-­‐1β	  (Figure	  4.9B).	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Figure	   4.10:	   Cell-­‐based	   verification	   of	   C27	   after	   IL-­‐1β 	   and	   TNFα 	   stimulation	   in	  MEF	   cells	   in	   p65	   translocation	  
experiments.	  Upon	   IL-­‐1β	   or	   TNFα	   stimulation	   (20min),	   p65	   translocates	   into	   the	  nucleus.	  At	   a	   concentration	  of	  
6.25µM,	  C27	  impairs	  nuclear	  translocation	  of	  p65	  after	  IL-­‐1β	  (A)	  and	  TNFα	  (B)	  stimulation.	  	  
	  
To	  further	  analyze	  the	  inhibitory	  potential	  of	  C27	  in	  a	  second	  assay,	  nuclear	  translocation	  of	  the	  
p65	   subunit	   of	   NF-­‐κB	   upon	   IL-­‐1β	   and	   TNFα	   stimulation	   was	   analyzed	   in	   MEF	   cells.	   After	  
treatment	   of	   the	   cells	  with	   6.25µM	   C27,	   cells	  were	   stimulated	  with	   the	   respective	   cytokine,	  
fixed	   and	   stained	   for	   p65	   immunofluorescence	   experiments.	   Representative	   images	   are	  
depicted	   in	   4.10.	   Upon	   stimulation	   with	   either	   IL-­‐1β	   or	   TNFα,	   p65	   translocated	   from	   the	  
cytoplasm	  into	  the	  nucleus.	  However,	  IL-­‐1β 	  stimulation	  led	  to	  a	  stronger	  accumulation	  of	  p65	  
in	  the	  nucleus	  compared	  to	  TNFα.	  C27	  treatment	  reduced	  p65	  nuclear	  translocation	  after	  IL-­‐1β	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In	   a	   third	   assay,	   expression	   of	   NF-­‐κB	   dependent	   target	   genes	   was	   analyzed	   by	   quantitative	  
realtime	  polymerase	  chain	  reaction	  (qPCR)	  after	  IL-­‐1β,	  LPS	  and	  TNFα	  stimulation.	  Similar	  to	  the	  
EMSA	  experiments,	  MEF	  cells	  were	  compound	  treated	  and	  stimulated.	  After	  extraction	  of	  RNA	  
from	  the	  cell	  lysates	  and	  reverse	  transcription	  into	  complementary	  DNA	  (cDNA),	  the	  cDNA	  was	  
used	  as	  the	  template	   for	  qPCR	  to	  analyze	  the	  expression	  of	  selected	  NF-­‐κB	  dependent	  target	  
genes.	  mRNA	  levels	  of	  A20	  were	  found	  to	  be	  upregulated	  by	  IL-­‐1β,	  TNFα and	  LPS	  (Figure	  4.11).	  
The	  expression	  of	  mRNA	  coding	  for	  ICAM-­‐1	  was	  only	  induced	  after	  IL-­‐1β	  and	  TNFα	  stimulation	  
(Figures	  4.11A	  and	  B).	  Treatment	  of	  MEF	  cells	  with	  C27	  caused	  a	  significant	  reduction	  in	  mRNA	  
expression	   for	   ICAM-­‐1	   and	   A20	   in	   a	   dose-­‐dependent	  manner	   in	   all	   three	   tested	   stimulation	  
experiments	  whereas	  an	  overall	  higher	  influence	  on	  ICAM-­‐1	  levels	  was	  observed	  (Figure	  4.11).	  
Taken	   together,	   the	   results	   of	   the	   EMSA,	   p65	   translocation	   and	  qPCR	   studies	   imply	   that	   C27	  
indeed	   causes	   a	   significant	   reduction	  of	  NF-­‐κB	   signaling,	   but	  does	  not	  differentially	   affect	   IL-­‐
1β/LPS	  and	  TNFα	  induced	  NF-­‐κB	  activation.	  
	  
	  
Figure	   4.11:	   Cell-­‐based	   verification	   of	   C27	   after	   IL-­‐1β ,	   LPS	   and	   TNFα 	   stimulation	   in	   MEF	   cells	   in	   qPCR	  
experiments.	   Quantitative	   realtime	   PCR	   studies	   after	   IL-­‐1β (60min)	   (A),	   LPS	   (75min)	   (B)	   or	   TNFα	   (60min)	   (C)	  
stimulation	   reveal	   dose-­‐dependent	   effects	   of	   C27	   in	  NF-­‐κB	   target	   gene	   expression.	   Specificity	   for	   IL-­‐1β	   and	   LPS	  
over	  TNFα	  signaling	  was	  not	  obtained.	  Means	  and	  standard	  deviation	  are	  shown.	  Significances	  are	  calculated	  using	  
Student´s	  t-­‐test	  (p-­‐value	  <	  0.01).	  
	  
Since	  C27	  displayed	   such	  a	   strong	  biochemical	   and	  cellular	  effect,	   further	   research	  was	  done	  
analyzing	   the	   mode	   of	   action	   of	   this	   compound.	   The	   influence	   of	   the	   compound	   on	   NF-­‐κB	  
signaling	   after	   IL-­‐1β	   stimulus	   was	   investigated	   in	   more	   detail.	   First,	   the	   endogenous	   auto-­‐
ubiquitination	  of	  TRAF6	  that	   is	  a	  prerequisite	   for	  NF-­‐κB	  activation	  after	   IL-­‐1β	   stimulation	  was	  
examined	  (Lamothe	  et	  al.,	  2007).	  For	  that,	  MEF	  cells	  were	  treated	  with	  increasing	  amounts	  of	  
C27.	  Upon	  stimulation,	  TRAF6	  was	   immunoprecipitated	  from	  the	  cell	   lysates	  and	  analyzed	  for	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of	   TRAF6	   auto-­‐ubiquitination	   (Figure	   4.12A).	   Surprisingly,	   5µM	   of	   C27	   did	   not	   affect	   TRAF6	  
auto-­‐ubiquitination.	  It	  appears	  that	  the	  amount	  of	  compound	  to	  interfere	  with	  NF-­‐κB	  signaling	  
was	   assay-­‐type-­‐dependent.	   Due	   to	   the	   need	   of	   different	   well	   formats,	   the	   ratio	   of	   cells	   to	  
compound	  varied	  among	  the	  assays.	  	  
	  
	  	   	  
Figure	  4.12:	  Determining	  the	  mode	  of	  action	  of	  C27	  in	  IL-­‐1β 	  signaling	  in	  MEF	  cells.	  (A)	  IL-­‐1β	  induced	  TRAF6	  auto-­‐
ubiquitination	  is	  reduced	  by	  pre-­‐treatment	  of	  cells	  with	  various	  concentrations	  of	  C27.	  (B)	  The	  activity	  of	  the	  IKK	  
complex	   after	   IL-­‐1β	   stimulation	   is	   dose	   dependently	   decreased	   by	   C27.	   (C)	   p-­‐IκBα	   ALPHASurefire	   experiments	  
reveal	  an	   inhibitory	  effect	  by	   increasing	  amounts	  of	  C27.	  Mean	  and	  standard	  deviations	  are	  depicted.	  Statistical	  
significance	   is	   verified	   using	   Student´s	   t-­‐test	   (p-­‐value	   <	   0.01).	   (D)	   ADME	   studies	   were	   performed	   by	   Bienta,	  
ENAMINE	  Ltd.	  and	  determine	  instability	  of	  C27	  in	  plasma.	  
	  
Next,	   the	  activity	  of	   the	   IKK	  complex	  was	  analyzed	   to	  determine	   the	  mechanism	  of	  action	  of	  
C27	   in	   cells.	   Again,	   MEF	   cells	   were	   pre-­‐treated	   with	   C27,	   stimulated	   and	   lysed.	  
Immunoprecipitated	   NEMO	   was	   incubated	   with	   recombinantly	   purified	   GST-­‐IκBα	   and	  
32Phosphorus	  (32P).	  The	  kinase	  activity	  was	  analyzed	  by	  SDS-­‐PAGE	  followed	  by	  autoradiography	  
and	  Western	  Blot.	  While	   1µM	  C27	  did	  not	   show	  any	  effect	   on	  phosphorylation	  of	  GST-­‐IκBα,	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5µM	   and	   10µM	   reduced	   the	   kinase	   activity	   dose-­‐dependently	   (Figure	   4.12B).	   An	   inhibitory	  
effect	  was	  also	  observed	   in	  the	  phosphorylation	   levels	  of	   IκBα	   in	   the	   lysate	  fraction	  that	  was	  
comparable	   for	   the	   phosphorylation	   status	   of	   IκBα	   in	   EMSA	   experiments	   (Figure	   4.9B).	   To	  
further	   confirm	   these	   results,	   p-­‐IκBα	   ALPHASurefire	   experiments	   were	   performed.	  
ALPHASurefire	  is	  an	  ALPHAScreen-­‐based	  technology	  using	  Donor	  and	  Acceptor	  beads	  to	  detect	  
protein	   phosphorylation	   from	   cell	   lysates.	   Dose-­‐dependent	   reduction	   of	   the	   levels	   of	  
phosphorylation	   of	   IκBα	   after	   compound	   treatment	   and	   IL-­‐1β	   stimulation	   again	   proved	   the	  
inhibitory	  effect	  of	  C27	  (Figure	  4.12C).	  Taking	  these	  results	  together,	  C27	  shows	  a	  strong	  effect	  
on	  IKK	  complex	  activity,	  phosphorylation	  of	  IκBα	  and	  NF-­‐κB	  activation.	  Contrary,	  TRAF6	  auto-­‐
ubiquitination	   is	   very	   mildly	   affected	   and	   is	   unlikely	   to	   cause	   such	   a	   strong	   impact	   on	  
downstream	   signaling	   events.	   Data	   obtained	   so	   far	   indicate	   that	   C27	   interferes	   with	   NF-­‐κB	  
signaling	   upstream	   of	   the	   IKK	   complex	   or	   targets	   the	   components	   of	   the	   IKK	   complex	   to	  
diminish	  its	  activity.	  	  	  
To	   further	   characterize	   the	   behavior	   of	   C27,	   absorption-­‐distribution-­‐metabolism-­‐excretion	  
(ADME)	   studies	  were	   performed	   to	   define	   pharmacokinetics	   and	   pharmacodynamics	   of	   C27.	  
Results	   are	   depicted	   in	   Figure	   4.12D.	   Plasma	   stability	   assays	   revealed	   C27	   as	   an	   instable	  
compound	  with	   a	   half-­‐life	   of	   16.7	  min.	  Whether	   C27	   is	   degraded	  or	   structurally	  modified	   by	  
plasma	   enzymes	   remains	   unclear	   up	   to	   this	   point.	   Due	   to	   the	   instability	   of	   C27	   in	   plasma,	  
plasma	   protein	   binding	   tests	   could	   not	   be	   performed	   successfully.	   The	  metabolic	   stability	   of	  
C27	   was	   assessed	   in	   mouse	   hepatic	   microsomes	   revealing	   a	   elimination	   constant	   kel=	  
0.0014/min,	  a	  half-­‐life	  of	  T1/2=	  50.19	  min	  and	  an	  intrinsic	  clearance	  of	  Clint=	  33.28	  µL/min/mg.	  
Additionally,	   the	   distribution	   coefficient	   (LogD)	   is	   determined	   to	   measure	   the	   balance	   of	  
lipophilicity	  and	  hydrophilicity.	  The	  LogD	  of	  C27	  was	  calculated	  to	  3.28	  and	  is	  considered	  to	  be	  
in	  the	  optimal	  range	  (for	  LogP,	  see	  4.8B).	  The	  Caco-­‐2	  (human	  colon	  adenocarcinoma	  cell)	  assay	  
was	  used	  to	  evaluate	  the	  permeability	  of	  C27	  that	  was	  assessed	  to	  46.75	  *	  10-­‐6cm/s	  providing	  a	  
good	  oral	  absorption	  (Lau	  et	  al.,	  2004).	  In	  Cytochrom	  (CYP)	  P450	  inhibition	  assays,	  C27	  inhibited	  
only	  two	  out	  of	  five	  tested	  CYP	  enzymes.	  No	  significant	  binding	  of	  C25	  to	  hERG	  was	  observed	  in	  
the	  hERG	  (human	  Ether-­‐a-­‐go-­‐go	  related	  gene)	  predictor	  assay.	  
Taking	  all	  results	  together,	  C27	  is	  a	  very	  active	  compound	  inhibiting	  NF-­‐κB	  signaling.	  However,	  
no	   pathway	   selectivity	   is	   observed	   as	   IL-­‐1β,	   LPS	   and	   TNFα	   induced	   NF-­‐κB	   activation	   was	  
impaired	  to	  the	  same	  extent.	  Furthermore,	  plasma	  stability	  assays	  revealed	  that	  C27	   is	  highly	  
instable	   in	   plasma	   environment	   and	   therefore	   would	   not	   be	   available	   for	   its	   activity	   in	   the	  
plasma.	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4.5	  Validation	  of	  C25	  in	  biochemical	  and	  cell-­‐based	  experiments	  
In	  the	  cellular	  verification	  of	  the	  27	  hit	  compounds,	  C25	  demonstrated	  very	  strong	  and	  specific	  
effects	   not	   only	   in	   vitro	   (Figure	   4.4A)	   but	   also	   in	   first	   cell-­‐based	   assays	   (Figure	   4.7A).	   The	  
chemical	  structure	  of	  C25	  is	  presented	  in	  Figure	  4.13A.	  It	  fulfills	  all	  four	  criteria	  of	  the	  Lipinski´s	  
rule	  of	  five	  and	  therefore	  is	  referred	  to	  be	  a	  drug-­‐like	  small	  molecule	  (Figure	  4.13B).	  	  
	  
	  	  	  	  	  	  	  	  	   	  
Figure	   4.13:	   Biochemical	   validation	   of	   C25.	   (A)	   Compound	   structure,	   chemical	   formula	   and	   name	   of	   C25.	   (B)	  
Parameters	   of	   the	   Lipinski´s	   rule	   of	   five	   for	   C25	   revealed	   a	   drug-­‐like	   small	   molecule.	   (C)	   ALPHAScreen	   assays	  
analyzing	   increasing	   concentrations	   of	   C25.	   C25	   impairs	   TRAF6WTStrepII-­‐Ubc13FH	   interaction	   dose-­‐dependently	  
while	   binding	   of	   GST-­‐OTUB1	   and	   GST-­‐RNF8	   to	   Ubc13FH	   remain	   unaffected.	   Mean	   and	   standard	   deviation	   are	  
depicted.	  (D)	  NMR	  studies	  of	  TRAF6WT	  and	  C25.	  C25	  directly	  binds	  TRAF6WT	  (NMR	  experiments	  were	  performed	  by	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4.5.1	  Biochemical	  analysis	  of	  C25	  
In	   the	   initial	   ALPHAScreen	   testing	   of	   reordered	   C25,	   a	   specific	   inhibition	   of	   TRAF6WTStrepII	  
binding	  to	  Ubc13FH	  in	  a	  dose-­‐dependent	  manner	  (Figure	  4.13C)	  was	  observed.	  IC50	  calculations	  
revealed	  a	  value	  in	  the	  very	  low	  micro	  molar	  range	  (1.1	  ±	  0.2µM).	  Besides,	  the	  interactions	  of	  
GST-­‐OTUB1-­‐Ubc13FH	   and	   GST-­‐RNF8-­‐Ubc13FH	   remained	   mainly	   unaffected,	   but	   a	   slight	  
reduction	   of	   the	   GST-­‐OTUB1-­‐Ubc13FH	   binding	   at	   100µM	   C25	   was	   observed	   (Figure	   4.13C).	  
These	  data	   imply	  that	  C25	   is	  a	  specifically	  acting	  compound	  up	  to	  100µM	   in	  vitro	  and	  targets	  
TRAF6WTStrepII	   rather	   than	  Ubc13FH.	   To	   further	   confirm	   this	   assumption,	   untagged	   TRAF6WT	  
was	  analyzed	  in	  NMR	  after	  C25	  treatment	  in	  a	  1:5	  ratio.	  Indeed,	  C25	  directly	  targets	  TRAF6WT	  as	  
several	   peaks	   are	   shifting	   and	   disappearing	   as	   marked	   with	   arrows	   in	   Figure	   4.13D.	   This	  
indicates	  a	  direct	  binding	  of	  the	  compound	  to	  TRAF6WT.	  Compared	  to	  the	  NMR	  spectra	  of	  C27	  
(Fig.	  4.8D)	   treated	  TRAF6WT,	   the	  same	  residues	  are	   targeted	  suggesting	  that	  both	  compounds	  
despite	  their	  structural	  heterogeneity	  bind	  similar	  amino	  acids	  within	  TRAF6.	  
To	  verify	  whether	  targeting	  TRAF6	  by	  C25	  indeed	  influences	  the	  binding	  of	  TRAF6	  to	  Ubc13	  and	  
subsequently	   its	   E3	   ligase	   activity,	   additional	   in	   vitro	   experiments	  were	   performed.	   First,	   the	  
interaction	   of	   recombinant	   purified	   GST-­‐TRAF6WT	   and	   Ubc13FH	   was	   analyzed	   in	   pulldown	  
assays.	  The	  usage	  of	  GST-­‐TRAF6WT	  was	  chosen	  to	  further	  ensure	  that	  C25	  does	  not	  affect	  the	  
StrepII-­‐tag	  of	  TRAF6WT	  in	  the	  initial	  ALPHAScreen	  experiments.	  GST-­‐TRAF6WT	  was	  pre-­‐incubated	  
with	  DMSO	  or	  compound	  followed	  by	  adding	  Ubc13FH.	  After	  immunoprecipitation	  of	  Ubc13FH,	  
binding	  of	  GST-­‐TRAF6WT	   to	  Ubc13FH	  was	  analyzed	  via	  Western	  Blot.	  As	  a	  control,	   the	  Ubc13-­‐
SPD	   mutant,	   a	   triplemutant	   that	   is	   not	   able	   to	   bind	   TRAF6,	   was	   included	   and	   revealed	   the	  
specificity	  of	  this	  pulldown	  assay.	  Increasing	  amounts	  of	  C25	  (10,	  20	  and	  30µM)	  led	  to	  a	  dose-­‐
dependent	  reduction	   in	  binding	  of	  GST-­‐TRAF6WT	  to	  Ubc13FH	  (Figure	  4.14A).	  Compared	  to	  the	  
ALPHAScreen,	  higher	  concentrations	  of	  C25	  were	  required	  in	  this	  assay	  due	  to	  a	  more	  than	  five	  
fold	  higher	   input	  of	  proteins.	   Second,	   the	   impact	  of	   an	   impaired	  TRAF6-­‐Ubc13	  binding	  on	  E3	  
ligase	  activity	  was	  analyzed	  in	  a	  functional	  in	  vitro	  ubiquitination	  assay.	  This	  method	  is	  based	  on	  
the	   ability	   of	   the	   TRAF6-­‐Ubc13	   complex	   to	   assembly	   free	   polyubiquitin	   chains.	   Untagged	  
TRAF6WT	  was	  pre-­‐incubated	  with	  DMSO	  or	  compound	  and	  applied	  to	  the	  reaction	  mix	  including	  
E1	   enzyme,	   the	   Ubc13/Uev1a	   complex,	   monoubiquitin	   and	   ATP	   for	   the	   assembly	   of	   free	  
ubiquitin	  chains.	  The	  formation	  of	  polyubiquitin	  chains	  were	  subsequently	  analyzed	  in	  Western	  
Blot	   experiments.	   Adding	   TRAF6WT	   led	   to	   the	   formation	   of	   free	   polyubiquitin	   chains	   under	  
DMSO	  conditions	  meaning	   that	   the	  purified	  protein	   is	   active	   in	   this	   experimental	   setup.	   Pre-­‐
incubation	  of	  TRAF6	  protein	  with	  increasing	  concentrations	  of	  C25	  (10,	  20	  and	  30µM)	  led	  to	  a	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dose-­‐dependent	   loss	   of	   polyubiquitin	   assembly	   indicating	   that	   targeting	   the	   RZ1	   domain	   of	  




Taken	  together,	  the	  completed	  in	  vitro	  assays	  gave	  rising	  evidence	  that	  C25	  specifically	  targets	  
the	  RZ1	  domain	  of	  TRAF6	  and	  that	  this	  binding	  negatively	  affects	  both	  the	  interaction	  to	  Ubc13	  
and	   the	   E3	   ligase	   activity	   of	   TRAF6.	  Next,	   the	   verification	   of	   this	   effectiveness	   needed	   to	   be	  
confirmed	  in	  cell-­‐based	  assays.	  	  
	  
4.5.2	  Verification	  of	  C25	  in	  cell-­‐based	  assays	  
Initial	  EMSA	  experiments	  revealed	  a	  moderate	   inhibition	  of	   IL-­‐1β	   induced	  NF-­‐κB	  activation	  by	  
C25	  while	  TNFα	  mediated	  NF-­‐κB	  activation	  remained	  unaffected	  (Figures	  4.7C	  and	  4.7D).	  First,	  
cytotoxicity	  studies	  were	  carried	  out	  in	  more	  detail.	  CellTiter-­‐Blue	  as	  well	  as	  Hoechst3342	  and	  
Mitotracker	   stainings	   were	   performed	   in	   both	   HepG2	   and	  MEF	   cells.	   CellTiter-­‐Blue	   stainings	  
demonstrated	  no	  substantial	  decrease	  in	  cell	  viability	  up	  to	  50µM	  C25	  in	  HepG2	  and	  MEF	  cells	  
(Fig.	  4.15A).	  Mitochondrial	  mass	  as	  well	  as	  nuclear	  area	  experiments	  did	  not	  exhibit	  any	  effects	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Figure	   4.14:	   Biochemical	  
validation	   of	   C25.	   (A)	  
Pulldown	   assay	   of	   GST-­‐
TRAF6WT	   and	   Ubc13FH.	  
C25	   impairs	   binding	   of	  
TRAF6	  to	  Ubc13	  in	  a	  dose-­‐
dependent	  manner.	   (B)	   In	  
vitro	  ubiquitination	  assays	  
reveal	   that	   C25	   dose-­‐
dependently	   reduces	   the	  
ability	  of	  TRAF6WT	  to	  form	  
free	  polyubiquitin	  chains.	  	  




Figure	  4.15:	  Cytotoxicity	  assays	  and	  cell-­‐based	  verification	  of	  C25	  after	  IL-­‐1β ,	  LPS	  and	  TNFα 	  stimulation	  in	  EMSA	  
experiments.	  (A)	  Cytotoxicity	  tests	  of	  C25	  in	  HepG2	  and	  MEF	  cells.	  C25	  is	  well	  tolerated	  by	  HepG2	  cells	  up	  to	  50µM	  
compound.	  MEF	  cells	  remain	  viable	  up	  to	  100µM	  compound.	  Means	  and	  standard	  deviations	  are	  shown.	  (B)	  Time-­‐
dependent	  experiments	  of	  MEF	  cells	  treated	  with	  30µM	  C25	  and	  stimulation	  with	  IL-­‐1β,	  LPS	  or	  TNFα	  analyzed	  in	  
EMSA	  and	  Western	  Blot	  experiments.	  While	  C25	  treatment	  does	  impair	  phosphorylation	  and	  degradation	  of	  IκBα	  
as	  well	  as	  NF-­‐κB	  activation	  after	  IL-­‐1β	  and	  LPS	  stimulation,	  TNFα	  signaling	  remains	  unaffected.	  	  
	  
Next,	  C25	  treated	  MEF	  cells	  were	  analyzed	   in	  EMSA	  after	   IL-­‐1β,	  LPS	  and	  TNFα	  stimulation	  for	  
the	  indicated	  time	  points	  (Fig.	  4.15B).	  Since	  IL-­‐1β and	  LPS	  use	  similar	  adaptor	  proteins,	  kinases	  
and	   ligases	   including	   TRAF6	   after	   receptor	   stimulation,	   C25	   is	   expected	   to	   reduce	   NF-­‐κB	  
activation	   in	   both	   pathways	   (Wertz	   and	   Dixit,	   2010).	   Due	   to	   the	   fact,	   that	   TNFα	   signaling	   is	  
independent	  of	  TRAF6,	  this	  pathway	  should	  not	  be	  affected	  by	  C25	  (Figure	  4.7B).	  Treatment	  of	  
MEF	   cells	   with	   30µM	   C25	   led	   to	   a	   moderate	   reduction	   of	   NF-­‐κB	   activation,	   as	   well	   as	  
phosphorylation	   and	   subsequent	   degradation	   of	   IκBα	   after	   IL-­‐1β	   stimulation	   (Fig.	   4.15B)	  
proving	  previous	  findings	  out	  of	  the	  initial	  EMSA	  experiments	  (Fig.	  4.7D	  and	  supplement	  10.5).	  
LPS	  mediated	  NF-­‐κB	  activation	  and	  phosphorylation	  of	  IκBα	  was	  decreased	  in	  a	  similar	  manner	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(Fig.	   4.15B).	   In	   contrast,	   C25	   treatment	   did	   not	   affect	   TNFα	   induced	   activation	   of	  NF-­‐κB	  nor	  
phosphorylation	  and	  degradation	  of	  IκBα	  (Fig.	  4.15B).	  To	  further	  define	  the	  influence	  of	  C25	  on	  
NF-­‐κB	   signaling,	   MEF	   cells	   were	   treated	   with	   25µM	   C25	   and	   analyzed	   in	   p65	   translocation	  
experiments.	  Upon	  IL-­‐1β	  stimulation,	  C25	  led	  to	  a	  mild	  effect	  in	  retaining	  p65	  in	  the	  cytoplasm	  
(Figure	  4.16A).	  After	  TNFα	  stimulation	  nuclear	  translocation	  of	  p65	  was	  not	  as	  strong	  as	  IL-­‐1β	  




Figure	  4.16:	  Cell-­‐based	  verification	  of	  C25	  after	  IL-­‐1β 	  and	  TNFα 	  stimulation	  in	  p65	  translocation	  assays	  in	  MEF	  
cells.	  Upon	  C25	   treatment,	  p65	   translocation	   induced	  by	   IL-­‐1β	   stimulation	   is	  mildly	  affected	   (A),	  whereas	  TNFα-­‐
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To	   further	   specify	   the	   mechanism	   of	   action	   of	   C25	   a	   more	   detailed	   investigation	   of	   NF-­‐κB	  
signaling	   after	   IL-­‐1β	   stimulation	   was	   carried	   out.	   First,	   the	   observed	   decrease	   in	  
phosphorylation	  levels	  of	  IκBα	  in	  the	  time-­‐dependent	  experiments	  after	  IL-­‐1β	  stimulation	  was	  
confirmed	  in	  p-­‐IκBα	  ALPHASurefire	  experiments	  (Fig.	  4.17A).	  Although	  treatment	  with	  C25	  led	  
to	   a	   significantly	   dose-­‐dependent	   decline	   of	   p-­‐IκBα	   after	   IL-­‐1β	   stimulation	   (Fig.	   4.17A),	   the	  
influence	  of	  C25	  was	  weaker	  compared	  to	  the	  time-­‐dependent	  data	  in	  Figure	  4.15B	  due	  to	  an	  
altered	  ratio	  of	  cells	  to	  compounds	  in	  different	  well	  formats.	  Furthermore,	  the	  levels	  of	  TNFα	  
induced	  p-­‐IκBα	  were	  determined	  using	  the	  ALPHASurefire	  method.	  These	  experiments	  showed	  
almost	   no	   impact	   of	   C25	   in	   TNFα	   signaling	   towards	   activation	  of	  NF-­‐κB	   (Fig.	   4.17A).	   Second,	  
mRNA	   levels	   of	   selected	   IL-­‐1β	   induced	   target	   genes	   (ICAM-­‐1	   and	   A20)	   were	   determined	   by	  
qPCR	   and	   are	  presented	   in	   Figure	   4.17B.	  Here,	   pre-­‐treatment	  of	   cells	  with	  C25	   led	   to	   a	   very	  
mild,	  but	  not	  significant	  effect	  on	  target	  gene	  expression.	  	  
	  
	  	  	   	  
Figure	   4.17:	   Verification	   of	   C25	   in	   ALPHASurefire	   and	   qPCR	   experiments	   in	  MEF	   cells	   in	   IL-­‐1β 	   induced	  NF-­‐κB	  
activation.	  (A)	  p-­‐IκBα	  ALPHASurefire	  experiments	  reveal	  a	  mild	  significant	  inhibitory	  effect	  by	  increasing	  amounts	  
of	  C25	  after	   IL-­‐1β	  stimulation.	  Phosphorylation	   levels	  of	   IκBα	   in	  TNFα	  signaling	  are	  not	  significantly	  affected.	  (B)	  
qPCR	  studies	  show	  very	  mild	  effects	  of	  C25	  in	  IL-­‐1β	   induced	  NF-­‐κB	  signaling.	  Means	  and	  standard	  deviations	  are	  
depicted.	  Statistical	  analyses	  are	  performed	  using	  Student´s	  T-­‐test	  (p-­‐value	  <	  0.01).	  
	  
Summarizing	   the	   biochemical	   data,	   in	   vitro	   C25	   is	   a	   highly	   active	   and	   specifically	   acting	  
compound	  that	  directly	  targets	  TRAF6	  causing	  impaired	  binding	  to	  Ubc13	  as	  well	  as	  reducing	  E3	  
ligase	  activity.	  However,	   this	   strong	  efficacy	  could	  not	  be	  confirmed	   in	  cell-­‐based	  assays.	  C25	  
only	   causes	  mild	   effects	   on	   phosphorylation	   and	   degradation	   of	   IκBα,	   NF-­‐κB	   activation	   and	  
target	  gene	  expression	  in	  IL-­‐1β	  signaling.	  Nevertheless,	  C25	  appears	  to	  act	  pathway	  specific	  as	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be	   a	   promising	   small	   molecule	   for	   further	   improvement	   by	   performing	   structure	   activity	  
relationship	  (SAR)	  screening.	  	  
	  
4.6	  Hit	  optimization	  	  
The	   stage	   of	   hit	   optimization	   is	   characterized	   by	   chemical	  modification	   of	   the	   compound	   to	  
obtain	   analogs	   with	   improved	   potency	   in	   vitro	   and	   in	   cells.	   With	   the	   medical	   advice	   of	   Dr.	  
Manfred	  Rösner,	  47	  analogs	  of	  C25	  were	  defined	  for	  testing.	  Three	  residues	  (R1,	  R2	  and	  R3	  in	  
Figure	  4.18A)	  of	  C25	  were	  selected	  to	  be	  subjects	  of	  variation.	  	  	  
	  
4.6.1	  Biochemical	  Structural	  activity	  relationships	  of	  C25	  
First,	   the	   47	   analogs	  were	   analyzed	   in	   triplicates	   for	   inhibitory	   function	   in	   all	   three	   available	  
ALPHAScreen	  settings	   in	  a	  seven-­‐point	  titration	  curve	  (0.07	  -­‐	  50µM).	  Out	  of	  these	  47	  analogs,	  
three	   compounds	   (C25-­‐0167,	   C25-­‐0189	   and	   C25-­‐0140)	   showed	   a	   slightly	   stronger	   or	  
comparable	   effect	   to	   C25	   while	   binding	   of	   GST-­‐OTUB1	   or	   GST-­‐RNF8	   to	   Ubc13FH	   was	   not	  
affected	   (Figure	   4.18B).	   Exact	   inhibition	   curve	   data	   and	   chemical	   structures	   of	   these	  
compounds	  are	   illustrated	  in	  Figure	  4.19.	  The	  IC50	  values	  were	  not	  significantly	  optimized	  and	  
inhibition	  curves	  did	  rather	  overlay	  with	  C25	  than	  improve.	  Furthermore,	  ten	  analogs	  revealed	  
IC50	   values	   from	   3µM	   to	   10µM	   for	   TRAF6WTStrepII-­‐Ubc13FH	   binding	   (Figure	   4.18B	   and	  
supplement	  10.6-­‐9).	  Only	  one	  of	  these,	  C25-­‐212,	  had	  an	  impact	  on	  GST-­‐RNF8	  and	  GST-­‐OTUB1	  
interaction	   to	  Ubc13FH	  as	  well,	  but	   to	  a	   lesser	  extent	   (Figure	  4.18B	  and	  data	  not	   shown).	  14	  
tested	  analogs	  did	  inhibit	  the	  TRAF6WTStrepII	  -­‐Ubc13FH	  interaction	  in	  an	  IC50	  range	  from	  10µM	  
to	   50µM	   while	   no	   influence	   on	   GST-­‐OTUB1-­‐Ubc13FH	   and	   GST-­‐RNF8-­‐Ubc13FH	   binding	   was	  
observed.	   For	   20	   tested	   analogs	   no	   inhibitory	   potential	   could	   be	   detected	   (Figure	   4.18B).	   It	  
appears	   that	   at	   least	   one	   of	   the	   aromatic	   structures	   at	   either	   R1	   or	   R2	   is	   required	   to	   target	  
TRAF6	  preventing	  its	  binding	  to	  Ubc13.	  Removing	  the	  triazolring	  at	  R3	  leads	  to	  a	  complete	  loss	  
of	  the	  inhibitory	  potential	  implying	  that	  the	  compounds	  target	  TRAF6	  with	  an	  aromatic	  residue	  
at	  either	  R1	  or	  R2	  and	  a	  heterocyclic	  structure	  at	  R3.	  In	  addition,	  when	  deleting	  one	  of	  the	  two	  
aromatic	  structures	  at	  R1	  or	  R2	  or	  overcoming	  the	  planarity	  of	  C25,	  a	  trend	  towards	  improved	  
solubility	  was	  recognized.	  Concluding	  the	  analog	  screening,	  out	  of	  47	  tested	  compounds,	  three	  
compounds	  showed	  a	  slightly	  enhancement	  in	  inhibiting	  TRAF6-­‐Ubc13	  in	  vitro	  but	  at	  the	  same	  
time	   did	   not	   influence	   the	   binding	   of	   GST-­‐OTUB	   to	   Ubc13FH.	   These	   compounds	   were	  
subsequently	  verified	  in	  cell-­‐based	  assays.	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Figure	  4.18:	  Biochemical	  analog	  screening	  using	  the	  ALPHAScreen	  technology.	  (A)	  Three	  residues	  (R1,	  R2	  and	  R3)	  
were	  subject	  of	  variation	   for	  structure	  activity	   relationship	  studies.	   (B)	  Summary	  of	  structural	  modifications,	   IC50	  
values	  and	  solubility	  of	  47	  analogs	  of	  C25	  tested	  in	  TRAF6WTStrepII-­‐Ubc13FH,	  GST-­‐OTUB1-­‐Ubc13FH	  and	  GST-­‐RNF8-­‐















C25 -­ Phenyl Piperazin CH3 2,8 >  50 >  50
C25-­0167 + 3-­MeO-­phenyl Piperazin CH3 1,5 >  50 >  50
C25-­0189 -­ 2-­Pyridyl Piperazin CH3 2,6 >  50 >  50
C25-­0140 + Benzyl Piperidin CH3 2,6 >  50 >  50
C25-­0196 -­ 4-­F-­phenyl Piperazin CH3 3,0 >  50 >  50
C25-­0058 -­ 4-­F-­phenyl Piperazin H 3,3 >  50 >  50
C25-­0174 -­ -­-­ Pyrrolidino CH3 3,4 >  50 >  50
C25-­0209 -­ 4-­MeO-­phenyl Piperazin CH3 4,5 >  50 >  50
C25-­0029 -­ 3-­MeO-­phenyl Piperazin H 4,6 >  50 >  50
C25-­0071 -­ 4-­MeO-­phenyl Piperazin H 5,4 >  50 >  50
C25-­0033 + Phenyl Piperazin H 6,0 >  50 >  50
C25-­0266 + 3-­Cl-­benzyl -­-­ CH3 6,7 >  50 >  50
C25-­0051 + 2-­Pyridyl Piperazin H 9,5 >  50 >  50
C25-­0212 + 5-­Me-­2-­furylmethyl -­-­ CH3 9,5 ~50 ~  50
C25-­0211 -­ 2-­F-­phenyl Piperazin CH3 10,4 >  50 >  50
C25-­0172 + Phenyl-­(CH2)3-­ -­-­ CH3 11,4 >  50 >  50
C25-­0002 + Benzyl Piperidin H 12,5 >  50 >  50
C25-­0175 -­ 2,5-­diMe-­phenyl Piperazin CH3 20,5 >  50 >  50
C25-­0253 + 4-­Cl-­benzyl -­-­ CH3 21,2 >  50 >  50
C25-­0198 + 3-­Indolylmethyl -­-­ CH3 23,7 >  50 >  50
C25-­0269 + 2-­Thienylmethyl -­-­ CH3 24,6 >  50 >  50
C25-­0224 + Benzyl -­-­ CH3 26,5 >  50 >  50
C25-­0034 + Phenyl-­(CH2)3-­ -­-­ H 32,4 >  50 >  50
C25-­0208 + Ethyl Piperazin CH3 34,0 >  50 >  50
C25-­0031 + 4-­Me Piperidino H 39,4 >  50 >  50
C25-­0036 + -­-­ Pyrrolidino H 40,0 >  50 >  50
C25-­0254 + 2-­F-­benzyl -­-­ CH3 40,4 >  50 >  50
C25-­0265 + 2-­Furylmethylthioethyl -­-­ CH3 42,7 >  50 >  50
C25-­0095 + 2-­Pyrimidinyl Piperazin H >  50 >  50 >  50
C25-­0142 + 3-­Pyridyl -­-­ CH3 >  50 >  50 >  50
C25-­0166 + 2-­MeO-­phenyl Piperazin CH3 >  50 >  50 >  50
C25-­0218 + Morpholinoethyl -­-­ CH3 >  50 >  50 >  50
C25-­0227 + 4-­Acetamidophenyl -­-­ CH3 >  50 >  50 >  50
C25-­0149 + 2,4-­DiF-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0155 + 3-­Ethoxycarbonyl-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0159 + 3-­F-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0183 + 3-­Methylbutyl -­-­ CH3 >  50 >  50 >  50
C25-­0214 + 4-­CF3O-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0223 + 4-­Acetyl-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0144 + 3-­MeO-­phenyl -­-­ CH3 >  50 >  50 >  50
C25-­0275 + -­-­ 2-­Furylethyl CH3 >  50 >  50 >  50
C25-­0028 + 2-­MeO-­phenyl Piperazin H >  50 >  50 >  50
C25-­0024 + 2-­Furylmethyl -­-­ H >  50 >  50 >  50
C25-­0054 + 4-­Fluorbenzyl -­-­ H >  50 >  50 >  50
C25-­0083 + Benzyl 4-­Piperidinyl H >  50 >  50 >  50
C25-­0643 + Phenyl Piperazin 4-­F-­phenyl >  50 >  50 >  50
C25-­1379 + 4-­F-­phenyl Piperazin Phenyl >  50 >  50 >  50
C25-­0089 + 4-­Acetamidophenyl -­-­ H >  50 >  50 >  50
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Figure	  4.19:	  Biochemical	  analog	  screening	  using	  the	  ALPHAScreen	  technology.	  Chemical	  structures,	  solubility	  and	  
titration	   curves	   in	   TRAF6WTStrepII-­‐Ubc13FH	   ALPHAScreen	   experiments	   of	   the	   three	   best	   hits	   out	   of	   the	   analog	  
screening:	   C25-­‐0167,	   C25-­‐0189	   and	   C25-­‐0140.	   Dose-­‐dependent	   effects	   of	   all	   compounds	   on	   TRAF6WTStrepII-­‐
Ubc13FH	   interaction	   are	   observed.	   Importantly,	   the	   binding	   of	   GST-­‐OTUB1	   and	   GST-­‐RNF8	   to	   Ubc13FH	   remain	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C25	  TRAF6-­‐Ubc13	  	  	  	  	  	  	  	  	  	  	  IC50: 2.8 ± 0.38 µM	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  OTUB1-­‐Ubc13	  
C25	  RNF8-­‐Ubc13	  
C25-­‐0167	  TRAF6-­‐Ubc13	  IC50: 1.5 ± 0.22 µM	  
C25-­‐0167	  OTUB1-­‐Ubc13	  
C25-­‐0167	  RNF8-­‐Ubc13	  
C25	  TRAF6-­‐Ubc13	  	  	  	  	  	  	  	  	  	  	  	  IC50: 2.8 ± 0.38 µM	  
C25-­‐0189	  TRAF6-­‐Ubc13	  IC50: 2.6 ± 0.25 µM	  
C25-­‐0189	  OTUB1-­‐Ubc13	  
C25-­‐0189	  RNF8-­‐Ubc13	  
C25	  TRAF6-­‐Ubc13	  	  	  	  	  	  	  	  	  	  	  	  IC50: 2.8 ± 0.38 µM	  
C25-­‐0140	  TRAF6-­‐Ubc13	  IC50: 1.5 ± 0.22 µM	  
C25-­‐0140	  OTUB1-­‐Ubc13	  
C25-­‐0140	  RNF8-­‐Ubc13	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4.6.2	  Verification	  of	  the	  three	  best	  analogs	  of	  C25	  in	  cell-­‐based	  assays	  
The	   three	   compounds	   C25-­‐0167,	   C25-­‐0189	   and	   C25-­‐0140	   exhibiting	   comparable	   in	   vitro	  
efficacies	   to	   C25	   were	   tested	   in	   cell-­‐based	   assays	   for	   their	   inhibitory	   potential	   on	   NF-­‐κB	  
activation.	   Initially,	   these	  compounds	  were	  examined	  for	  cytotoxicity	   in	  HepG2	  and	  MEF	  cells	  
using	   the	   CellTiter-­‐Blue	   technology.	   Whereas	   HepG2	   cells	   exhibited	   slight	   sensitivity	   to	   the	  
compounds	   C25-­‐0140	   and	   C25-­‐0167,	   all	   tested	   compounds	  were	  well	   tolerated	   by	  MEF	   cells	  
(Figure	  4.20A).	  Next,	  EMSA	  experiments	  with	  20µM	  and	  30µM	  compound	  and	  IL-­‐1β	  stimulation	  
were	   performed.	   Results	   are	   presented	   in	   Figure	   4.20B	   and	   revealed	   C25-­‐0140	   as	   the	  
compound	  with	  the	  strongest	  inhibitory	  effect.	  To	  further	  prove	  this	  observation,	  the	  levels	  of	  
p-­‐IκBα	  in	  ALPHASurefire	  experiments	  after	  IL-­‐1β	  stimulation	  were	  analyzed.	  In	  this	  experiment,	  
all	  three	  investigated	  compounds	  showed	  improved	  efficacy	  compared	  to	  C25.	  Again,	  C25-­‐0140	  
demonstrated	   the	   best	   inhibitory	   potential	   with	   dose-­‐dependent	   inhibition	   using	   25µM	   and	  
50µM	   compound	   concentration	   whereas	   C25-­‐0167	   and	   C25-­‐0189	   did	   not	   (Figure	   4.20C).	   As	  
depicted	  in	  Figure	  4.18B,	  C25	  and	  C25-­‐0189	  were	  not	  well	  dissolved	  in	  DMSO	  while	  C25-­‐0140	  
and	  C25-­‐0167	  were	   completely	   soluble	   in	  DMSO.	  The	   improved	  potency	  of	  C25-­‐0140	   in	  MEF	  
cells	  might	  arise	  from	  the	  better	  solubility	   in	  contrast	  to	  C25.	  For	  pathway	  specificity	  tests,	  p-­‐
IκBα	  ALPHASurefire	  experiments	  were	  accomplished	  after	  treatment	  of	  MEF	  cells	  with	  50µM	  of	  
each	  compound	  and	  subsequent	  TNFα	  stimulation.	  Data	  in	  Figure	  4.20D	  show	  that	  compounds	  
that	  are	  less	  effective	  in	  IL-­‐1β	  signaling	  (C25,	  C25-­‐0167	  and	  C25-­‐0189)	  did	  almost	  not	  influence	  
TNFα	   stimulated	  phosphorylation	  of	   IκBα.	  However,	  C25-­‐0140	  did	   impact	  p-­‐IκBα	   after	   TNFα	  
stimulation	  to	  the	  same	  extent	  as	  in	  IL-­‐1β	  signaling	  (Fig.	  4.20C	  and	  D).	  	  
To	  summarize	  the	  analog	  screening,	  three	  out	  of	  47	  tested	  compounds	  showed	  comparable	  in	  
vitro	  activity	  to	  the	  hit	  compound	  C25:	  C25-­‐0140,	  C25-­‐0167	  and	  C25-­‐0189.	  Out	  of	  these	  three	  
compounds	   C25-­‐0140	   demonstrated	   the	   strongest	   inhibitory	   potential	   in	   IL-­‐1β	   signaling.	  
However,	   this	   effect	   is	   also	   given	   after	   TNFα	   stimulation	   suggesting	   no	   pathway	   specificity.	  
Nevertheless,	  due	  to	  the	  improved	  potency	  of	  C25-­‐0140,	  this	  compound	  was	  subject	  for	  further	  
investigation	   due	   to	   the	   involvement	   of	   both	   IL-­‐1β	   and	   TNFα	   signaling	   in	   most	   chronic	  
inflammatory	  diseases.	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Figure	  4.20:	  Verification	  of	  the	  best	  three	  analogs	  of	  C25	  in	  cell-­‐based	  assays	  in	  MEF	  cells.	  (A)	  Cytotoxicity	  studies	  
of	  C25,	  C25-­‐0140,	  C25-­‐0167	  and	  C25-­‐0189	  in	  CellTiter-­‐Blue	  experiments.	  (B)	  EMSA	  studies	  of	  C25,	  C25-­‐0140,	  C25-­‐
0167	   and	   C25-­‐0189	   after	   IL-­‐1β stimulation.	   C25-­‐0140	   shows	   the	   strongest	   inhibitory	   potential.	   (C)	   p-­‐IκBα	  
ALPHASurefire	  experiments	  confirm	  C25-­‐0140	  as	  the	  most	  inhibitory	  compound	  after	  IL-­‐1β	  stimulation.	  (D)	  p-­‐IκBα	  
ALPHASurefire	   experiments	   after	   TNFα	   stimulation	   of	   compound-­‐treated	   MEF	   cells	   [50µM]	   show	   no	   pathway	  
specificity	  of	  C25-­‐0140.	  Means	  and	  standard	  deviations	  are	  shown.	  Statistical	  significances	  are	  determined	  using	  
Student´s	  t-­‐test	  (p-­‐value	  <	  0.01).	  	  
	  
4.7	  In-­‐depth	  analysis	  of	  C25-­‐0140	  
Out	  of	   the	  analog	   screening,	  C25-­‐0140	  appeared	   to	  be	   the	   strongest	   inhibitory	   compound	   in	  
cells.	  To	  verify	  these	  data,	   in	  vitro	  as	  well	  as	  cell-­‐based	  assays	  were	  carried	  out.	  Compared	  to	  
C25,	  the	  Phenyl-­‐residue	  at	  R1	  is	  replaced	  by	  a	  Benzyl-­‐group	  in	  C25-­‐0140	  and	  R2	  is	  changed	  to	  a	  
Piperidin.	  With	  modifying	   these	   two	  groups	   the	  planar	   structure	  of	  C25	   is	  overcome	  and	   the	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formula	  and	  name	  of	  C25-­‐0140	  are	  depicted	  in	  Figure	  4.21A.	  The	  parameters	  for	  analyzing	  the	  
criteria	  of	  the	  Lipinski´s	  rule	  are	  depicted	  in	  Figure	  4.21B	  and	  describe	  C25-­‐0140	  as	  a	  drug-­‐like	  
and	  potential	  orally	  available	  compound.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   4.21:	   Biochemical	   validation	   of	   C25-­‐0140.	   (A)	  Compound	   structure,	   chemical	   formula	   and	  name	  of	  C25-­‐
0140.	  (B)	  Chemical	  parameters	  of	  C25-­‐0140	  meet	  the	  Lipinski´s	  rule	  of	  five	  and	  determine	  C25-­‐0140	  as	  a	  drugable	  
compound.	   (D)	  NMR	  studies	  of	  TRAF6WT	  and	  C25-­‐0140	  reveal	  a	  direct	  binding	  of	   the	  compound	  to	  TRAF6	   (NMR	  
experiments	  were	  performed	  by	  Dr.	  Grzegorz	  Popowicz	  from	  the	   Institute	  of	  Structural	  Biology	  at	  the	  Helmholtz	  
Zentrum	  München).	  
	  
4.7.1	  Biochemical	  studies	  of	  C25-­‐0140	  
In	   the	   analog	   screening	   described	   in	   section	   4.6,	   C25-­‐0140	   was	   analyzed	   for	   affecting	  
TRAF6WTStrepII-­‐Ubc13FH	  binding	  as	  well	  as	  the	   interactions	  of	  GST-­‐OTUB1-­‐Ubc13FH	  and	  GST-­‐
RNF8-­‐Ubc13FH.	  Dose-­‐response	   curves	   are	   presented	   in	   Figure	   4.19.	   The	   binding	   of	   TRAF6	   to	  
Ubc13	  was	   impaired	   in	  a	  similar	  manner	  as	  C25.	  Still,	   the	   interaction	  of	  Ubc13	  to	  OTUB1	  and	  
RNF8	  was	  not	  altered	  at	  all	  under	   these	  conditions.	  To	  verify	  a	  direct	  binding	  of	  C25-­‐0140	  to	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displayed	   in	   Figure	   4.21C.	   Similar	   to	   C25,	   multiple	   peaks	   did	   shift	   or	   disappear	   after	   adding	  
compound	  C25-­‐0140.	  Thereby,	  C25-­‐0140	  shows	  a	  similar	  pattern	  of	  peaks	  changing	  compared	  
to	  C25	  (Figure	  4.13C).	  	  
The	   direct	   binding	   of	   C25-­‐0140	   to	   TRAF6	   RZ1	  was	   further	   analyzed	   by	   pulldown	   assays.	   Pre-­‐
incubation	  of	  GST-­‐TRAF6WT	  with	   increasing	  amounts	  of	  C25-­‐0140	   (10,	  20	  and	  30µM)	   led	   to	  a	  
slight	   reduction	   in	  binding	  to	  Ubc13FH	  (Figure	  4.22A).	  Next,	   the	  effect	  of	  an	   impaired	  TRAF6-­‐
Ubc13	  binding	  was	  determined	  in	  a	  functional	  in	  vitro	  ubiquitination	  assay.	  Targeting	  untagged	  
TRAF6WT	  with	   increasing	  compound	  concentrations	  of	  C25-­‐0140	   led	  to	  a	  decreased	  formation	  
of	   polyubiquitin	   chains	   to	   the	   levels	   of	   the	   Ubc13	   binding	   deficient	   mutant	   TRAF6D57K	   (Fig.	  
4.22B).	  In	  comparison	  to	  C25	  (Fig.	  4.14B),	  C25-­‐0140	  is	  slightly	  more	  active	  at	  a	  concentration	  of	  
20µM.	   The	   discrepancy	   of	   the	   efficiency	   of	   C25-­‐0140	   between	   pulldown	   assays	   and	  
ubiquitination	  assay	  is	  due	  to	  the	  higher	  concentration	  of	  proteins	  that	  is	  required	  for	  pulldown	  
assays.	   To	   conclude,	   in	   vitro	   data	   showed	   that	   C25-­‐0140	   does	   not	   demonstrate	   a	   significant	  





4.7.2	  Investigation	  of	  C25-­‐0140	  in	  cell-­‐based	  assays	  
Although	  C25-­‐0140	  did	  not	  show	  improved	  efficiency	  in	  inhibiting	  the	  TRAF6-­‐Ubc13	  interaction	  
in	  vitro,	  EMSA	  and	  ALPHASurefire	  experiments	  revealed	  an	  elevated	  inhibitory	  potency	  of	  C25-­‐
0140	  (Fig.	  4.20A).	  However,	  this	  observation	  applies	  to	  both	  IL-­‐1β	  and	  TNFα	  signaling	  towards	  
NF-­‐κB.	  For	  further	  investigation,	  detailed	  cytotoxic	  analysis	  was	  performed	  in	  HepG2	  as	  well	  as	  
in	  MEF	  cells	  first.	  CellTiter-­‐Blue	  experiments	  in	  HepG2	  cells	  seemed	  to	  be	  slightly	  influenced	  by	  
C25-­‐0140	  although	  this	  effect	  did	  not	  show	  any	  dose-­‐dependency.	  Whereas	  the	  mitochondrial	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Figure	   4.22:	   Biochemical	  
validation	   of	   C25-­‐0140.	   (A)	   In	  
vitro	   pulldown	   assay	   of	   GST-­‐
TRAF6WT	   and	   Ubc13FH.	   C25-­‐
0140	   reduces	   TRAF6	   binding	  
to	   Ubc13	   dose-­‐dependently.	  
(B)	   Pre-­‐incubation	   of	   TRAF6WT	  
with	  C25-­‐0140	  leads	  to	  a	  dose-­‐
dependent	   decrease	   in	  
assembling	   free	   polyubiquitin	  
chains	   in	   in	   vitro	  
ubiquitination	  assays.	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mass	  detected	  by	  Mitotracker	  staining	  remained	  unaffected,	  the	  nucleus	  area	  estimated	  from	  
the	  Hoechst	  33342	  staining	  did	  decrease	  at	  100µM	  compound	  concentration	  in	  the	  HepG2	  cell	  
line	  (Figure	  4.23A).	   In	  MEF	  cells,	  CellTiter-­‐Blue	  assays	  did	  not	  show	  any	   influence	  of	  C25-­‐0140	  
on	  cell	  viability	  (Fig.	  4.23A).	  This	  was	  also	  true	  for	  the	  nucleus	  area	  (Fig.	  4.23A).	  However,	  the	  
mitochondrial	  mass	  was	   increased	  by	  approximately	  25%	  starting	  at	  a	  concentration	  of	  50µM	  
C25-­‐0140	  (Fig.	  4.23A).	  	  
	  
	  
Figure	  4.23:	  Cytotoxicity	  tests	  and	  cell-­‐based	  verification	  of	  C25-­‐0140	  in	  EMSA	  experiments.	  (A)	  Cytotoxicity	  tests	  
of	  C25-­‐0140	  in	  HepG2	  and	  MEF	  cells	  revealing	  that	  MEF	  cells	  tolerate	  C25-­‐0140	  better	  than	  HepG2	  cells	  (B)	  C25-­‐
0140	   treated	   MEF	   cells	   show	   a	   delayed	   and	   reduced	   activation	   of	   NF-­‐κB	   after	   IL-­‐1β	   stimulation	   (C)	   C25-­‐0140	  
causes	  dose-­‐dependent	  decrease	  of	  NF-­‐κB	  activation	  after	  both	  IL-­‐1β.	  	  
	  
Next,	  the	  influence	  of	  C25-­‐0140	  on	  NF-­‐κB	  activation	  after	  IL-­‐1β	  was	  analyzed	  in	  time-­‐	  and	  dose-­‐
dependent	  EMSA	  experiments.	  Treatment	  of	  cells	  with	  30µM	  C25-­‐0140	   led	   to	  a	   reduced	  and	  
delayed	  activation	  of	  NF-­‐κB	  in	  IL-­‐1β	  stimulation	  experiments	  (Fig.	  4.23B).	  Pre-­‐treatment	  of	  MEF	  
cells	  with	  increasing	  amounts	  of	  C25-­‐0140	  (10-­‐30µM)	  led	  to	  a	  dose-­‐dependent	  reduction	  of	  NF-­‐
κB	  activation	  (Fig.	  4.23C).	  In	  p65	  translocation	  experiments,	  cells	  were	  pre-­‐treated	  with	  12.5µM	  
C25-­‐0140.	  Compound	  treatment	  reduced	  IL-­‐1β	  and	  TNFα	  induced	  nuclear	  translocation	  of	  p65	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Figure	  4.24:	  Verification	  of	  the	  inhibitory	  potential	  of	  C25-­‐0140	  in	  p65	  translocation	  assays.	  MEF	  cells	  were	  pre-­‐
treated	  with	   12.5µM	  C25-­‐0140	   and	   stimulated	  with	   either	   IL-­‐1β	   (A)	   or	   TNFα	   (B)	   for	   20	  min.	   C25-­‐0140	   reduced	  
nuclear	  translocation	  of	  p65	  in	  both	  stimulation	  experiments.	  	  	  
	  
To	   further	   analyze	   the	   pathway	   specificity	   of	   C25-­‐0140,	   target	   gene	   expression	   experiments	  
were	  performed	  using	  qPCR.	   In	  order	  to	  compare	  the	  efficiency	  of	  the	  compound	  to	  all	   three	  
signaling	  pathways	  (IL-­‐1β,	  LPS	  and	  TNFα),	  the	  same	  target	  genes	  were	  chosen	  for	  all	  stimulation	  
experiments.	  However,	  only	  A20	  was	  found	  to	  be	  induced	  by	  all	  of	  the	  stimulants.	  ICAM-­‐1	  gene	  
expression	   was	   only	   regulated	   by	   IL-­‐1β	   and	   TNFα	   stimulation.	   Instead,	   IL-­‐6	   expression	   was	  
analyzed	  in	  the	  case	  of	  LPS	  stimulation.	  For	  A20,	  only	  a	  mild,	  but	  dose-­‐dependent	  reduction	  of	  
mRNA	  expression	  was	  obtained	  for	  all	   three	  stimulants	  up	  to	  20µM	  C25-­‐0140	  treatment	   (Fig.	  
4.25).	  However,	   LPS-­‐induced	  upregulation	  of	  A20	   could	  not	   significantly	   be	   impaired	  by	  C25-­‐
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stimulation	  with	  a	  slightly	  higher	  impact	  on	  TNFα	  signaling.	  Also,	  IL-­‐6	  mRNA	  induction	  after	  LPS	  
stimulation	   was	   diminished	   dose-­‐dependently	   and	   to	   a	   higher	   extent	   than	   A20.	   In	   general,	  
compared	   to	   the	   effects	   of	   C25	   in	   qPCR	   experiments	   (Fig.	   4.17B)	   a	   clearly	   higher	   inhibitory	  
potential	  was	  accomplished	  with	  C25-­‐0140.	  
	  
	  
Figure	  4.25:	  Investigation	  of	  C25-­‐0140	  in	  NF-­‐κB	  target	  gene	  expression	  in	  qPCR	  experiments.	  qPCR	  studies	  after	  
IL-­‐1β	  (60	  min)	  (A),	  LPS	  (75	  min)	  (B)	  or	  TNFα	  (60	  min)	  (C)	  stimulation	  lead	  to	  a	  moderate	  reduction	  of	  target	  gene	  
expression	   but	   no	   pathway	   selectivity	   is	   obtained.	   Mean	   and	   standard	   deviation	   are	   depicted.	   Statistical	  
significances	  are	  calculated	  using	  Student´s	  t-­‐test	  (p-­‐value	  <	  0.01).	  
	  
To	  conclude	  the	  EMSA	  and	  qPCR	  experiments,	  C25-­‐0140	  clearly	  shows	  an	  appropriate	  inhibitory	  
effect	  on	  NF-­‐κB	  activation.	  However,	  this	  influence	  appears	  to	  not	  be	  pathway	  specific	  as	  all	  the	  
tested	  signaling	  pathways	  IL-­‐1β,	  LPS	  and	  TNFα	  were	  affected.	  	  
To	  further	  characterize	  the	  mechanism	  of	  action	  of	  C25-­‐0140,	  additional	  experiments	  upstream	  
of	  NF-­‐κB	  activation	  and	   target	  gene	  expression	  were	  performed	  after	   IL-­‐1β	   stimulation.	  First,	  
endogenous	   TRAF6	   auto-­‐ubiquitination	   after	   stimulation	   was	   examined	   using	   increasing	  
concentrations	  of	  C25-­‐0140	  (10,	  20	  and	  30µM).	  Already	  at	  a	  concentration	  of	  10µM	  C25-­‐0140,	  
TRAF6	   ubiquitination	  was	   diminished	   compared	   to	   DMSO	   treated	   cells	   (Fig.	   4.26A).	   Stronger	  
effects	  were	   achieved	  with	   higher	   concentrations	   and	  were	   even	   completely	   abrogated	  with	  
30µM	   C25-­‐0140	   (Fig.	   4.26A).	   Second,	   the	   phosphorylation	   of	   IκBα	   in	   ALPHASurefire	  
experiments	  after	   IL-­‐1β	   stimulation	  was	  diminished	   in	  a	  dose-­‐dependent	  manner	   (Fig.	   4.26B)	  
and	  was	  markedly	  improved	  compared	  to	  C25	  (Fig	  4.17A).	  Last,	  the	  activity	  of	  the	  IKK	  complex	  
after	  IL-­‐1β	  stimulation	  was	  analyzed.	  Pre-­‐treatment	  of	  MEF	  cells	  with	  increasing	  concentrations	  
of	   C25-­‐0140	   led	   to	   a	   decrease	   in	   phosphorylation	   of	   recombinant	   GST-­‐IκBα	   by	   the	  
immunoprecipitated	   IKK	   complex	   comparable	   to	   the	   unstimulated	   control	   (Fig	   4.26C).	   This	  
observation	  is	  also	  true	  for	  p-­‐IκBα	   levels	  in	  the	  lysate	  samples	  that	  are	  strongly	  reduced	  after	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Figure	  4.26:	  C25-­‐0140	   impairs	   IL-­‐1β 	   stimulated	  NF-­‐κB	  signaling	  upstream	  of	  NF-­‐κB	  activation	   in	  MEF	  cells.	   (A)	  
Pre-­‐treatment	   of	   MEF	   cells	   with	   C25-­‐0140	   leads	   to	   a	   dose-­‐dependent	   reduction	   of	   IL-­‐1β	   induced	   TRAF6	   auto-­‐
ubiquitination.	   (B)	   p-­‐IκBα	   ALPHASurefire	   experiments	   reveal	   an	   inhibitory	   effect	   by	   increasing	   amounts	   of	   C25-­‐
0140	  after	  IL-­‐1β stimulation.	  Mean	  and	  standard	  deviation	  are	  shown.	  Statistical	  significances	  are	  calculated	  using	  
Student´s	   t-­‐test	   (p-­‐value	   <	   0.01).	   (C)	   C25-­‐0140	   decreases	   the	   activity	   of	   the	   IKK	   complex	   in	   a	   dose-­‐dependent	  
manner.	   (D)	  ADME	  studies	  of	  C25-­‐0140	  carried	  out	  by	  Bienta,	  ENAMINE	  Ltd.	  Except	  CYP450	  inhibition,	  C25-­‐0140	  
exhibits	  good	  parameter. 
	  
Summarizing	  the	  assays	  analyzing	  the	  impacts	  of	  C25-­‐0140	  upstream	  of	  NF-­‐κB	  activation,	  C25-­‐
0140	   targets	  TRAF6	  auto-­‐ubiquitination	  which	   leads	   to	   impaired	  activity	  of	   the	   IKK	  assay	  and	  
reduced	  p-­‐IκBα	  levels	  causing	  a	  diminished	  NF-­‐κB	  activation	  and	  target	  gene	  expression.	  	  
For	   further	   analysis	   of	   C25-­‐0140,	   ADME	   studies	   were	   performed.	   An	   overview	   of	   the	  
experiments,	   tested	   concentrations	   as	   well	   as	   the	   results	   is	   given	   in	   Figure	   4.26D.	   Plasma	  
stability	  assays	  did	  not	  observe	  any	  degradation	  of	  C25-­‐0140	   in	  over	  240	  minutes	   in	  a	  mouse	  
plasma	  environment	  referring	  to	  highly	  stable	  compound.	  However,	  the	  compound	  was	  96.8%	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0140	  with	   an	   elimination	   constant	   kel=	   0.004/min,	   a	   half	   life	   of	   T1/2=	   171.63	  minutes	   and	   an	  
intrinsic	   clearance	  Clint=	   9.73µL/min/mg.	   The	  distribution	   coefficient	   (LogD)	  was	   estimated	   to	  
2.83,	  which	  is	  considered	  to	  be	  in	  an	  optimal	  range	  (for	  LogP,	  see	  4.21B).	  In	  the	  caco-­‐2	  assay,	  
the	   permeability	   coefficient	   was	   calculated	   to	   48.02*10-­‐6/cm/s	   referring	   to	   an	   optimal	  
permeability	  of	  C25-­‐0140	  (Huang	  et	  al.,	  2009).	  In	  the	  CYP450	  inhibition	  assay,	  C25-­‐0140	  shows	  
inhibition	  of	  all	   tested	  CYP450	  subsets	  to	  a	  different	  extent.	   In	  the	  hERG	  predictor	  assay	  C25-­‐
0140	   inhibited	  28.3%	  of	   tracer	  binding	  at	  a	   concentration	  of	  50µM	  and	  with	   this	   relates	   to	  a	  
modest	  inhibition.	  Thus,	  except	  its	  activity	  on	  CYPs,	  C25-­‐0140	  is	  a	  compound	  with	  overall	  good	  
ADME	  parameters.	  
After	  testing	  the	  behavior	  of	  C25-­‐0140	  in	  ADME	  studies,	  this	  compound	  was	  analyzed	  in	  a	  low-­‐
grade	  chronic	  inflammation	  mouse	  model	  to	  test	  its	  pharmacological	  potency.	  	  
	  
4.7.3	  Analysis	  of	  the	  effect	  of	  C25-­‐0140	  in	  an	  obese	  mouse	  model	  
Chronic	   inflammation	   is	   widely	   observed	   in	   obesity.	   In	   obese	  mouse	  models,	   a	   high-­‐fat-­‐diet	  
(HFD)	   increases	   NF-­‐κB	   activation	   (Carlsen	   et	   al.,	   2009)	   and	   leads	   to	   upregulation	   of	  
inflammatory	   genes	   like	   TNFα,	   IL-­‐1β	   and	   IL-­‐6	   in	   the	   epidermal	   white	   adipose	   tissue	   (eWAT)	  
(Makki	  et	  al.,	  2013).	  Furthermore,	  mice	  that	  are	  mutated	  in	  CD40-­‐TRAF6	  signaling	  show	  milder	  
body	   weight	   gain,	   lower	   fat	   mass	   as	   well	   as	   improved	   insulin	   sensitivity	   and	   reduced	  
inflammation	   in	   adipose	   tissue	   in	   HFD	   experiments	   compared	   to	   CD40	   wildtype	   mice	  
(Chatzigeorgiou	  et	  al.,	  2014).	  As	  C25-­‐0140	  exhibits	   the	  potential	   to	   significantly	   inhibit	  TRAF6	  
induced	   NF-­‐κB	   activation	   in	   vitro	   and	   in	  MEF	   cells,	   obese	  mice	   were	   chosen	   to	   analyze	   the	  
effect	  of	  TRAF6-­‐Ubc13	   inhibition	   in	  a	  mouse	  model.	  The	  small	  molecule	  SMI	  6860766	  targets	  
the	  MATH	  domain	  of	  TRAF6	  and	  was	  analyzed	  also	  in	  a	  HFD	  obese	  mouse	  model	  (Van	  Den	  Berg	  
et	  al.,	  2014).	  This	  allowed	  comparison	  of	  both	  compounds	  in	  affecting	  the	  chronic	  inflammation	  
as	  well	  as	   the	  glucose	   intolerance.	   In	  cooperation	  with	   the	   Institute	   for	  Diabetes	  and	  Obesity	  
(IDO)	  16	  mice	  were	  set	  on	  a	  HFD	  for	  at	   least	  12	  months	  gaining	  obesity	  and	  Type	   II	  Diabetes	  
Mellitus	   associated	  with	   insulin	   resistance.	   Reaching	   a	   body	  weight	   of	   at	   least	   40g	   (average	  
body	  weight	  =	  55g),	  these	  mice	  were	  divided	   into	  two	  groups	  and	  treated	  with	  either	  control	  
solution	  or	  C25-­‐0140	  every	  24	  hours	  with	  a	  dose	  of	  14µmol/kg	  (=6.4mg/kg)	  intra	  peritoneal	  for	  
20	  days.	  Every	  day	  before	   injection,	   the	  body	  weight	  of	   the	  mice	  and	   their	   food	   intake	  were	  
monitored.	   The	   results	   of	   these	   measurements	   are	   summarized	   in	   Figure	   4.27A	   and	   4.27B.	  
Whereas	  the	  control	   treated	  mice	  constantly	  gained	  body	  weight	  under	  HFD	  conditions,	  C25-­‐
0140	   treated	   individuals	   did	   hardly	   increase	   their	   body	  weight	   over	   the	   20	   test	   days	   (Figure	  
4.27A).	   Importantly,	   food	   intake	   did	   not	   differ	   between	   the	   two	   groups	   over	   the	   entire	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treatment	  period	  (Figure	  4.27B).	  Given	  these	  observations	  and	  the	  evidence,	  that	  mice	  with	  a	  
mutated	  CD40-­‐TRAF6	  signaling	  show	  improved	  insulin	  sensitivity,	  a	  glucose	  tolerance	  test	  (GTT)	  
was	  performed	  on	  day	  18.	  A	  GTT	  is	  conducted	  to	  investigate	  the	  clearance	  of	  the	  glucose	  out	  of	  
the	  blood.	  Therefore,	  glucose	  was	  applied	  to	  the	  mice	  two	  hours	  after	  administration	  of	  C25-­‐
0140.	   Blood	   samples	  were	   taken	   before,	   15	  min,	   30	  min,	   60	  min	   and	   120	  min	   after	   glucose	  
administration	  and	  the	  amount	  of	  glucose	  was	  measured	  using	  commercial	  available	  test	  strips.	  
Data	  out	  of	   the	  GTT	  are	  presented	   in	  Figure	  4.27C.	  After	  applying	  glucose	   to	   the	  mice,	  blood	  
glucose	   levels	   increased	   within	   15	  min.	   Afterwards,	   glucose	   is	   constantly	   cleared	   out	   of	   the	  
body.	   However,	   no	   significant	   alteration	   in	   glucose	   clearance	   between	   the	   control	   and	   C25-­‐
0140	   treated	   mice	   was	   obtained	   in	   either	   blood	   glucose	   levels	   or	   area	   under	   the	   curve	  
calculations	  (Figure	  4.27C).	  
	  
	  	  	  	  	  	   	  
Figure	   4.27:	   C25-­‐0140	   affects	   body	   weight	   gain	   in	   high-­‐fat-­‐diet	   experiments	   while	   food	   intake	   and	   glucose	  
intolerance	   remains	   unchanged.	   (A)	  C25-­‐0140	   treated	  mice	   show	  milder	  body	  weight	  gain	   than	  control	  mice	   in	  
high	  fat	  diet	  studies.	  n=	  8	  in	  each	  group	  (B)	  Food	  intake	  remains	  unaffected	  in	  both	  groups.	  n=	  8	  in	  each	  group	  (C)	  
C25-­‐0140	   does	   not	   alter	   clearance	   of	   blood	   glucose	   in	   a	   glucose	   tolerance	   test.	   n=	   8	   in	   each	   group.	  Mean	   and	  
standard	   deviations	   are	   depicted.	   Statistical	   significances	   are	   determined	   by	   two-­‐way	  Anova	   test	   (body	  weight)	  
and	  Student´s	  t-­‐test	  (GTT)	  (p-­‐value	  <	  0.01).	  These	  experiments	  were	  conducted	  in	  collaboration	  with	  members	  of	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To	   further	   analyze	   the	   mechanism	   behind	   the	   stop	   of	   gaining	   weight	   during	   C25-­‐0140	  
treatment,	   all	   mice	   were	   sacrificed	   on	   day	   20	   two	   hours	   after	   compound	   administration.	  
Epidermal	  white	  adipose	  tissue	  was	  removed	  from	  the	  body	  and	  frozen	  in	  liquid	  nitrogen.	  For	  
evaluation	  of	  the	  inflammatory	  status	  of	  the	  treated	  mice,	  protein	  and	  RNA	  was	  isolated	  from	  
the	  white	  adipose	  tissue.	  First,	  the	  protein	  levels	  of	  phosphorylated	  IκBα	  and	  total	  IκBα	  were	  
determined	  using	   the	  ALPHASurefire	  assays.	  The	  ratio	  of	  p-­‐IκBα	   to	   IκBα	  of	  all	  eight	  mice	  per	  
group	   are	   illustrated	   in	   Figure	   4.28A.	   Treatment	   of	   obese	   mice	   with	   C25-­‐0140	   led	   to	   a	  
decreased	  ratio	  of	  p-­‐IκBα	   to	   IκBα	   implying	  that	   less	   IκBα	   is	  phosphorylated	  and	  at	   the	  same	  
time	  the	  degradation	  of	  IκBα	  is	  impaired.	  Although	  these	  results	  were	  not	  significant	  after	  the	  
Student´s	   t-­‐test,	   this	   is	   a	   first	   hint	   of	   reduced	   inflammation	   in	   the	  white	   adipose	   tissue	   after	  
C25-­‐0140	   treatment.	  Next,	  RNA	  was	   isolated	   from	   five	  mice,	   reversely	   transcribed	   into	   cDNA	  
and	  analyzed	  in	  qPCR	  experiments	  for	  the	  expression	  of	  several	  inflammatory	  marker	  and	  NF-­‐
κB	  target	  genes.	  The	  levels	  of	  target	  gene	  expression	  were	  related	  to	  the	  housekeeping	  gene	  β-­‐
Actin.	   IL-­‐1β,	   IL-­‐2	   and	   TNFα	   gene	   expression	   were	   investigated	   as	   primary	   examples	   for	  
proinflammatory	  cytokines	  and	  are	  depicted	   in	  Figure	  4.28B.	  The	  gene	  expression	  of	  all	   three	  
cytokines	  is	  downregulated	  with	  IL-­‐1β	  and	  IL-­‐2	  mRNA	  exhibiting	  the	  strongest	  effect	  while	  TNFα	  
is	  only	  mildly	   impaired.	  The	  decrease	   in	   IL-­‐1β	  mRNA	  expression	  was	   the	  only	   significant	  data	  
set.	  For	   further	  NF-­‐κB	  target	  gene	  studies	   ICAM-­‐1,	  A20,	  VCAM-­‐1	  and	   IκBα	  were	  selected	  and	  
results	  are	  illustrated	  in	  Figure	  4.28C.	  Whereas	  ICAM-­‐1	  and	  A20	  mRNA	  levels	  were	  diminished	  
to	  a	  lesser	  extent,	  VCAM	  and	  IκBα	  gene	  expressions	  were	  affected	  stronger.	  Although,	  only	  for	  
VCAM	  a	  significant	  reduction	  was	  obtained,	  the	  downregulation	  of	  all	  investigated	  target	  genes	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Figure	   4.28:	   C25-­‐0140	   reduces	   inflammation	   of	   epidermal	  white	   adipose	   tissue	   of	   obese	  mice	  mildly.	   (A)	  The	  
ratio	  of	  p-­‐IκBα/IκBα	  protein	  levels	  is	  reduced	  after	  C25-­‐0140	  treatment.	  n=	  8	  in	  each	  group	  (B)	  mRNA	  levels	  of	  the	  
proinflammatory	  cytokines	   IL-­‐2,	   IL-­‐1β	  and	  TNFα	  are	  decreased	   in	  C25-­‐0140	  treated	  mice.	  n=	  5	   in	  each	  group	  (C)	  
C25-­‐0140	   administration	   leads	   to	   diminished	   NF-­‐κB	   target	   genes	   expression.	   n=	   5	   in	   each	   group.	   Mean	   and	  
standard	  deviation	  are	  depicted.	  Statistical	  significances	  are	  calculated	  using	  Student´s	  t-­‐test	  (p-­‐value	  <	  0.1).	  	  
	  
Summarizing	  all	  data	  testing	  C25-­‐0140	  in	  an	  obese	  and	  diabetic	  mouse	  model,	  treatment	  with	  
this	   small	  molecule	   leads	   to	  a	  milder	  weight	  gain	  of	  mice	   set	  on	  a	  high-­‐fat-­‐diet	   compared	   to	  
control	  mice.	  More	  importantly,	  this	  observation	  was	  not	  due	  to	  reduced	  food	  intake.	  However,	  
clearance	  of	  the	  blood	  glucose	  was	  not	  significantly	  changed.	  In	  contrast,	  protein	  and	  RNA	  data	  
performed	   from	   the	   white	   adipose	   tissue	   of	   C25-­‐0140	   treated	   mice	   revealed	   a	   slight	  
improvement	   of	   the	   inflammatory	   status.	   Further	   analysis	   will	   be	   necessary	   to	   unravel	   the	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5	  Discussion	  
	  
The	  E3	  ubiquitin	  ligase	  TRAF6	  is	  well	  known	  to	  regulate	  signaling	  in	  innate	  and	  adaptive	  immune	  
response	   (Kobayashi	   et	   al.,	   2004).	   Upon	   stimulation,	   TRAF6	   interacts	   with	   the	   E2	   complex	  
Ubc13/Uev1a	  to	  facilitate	  auto-­‐ubiquitination	  and	  subsequent	  K63-­‐linked	  polyubiquitination	  of	  
substrates	  to	  mediate	  signal	  transduction	  towards	  NF-­‐κB	  activation	  (Lamothe	  et	  al.,	  2007).	  The	  
N-­‐terminal	  RING-­‐Zincfinger1	  (RZ1)	  domain	  of	  TRAF6	  is	  responsible	  for	  Ubc13	  binding	  (Yin	  et	  al.,	  
2009)	   and	  was	   therefore	   selected	   to	  be	   targeted	  by	   small	  molecules.	   For	   the	   identification	  of	  
compounds	  specifically	  binding	  to	  the	  TRAF6	  RZ1	  domain	  and	  thereby	  preventing	  the	  interaction	  
to	   Ubc13,	   25,000	   small	   molecules	   were	   analyzed	   in	   a	   High-­‐Throughput-­‐Screening	   (HTS)	  
campaign	   using	   the	   ALPHAScreen	   technology.	   Out	   of	   this	   screening,	   27	   hit	   compounds	   were	  
further	  investigated	  in	  vitro	  as	  well	  as	  in	  cell-­‐based	  experiments.	  The	  most	  promising	  hits	  were	  
investigated	  in	  more	  detail.	  C27	  is	  a	  strong	  inhibitor	  of	  the	  TRAF6-­‐Ubc13	  interaction	  leading	  to	  a	  
highly	  impaired	  NF-­‐κB	  activation.	  However,	  this	  effect	  is	  not	  selective	  for	  IL-­‐1β/LPS	  signaling	  as	  
TNFα	  signaling	  is	  affected	  to	  the	  same	  extent	  as	  well.	  In	  contrast,	  C25	  showed	  a	  more	  pathway	  
specific	  but	   less	  effective	   inhibition	  of	  NF-­‐κB	  activation	  upon	  IL-­‐1β	  and	  LPS	  compared	  to	  TNFα	  
stimulation.	  To	  further	  improve	  the	  efficacy	  of	  this	  compound,	  analog	  screening	  was	  performed	  
revealing	  C25-­‐0140	  as	  a	  stronger	  inhibitor	  of	  NF-­‐κB.	  However,	  in	  cells	  this	  impact	  also	  affects	  IL-­‐
1β/LPS	  as	  well	  as	  TNFα	  signaling	  to	  the	  same	  extent	  although	  in	  ALPHAScreen	  assays	  this	  small	  
molecule	  acts	  very	  selective	  for	  only	  targeting	  TRAF6	  in	  vitro.	  Nevertheless,	  this	  small	  molecule	  
was	   investigated	   in	   a	   low-­‐grade	   chronic	   inflammation	   obesity	  mouse	  model	   to	   prove	   its	   anti-­‐
inflammatory	  potential.	  Upon	  compound	  treatment,	  these	  mice	  did	  not	  gain	  weight	  while	  on	  a	  
high-­‐fat-­‐diet	   compared	   to	   control	   mice.	   A	   mild	   inhibitory	   effect	   on	   inflammation,	   but	   no	  
improvement	  of	  glucose	  clearance	  out	  of	  the	  blood	  was	  observed.	  	  
	  
5.1	   Targeting	   the	   TRAF6-­‐Ubc13	   interaction:	   a	   novel	   approach	   for	   interfering	  with	   E3	  
ligase	  activity	  by	  protein-­‐protein-­‐interaction	  inhibition	  	  
Functional	   genomic	   studies	   predict	   that	   approximately	   3,000	   disease	  modifying	   proteins	   exist	  
(Russ	   and	   Lampel,	   2005).	  However,	   up	   to	  date	   around	  400	  of	   these	  proteins	   are	   targeted	   for	  
therapeutic	   intervention	   mainly	   belonging	   to	   the	   families	   of	   G	   protein-­‐coupled	   receptors,	  
enzymes,	   ion	  channels,	  protein	  kinases	  and	  others	  (Russ	  and	  Lampel,	  2005).	  Although	  protein-­‐
protein-­‐interactions	   (PPIs)	   are	   vital	   to	  most	   biological	   processes	   and	   are	   critical	   in	   regulating	  
physiology	   and	   pathology,	   they	   remain	   rather	   underexplored	   in	   the	   field	   of	   drug	   discovery.	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Reasons	  for	  that	  might	  be	  the	  large	  interaction	  surface	  area	  involved	  in	  protein-­‐protein-­‐binding	  
(1,500	   –	   3,000Å2)	   and	   the	   lack	   of	   deep	   pockets	   for	   small	   molecule	   binding	   (Jin	   et	   al.,	   2014).	  
Nevertheless,	  with	  rising	  advancements	  in	  establishing	  new	  assay	  technologies	  it	  is	  much	  easier	  
to	   determine	   binding	   energetics	   at	   the	   macromolecular	   interface	   and	   hotspot	   residues	   and	  
inhibitors	   of	   protein-­‐protein-­‐interactions	   are	   likely	   to	   present	   the	   next	   generation	   of	   highly	  
innovative	  drugs	  providing	  specificity	  and	  selectivity	  (Buckley	  and	  Crews,	  2014). Published	  small	  
molecules	   targeting	   protein-­‐protein	   interactions	   bind	  with	   drug-­‐like	   potencies	   to	   hotspots	   on	  
the	  contact	  surface	  of	   the	  target	  protein.	  Hotspots	  are	  a	  small	   subset	  of	   residues	  of	  a	  binding	  
interface	  that	  are	  involved	  in	  the	  interaction.	  The	  discovered	  small	  molecules	  interact	  with	  much	  
higher	  efficiencies	  than	  the	  contact	  atoms	  of	  the	  natural	  protein	  partner	  (Wells	  and	  McClendon,	  
2007).  
Alterations	   in	   the	   function	   of	   components	   of	   the	   ubiquitin	   proteasome	   system	   (UPS)	   are	  
associated	  with	  a	  variety	  of	  disease	   states	   including	  oncogenesis,	   inflammation	  and	  metabolic	  
dysfunction	   (Guèdat	   and	   Colland,	   2007).	   The	   involvement	   of	   many	   components	   of	   the	   UPS	  
implies	   that	   there	   exists	   a	   large	   number	   of	   potential	   target	   sites	   for	   pharmacological	  
interference	  in	  the	  ubiquitin	  regulatory	  machinery	  (Guèdat	  and	  Colland,	  2007).	  Within	  the	  UPS,	  
E3	   ligases	  represent	  an	  attractive	  drug	  target.	  Each	  E3	   ligase	  binds	  and	  ubiquitinates	  a	   limited	  
set	   of	   substrates	   and	   is	   therefore	   involved	   in	   only	   a	   few	   selected	   regulatory	   pathways	  
(Goldenberg	  et	  al.,	  2005).	  Hence,	  inhibition	  of	  a	  particular	  E3	  is	  expected	  to	  affect	  only	  a	  defined	  
number	   of	   pathways	   that	   are	   regulated	   by	   this	   enzyme.	   Furthermore,	   specifically	   targeting	   a	  
limited	  group	  of	  substrates	  might	  lead	  to	  fewer	  toxic	  side	  effects	  and	  to	  a	  more	  suitable	  targeted	  
therapy	   (Landré	  et	  al.,	  2014).	  With	  the	  selectivity	  of	  ubiquitination	  provided	  by	  the	  E3	   ligases,	  
the	   specificity	   issues	   observed	   with	   proteasome	   or	   E1	   and	   E2	   inhibitors	   could	   therefore	   be	  
overcome.	  As	  proteasome	  activity	  is	  essential	  for	  the	  survival	  of	  any	  cell,	  proteasome	  inhibition	  
targets	   an	   essential	   cell	   function	   (Guèdat	   and	   Colland,	   2007).	   Bortezomib,	   a	   proteasome	  
inhibitor	  approved	  by	  the	  Food	  and	  Drug	  Administration	  (FDA),	   is	  clinically	  effective	  in	  treating	  
multiple	  myeloma	  and	   relapsed	  mantle	   cell	   lymphoma	   (Skaar	   et	   al.,	   2014).	   Besides	   its	   clinical	  
success,	  numerous	  side	  effects	  have	  been	  reported	  and	  multiple	  myelomas	  evolving	  Bortezomib	  
resistance	  have	  been	  observed	  (Skaar	  et	  al.,	  2014).	  Like	  inhibition	  of	  the	  proteasome,	  targeting	  
an	  E1	  enzyme	  not	  only	   impairs	  degradation	  of	  all	  proteins	  that	  are	  targeted	  for	  destruction	  by	  
the	  UPS,	  but	  also	  all	  pathways	  that	  require	  ubiquitination	  for	  a	  regulatory,	  non-­‐proteolytic	  role	  
(Landré	   et	   al.,	   2014).	   The	   compound	  MLN4924	   targets	   the	   nucleotide-­‐binding	   site	   of	   the	   E1	  
enzyme	   NAE	   (NEDD8	   activating	   enzyme)	   and	   indirectly	   affects	   the	   UPS	   as	   NEDDylation	   is	  
essential	   for	   the	   activation	   of	   the	   SCF-­‐Cullin-­‐containing	   E3	   complex	   (Soucy	   et	   al.,	   2009).	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Substrates	  of	   the	  SCF-­‐complex	   including	  p27,	  HIF1α	   and	   IκB	  play	   fundamental	   roles	   in	   cancer	  
development.	  Upon	  SCF-­‐complex	  inhibition	  by	  MLN4924	  these	  substrates	  accumulate	  and	  lead	  
to	   cell	   cycle	   arrest,	   senescence	   and	   apoptosis	   (Soucy	   et	   al.,	   2009).	   This	   small	   molecule	   is	  
currently	   being	   tested	   in	   phase	   I/II	   clinical	   trials	   for	   treatment	   of	   hematologic	   and	   non-­‐
hematologic	   malignancies	   (Landré	   et	   al.,	   2014).	   However,	   E1	   inhibitors	   need	   to	   be	   further	  
investigated	  focusing	  on	  specificity	  and	  cell	  pharmacology	  due	  to	  the	  fact	  that	  targeting	  the	  E1	  
machinery	  might	  affect	  multiple	  pathways.	  It	  cannot	  be	  excluded	  that	  many	  of	  these	  pathways	  
could	  be	  critical	  for	  the	  function	  of	  vital	  cells	  (Guèdat	  and	  Colland,	  2007).	  
E2	   enzymes	   are	   shown	   to	   play	   a	   role	   in	   determination	   of	   the	   type	   of	   the	   polyubiquitin	   chain	  
linkage.	   E2	   enzymes	   bind	   E1,	   E3	   and	   ubiquitin,	   and	   can	   be	   targeted	   at	   different	   interaction	  
surfaces.	   An	   inhibitor	   of	   the	   Ubc13/Uev1a	   complex	   blocks	   the	   formation	   of	   the	   E2-­‐ubiquitin	  
thioester	   conjugate	  preventing	   the	   synthesis	   of	   K63-­‐linked	  polyubiquitin	   chains	   that	   results	   in	  
impaired	  NF-­‐κB	  activation	  followed	  by	  reduced	  proliferation	  and	  viability	  of	  cancer	  cells	  (Pulvino	  
et	   al.,	   2012).	   Each	   E2	   can	   associate	   and	   cooperate	   with	   a	   specific	   set	   of	   E3s.	   Thus,	   a	   more	  
selective	  approach	  for	  small	  molecule	  inhibition	  might	  be	  to	  interfere	  with	  this	  E2-­‐E3	  interaction	  
(Landré	  et	  al.,	  2014).	   In	  this	  thesis,	  a	  novel	  approach	  was	  taken	  to	  specifically	  target	  the	  E2-­‐E3	  
interaction	   of	   TRAF6	   and	   Ubc13	   to	   selectively	   interfere	   with	   TRAF6-­‐dependent	   downstream	  
signaling.	  Since	  most	  of	  the	  E3	  ligases	  bind	  several	  E2	  enzymes,	  in	  the	  case	  of	  TRAF6	  Ubc13	  and	  
UbcH5	  (Yin	  et	  al.,	  2009),	  it	  was	  aimed	  at	  targeting	  the	  interaction	  site	  at	  the	  E3	  ligase	  (Landré	  et	  
al.,	   2014).	   TRAF6	   can	  be	   targeted	   at	   either	   the	  N-­‐terminal	   RING-­‐Zincfinger1	  or	   the	  C-­‐terminal	  
MATH	  domain.	  Whereas	  the	  MATH	  domain	  mediates	  adaptor	  protein	  functions	  and	  binding	  of	  
substrate	  proteins,	  the	  N-­‐terminal	  RZ1	  domain	  provides	  interaction	  to	  E2	  enzymes	  and	  E3	  ligase	  
activity.	  Inhibitors	  (6877002	  and	  its	  analog	  6860776)	  targeting	  the	  MATH	  domain	  of	  TRAF6	  are	  
already	  described	  and	  are	  shown	  to	  impair	  LPS	  induced	  NF-­‐κB	  activation	  as	  well	  as	  to	  improve	  
glucose	  tolerance	  in	  obesity	  by	  reducing	  the	  accumulation	  of	  immune	  cells	  in	  adipose	  tissue	  and	  
turning	  the	  immune	  response	  towards	  an	  anti-­‐inflammatory	  profile	  (Chatzigeorgiou	  et	  al.,	  2014).	  
In	  general,	  E3	  inhibitors	  in	  PPIs	  that	  have	  been	  reported	  so	  far	  target	  the	  binding	  of	  the	  E3	  ligase	  
to	  its	  substrate	  or	  disrupt	  interaction	  of	  proteins	  within	  E3	  multiprotein	  complexes	  (Skaar	  et	  al.,	  
2014).	  	  
Therefore,	   a	  novel	   approach	   is	   targeting	   the	  N-­‐terminal	  RING	  Zincfinger1	  domain	  of	   TRAF6	   to	  
prevent	   its	  binding	   to	  E2	  enzymes	  and	   to	   impair	   the	  E3	   ligase	   function	  at	   the	   same	   time.	  The	  
TRAF6-­‐Ubc13	   interaction	  displays	  several	  advantages	   for	  small	  molecule	   interference.	  As	  most	  
of	   the	   E2-­‐E3	   interactions,	   the	   binding	   of	   TRAF6	   to	  Ubc13	   is	   transient	   and	   competes	  with	   the	  
binding	   of	   E1	   to	   E2	   (Berndsen	   and	   Wolberger,	   2014).	   A	   dissociation	   constant	   in	   the	   low	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micromole	  range	  (Kd=1.6µM)	   is	  described	  for	  TRAF6-­‐Ubc13	  (Yin	  et	  al.,	  2009),	  suggesting	  that	  a	  
disruption	   of	   this	   complex	   by	   a	   small	   molecule	   is	   feasible.	   Importantly,	   the	   relatively	   small	  
interaction	  surface	  of	  only	  1000	  Å2	  and	  the	  surface	  exposure	  of	  several	  critical	  residues	  involved	  
in	  binding	  of	  the	  RZ1	  domain	  to	  Ubc13	  suggests	  that	  there	  are	  several	  options	  for	  the	  docking	  of	  
a	  small	  molecule	  to	  prevent	  this	  interaction.	  Indeed,	  27	  compounds	  were	  identified	  and	  verified	  
as	   the	   first	   small	  molecule	   inhibitors	   that	   interfere	  with	   the	   interaction	   of	   TRAF6-­‐Ubc13	   in	   in	  
vitro	   binding	   assays.	   For	   the	   tested	   compounds,	   it	   was	   also	   shown	   that	   disruption	   of	   Ubc13	  
binding	  severely	  impaired	  E3	  ligase	  function,	  demonstrating	  that	  the	  E2-­‐E3	  interface	  represents	  
a	  powerful	  strategy	  to	  target	  E3	  ligase	  activity.	  Further,	  the	  inhibitors	  act	  specific,	  because	  none	  
of	  the	  compounds	  interfered	  with	  the	  interaction	  of	  the	  related	  RING	  E3	  ligase	  RNF8	  and	  Ubc13.	  
This	  is	  important	  as	  it	  provides	  a	  proof	  of	  concept	  that	  selective	  inhibition	  of	  E2-­‐E3	  interactions	  
represents	   a	   feasible	   strategy	   to	   target	   E3	   ligase	   function.	   The	   identified	   compounds	   display	  
diverse	   molecular	   structures	   and	   contain	   different	   scaffolds	   suggesting	   that	   selectivity	   in	  
targeting	  the	  RZ1	  domain	  in	  TRAF6	  can	  be	  achieved	  with	  diverse	  chemical	  moieties.	  Despite	  the	  
considerable	  heterogeneity	  of	  the	  compounds,	  all	  27	  identified	  molecules	  harbor	  at	  least	  three	  
aromatic	   structures	   including	   at	   least	   one	   heterocycle	   containing	   nitrogen	   or	   oxygen	   atoms	  
suggesting	  that	  these	  structures	  are	  preferably	  to	  target	  the	  N-­‐terminal	  domain	  of	  TRAF6.	  The	  
small	   molecules	   might	   either	   directly	   bind	   to	   the	   TRAF6-­‐E2	   interface	   to	   compete	   for	   Ubc13	  
association	   or	   they	   might	   change	   the	   structural	   conformation	   of	   TRAF6	   RZ1	   and	   thereby	  
indirectly	  abrogate	  binding	  of	  Ubc13.	  The	   identification	  of	  a	   large	  number	  of	   compounds	   that	  
specifically	  target	  the	  TRAF6-­‐Ubc13	  interaction	  clearly	  proves	  that	  it	  is	  indeed	  possible	  to	  target	  
the	   E2-­‐E3	   interaction	   surface	   and	   prevent	   binding	   of	   E2	   enzymes	   to	   E3	   ligases	   resulting	   in	  
impaired	  E3	  ligase	  activity.	  Also,	  these	  small	  molecules	  indicate	  that	  targeting	  of	  such	  a	  relatively	  
short	   and	   low	   affinity	   binding	   E2-­‐E3	   surface	   might	   overcome	   several	   obstacles	   that	   are	  
associated	  with	  PPI	   inhibition	  often	  including	  the	  large	  interaction	  surface	  area	  and	  the	  lack	  of	  
deep	  pockets.	  	  
As	  already	  mentioned,	  a	  different	  strategy	  to	  interfere	  with	  TRAF6	  adaptor	  protein	  function	  is	  to	  
target	  the	  C-­‐terminal	  MATH	  instead	  of	  the	  RING-­‐Zincfinger1	  domain	  to	  prevent	  protein-­‐protein-­‐
interaction.	  One	  recent	  approach	  was	  to	  impair	  TRAF6-­‐CD40	  signaling	  that	  involves	  the	  binding	  
of	  the	  TRAF6	  MATH	  domain	  to	  the	  cytosolic	  domain	  of	  the	  CD40	  receptor	  (Chatzigeorgiou	  et	  al.,	  
2014).	  In	  a	  screening	  cascade,	  800	  out	  of	  400,000	  compounds	  were	  identified	  by	  computational	  
approaches	  by	  applying	  ADME/toxicity	  filters	  (using	  the	  Lipinski´s	  rule	  of	  5)	  as	  well	  as	  performing	  
rigid	   and	   flexible	   docking	   (Chatzigeorgiou	   et	   al.,	   2014).	   The	   800	   top-­‐scoring	   compounds	  were	  
analyzed	  in	  a	  NF-­‐κB	  reporter	  gene	  assay	  in	  the	  RAW	  264.7	  cell	  line	  revealing	  51	  compounds	  that	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reduced	   NF-­‐κB	   activation	   by	   at	   least	   50%	   at	   10µM.	   Analog	   screening	   of	   the	   initial	   best	  
compound	   6877002	   revealed	   six	   bioactive	   analogs	   that	   all	   inhibited	   NF-­‐κB	   activation	   in	   RAW	  
264.7	  cells	  dose-­‐dependently	  as	  well	  as	  suppression	  of	  CD40-­‐induced	  expression	  of	  IL-­‐1β	  and	  IL-­‐
6	  in	  primary	  macrophages	  (Chatzigeorgiou	  et	  al.,	  2014).	  In	  a	  LPS-­‐stimulated	  NF-­‐κB	  reporter	  gene	  
assay	   IC50	   values	   were	   determined	   for	   these	   compounds.	   The	   initial	   small	   molecule	   6877002	  
reduced	  NF-­‐κB	  activation	  with	   IC50	  =	  15.9µM	  whereas	   the	  analog	  6860776	  exhibited	  an	   IC50	  =	  
0.3µM	   (Chatzigeorgiou	   et	   al.,	   2014).	   Compared	   to	   that,	   compounds	   identified	   in	   this	   thesis	  
demonstrated	   higher	   IC50	   values	   in	   cells.	   C25	   displayed	   IC50	   values	   above	   50µM	   in	   p-­‐IκBα	  
ALPHASurefire	   and	  qPCR	  experiments	  while	   the	  analog	  C25-­‐0140	   showed	   IC50	   values	  between	  
10µM	  and	  20µM	  dependent	  on	  IL-­‐1β,	  LPS	  or	  TNFα	  stimulation	  (Figures	  4.17,	  4.20	  and	  4.25).	  This	  
indicates	   that	   the	   compounds	   efficiency	   needs	   to	   be	   further	   improved.	   However,	   it	   is	   not	  
possible	  to	   judge	  the	  specificity	  of	  the	  compounds	  6877002	  and	  6860776,	  because	  analyses	  of	  
pathways	  that	  do	  not	  require	  TRAF6	  for	  signaling	  have	  not	  been	  performed.	  Furthermore,	   the	  
disruption	  of	  the	  TRAF6-­‐CD40	  complex	  was	  not	  shown	  in	  vitro	  and	  therefore	  it	  is	  not	  possible	  to	  
correlate	  cell	  data	  with	  the	  suggested	  in	  vitro	  effects	  of	  the	  compounds.	  The	  common	  structure	  
of	   6877002	   and	   the	   analogs	   consists	   of	   two	   Ring	   structures	   with	   different	   substituents	  
connected	  by	  the	  same	  linker	  (Chatzigeorgiou	  et	  al.,	  2014).	  Compared	  to	  that,	  C27	  contains	  four	  
heterocyclic	   structures	   (Figure	  4.8),	  while	  C25	  and	  C25-­‐0140	   consist	  of	   five	  different	   aromatic	  
structures	  as	  well	  as	  multiple	  substituents	  and	  thus,	  provide	  more	  contact	  residues	  for	  targeting	  
amino	  acids	  (Figure	  4.19).	  	  
Altogether,	   it	   is	   possible	   to	   identify	   TRAF6	   interacting	   compounds	   using	   different	   strategies	  
involving	   computational	   approaches	   as	   well	   as	   in	   vitro	   and	   cell-­‐based	   experiments.	   Thereby,	  
TRAF6	   can	   be	   targeted	   at	   the	   N-­‐terminal	   RZ1	   domain	   or	   the	   C-­‐terminal	   MATH	   domain.	  
Interfering	  with	  these	  binding	  interfaces	  leads	  to	  impaired	  of	  NF-­‐κB	  signaling	  in	  both	  cases.	  
	  
5.2	  Identification	  and	  verification	  of	  TRAF6-­‐Ubc13	  inhibitors	  in	  vitro	  
5.2.1	  High-­‐Throughput	  assays	  for	  screening	  of	  selective	  TRAF6-­‐Ubc13	  inhibitors	  
For	  the	  identification	  of	  small	  molecules	  targeting	  the	  RZ1	  domain	  of	  TRAF6	  to	  prevent	  binding	  
to	  Ubc13,	  a	  HTS	  campaign	  was	  conducted.	  The	  ALPHAScreen	  technology	  was	  preferred	  as	  this	  
technology	  demonstrates	  several	  advantages	   for	  a	  HTS	  assay.	  First,	   it	   is	  a	  homogeneous	  assay	  
that	  allows	  measuring	  by	  mix	  and	  read	  only.	  Second,	  it	  is	  a	  proximity	  assay	  with	  a	  broad	  energy	  
transfer	  distance	  of	  around	  200nm	  between	  donor	  and	  acceptor	  beads.	  Third,	   it	  displays	  very	  
high	  sensitivity	  and	  very	  low	  background	  levels	  resulting	  in	  a	  high	  signal/background	  ratio.	  Upon	  
excitation	   one	   donor	   bead	   can	   generate	   up	   to	   60,000	   singlet	   oxygen	   molecules	   per	   second	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resulting	  in	  high	  signal	  amplification.	  The	  ALPHAScreen	  technology	  can	  therefore	  be	  used	  for	  low	  
to	  high	  affinity	  binding	  interactions	  (pM	  to	  mM).	  The	  high	  sensitivity	  allows	  minimizing	  the	  assay	  
volume	   making	   it	   very	   cost	   effective.	   Last,	   the	   donor	   and	   acceptor	   beads	   exhibit	   a	   strong	  
resistance	  to	  DMSO	  (up	  to	  20%	  in	  Ungermannova	  et	  al.,	  2013)	  as	  well	  as	  the	  stable	  signal	  up	  to	  
six	   hours	   (Ungermannova	   et	   al.,	   2013).	   However,	   due	   to	   its	   complex	   chemistry,	   one	   of	   the	  
disadvantages	   of	   this	   assay	   is	   the	   high	   rate	   of	   false	   positive	   hits	   interfering	   in	   binding	  
interactions	   by	   either	   forming	   aggregates	   or	   impairing	   assay	   signaling.	   Light	   scattering	   is	  
produced	   by	   insoluble	   compound	   aggregates	   that	   are	   misfolded	   upon	   dilution	   in	   aqueous	  
buffers.	   Small	  molecules	   impeding	  with	   the	  ALPHAScreen	   technology	  are	   referred	   to	   frequent	  
hitters	  (Schorpp	  et	  al.,	  2014)	  and	  could	  be	  either	  singlet	  oxygen	  quencher,	  color	  quencher	  (also	  
known	  as	   inner	   filters)	  or	  acceptor	  bead	  competitors,	  which	   is	  more	   commonly	   for	   the	  Nickel	  
Chelate	   Acceptor	   beads	   (Perkin	   Elmer,	   TruHitsKit).	   These	   ALPHAScreen	   frequent	   hitter	  
(ALPHAScreen-­‐FH)	  molecules	  need	  to	  be	  extracted	  from	  the	  hit	  list	  by	  counter	  screens,	  the	  pan-­‐
assay-­‐interference-­‐compounds	   (PAINS)	   filters	   (Baell	   and	   Holloway,	   2010)	   or	   additional	   filters	  
including	  His-­‐frequent	  hitters	  (Schorpp	  et	  al.,	  2014)	  or	  the	  TruHits	  Kit	  provided	  by	  Perkin	  Elmer.	  
Frequent	  hitter	  detection	  and	   the	  TruHits	  kit	  was	  chosen	  here	  as	  a	   strategy	   to	  eliminate	   false	  
positive	   hits.	   Filters	   to	   identify	   ALPHAScreen-­‐His-­‐FH	   were	   developed	   based	   on	   the	   data	  
originated	   from	   four	   robust	  ALPHAScreen	   assays	   that	   involved	  His-­‐tagged	  proteins	   and	  Nickel	  
Chelate	  beads	  and	  were	  performed	  at	  the	  Assay	  Development	  and	  Screening	  (ADSP)	  platform	  at	  
the	   Helmholtz	   Zentrum	   München.	   Out	   of	   25,000	   screened	   molecules,	   60	   compounds	   were	  
identified	  as	  ALPHAScreen-­‐FHs	  and	  77	   small	  molecules	  were	  determined	  as	  ALPHAScreen-­‐His-­‐
FHs	  (Schorpp	  et	  al.,	  2014).	  The	  analysis	  of	  the	  initial	  screening	  data	  using	  PAINS	  filters	  identified	  
the	  majority	  of	  the	  ALPHAScreen-­‐FHs	  (52	  out	  of	  60),	  whereas	  only	  two	  out	  of	  77	  ALPHAScreen-­‐
His-­‐FHs	   were	   discovered.	   The	   design	   of	   the	   PAINS	   filters	   resulted	   from	   frequent	   hitters	   that	  
initially	   hit	   six	   ALPHAScreen	   assays,	   but	   also	   interfered	   with	   other	   technologies	   (Baell	   and	  
Holloway,	   2010).	   The	   PAINS	   filter	   did	   not	   recognize	   eight	   compounds.	   These	   small	  molecules	  
predominantly	   comprised	   fused	  aromatic	   systems	  or	  quinone	  moieties	   in	   their	   structures	   and	  
are	  assumed	  to	  quench	  excitation/emitted	  radiation	  or	  singlet	  oxygen.	  Six	  additional	  filters	  for	  
ALPHAScreen-­‐FHs	   were	   developed	   because	   of	   the	   structurally	   diversity	   of	   these	   compounds	  
(Schorpp	  et	  al.,	  2014).	  For	  the	  ALPHAScreen-­‐His-­‐FHs,	  new	  filters	  needed	  to	  be	  developed	  as	  only	  
two	   out	   of	   77	   small	  molecules	  were	   identified	   by	   the	   PAINS	   filters.	   18	   of	   the	   77	   compounds	  
comprise	   a	   common	  molecular	   fragment	   (Figure	   5.1A).	   This	   molecular	   structure	   is	   known	   to	  
form	   bifurcated	   hydrogen	   bonds	   with	   XH-­‐donating	   groups	   (X=N,	   O)	   (Slepukhin	   et	   al.,	   2013;	  
Salmina	  et	  al.,	  2011)	  and	  to	  cause	  coordination	  complexes	  with	  metal	  ions	  (Kaim,	  2002).	  Due	  to	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the	  good	  NH-­‐donor	  properties	  of	  the	  imidazole	  rings	  of	  the	  His-­‐residues	  of	  tagged	  proteins,	  the	  
molecular	   fragment	   is	  assumed	  to	   form	  bifurcated	  hydrogen-­‐bond	  complexes	  with	   the	  His-­‐tag	  
and	   to	   prevent	   immobilization	   of	   the	   proteins	   on	   the	   bead	   surface	   (Figure	   5.1B).	   The	   same	  
compounds	  may	  act	  as	  chelating	  agents	  as	  well	  and	  absorb	  on	  the	  bead	  surface	  (Figure	  5.1C).	  In	  
both	   cases,	   the	   generation	   of	   an	   ALPHAScreen	   signal	   is	   disrupted.	   The	   remaining	   59	  
ALPHAScreen-­‐His-­‐FHs	  are	  mostly	  known	  chelating	  agents	  such	  as	  8-­‐hydroxyquinolines	  (Albrecht	  
et	  al.,	  2008),	  picolylamines	  (Chen	  et	  al.,	  2011;	  Bratsos	  et	  al.,	  2011)	  and	  pyridines	  (Constable	  et	  
al.,	  1998)	  and	  are	  known	  to	  bind	  zinc	   (II)	  metalloproteins	   (Agrawal	  et	  al.,	  2010).	  Therefore,	  19	  
additional	   filters	   were	   developed	   to	   identify	   ALPHAScreen-­‐His-­‐FHs	   (Schorpp	   et	   al.,	   2014).	   All	  
newly	  developed	  filters	  are	  available	  at	  the	  OCHEM	  website	  (http://ochem.eu/alters)	  and	  can	  be	  
freely	  accessed	  by	  users	  to	  filter	  results	  of	  their	  HTS	  campaigns.	  In	  conclusion,	  the	  utilization	  of	  
different	  filters	  allowed	  the	  elimination	  of	  many	  false	  positive	  hit	  compounds.	  In	  this	  work,	  out	  
of	  520	  primary	  hit	  compounds	  137	  small	  molecules	  were	  identified	  as	  frequent	  hitters	  and	  were	  
excluded	   from	   the	   hit	   list.	   383	   compounds	   remained	   for	   further	   investigation.	   Although	  
chemoinformatic	   filters	   are	   necessary	   to	   predict	   frequent	   hitters,	   it	   cannot	   replace	   in	   vitro	  





In	  order	   to	  obtain	  compounds	   that	  specifically	   target	   the	  TRAF6	  RING-­‐Zincfinger1	  domain,	   the	  
primary	   hit	   compounds	   were	   tested	   to	   impact	   the	   interaction	   of	   OTUB1	   and	   Ubc13	   in	  
ALPHAScreen	   experiments.	   Superposition	   of	   the	   structure	   of	   Ubc13	   bound	   to	   TRAF6	   showed	  
that	  the	  binding	  site	  for	  the	  DUB	  OTUB1	  overlaps	  with	  the	  E3	  RING	  binding	  site	  (Wiener	  et	  al.,	  
2012).	  Out	  of	  383	  tested	  molecules,	  205	  affected	  the	  OTUB1-­‐Ubc13	   interaction	  as	  well.	  These	  
205	   compounds	   were	   assumed	   to	   target	   Ubc13	   and	   were	   excluded	   from	   the	   hit	   list.	   Serial	  
dilution	   experiments	   using	   the	   ALPHAScreen	   technology	   further	   excluded	   151	   compounds	  
A B
C
Figure	  5.1.	  Potential	  mechanism	  of	  action	  
of	   the	   identified	   ALPHAScreen-­‐His-­‐
Frequent	  Hitters	  (FH).	  Dashed	  lines	  depict	  
interactions.	   Figures	   from	   Schorpp	   et	   al.,	  
2014.	   (A)	   18	   ALPHAScreen-­‐His-­‐FHs	   share	  
this	   common	   molecular	   fragment.	   (B)	  
Hypothetical	   hydrogen	   bonds	   that	   are	  
formed	   between	   the	   molecular	   fragment	  
and	   the	   His-­‐tag	   of	   the	   protein.	   (C)	  
Hypothetical	   chelate	   complex	   formation	  
by	   the	   molecular	   fragment	   and	   the	   Ni2+-­‐
ions	  of	  the	  acceptor	  bead	  surface.	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without	   concentration-­‐dependent	   effects.	   To	   further	   ensure	   that	   the	   27	   hit	   compounds	  
specifically	  target	  TRAF6	  instead	  of	  general	  RING	  domains,	  the	  effect	  of	  these	  compound	  on	  the	  
interaction	  of	  the	  E3	  RING	  ligase	  RNF8	  and	  Ubc13	  were	  analyzed	  as	  the	  RING	  domains	  of	  TRAF6	  
and	  RNF8	  exhibit	  significantly	  similar	  structures	  (Figure	  5.2B	  and	  supplement	  10.11).	  None	  of	  the	  
27	  tested	  compounds	  impaired	  the	  interaction	  of	  RNF8	  to	  Ubc13	  proving	  that	  these	  compounds	  
specifically	   inhibit	   the	   TRAF6-­‐Ubc13	   interaction	   in	   vitro.	   The	  ALPHAScreen	   technology	  with	   all	  
the	   advantages	  mentioned	  above	  displays	   an	  excellent	   tool	   in	  High-­‐Throughput-­‐Screening	  not	  
only	  as	  a	  primary	  screening	  assay	  but	  also	  for	  counter	  screening	  assays	  to	  achieve	  specificity	  of	  
the	  analyzed	  small	  molecules.	  	  
	  
5.2.2	  Low-­‐Throughput	  assays	  for	  verifying	  selected	  TRAF6-­‐Ubc13	  inhibitors	  
The	  High-­‐Throughput	  assays	  allowed	  reducing	  the	  number	  of	  putative	  candidates	  to	  a	  number	  
that	   could	   be	   confirmed	   in	   secondary	   Low-­‐Throughput	   assays.	   First,	   a	   pulldown	   assay	   was	  
established	  to	  test	  the	  compounds	  in	  a	  secondary	  assay	  that	  is	  different	  from	  the	  ALPHAScreen	  
technology	   and	   involves	   a	   different	   tag	   combination	   as	   well.	   A	   pulldown	   assay	   is	   used	   to	  
determine	  interactions	  between	  molecules	  in	  solution	  via	  immobilization	  of	  the	  bait	  protein	  to	  
beads	  and	   incubation	  with	   the	   interaction	  partner.	  After	  washing,	   the	   complex	   is	   eluted	   from	  
the	  beads	  and	  analyzed	  in	  SDS-­‐Page	  and	  Western	  Blot.	  Only	  a	  limited	  number	  of	  small	  molecules	  
could	  be	  validated.	  Both	  compounds,	  C25	  and	  C25-­‐0140,	  reduced	  the	  binding	  of	  TRAF6	  to	  Ubc13	  
dose-­‐dependently	   in	  pulldown	  assays	   (Figures	  4.14	  and	  4.22).	  Second,	   in	  order	   to	  confirm	  the	  
binding	   of	   the	   compounds	   to	   the	   TRAF6	   RZ1	   domain,	   NMR	   experiments	   were	   established	   to	  
verify	   that	   the	   compounds	   are	   indeed	   binding	   to	   TRAF6.	   The	  NMR	   technology	   uses	  magnetic	  
properties	   of	   certain	   atomic	   nuclei	   and	   not	   only	   allows	   the	   verification	   of	   a	   direct	   binding	  
between	  two	  interaction	  partners	  but	  is	  also	  used	  to	  determine	  the	  amino	  acids	  that	  are	  involve	  
in	   binding.	   For	   this,	   untagged	   TRAF6	   was	   measured	   in	   NMR	   experiments	   after	   compound	  
treatment.	  The	  compounds	  C27,	  C25	  and	  C25-­‐0140	  caused	  shifting	  or	  disappearing	  of	  peaks	  of	  
the	  TRAF6	  spectrum	  indicating	  that	  these	  small	  molecules	  are	  directly	  binding	  to	  the	  TRAF6	  RZ1	  
domain	  (Figure	  4.8,	  4.13	  and	  4.21).	  
In	   addition,	   a	   number	   of	   assays	   were	   considered	   or	   conducted	   to	   study	   the	   effects	   of	   the	  
inhibitors	   including	   time	   resolved	   Förster	   resonance	   energy	   transfer	   (TR-­‐FRET),	   DELFIA	  
(Dissociation-­‐Enhanced	   Lanthanide	   Fluorescence	   Immunoassay)	   and	   MST	   (Microscale	  
Thermophoresis)	   but	   for	   good	   reasons	   these	   analyses	  were	   not	   prioritized	   or	   did	   not	   lead	   to	  
reliable	   assays.	   TR-­‐FRET	   is	   a	   proximity-­‐based	   assay	  build	   on	   the	   energy	   transfer	   between	   two	  
fluorophores.	  The	  distance	  allowing	  energy	  transfer	  between	  the	  fluorophores	  has	  a	  maximum	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of	   10nm,	   which	   is	   close	   to	   the	   distance	   of	   large	   molecules	   (as	   antibody	   or	   hemoglobin)	  
(Glickmann	  et	  al.,	  2002).	  The	  structural	  analysis	  of	  the	  TRAF6-­‐Ubc13	  interface	  (Yin	  et	  al.,	  2009)	  
suggested	  that	  the	  terminal	  tags	  are	  too	  distant	  for	  an	  energy	  transfer	  in	  TR-­‐FRET	  and	  therefore	  
this	   technique	  was	  not	   proceeded.	  Nevertheless,	   TR-­‐FRET	   assays	  were	  established	   to	  monitor	  
assembly	  of	  polyubiquitin	  chains	  using	  tagged	  ubiquitin	  moieties	  (Hong	  et	  al.,	  2003)	  and	  hence	  it	  
may	   be	   interesting	   to	   establish	   TR-­‐FRET	   as	   a	   secondary	   assay	   to	   analyze	   TRAF6	   activity	   in	  
response	  to	  compound	  inhibition.	  The	  DELFIA	  system	  provides	  an	  ELISA-­‐based	  assay	  and	  works	  
in	  a	   static	  environment	  with	  proteins	   immobilized	   to	  a	  plate	   instead	  of	  proteins	   in	   solution.	   It	  
was	  established	  for	  analyzing	  other	  low	  affinity	  PPIs	  like	  the	  interaction	  of	  ubiquitin	  chains	  to	  the	  
ubiquitin	   binding	   domain	   of	   NEMO	   (Hadian	   et	   al.,	   2011).	   However,	   a	   specific	   interaction	   of	  
TRAF6	   and	   Ubc13	   in	   DELFIA	   assays	   could	   not	   be	   confirmed.	   Potentially,	   the	   immobile	  
environment	   in	   the	   plate	   bound	   format	   does	   not	   allow	   detection	   of	   this	   interaction.	  
Alternatively,	   the	   required	   extensive	  washing	   steps	  might	   interfere	  with	   the	   transient	   TRAF6-­‐
Ubc13	   interaction.	   Finally,	   MST	   uses	   the	   motion	   of	   molecules	   in	   microscopic	   temperature	  
gradients	   and	   can	   be	   used	   to	   detect	   binding	   of	   proteins	   or	   small	   molecules	   to	   fluorescently	  
labeled	   proteins	   (Jerabek-­‐Willemsen	   et	   al.,	   2011).	   However,	   a	   specific	   binding	   of	   Ubc13	   to	  
fluorescently	  labeled	  TRAF6	  could	  not	  be	  detected,	  putatively	  because	  the	  labeling	  might	  involve	  
amino	   acids	   that	   are	   critical	   for	   binding	   or	   due	   to	   potential	   oligomerization	   of	   the	   complex.	  
Therefore,	  these	  approaches	  were	  not	  further	  pursued	  and	  NMR	  and	  pulldown	  studies	  to	  detect	  
binding	  of	  compounds	  to	  TRAF6	  in	  Low-­‐Throughput	  assays	  were	  preferred	  instead.	  
	  
5.3	  Verification	  of	  the	  newly	  identified	  TRAF6-­‐Ubc13	  inhibitors	  in	  cell-­‐based	  assays	  
To	  directly	  analyze	  the	  effects	  of	  the	  compounds	  identified	   in	  vitro,	   it	  was	  aimed	  to	  establish	  a	  
reliable	  interaction	  assay	  between	  TRAF6	  and	  Ubc13	  in	  cells.	  However,	  neither	  the	  endogenous	  
interaction	  after	   IL-­‐1β stimulation	  as	  published	   in	  Shembade	  et	  al.	   in	  2010	  could	  be	  confirmed	  
nor	   could	   co-­‐immunoprecipitation	   studies	   and	   FRET	   experiments	   after	   overexpression	   of	   the	  
proteins	  in	  Hek293	  and	  MEF	  cells	  reveal	  a	  stable	  binding	  of	  TRAF6	  and	  Ubc13	  (data	  not	  shown).	  
Most	   of	   the	   E2-­‐E3	   interactions	   including	   TRAF6	   and	   Ubc13	   are	   transient	   and	   also	   display	  
dissociation	  constants	  in	  the	  low	  micromole	  range	  (Berndsen	  and	  Wolberger,	  2014).	  In	  cells,	  this	  
interaction	  is	  stimulation	  dependent	  and	  does	  not	  occur	  in	  unstimulated	  cells	  and	  is	  difficult	  to	  
detect	  reliably	  (Shembade	  et	  al.,	  2010).	  Therefore,	  determining	  the	  influence	  of	  the	  compounds	  
on	  NF-­‐κB	  activation	  as	  a	  functional	  readout	  for	  an	  active	  TRAF6-­‐Ubc13	  complex	  was	  preferred.	  
For	  the	  verification	  of	  the	  hit	  compounds	  in	  cell-­‐based	  assays,	  the	  Electrophoretic-­‐Mobility-­‐Shift-­‐
Assay	  (EMSA)	  was	  selected	  to	  analyze	  the	  activation	  of	  NF-­‐κB.	  The	  EMSA	  technology	  has	  many	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advantages	  like	  exhibiting	  robustness	  as	  well	  as	  high	  sensitivity	  and	  at	  the	  same	  time	  no	  signal	  
amplification	  due	   to	   the	  use	  of	   radioisotope-­‐labeled	  nucleic	  acids	   (Hellmann	  and	  Fried,	  2007).	  
Because	  of	  the	  high	  sensitivity,	  this	  assay	  permits	  working	  with	  crude	  cell	  extracts	  and	  only	  low	  
concentrations	  of	  protein	  and	  nucleic	  acids	  are	   required	   (Hellmann	  and	  Fried,	  2007).	   In	  EMSA	  
experiments,	   the	  effects	  of	   the	  compounds	  on	  NF-­‐κB	  activation	  were	  analyzed	  after	   IL-­‐1β	  and	  
TNFα	  stimulation.	  This	  emerged	  as	  an	  optimal	  opportunity	  to	  determine	  the	  impact	  of	  the	  small	  
molecules	  on	  NF-­‐κB	  signaling	  in	  a	  fast	  and	  highly	  sensitive	  manner.	  At	  an	  early	  stage,	  these	  data	  
allowed	  to	  focus	  on	  inhibitors	  that	  were	  also	  active	  in	  a	  cellular	  context.	  The	  results	  then	  served	  
as	   a	   starting	  point	   to	   further	   test	   the	  best	  hits	   in	   assays	  downstream	  and	  upstream	  of	  NF-­‐κB	  
DNA-­‐binding	  activity.	  
Based	  on	  EMSA	  analyses	  two	  initial	  hits	  (C27	  and	  C25)	  were	  chosen	  for	  further	  evaluation	  that	  
included	   NF-­‐κB	   induced	   target	   gene	   expression,	   nuclear	   translocation	   of	   NF-­‐κB	   dimers,	   the	  
phosphorylation	   and	   degradation	   of	   IκBα,	   activation	   of	   the	   IKK	   complex	   as	   well	   as	   auto-­‐
ubiquitination	  of	  TRAF6.	  All	  experiments	  were	  performed	  after	  stimulation	  with	  the	  respective	  
cytokine	  and	  on	  endogenous	  level	  to	  avoid	  unspecific	  effects	  due	  to	  overexpression	  of	  proteins.	  
Downstream	  of	  NF-­‐κB	  activation,	  target	  genes	  were	  analyzed	  in	  qPCR	  experiments	  and	  revealed	  
dose-­‐dependent	   inhibition	   of	   ICAM-­‐1	   and	   A20	   after	   compound	   treatment	  with	   C27	   and	   C25-­‐
0140	   and	   stimulation	   of	   IL-­‐1β,	   TNFα	   and	   LPS.	   Upstream	   of	   NF-­‐κB	  DNA-­‐binding,	   translocation	  
activity	  of	  the	  NF-­‐κB	  dimer	  was	  analyzed	  in	  a	  p65	  translocation	  assay	  via	  immunofluorescence.	  
Phosphorylation	   of	   IκBα	   was	   determined	   in	   two	   independent	   assays:	   Western	   Blot	   and	  
ALPHASurefire	  experiments.	  Degradation	  of	  IκBα	  was	  detected	  in	  Western	  Blot	  and	  the	  activity	  
of	   the	   IKK	   complex	   investigated	   in	   a	   kinase	   assay.	   All	   performed	   experiments	   showed	   dose-­‐
dependent	  effects	  of	  the	  compounds.	  Thereby,	  C27	  and	  C25-­‐0140	  affected	   inhibition	  of	  NF-­‐κB	  
activation	  stronger	  than	  C25,	  but	  did	  not	  act	  pathway	  specific.	  In	  a	  functional	  assay	  the	  E3	  ligase	  
activity	   of	   TRAF6	   was	   verified	   by	   detecting	   the	   auto-­‐ubiquitination	   of	   TRAF6	   upon	   IL-­‐1β	  
stimulation.	  TRAF6	  only	  exhibits	  E3	   ligase	  activity	  upon	  binding	  to	  Ubc13.	  Therefore,	   inhibition	  
of	  the	  activity	  of	  TRAF6	  concludes	  an	  impaired	  interaction	  of	  TRAF6	  and	  Ubc13.	  Upon	  compound	  
treatment	   with	   C27	   or	   C25-­‐0140,	   endogenous	   TRAF6	   ubiquitination	   was	   diminished	   in	   both	  
cases	   leading	   to	   the	   conclusion	   that	   the	   TRAF6-­‐Ubc13	   interaction	   in	   cells	   indeed	   might	   be	  
affected.	  	  
The	   verification	   of	   the	   compounds	   effects	   in	   cells	   involved	   a	   variety	   of	   diverse	   assay	  
technologies	   including	   EMSA,	   qPCR,	   Western	   Blot,	   Kinase	   assay,	   ALPHASurefire	   and	  
immunoprecipitation	  experiments.	   This	   is	   an	   important	   criterion	  during	  hit	   verification	   in	   cell-­‐
based	  assays	  and	  to	  exclude	  the	  possibility	  of	  assay-­‐related	  effects	  after	  compound	  treatment.	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Inhibitory	  effects	  in	  all	  performed	  assays	  strongly	  support	  the	  negative	  regulatory	  impact	  of	  the	  
tested	  compounds	  on	  multiple	  levels	  of	  the	  NF-­‐κB	  signaling	  cascade.	  	  
	  
5.4	  Selectivity	  of	  compounds	  targeting	  the	  RING-­‐Zincfinger1	  domain	  of	  TRAF6	  
Out	  of	   the	  HTS	   campaign	  and	  a	   secondary	  optimization	   three	   compounds	   (C27,	  C25	  and	  C25-­‐
0140)	   were	   identified	   as	   inhibitors	   selectively	   targeting	   the	   TRAF6-­‐Ubc13	   binding	   in	   vitro.	  
However,	  in	  cell-­‐based	  assays	  only	  C25	  showed	  pathway	  selectivity	  towards	  IL-­‐1β/LPS	  signaling	  
whereas	  C27	  and	  C25-­‐0140	  inhibited	  activation	  of	  NF-­‐κB	  to	  a	  stronger	  extent	  but	  not	  selectively.	  
Selectivity	   was	   determined	   via	   analysis	   of	   NF-­‐κB	   activation	   after	   IL-­‐1β,	   LPS	   and	   TNFα	  
stimulation.	  Whereas	  IL-­‐1β	  and	  LPS	  stimulation	  induce	  TRAF6-­‐dependent	  signaling,	  TNFα	   leads	  
to	  NF-­‐κB	  activation	  independent	  of	  TRAF6.	  C25	  is	  a	  small	  molecule	  exhibiting	  only	  mild	  impacts	  
on	  NF-­‐κB	  activation	  after	  IL-­‐1β	  and	  LPS	  stimulation.	  However,	  TNFα	  induced	  NF-­‐κB	  activation	  is	  
not	  affected.	  In	  contrast,	  compounds	  like	  C27	  and	  C25-­‐0140	  strongly	  affecting	  TRAF6-­‐dependent	  
NF-­‐κB	   activation	   by	   IL-­‐1β	   and	   LPS	   also	   reduced	   TNFα	   induced	   NF-­‐κB	   activation	   to	   the	   same	  
extent.	  An	  influence	  of	  TRAF6	  in	  TNFα	  induced	  NF-­‐κB	  signaling	  is	  very	  unlikely,	  because	  TRAF6-­‐/-­‐	  
MEF	  cells	  exhibit	  no	  altered	  NF-­‐κB	  activation	  upon	  TNFα	  stimulation	  (Figure	  4.7B).	  Two	  possible	  
scenarios	  may	   explain	   the	   non-­‐selective	   inhibition	   of	   the	   stronger	   acting	   compounds	   in	   cells:	  
first,	  other	  RING	  domains	  of	  proteins	  containing	   this	   structure	  are	   targeted	  as	  well	  or	   second,	  
the	  compounds	  bind	  to	  additional	  proteins	  within	  the	  NF-­‐κB	  signaling	  pathway	  that	  are	  different	  
from	  RING	  containing	  proteins.	  	  
A	   first	   explanation	   for	   the	   non-­‐pathway	   selective	   effects	   of	   C27	   and	   C25-­‐0140	   could	   be	   that	  
RING	  domains	  of	  other	  members	  of	  the	  TRAF	  protein	  family	  members	  or	  additional	  E3	  ubiquitin	  
ligases	  harboring	  a	  RING	  domain	  might	  be	   targeted	  as	  well.	   Five	  E3	   ligases	   containing	  a	  RING	  
motif	   are	   involved	   in	   TNFα	   induced	  NF-­‐κB	   activation	   to	  modify	   the	   components	   of	   the	   TNFR	  
signaling	   complex	   with	   non-­‐degrading,	   regulatory	   K63-­‐linked	   polyubiquitin	   chains:	   the	   RING	  
domain-­‐containing	  molecules	  TRAF2,	  cIAP1	  and	  cIAP2	  and	  the	  RBR	  (RING1-­‐BetweenRING-­‐RING2)	  
E3	   ligases	  HOIL-­‐1	   and	  HOIP	  of	   the	   LUBAC	   complex	   (Wajant	   and	   Scheurich,	   2011).	  All	   RING	  E3	  
ligases	  contain	  a	  Zincfinger	  type	  RING	  domain	  with	  40-­‐60	  residues	  presenting	  a	  Cys-­‐X2-­‐Cys-­‐X9-­‐39-­‐
Cys-­‐X1-­‐3-­‐His-­‐X2-­‐3-­‐Cys-­‐X2-­‐Cys-­‐X4-­‐48-­‐Cys-­‐X2-­‐Cys	  motif	  (where	  X	  can	  be	  any	  amino	  acid;	  histidines	  and	  
cysteines	  are	  sometimes	  exchanged)	   (Budhidarmo	  et	  al.,	  2012).	  All	  RING	  E3	   ligases	  coordinate	  
two	  zinc	  ions	  in	  a	  cross	  brace	  arrangement.	  The	  core	  of	  the	  RING	  domain	  displays	  two	  β-­‐strands	  
(βA	   and	   βB),	   one	  α-­‐helix	   (αA)	   and	   two	   loops	   (loop1	   and	   loop2)	   that	   surround	   the	   first	   and	  
second	  zinc	  coordination	  sites	  and	  contact	  the	  E2	  enzyme	  (Budhidarmo	  et	  al.,	  2012).	  However,	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TRAF2	   might	   be	   excluded	   from	   the	   list	   of	   potentially	   targeted	   proteins,	   because	   the	   RING	  
domain	  of	  TRAF2	  is	  not	  required	  for	  TNFα induced	  IKK/NF-­‐κB	  signaling	  (Zhang	  et	  al.,	  2010).	  The	  
RING	   E3	   ubiquitin	   ligases	   cIAP1	   and	   cIAP2	   contain	   a	   RING	  motif	   as	  well	   and	   are	   essential	   for	  
TNFα	  induced	  NF-­‐κB	  signaling	  (Mahoney	  et	  al.,	  2008).	  According	  to	  the	  similar	  structure	  of	  RING	  
E3	  ligases,	  the	  possibility	  arises	  that	  the	  compounds	  C27	  and	  C25-­‐0140	  might	  target	  cIAP1	  and	  
cIAP2	   for	   inhibition	   resulting	   in	   impaired	   TNFα	   induced	  NF-­‐κB	   activation	   as	  well.	   To	   test	   this	  
hypothesis	   a	   structural	   alignment	   using	   the	   FATCAT	   software	   (flexible	   structure	   alignment	   by	  
chaining	  aligned	  fragment	  pairs	  allowing	  twists)	  was	  conducted.	  For	  cIAP1,	  no	  crystal	  structure	  
of	  the	  RING	  domain	  is	  available,	  but	  the	  RING	  domain	  of	  cIAP2	  (PDB:	  3eb5)	  is	  annotated	  in	  the	  
Protein	  Data	  Bank	  (PDB)	  and	  was	  structural	  aligned	  to	  the	  RING	  domain	  of	  TRAF6	  (PDB:	  2jmd)	  as	  
illustrated	   in	   Figure	   5.2A.	   Between	   the	   two	   proteins,	   out	   of	   62	   compared	   positions	   55	   were	  
equivalent	  even	  without	  a	  twist	  (supplement	  10.10).	  A	  p-­‐value	  of	  0.0138	  confirms	  the	  significant	  
similarity	  between	  both	  domains	  (supplement	  10.10).	   In	  the	  structural	  alignment	  the	  similarity	  
of	   the	   β-­‐strands,	   α-­‐helices	   and	   the	   loops	   are	   visible.	   The	   interaction	   surface	   to	   Ubc13	   is	  
indicated	  by	  the	  arrows	  in	  Figure	  5.2A.	  	  
In	  the	  hit	  verification	  process	  of	  compounds	  specifically	  targeting	  the	  RZ1	  domain	  of	  TRAF6,	  the	  
RING	   E3	   ligase	   RNF8	   was	   included	   in	   the	   screening	   procedure.	   The	   structures	   of	   the	   RING	  
domains	   of	   TRAF6	   and	   RNF8	   also	   exhibit	   a	   significant	   similarity	   (p-­‐value	   =	   0.000204)	   and	   59	  
equivalent	  positions	  out	  of	  62	  compared	  residues	  without	  a	  twist	  (Figure	  5.2B	  and	  supplement	  
10.11).	   Compounds	   targeting	   general	   RING	   domains	   would	   interfere	   in	   both	   assays,	   TRAF6-­‐
Ubc13	  and	  RNF8-­‐Ubc13.	  However,	  none	  of	  the	  27	  hit	  compounds	  that	  interrupted	  TRAF6-­‐Ubc13	  
binding	   inhibited	   the	  RNF8-­‐Ubc13	   interaction	   indicating	   that	   the	   identified	  compounds	   indeed	  
target	  only	  the	  TRAF6-­‐Ubc13	  interaction	  surface.	   In	  NMR	  experiments,	  C27,	  C25	  and	  C25-­‐0140	  
caused	   shifting	   of	   the	   same	   peaks	   within	   the	   TRAF6	   proteins	   suggesting	   that	   the	   multiple	  
heterocyclic	   structures,	   that	   have	   all	   three	   compounds	   in	   common,	   target	   identical	   residues	  
within	  the	  RZ1	  domain	  of	  TRAF6.	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Due	  to	  the	  fact	  that	  the	  compounds	  affect	  the	  RZ1	  domain	  of	  TRAF6,	  but	  not	  the	  RING	  domain	  
of	  RNF8,	   it	   is	  most	   likely	   that	  the	  Zincfinger1	  domain	  of	  TRAF6	   is	   targeted	  because	  RNF8	  does	  
not	  contains	  such	  a	  Zincfinger	  motif.	  The	  Zincfinger1	  domain	  of	  TRAF6	  is	  not	  directly	  involved	  in	  
the	  Ubc13	  interaction	  but	  plays	  a	  critical	  role	  in	  maintaining	  the	  structural	  conformation	  of	  the	  
RING	   domain	   to	   allow	   binding	   to	   Ubc13.	   Without	   the	   Zincfinger1	   motif,	   TRAF6	   auto-­‐
ubiquitination	  as	  well	  as	  interaction	  to	  Ubc13	  is	   impaired	  (Lamothe	  et	  al.,	  2008).	  Targeting	  the	  
Zincfinger1	  domain	  of	  TRAF6	  might	  cause	  conformational	  changes	  within	  the	  RING	  domain	  in	  a	  
way	  that	  the	  interaction	  surface	  is	  no	  longer	  available	  for	  Ubc13	  binding.	  As	  a	  consequence,	  it	  is	  
unlikely	  that	  RING	  domains	  of	  additional	  E3	   ligases	  or	  other	  proteins	  containing	  RING	  domains	  
are	   targeted	  by	   the	  compounds	  C27,	  C25	  and	  C25-­‐0140.	  However,	   it	   cannot	  be	  excluded	   that	  
Zincfinger	  domains	  of	  other	  proteins	  are	  targeted	  including	  the	  two	  Zincfinger	  motifs	  within	  the	  
RBR	  domain	  of	  the	  E3	  ligase	  HOIP,	  which	  is	  a	  unique	  feature	  of	  HOIP	  (Stieglitz	  et	  al.,	  2013;	  Spratt	  







Figure	   5.2:	   Comparison	   of	   RING	  
containing	   E3	   ubiquitin	   ligases	   cIAP2	  
and	   RNF8	   with	   the	   TRAF6	   RING	  
domain.	   Structural	   alignments	   were	  
performed	   using	   the	   FATCAT	   software	  
provided	   by	   the	   Godzik´s	   lab.	   The	  
interaction	  surface	  to	  Ubc13	  is	  indicates	  
by	   arrows.	   (A)	   Structural	   alignment	   of	  
the	  RING	  domains	  of	  TRAF6	  (PDB:	  2jmd)	  
and	   cIAP2	   (PDB:	   3eb5).	   The	   RING	  
domains	   are	   structural	   significantly	  
similar.	   (B)	   Structural	   alignment	   of	   the	  
RING	  domains	  of	  TRAF6	  (PDB:	  2jmd)	  and	  
RNF8	   (PDB:	   4yac)	   revealed	   structural	  
similarity	  between	  both	  domains.	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A	  second	  explanation	  for	  the	  non-­‐selective	  effects	  of	  the	  compounds	  C27	  and	  C25-­‐0140	  could	  be	  
that	   the	  compounds	   target	  additional	  protein	  domains	  different	   from	  TRAF6	  within	   the	  NF-­‐κB	  
signaling	  in	  cells.	  Due	  to	  the	  fact	  that	  IL-­‐1β,	  LPS	  and	  TNFα	  induced	  NF-­‐κB	  activation	  are	  reduced	  
to	   the	   same	   extent,	   it	  might	   be	   conceivable	   that	   signaling	   components	   are	   targeted	   that	   are	  
used	  by	  all	   three	  receptor	  signaling	  pathways.	  Upon	   IL-­‐1β,	  LPS	  and	  TNFα	   stimulation,	   reduced	  
phosphorylation	  and	  degradation	  of	   IκBα	  was	  detected	  after	   compound	   treatment.	   Effects	  of	  
the	   compounds	   in	   IκBα	   signaling,	   nuclear	   translocation	   of	   the	  NF-­‐κB	   dimers,	   its	   DNA-­‐binding	  
activity	  as	  well	  as	  transcriptional	  regulation	  of	  target	  genes	  can	  therefore	  be	  excluded.	  Signaling	  
components	  acting	  upstream	  of	   the	  phosphorylation	  of	   IκBα	  might	  be	  targeted	   instead.	  Upon	  
IL-­‐1β	   stimulation,	   the	   activity	   of	   the	   IKK	   complex	  was	   diminished	   after	   compound	   treatment.	  
This	   implies	   that	   the	   activity	   of	   the	   IKK	   complex	   itself	   is	   impaired	   or	   that	   signaling	   events	  
upstream	  of	  the	  IKK	  complex	  activation	  are	  targeted.	  This	  would	  include	  the	  activity	  of	  either	  the	  
LUBAC	  complex	  or	  the	  TAB/TAK1	  complex.	  Furthermore,	  it	  cannot	  be	  excluded	  that	  the	  activity	  
of	  E1	  enzymes	  or	  E2	  complexes	  within	  the	  ubiquitination	  process	  are	  impaired	  as	  well.	  Replacing	  
TRAF6	   with	   the	   E3	   ligase	   RNF8	   in	   in	   vitro	   ubiquitination	   assays	   could	   help	   to	   analyze	   the	  
influence	  on	  E1	  and	  E2	  enzymes.	  	  
Altogether,	  it	  can	  be	  clearly	  stated	  that	  the	  identified	  compounds	  directly	  target	  the	  RZ1	  domain	  
of	  TRAF6	  but	  that	  other	  protein	  domains	  within	  the	  NF-­‐κB	  signaling	  cascade	  might	  be	  subjects	  to	  
compound	  binding	  as	  well.	  	  
	  
5.5.	  Targeting	  the	  RING-­‐Zincfinger1	  domain	  of	  TRAF6	  	  
An	  intact	  RING-­‐Zincfinger1	  domain	  of	  TRAF6	  is	  required	  for	  the	  interaction	  with	  the	  E2	  enzyme	  
complex	  Ubc13/Uev1a,	  its	  K63-­‐linked	  auto-­‐ubiquitination	  and	  the	  ability	  to	  activate	  IKK	  and	  NF-­‐
κB	   upon	   stimulation	   (Lamothe	   et	   al.,	   2008).	   In	   order	   to	   prevent	   TRAF6-­‐dependent	   NF-­‐κB	  
activation	  multiple	   possibilities	   in	   targeting	   the	   TRAF6	   RZ1	   domain	   are	   given.	   First,	   the	   lysine	  
residue	   124	   (K124)	   is	   the	   critical	   ubiquitin	   acceptor	   site	   residue	   that	   is	   responsible	   for	   TRAF6-­‐
auto-­‐ubiquitination.	  Mutation	  of	  this	  site	  abrogated	  TRAF6-­‐mediated	  NEMO	  ubiquitination,	  TAK1	  
and	   IKK	  activity	  as	  well	   as	  NF-­‐κB	  activation	  upon	  stimulation	   (Lamothe	  et	  al.,	   2007).	  However,	  
this	   mutant	   is	   still	   able	   to	   interact	   with	   Ubc13	   and	   to	   form	   TRAF6	   dimers	   (Yin	   et	   al.,	   2009).	  
Second,	   the	   interaction	   to	   Ubc13	   requires	   an	   intact	   RING-­‐Zincfinger1	   domain.	   Single	   point	  
mutations	  within	  the	  RING	  domain	  including	  D75K,	  C70A,	  I72F	  abolished	  the	  interaction	  to	  Ubc13	  
(Yin	   et	   al.,	   2009).	   Although	   the	   Zincfinger1	   domain	   of	   TRAF6	   is	   not	   directly	   involved	   in	  Ubc13	  
binding,	  it	  plays	  a	  critical	  structural	  role	  in	  holding	  the	  RING	  domain	  in	  place	  for	  binding	  to	  Ubc13	  
(Yin	  et	  al.,	  2009).	  Third,	  TRAF6	  dimerization	   is	   required	   for	   the	  higher-­‐order	  oligomerization	  of	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TRAF6	  to	  mediate	  IL-­‐1β	   induced	  IKK	  activation	  and	  IκBα	  phosphorylation	  (Yin	  et	  al.,	  2009).	  The	  
TRAF6	   dimerization	  mutants	   Q82A,	   R88A,	   F118A,	   N121A	   and	   E126Q	   within	   the	   RING	   domain	  
caused	  a	  significant	  reduction	  of	  TRAF6	  dependent	  NF-­‐κB	  activation	  (Yin	  et	  al.,	  2009;	  Megas	  et	  
al.,	  2011).	  The	  TRAF6	  dimerization	  interface	  lies	  apart	  from	  the	  Ubc13	  interaction	  site	  and	  TRAF6	  
dimerization	  mutants	  were	  still	  able	  to	  interact	  with	  Ubc13(Yin	  et	  al.,	  2009).	  
Altogether,	  it	  is	  possible	  to	  target	  multiple	  residues	  within	  the	  TRAF6	  RZ1	  domain	  to	  prevent	  NF-­‐
κB	   activation:	   a)	   the	   ubiquitin	   acceptor	   side	   residue	   K124;	   b)	   the	   Ubc13-­‐interacting	   residues	  
including	  D57,	  C70	  and	  I72;	  c)	  the	  residues	  of	  the	  Zincfinger1	  domain	  of	  TRAF6	  that	  might	  cause	  
conformational	   changes	   within	   the	   RING	   domain;	   d)	   the	   residues	   responsible	   for	   TRAF6	  




The	  compounds	  C27,	  C25	  and	  C25-­‐0140	  directly	  bind	  the	  TRAF6	  RING-­‐Zincfinger1	  domain	  in	  NMR	  
experiments.	  Due	   to	  a	  missing	  assignment	  of	   the	  NMR	  data	  of	  TRAF6,	   it	   is	  not	   yet	  possible	   to	  
define	  the	  residues	  that	  are	  targeted	  by	  the	  compounds.	  Targeting	  the	  K124	  residue	  as	  well	  as	  
interfering	  with	   the	   dimerization	   residues	   by	   the	   compounds	   can	   be	   excluded	   due	   to	   the	   fact	  
that	   all	   compounds	   interrupt	   the	   TRAF6-­‐Ubc13	   interaction	  whereas	   the	   K124	  mutant	   and	   the	  
TRAF6	  dimerization	  mutants	   still	   exhibit	   TRAF6-­‐Ubc13	  binding.	  However,	   one	  possibility	  would	  
be	   that	   residues	  within	   the	   RING	  domain	   that	   are	   responsible	   for	  Ubc13	   binding	   are	   targeted	  
resulting	  in	  impaired	  binding	  to	  Ubc13.	  Another	  option	  would	  be	  that	  the	  compounds	  bind	  apart	  















Figure	   5.3.	   4	   different	   possibilities	   to	  
target	   the	   RING-­‐Zincfinger1	   domain	   of	  
TRAF6	   (blue)	   to	   interfere	   with	   NF-­‐κB	  
signaling.	  Targeting	  the	  Lysine	  124	  residue	  
(K124	   in	   purple)	   (a)	   covers	   the	   ubiquitin	  
acceptor	   side	   for	   TRAF6	   auto-­‐
ubiquitination.	   Binding	   to	   the	   Ubc13-­‐
interacting	   residues	   (b)	   prevents	  
interaction	   to	   the	   E2	   complex	  
Ubc13/Uev1a.	  (c)	  Targeting	  residues	  of	  the	  
Zincfinger1	   (ZF1)	   domain	   of	   TRAF6	   might	  
cause	   conformational	   changes	  of	  the	  RING	  
domain.	   (d)	   Binding	   to	   the	   residues	   that	  
are	   responsible	   for	   TRAF6	   dimerization	  
abolished	   higher-­‐order	   oligomerization	   for	  
signal	  progression.	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of	   the	   RING	   domain	   and	   thereby	   preventing	   binding	   to	   Ubc13.	   NMR	   assignments	   or	  
crystallography	  will	  help	  to	  identify	  the	  exact	  residues	  that	  are	  targeted	  by	  the	  compounds.	  	  
	  
5.6	  Targeting	  the	  TRAF6-­‐Ubc13	  interaction	  for	  therapeutic	  intervention	  
The	  interaction	  of	  TRAF6-­‐Ubc13	  is	   involved	  in	  a	  variety	  of	  signaling	  pathways	  like	  IL-­‐1β	  and	  LPS	  
signaling	   leading	  to	  the	  activation	  of	  NF-­‐κB.	  Retroviral	   transfection	  of	  TRAF6-­‐deficient	  MEF	  cell	  
with	   wildtype	   TRAF6	   rescued	   TRAF6	   auto-­‐ubiquitination	   as	   well	   as	   signaling	   towards	   NF-­‐κB	  
activation	   whereas	   the	   Ubc13	   binding	   mutants	   could	   not	   (Yin	   et	   al.,	   2009).	   Upregulation	   of	  
TRAF6-­‐dependent	  pathways	  including	  IL-­‐1β	  and	  LPS	  signaling	  are	  a	  main	  cause	  for	  autoimmune	  
diseases	   and	   chronic	   inflammation.	   Targeting	   this	   binding	   and	   therefore	   abrogating	   NF-­‐κB	  
mediated	  inflammation	  could	  help	  to	  relieve	  the	  clinical	  symptoms.	  	  
	  
5.6.1	  Targeting	  TRAF6	  in	  Obesity	  
Obesity	  induced	  inflammation	  is	  an	  important	  contributor	  to	  the	  induction	  of	  insulin	  resistance.	  
Free	  fatty	  acids	  are	  bound	  by	  the	  liver	  secretory	  protein	  FetuinA	  and	  target	  the	  TLR2/4	  receptors	  
leading	   to	   chronic	   inflammatory	   signaling	   involving	   TRAF6	   in	   obesity	   and	   diabetes	   (Pal	   et	   al.,	  
2012;	   Yin	   et	   al.,	   2014).	   Mice	   deficient	   in	   CD40-­‐TRAF6	   signaling	   did	   not	   gain	   body	   weight	  
compared	  to	  control	  mice	  in	  HFD	  experiments	  and	  showed	  reduced	  basal	  glucose	  levels	  as	  well	  
as	   improved	   insulin	   sensitivity	   (Chatzigeorgiou	   et	   al.,	   2014).	   Targeting	   the	   MATH	   domain	   of	  
TRAF6	  with	  the	  compound	  SMI	  6860766	  to	  prevent	  the	  CD40-­‐TRAF6	  interaction	  did	  not	  lead	  to	  
improved	   body	   weight,	   but	   to	   an	   ameliorated	   glucose	   tolerance	   test	   although	   basal	   levels	   of	  
glucose	   and	   insulin	   in	   plasma	   did	   not	   differ	   among	   compound	   and	   control	   treated	   mice.	   A	  
reduced	  leukocyte	  count	  in	  the	  adipose	  tissues	  of	  these	  individuals	  let	  to	  improved	  inflammation	  
as	  well	  (Van	  den	  Berg	  et	  al.,	  2014).	  As	  the	  SMI	  6860766	  inhibitor	  was	  the	  first	  small	  molecule	  that	  
targets	  TRAF6	  and	  was	  tested	  in	  a	  mouse	  model,	  C25-­‐0140	  was	  also	  analyzed	  in	  a	  diet-­‐induced	  
obesity	  (DIO)	  mouse	  model.	  This	  not	  only	  enabled	  comparison	  of	  the	  efficiency	  of	  the	  compound	  
identified	  in	  this	  work,	  but	  also	  led	  to	  the	  analysis	  of	  the	  differential	  effects	  when	  targeting	  the	  
MATH	   domain	   or	   the	   RING-­‐Zincfinger1	   domain	   of	   TRAF6.	   When	   testing	   C25-­‐0140	   in	   the	   DIO	  
mouse	   model,	   a	   significant	   improvement	   in	   body	   weight	   was	   observed.	   Whereas	   the	   gene	  
expression	  of	   pro-­‐inflammatory	   cytokines	   and	  NF-­‐κB	   target	   genes	   tent	   to	  be	   reduced,	   glucose	  
clearance	  out	  of	  the	  blood	  could	  not	  be	  improved.	  	  
Differences	  in	  the	  mouse	  studies	  between	  testing	  SMI	  6860766	  and	  C25-­‐0140	  were	  bodyweight	  
and	   time	   period	   of	   the	   HFD	   before	   starting	   the	   studies	   as	   well	   as	   the	   treatment	   period.	   SMI	  
6860766	   treated	  mice	  were	   fed	  with	   a	  HFD	   for	   12	  weeks	  only	  until	   reaching	   an	   average	  body	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weight	  of	  around	  33g	  (Van	  den	  Berg	  et	  al.,	  2014).	  Compared	  to	  that,	  mice	  that	  received	  C25-­‐0140	  
were	  set	  on	  a	  HFD	  for	  at	  least	  one	  year	  and	  exhibited	  an	  average	  bodyweight	  of	  55g.	  Mice	  were	  
SMI	   6860766	   treated	   for	   six	   weeks	   with	   a	   concentration	   of	   10µmol/kg	   compared	   to	   20	   days	  
treatment	  with	   14µmol/kg	   C25-­‐0140.	   The	   application	   of	   compounds	   for	   20	   days	   is	   a	   standard	  
protocol	   at	   the	   Institute	   of	   Diabetes	   and	   Obesity	   at	   the	   Helmholtz	   Zentrum	   München.	   The	  
standard	  protocol	  for	  glucose	  tolerance	  tests	  differed	  between	  the	  two	  groups	  as	  well.	  While	  SMI	  
6860766	   treated	   mice	   were	   starved	   for	   12	   hours	   and	   injected	   with	   1mg	   glucose	   per	   gram	  
bodyweight,	  mice	   receiving	  C25-­‐0140	  were	   starved	   for	   6	  hours	  only	   and	   then	   challenged	  with	  
1.5mg	   glucose	   per	   gram	   bodyweight.	   Comparing	   the	   two	   mouse	   studies,	   mice	   in	   C25-­‐0140	  
testing	  displayed	  a	  higher	  bodyweight	  and	  received	  HFD	  for	  a	  longer	  period	  assuming	  that	  clinical	  
symptoms	   like	   glucose	   intolerance	   as	   well	   as	   the	   grade	   of	   chronic	   inflammation	   were	   more	  
elevated	   in	   these	  mice.	   Therefore,	   the	   initial	   clinical	   conditions	   for	   C25-­‐0140	   treatment	   were	  
severe	  compared	  to	   the	  SMI	  6860766	  treatment	  study.	  This	  could	  be	  one	  possible	  explanation	  
for	   the	   only	   slight	   improvement	   of	   the	   inflammatory	   status	   upon	   C25-­‐0140	   treatment.	   Also,	  
parameters	   for	   pharmacodynamics	   and	   pharmacokinetics	   of	   6860766	   are	   not	   published	   and	  
toxicokinetics	  of	   the	  compounds	  cannot	  be	  compared.	  Although	  the	  daily	  applied	  dose	  of	  C25-­‐
0140	  was	  higher,	  these	  mice	  were	  only	  treated	  for	  half	  of	  the	  period	  of	  SMI	  6860766	  treatment.	  
A	  longer	  treatment	  period	  might	  have	  demonstrated	  a	  stronger	  effect	  of	  C25-­‐0140	  regarding	  the	  
chronic	   inflammation.	   However,	   Van	   den	   Berg	   et	   al.	   obtained	   enhanced	   glucose	   tolerance	  
already	  after	  three	  weeks	  of	  SMI	  6860766	  treatment	  (Van	  den	  Berg	  et	  al.,	  2014).	  C25-­‐0140	  did	  
not	   ameliorate	   the	   glucose	   clearance	   out	   of	   the	   blood	   after	   20	   days	   of	   treatment.	   Although	  
inflammation	   parameters	   in	   both	   studies	   were	   improved,	   targeting	   the	   RZ1	   domain	   of	   TRAF6	  
instead	   of	   the	   MATH	   domain	   does	   not	   enhance	   glucose	   tolerance,	   but	   reduces	   bodyweight	  
instead.	  	  
The	   differential	   effects	   obtained	   upon	   SMI	   6860776	   and	   C25-­‐0140	   treatment	   might	   also	   be	  
caused	  by	  the	  distinct	  mode	  of	  action	  of	  both	  compounds.	  SMI	  6860776	  targets	  the	  C-­‐terminal	  
MATH	   domain	   and	   causes	   disruption	   of	   the	   interaction	   to	   receptors,	   adaptor	   proteins	   and	  
substrates	  as	  well	  as	  impaired	  trimerization	  of	  the	  TRAF6	  molecules.	  In	  contrast,	  C25-­‐0140	  binds	  
to	  the	  N-­‐terminal	  RZ1	  domain	  to	  prevent	  interaction	  to	  Ubc13,	  E3	  ligase	  activity	  and	  dimerization	  
of	   TRAF6.	   Interfering	  with	   the	   functions	   carried	  out	  by	   the	  C-­‐terminal	   domain	  of	   TRAF6	  might	  
exert	  different	  effects	  than	  inhibition	  of	  the	  RZ1	  domain.	  This	  might	  also	  be	  reflected	  in	   insulin	  
downstream	  signaling.	  Activated	  insulin-­‐like	  growth	  factor-­‐1	  (IGF-­‐1)	  receptor	  may	  directly	  engage	  
TRAF6	  activation	  as	  ubiquitination	  of	  TRAF6	  as	  well	  as	  its	  interaction	  with	  the	  IGF-­‐1	  receptor	  was	  
induced	  after	  IGF-­‐1	  stimulation	  (Yang	  et	  al.,	  2009).	  TRAF6	  was	  found	  to	  be	  a	  direct	  E3	  ligase	  for	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Akt	  to	  mediate	  Akt	  ubiquitination,	  membrane	  recruitment,	  phosphorylation	  at	  Threonin	  308	  and	  
enhancing	   its	   activity	   towards	   GSK3β	   (Glycogen	   Synthase	   Kinase	   3β)	   upon	   IGF-­‐1	   stimulation	  
leading	  to	  the	  suppression	  of	  gluconeogenesis	  (Yang	  et	  al.,	  2009).	  Further	  research	  of	  Cheng	  et	  
al.	   in	  2013	  on	  sensitizing	   insulin	  signaling	  in	  hepatocytes	  revealed	  that	  TRAF6	  is	  responsible	  for	  
the	   K63-­‐linked	   polyubiquitination	   of	   APPL1	   (adaptor	   protein,	   phosphotyrosine	   interaction,	   PH	  
(pleckstrin	   homology)	   domain	   and	   leucine	   zipper	   containing	   1)	   at	   Lysine	   160	   upon	   insulin	  
stimulation	   (Cheng	   et	   al.,	   2013).	   Hepatic	   overexpression	   of	   APPL1	   enhanced	   insulin	   induced	  
phosphorylation	  of	  Akt	  and	  its	  downstream	  substrate	  GSK3β	  resulting	  in	  a	  significant	  reduction	  
of	  plasma	  glucose	  and	   insulin	   levels	   in	  HFD	  mice.	  Such	  effects	  were	  not	  observed	   in	  mice	  with	  
hepatic	  overexpression	  of	  the	  APPL1	  K160R	  mutant.	  Hepatocytes	  with	  reduced	  TRAF6	  expression	  
showed	   impairment	   in	   APPL1	   ubiquitination,	   its	   membrane	   recruitment	   as	   well	   as	  
phosphorylation	  of	  Akt	  and	  its	  downstream	  substrate	  GSK3β.	  As	  a	  result,	  insulin	  was	  not	  able	  to	  
suppress	  glucose	  production	  anymore	  due	  to	  an	  increase	  in	  mRNA	  and	  protein	  expression	  of	  the	  
gluconeogenic	   genes	   phosphoenolpyruvate-­‐carboxykinase	   (PEPCK)	   and	   glucose-­‐6-­‐phosphatase	  
(G6Pase)	   (Cheng	   et	   al.,	   2013).	   The	   authors	   proclaim	   that	   TRAF6	   is	   an	   obligatory	   signaling	  
component	   that	   mediates	   insulin	   actions	   in	   hepatocytes	   by	   promoting	   ubiquitin	   dependent	  
membrane	   targeting	   of	   the	   APPL1-­‐Akt	   complex.	   Thereby,	   suppression	   of	   TRAF6	   abolishes	   the	  
insulin	  sensitizing	  actions	  of	  APPL1.	  The	  described	  insulin	  sensitizing	  process	  strongly	  depends	  on	  
the	  E3	   ligase	  activity	  of	  TRAF6.	  No	   function	  of	   the	  MATH	  domain	  of	  TRAF6	   is	  described	   in	   this	  
signaling	   so	   far.	   Targeting	   the	   RZ1	   domain	   of	   TRAF6	   would	   lead	   to	   an	   abrogation	   of	   insulin	  
induced	  signaling	  and	  worsening	  of	  the	  glucose	  tolerance.	  This	  might	  explain	  why	  treatment	  of	  
obese	  mice	  with	  C25-­‐0140	  does	  not	  improve	  glucose	  clearance	  out	  of	  the	  blood.	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In	   general,	   it	   appears	   that	   the	  RZ1	  domain	  of	   TRAF6	  plays	   a	  dual	   role	   in	  diet-­‐induced	  obesity.	  
Figure	  5.4	  illustrates	  both	  functions.	  First,	  due	  to	  its	  recruitment	  to	  the	  TLR2/4	  receptor	  complex	  
triggered	   by	   the	   free	   fatty	   acid	   –	   FetuinA	   ligand,	   it	   plays	   an	   important	   role	   in	   causing	   chronic	  
inflammation	   in	   diabetic	   and	   obese	   individuals.	   Here,	   inhibiting	   TRAF6	   might	   lead	   to	   the	  
desirable	   effect	   of	   lowering	   inflammation.	   However,	   as	   a	   second	   function	   of	   the	   RZ1	   domain,	  
TRAF6	   is	   also	   known	   as	   an	   important	   key	   mediator	   in	   insulin	   sensitizing	   to	   enhance	   the	  
suppression	  of	  gluconeogenesis	  via	  the	  APPL1-­‐Akt-­‐GSK3β	  axis.	  Impairing	  TRAF6	  activity	  in	  insulin	  
signaling	  would	   induce	   increased	   insulin	   insensitivity	  and	  reduced	  glucose	  clearance	  out	  of	   the	  
blood.	  	  
Surprisingly,	  Kwon	  et	  al.	   found	  that	   IL-­‐13,	  an	  anti-­‐inflammatory	  cytokine,	   is	   induced	   in	  adipose	  
tissue	  of	  obese	  humans	  and	  HFD-­‐mice.	  Pro-­‐inflammatory	  cytokines	  like	  IL-­‐1β	  and	  TNFα	  mediate	  
IL-­‐13	  production	   in	   adipocytes	   in	   an	   IKKβ	   dependent	  manner.	  Adipocyte-­‐specific	   IKKβ	   deletion	  
diminished	   IL-­‐13	   expression	   and	   enhanced	   the	   production	   of	   inflammatory	   cytokines	   and	  
infiltration	  of	   pro-­‐inflammatory	   immune	   cells	   in	   adipose	   tissue	   resulting	   in	   a	  worsening	  of	   the	  
insulin	  resistant	  state.	  The	  authors	  proclaim	  that	  although	  IKKβ	  activates	  the	  expression	  of	  pro-­‐
inflammatory	   cytokine,	   it	   also	   induces	   the	   production	   of	   the	   anti-­‐inflammatory	   IL-­‐13	   in	  
adipocytes,	  which	  counteracts	  adipose	  tissue	  inflammation	  and	  insulin	  resistance.	  With	  targeting	  
TRAF6,	   the	  activity	  of	   IKKβ	  might	  be	   impaired	  and	  therefore	   IL-­‐13	  production	  together	  with	   its	  

























































Figure	   5.4:	   The	   dual	   functions	   of	  
TRAF6	   in	   diet-­‐induced	   obesity.	  
TRAF6	   is	   a	   major	   key	   player	   in	  
maintaining	   inflammation	   of	  
obesity	  through	  its	  involvement	  in	  
TLR4	  signaling	   leading	  to	  elevated	  
NF-­‐κB	   signaling.	   Additionally,	  
TRAF6	   is	   required	   for	   the	   insulin	  
sensitizing	   actions	   by	   activating	  
the	   APPL1-­‐Akt	   axis	   after	   insulin	  
stimulation	   in	   order	   to	   abrogate	  
gluconeogenesis	   and	   initiating	  
glucose	  uptake	  and	  storage.	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inflammatory	   action	   of	   IL-­‐13	   but	   not	   the	   improvement	   of	   glucose	   clearance	   could	   be	  
compensated	  when	  inhibiting	  TRAF6	  RZ1.	   
Considering	  all	  the	  multiple	  effects	  of	  TRAF6	  in	  inflammation	  and	  insulin	  signaling,	  targeting	  the	  
RZ1	   domain	   of	   TRAF6	   in	   diet-­‐induced	   obesity	   appears	   to	   be	   a	   double-­‐edged	   sword	   as	  
inflammation	  will	  be	  ameliorated	  whereas	  insulin	  resistance	  might	  not	  be	  improved.	  Therefore,	  
further	   research	   will	   be	   necessary	   to	   evaluate	   the	   feasibility	   of	   targeting	   TRAF6	   RZ1	   for	   the	  
treatment	  of	  obesity.	  	  	  
	  
5.6.2	  Targeting	  TRAF6	  in	  rheumatoid	  arthritis	  
Single	  nucleotide	  polymorphisms	  (SNPs)	  studies	  have	  linked	  TRAF6	  to	  autoimmune	  diseases	  such	  
as	   rheumatoid	   arthritis	   (RA)	   (Namjou	   et	   al.,	   2012).	   RA	   is	   a	   common	   autoimmune	   disease	  
associated	   with	   systemic	   inflammation	   that	   causes	   swelling	   and	   deformation	   of	   the	   joints	  
including	   destruction	   of	   bones	   and	   cartilage.	   Arthritis	   in	   RA	   develops	   in	   four	   steps.	   In	   the	  
induction	   phase	   injuries,	   infections	   or	   exposures	   to	   toxic	   substances	   (smoking)	   activate	   the	  
inflammatory	  cascade	   leading	  to	   infiltration	  of	  monocytes/macrophages	   into	  the	  synovium	  and	  
secretion	  of	  pro-­‐inflammatory	  cytokines	  like	  IL-­‐1β,	  TNFα,	   IL-­‐17	  and	  IL-­‐10	  (Kirkham	  et	  al.,	  2006).	  
The	   inflammation	   phase	   is	   characterized	   by	   presenting	   the	   selfantigens	   and	   subsequent	  
polyclonal	  activation	  of	  T	  cells	  and	  B	  cells.	  Next,	  the	  cartilage	  autoantigens,	  which	  are	  normally	  
not	   accessible	   to	   the	   immune	   system,	   become	   exposed	   by	   damage	   introducing	   the	   self-­‐
perpetuation	  phase.	  In	  the	  last	  phase,	  the	  destruction	  phase,	  synovial	  fibroblasts	  and	  osteoclasts	  
are	  activated	  by	  proinflammatory	  cytokines	  such	  as	  TNFα	  and	   IL-­‐6	  causing	  destruction	  of	  bone	  
and	   cartilage.	   TRAF6	   levels	   were	   shown	   to	   be	   elevated	   in	   the	   synovium	   and	   correlated	   with	  
synovitis	  severity	  leading	  to	  the	  hypothesis	  that	  synovial	  TRAF6	  is	  involved	  in	  the	  pathogenesis	  of	  
synovial	   inflammation	   and	   osteoclast	   differentiation	   (Zhu	   et	   al.,	   2012).	   Indeed,	   the	   RING-­‐
Zincfinger1	  domain	  of	  TRAF6	  is	  integrated	  into	  several	  signaling	  pathways	  in	  RA:	  i)	  IL-­‐1β	  and	  TLR	  
signaling	  in	  immune	  cells	  like	  macrophages,	  ii)	  in	  T	  cells	  signaling	  via	  the	  T	  cell	  receptor	  complex,	  
iii)	   in	  B	   cell	   signaling	  after	  CD40	   stimulation,	   iv)	   IL-­‐17	   signaling	   in	   immune	  cells,	   epithelial	   cells	  
and	   fibroblast	   (Xie,	   2013)	   and	   v)	   osteoclast	   differentiation	   (Lamothe	   et	   al.,	   2007).	   Therefore,	  
targeting	  TRAF6	  in	  RA	  would	  not	  only	  affect	  the	  systemic	  inflammation	  but	  also	  the	  destruction	  
of	  the	  bones	  and	  cartilage.	  Current	  therapies	  against	  TNFα,	  IL-­‐1β	  and	  IL-­‐6	  in	  addition	  to	  T	  cell	  and	  
B	   cell	   inhibitors	   have	   indeed	   resulted	   in	   favorable	   clinical	   outcomes	   in	   patients	   with	   RA	  
(Scheinecker	  et	  al.,	  2008),	  but	  ameliorate	  the	  systemic	  inflammation	  only	  and	  do	  not	  target	  the	  
destruction	   of	   the	   bones	   and	   cartilage	   by	   osteoclasts.	   A	   recent	   study	   investigating	  Vitisin	   A,	   a	  
resveratrol	  tetramer	  found	  in	  Vitis	  thunbergii,	   led	  to	   inhibition	  of	  osteoclast	  differentiation	  and	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bone	  resorption	  by	  preventing	  RANKL	  induced	  TRAF6	  ubiquitination	  and	  TRAF6-­‐TAK1	  formation	  
(Chiou	   et	   al.,	   2014).	   Targeting	   the	   TRAF6	   ubiquitination	   appears	   to	   be	   sufficient	   to	   impair	   the	  
destruction	  process	  of	  bones	  and	  cartilage	  in	  RA.	  C25-­‐0140	  is	  shown	  to	  directly	  bind	  TRAF6	  and	  
to	   prevent	   endogenous	   TRAF6	   auto-­‐ubiquitination	   in	  MEF	   cells	   after	   IL-­‐1β	   stimulation	   (Figure	  
4.26).	  Therefore,	  targeting	  TRAF6	  with	  C25-­‐0140	   in	  RA	  and	  other	  autoimmune	  disorders	  would	  
specifically	  interfere	  with	  IL-­‐1β,	  T	  cell	  and	  B	  cell	  signaling	  as	  well	  as	  osteoclast	  differentiation.	  	  
	  
5.6.3	  Targeting	  TRAF6	  in	  cancer	  
A	  detailed	  analysis	  of	  lung	  cancer	  cell	  lines	  and	  primary	  tumors	  identified	  an	  amplification	  of	  the	  
TRAF6	  gene	  at	   chromosome	  11p13	   (Starczynowski	  et	  al.,	  2011).	  Concomitant	  with	   this	   finding,	  
TRAF6	  mRNA	  was	  overexpressed	  in	   lung	  cancers.	   Inhibition	  of	  TRAF6	  in	  human	  lung	  cancer	  cell	  
lines	   led	  to	  a	  reduction	  in	  NF-­‐κB	  activation,	  cell	  growth	  and	  tumor	  formation	  (Starczynowski	  et	  
al.,	   2011).	   Increased	   levels	   of	   TRAF6	  expression	   in	   human	   lung	   adenocarcinoma	   cells	   could	  be	  
confirmed	   by	   Zhong	   et	   al.	   in	   2012.	   In	   osteosarcoma	   patient	   samples,	   TRAF6	  mRNA	   as	  well	   as	  
proteins	   levels	  were	   elevated	   compared	   to	   normal	   bone	   tissue	   (Meng	   at	   el.,	   2012).	   The	   same	  
group	  revealed	  a	  shift	  towards	  G1	  phase	  in	  cell	  cycle	  progression	  in	  TRAF6	  deficient	  cells	  leaving	  
less	  cells	   in	  S	  and	  G2	  phase	  (Meng	  et	  al.,	  2012).	  In	  addition,	  they	  found	  decreased	  cell	   invasion	  
ability	  and	   increased	  apoptotic	  cell	  number	   in	  TRAF6	  depleted	  cells.	  These	  results	   suggest	   that	  
TRAF6	   might	   be	   involved	   in	   invasion	   and	   metastasis	   of	   osteosarcoma.	   At	   the	   same	   time	   this	  
implies	  that	  a	  downregulation	  of	  TRAF6	  might	  inhibit	  the	  proliferation	  of	  cancer	  cells	  leading	  to	  
cell	  cycle	  arrest	  in	  G1	  phase.	  To	  further	  unravel	  the	  role	  of	  TRAF6	  in	  cancer,	  Sun	  et	  al.	  found	  that	  
TRAF6	   upregulates	   the	   expression	   of	   the	   hypoxia-­‐inducible	   factor	   (HIF)-­‐1α	   independently	   of	  
oxygen.	   HIF-­‐1α	   protein	   but	   not	  mRNA	   levels	   were	   affected.	   They	   found	   that	   TRAF6	  mediates	  
K63-­‐linked	  polyubiquitination	  of	  HIF-­‐1α	   after	  binding	   to	   the	  protein	   to	  promote	   tumor	  growth	  
and	  angiogenesis	  (Sun	  et	  al.,	  2013).	  Just	  recently,	  the	  same	  group	  detected	  TRAF6	  upregulated	  in	  
colon	  cancer	  in	  correlation	  with	  the	  tumor	  grade	  (Sun	  et	  al.,	  2014).	  Different	  from	  other	  reports	  
knockdown	  of	  TRAF6	  did	  not	  reduce	  the	  survival	  of	  colon	  cancer	  cells	  but	  rather	  sensitized	  the	  
cancer	   cells	   to	   the	   treatment	   with	   the	   conventional	   anti-­‐cancer	   drugs	   5-­‐fluorouracil	   and	  
etoposide	  (Sun	  et	  al.,	  2014).	  
An	  increased	  sensitivity	  to	  anti-­‐cancer	  drugs	  of	  cells	   lacking	  TRAF6	  might	  also	  be	  related	  to	  the	  
involvement	  of	  TRAF6	  in	  DNA	  damage	  response	  (Hinz	  et	  al.,	  2010).	  After	  genotoxic	  stress,	  ATM	  is	  
required	   for	   the	   activation	   of	   TRAF6	   E3	   ubiquitin	   ligase	   activity	   resulting	   in	   Ubc13	   dependent	  
K63-­‐linked	  polyubiquitination	  and	   cIAP1	   recruitment.	   The	  ATM-­‐TRAF6-­‐cIAP1	   complex	  mediates	  
TAB2-­‐dependent	  TAK1	  phosphorylation	  leading	  to	  IKKγ	  monoubiquitination	  at	  K285	  followed	  by	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NF-­‐κB	  activation	  (Hinz	  et	  al.,	  2010).	  Upon	  DNA	  damage,	  the	  E3	  ligase	  activity	  of	  TRAF6	  is	  required	  
not	  only	   to	  promote	  TRAF-­‐mediated	  polyubiquitination	   in	   conjungtion	  with	  Ubc13,	  but	   also	   to	  
catalyze	  the	  monoubiquitination	  of	  IKKγ	  (Hinz	  et	  al.,	  2010).	  As	  C25-­‐0140	  directly	  interferes	  with	  
the	   TRAF6	   E3	   ligase	   activity	   in	   MEF	   cells	   upon	   IL-­‐1β	   stimulation,	   inhibitory	   effects	   on	   NF-­‐κB	  
activation	   and	   cancer	   cell	   proliferation	   upon	   genotoxic	   stress	   are	   anticipated.	   As	   mentioned,	  
TRAF6	   protein	   levels	   are	   upregulated	   in	   various	   cancer	   samples	   and	   were	   associated	   with	  
invasion	   and	   metastasis	   of	   the	   tumors	   as	   well	   as	   increasing	   the	   sensitivity	   to	   anti-­‐cancer	  
treatment.	   Targeting	   the	   RING-­‐Zincfinger1	   domain	   of	   TRAF6	   might	   not	   only	   impair	   NF-­‐κB	  
signaling	  induced	  by	  anti-­‐cancer	  drugs,	  but	  would	  also	  hold	  these	  cells	  back	  in	  G1	  phase	  to	  stop	  
cancer	  proliferation	  and	   increase	   the	   sensitivity	  against	  anti-­‐cancer	  drug	   treatment.	  Therefore,	  
interfering	   with	   TRAF6	   N-­‐terminal	   dependent	   signaling	   during	   cancer	   treatment	   might	   be	  
promising.	  	  
Elevated	   NF-­‐κB	   activation	   in	   cancer	   cells	   provide	   a	   survival	   mechanism	   by	   upregulating	   anti-­‐
apoptotic	  genes	  resulting	  in	  drug	  and	  treatment	  resistance.	  For	  example,	  the	  induction	  of	  NF-­‐κB	  
activation	  by	  radiotherapy	  induced	  DNA	  damage	  response	  is	  one	  of	  the	  main	  causes	  for	  cancer	  
cells	  to	  evade	  this	  therapy	  (Kozakai	  et	  al.,	  2012).	  These	  resistances	  might	  be	  mediated	  through	  by	  
the	  ATM-­‐TRAF6-­‐cIAP1	  axis.	  A	  combination	  of	  NF-­‐κB	  inactivation	  and	  radiotherapy	  could	  facilitate	  
the	   overcome	   of	   radio-­‐resistant	   responses	   and	   may	   become	   a	   new	   therapeutic	   option	   for	  
treating	  cancer	  as	   it	  could	  be	  already	  proved	  for	  prostate	  cancer	  (Kozakai	  et	  al.,	  2012).	  Further	  
combination	   studies	   of	   chemotherapeutic	   reagents	   (glucocorticoid	   Dexamethason)	   and	   NF-­‐κB	  
targeting	   drugs	   (proteasome	   inhibitor	   Bortezomib)	   confirmed	   the	   increased	   cytotoxicity	   in	  
multiple	  myeloma	  cells	  (Salem	  et	  al.,	  2013).	  Although	  inhibiting	  NF-­‐κB	  during	  cancer	  treatment	  
so	   far	   appears	   to	   be	   successful,	   cancer	   cells	   acquire	   resistance	   to	   the	   drug	   (for	   example	  
Bortezomib)	   limiting	   its	   efficacy	   (Lü	   and	  Wang,	   2013).	   Therefore,	   the	   need	   for	   drugs	   affecting	  
new	  targets	  like	  TRAF6	  within	  NF-­‐κB	  signaling	  is	  given.	  Activation	  of	  NF-­‐κB	  upon	  genotoxic	  stress	  
depends	  on	  the	  E3	  ligase	  activity	  of	  TRAF6	  (Hinz	  et	  al.,	  2010).	  C25-­‐0140	  directly	  targets	  the	  RZ1	  
domain	   of	   TRAF6	   and	   caused	   impaired	   NF-­‐κB	   activation.	   Treatment	   with	   C25-­‐0140	   would	  
probably	   reduce	   NF-­‐κB	   activation	   accompanied	   with	   induced	   cell	   death	   of	   cancer	   cells.	   This	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6	  Outlook	  
	  
All	  investigated	  compounds	  directly	  target	  the	  RING-­‐Zincfinger1	  domain	  of	  the	  E3	  ligase	  TRAF6.	  
In	  stimulation	  experiments,	  the	  compounds	  C27	  and	  C25-­‐0140	  cause	  a	  non-­‐pathway	  selective	  
inhibition	  of	  NF-­‐κB	  activation.	  Further	  experiments	  upstream	  of	  the	  phosphorylation	  of	  IκBα	  in	  
IL1-­‐β/LPS	   and	   TNFα	   induced	   signaling	   will	   be	   necessary	   to	   identify	   additional	   targets	   of	   the	  
compounds	  C27	   and	  C25-­‐0140.	   For	   example,	   chemical	   proteomics	   approaches	  might	   identify	  
further	   proteins	   that	   are	   bound	   by	   these	   compounds.	   This	   will	   help	   to	   define	   the	   mode	   of	  
action	   of	   these	   compounds	   and	   will	   be	   basis	   for	   further	   research	   to	   unravel	   the	   strong	  
inhibitory	  effects	  towards	  NF-­‐κB	  signaling.	  
Although	   the	   interaction	  of	  TRAF6-­‐Ubc13	  displays	   several	  advantages	   for	   targeting	  a	  protein-­‐
protein-­‐interaction,	   it	   appears	   to	   be	   difficult	   to	   target	   this	   binding	   specifically.	   Therefore,	  
another	   important	   focus	   will	   be	   to	   improve	   the	   selectivity	   and	   efficacy	   of	   C25-­‐0140.	  
Crystallography	  studies	  or	  NMR	  assignments	  need	  to	  be	  performed	  to	  define	  the	  exact	  residues	  
that	   are	   targeted	   by	   the	   compounds.	   This	  will	   be	   basis	   for	   further	   analog	   design	   to	   increase	  
specificity	   and	   reduce	   potential	   side	   effects	   as	   well	   as	   to	   improve	   the	   efficacy	   of	   the	  
compounds.	  Crystallography	  experiments	  have	  been	  initiated	  already	  and	  growth	  of	  crystals	  is	  
obtained	  but	  need	  to	  be	  further	  improved.	  	  	  
In	   the	   diet	   induced	   obesity	   mouse	   study,	   C25-­‐0140	   reduced	   body	   weight	   gain	   but	   no	  
improvement	   in	  glucose	   tolerance.	   It	  will	  be	  necessary	   to	   identify	   the	  mechanism	  behind	   the	  
effect	   on	   weight	   gain	   upon	   compound	   treatment.	   First	   experiments	   could	   be	   expression	  
profiling	  of	  genes	  involved	  in	  fatty	  acid	  or	  carbohydrate	  metabolism.	  It	  will	  also	  be	  interesting	  
to	  further	  analyze	  the	  differential	  effects	  of	  the	  N-­‐terminal	  and	  C-­‐terminal	  domains	  of	  TRAF6	  in	  
obesity.	  	  
TRAF6	   is	   upregulated	   in	   diseases	   that	   exhibit	   chronic	   NF-­‐κB	   signaling	   including	   autoimmune	  
diseases	  and	  various	  cancers.	  Inhibition	  of	  the	  TRAF6	  auto-­‐ubiquination	  is	  shown	  to	  reduce	  NF-­‐
κB	   activation	   as	   well	   as	   osteoclast	   differentiation	   and	   bone	   resorption	   activity	   (Chiou	   et	   al.,	  
2014).	  A	  mouse	  model	   for	  RA	  will	   therefore	  be	  considered	  for	  testing	  C25-­‐0140	  (or	   improved	  
chemical	   analogs)	   to	   relieve	   the	   clinical	   symptoms	   of	   this	   autoimmune	   disease.	   In	   a	   cancer	  
mouse	   model	   like	   osteosarcoma,	   C25-­‐0140	   should	   be	   analyzed	   as	   well	   as	   it	   might	   sensitize	  
cancer	  cells	  to	  chemotherapeutic	  induced	  apoptosis.	  Also,	  a	  combinatorial	  therapy	  of	  C25-­‐0140	  
and	  other	  inhibitors	  of	  NF-­‐κB	  for	  potential	  synergistic	  effects	  should	  be	  taken	  into	  account.	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7.	  Material	  and	  Methods	  
7.1	  Material	  
7.1.1	  Instruments	  and	  Equipment	  
Instrument	  /	  Equipment	   Company	  
Agarose	  gel	  chambers	   Neolab,	  Munich	  
Amersham	  Hyperfilm	  ECL	   GE	  Healthcare,	  Munich	  
Amicons	  cut	  off	  3kD;	  5mL,	  15mL,	  	   Millipore,	  Schwabach	  
ÄKTA	  purifier	   GE	  Healthcare,	  Munich	  
Bacteria	  culture	  flasks	   Schott,	  Zwiesel	  	  
Bacteria	  incubators	   Sartorius,	   Göttingen;	   Memmert,	  
Schwabach	  
Centrifuges	  
Beckmann	  Avanti	  J-­‐26	  XP	  	  
(rotors:	  JA-­‐10;	  JA	  25.5;	  JS5.3)	  
Cooling	  centrifuge	  cell	  culture	  5810R	  
Cooling	  lab	  centrifuge	  5417R	  
	  




Centrifuge	  bottles	  500mL,	  50mL	   Beckmann	  Coulter,	  Krefeld	  
Cell	  counting	  chambers	   Neolab,	  Munich	  
Cell	  culture	  flasks/dishes	   BD,	  Heidelberg;	  Nunc	  
Cell	  scraper	   Sarstedt,	  Newton	  in	  USA	  
CO2	  incubator	   Binder,	  Tuttlingen	  
Cover	  foil	  qPCR	   4titude,	  Berlin	  
Cover	   foil	   384-­‐well	   opti	   and	  
proxiplates	  
LVL	  Technologies,	  Crailsheim	  
Cryo	  vials	   Greiner,	  Frickenhausen	  
Cuvettes	   Brand,	  Wertheim	  
Cyclone	  3G	  working	  station	   Perkin	  Elmer,	  Wiesbaden	  
Developer	  Optimax	  typ	  TR	   MS	  Laboratory	  instruments,	  Wiesloch	  
EMSA	  gel	  chamber	   Roth,	  Karlsruhe	  
Envision	  plate	  reader	   Perkin	  Elmer,	  Wiesbaden	  
Eppendorf	  tubes	  1.5mL,	  2mL	   Eppendorf,	  Hamburg	  
Falcon	  tubes	  15mL,	  50mL	   Neolab,	  Munich	  
FlexDrop	   Perkin	  Elmer,	  Wiesbaden	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Fridge	  and	  freezers	  (-­‐20°,	  -­‐80°C)	   Liebherr,	  Ochsenhausen	  
Fuji	  medical	  x-­‐ray	  film	   Kisker	  Biotech,	  Steinfurt	  
Glass	  bottle	  1L,	  500mL,	  250mL	   Schott,	  Zwiesel	  
Gel	  dryer	   Biorad,	  Hercules,	  USA	  
HiTrap	  Desalting	  column	  5mL	   GE	  Healthcare,	  Munich	  
Light	  Cycler	  480	   Roche	  Diagnostics,	  Mannheim	  
Light	  Cycler	  96	  well	  plates	   4titude,	  Berlin	  
Magnetic	  stirrer	   IKA	  Labortechnik,	  Staufen	  
Microwave	   SHARP,	  Hamburg	  
Nanodrop	   Thermo	  Scientific,	  Rockford	  in	  USA	  
Operetta	   Perkin	  Elmer,	  Wiesbaden	  
Pipettes	   (5000µL,	   1000µL,	   200µL,	  
100µL,	  20µL,	  10µL,	  2.5µL)	  
Eppendorf,	  Hamburg	  
Pipette	  tips	  	   Eppendorf,	  Hamburg	  
Plastic	   pipettes	   (50mL,	   25mL,	   10mL,	  
5mL,	  2mL)	  
Greiner	  Bio-­‐one,	  Kremsmünster	  in	  Austria	  
Petri	  dishes	  	   Greiner	  Bio-­‐one,	  Kremsmünster	  in	  Austria	  
pH	  meter	   Hanna	  Instruments,	  Ann	  Arbor	  in	  USA	  
Photometer	   Eppendorf,	  Hamburg	  
RNAse-­‐free	  tips	   StarLab,	  Hamburg	  
Rotator	   Neolab,	  Munich	  
Power	  supply	   Consort,	  Turnhout	  in	  Belgium	  
PVDF-­‐membran	   Millipore,	  Schwabach	  
Scalpel	   B.	  Braun,	  Melsungen	  	  
Sciclone	  G3	   Perkin	  Elmer,	  Wiesbaden	  
SDS-­‐PAGE	  gel	  chamber	   PHASE,	  Lübeck	  
Semi-­‐dry	  blotter	   Roth,	  Karlsruhe	  
Sonifier	  U9200S	   Hielscher	  Ultrasonics,	  Teltow	  
Superdex	  75	  100/300GL	   GE	  Healthcare,	  Munich	  
Superdex	  75	  HiLoad	  16/600	   GE	  Healthcare,	  Munich	  
StrepTrap	  HP	  column	  1mL	   GE	  Healthcare,	  Munich	  	  
Syringe	  26G	   B.	  Braun,	  Melsungen	  
Tissue	  culture	  hoods	   Nunc	  -­‐	  Thermo	  Scientific,	  Rockford,	  USA	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Thermocycler	   Eppendorf,	  Hamburg	  
Ultrasonic	  bath	  SONOREX	  RK	  103	   Bandelin,	  Berlin	  	  
UV-­‐table	   Herolab,	  Wiesloch	  
Vortexer	   Scientific	  industries,	  Bohemia	  in	  USA	  
Whatman	  paper	   Whatman,	  Dassel	  
Water-­‐jet	  vacuum	  pump	   Schott,	  Zwiesel	  
384	  opti	  plates	   Perkin	  Elmer,	  Wiesbaden	  
384	  proxi	  plates	   Perkin	  Elmer,	  Wiesbaden	  	  
Greiner	  384	  µclear	  plates	   Sigma-­‐Aldrich,	  Taufkirchen	  	  
	  
7.1.2	  Chemicals	  	  
Acrylamid/Bisacrylamid	   Roth,	  Karlsruhe	  
Adenosin-­‐tri-­‐phosphate,	  ATP	   Sigma-­‐Aldrich,	  Taufkirchen	  
[32P]-­‐α-­‐ATP,	  10mCi/mL	   Perkin	  Elmer,	  Wiesbaden	  
[32P]-­‐ γ-­‐ATP,	  10mCi/mL	   Perkin	  Elmer,	  Wiesbaden	  
Agarose	   Biozym,	  Hessisch	  Oldendorf	  
Amino	   acids	   for	   S.	   cerevisiae	   plates	  
(Try,	  His,	  Leu,	  Phe,	  Glu,	  Asp,	  Val,	  Thr,	  
Ser)	  	  
Roth,	  Karlsruhe	  
Ammonium	  persulfate,	  APS	   BioRad,	  Munich	  
Ampicillin	   Roth,	  Karlsruhe	  
Ammonium	  chloride	   Roth,	  Karlsruhe	  
Ammonium	  –	  N15	  chloride	   Sigma-­‐Aldrich,	  Taufkirchen	  
Anhydrotetracycline	  ATC	   IBA,	  Goettingen	  
Antibiotics	  (eukaryotic	  cell	  culture)	   Life	  Technologies,	  Darmstadt	  
β-­‐Glycerophosphate	   Sigma-­‐Aldrich,	  Taufkirchen	  
Biotin	   Sigma-­‐Aldrich,	  Taufkirchen	  
Bovine	  Serum	  Albumin	  (BSA)	  	   Sigma-­‐Aldrich,	  Taufkirchen	  
Bovine	  Serum	  Albumin	  (BSA)	   PAA,	  Pasching	  in	  Austria	  
Bovine	   Serum	   Albumin	   (BSA)	  
10mg/mL	  
New	  England	  Biolab,	  Frankfurt	  
Boric	  acid	   Roth,	  Karlsruhe	  
Bradford	  reagent	   BioRad,	  Munich	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Calciumchloride-­‐Dihydrate	   Roth,	  Karlsruhe	  
Chloramphenicol	  	   Roth,	  Karlsruhe	  
Cobalt(II)Chloride-­‐Hexahydrate	   Roth,	  Karlsruhe	  
Coomassie	  Brilliant	  Blue	  R250	   Roth,	  Karlsruhe	  
Copper(II)Chloride-­‐Dihydrate	   Roth,	  Karlsruhe	  
Creatine	  phosphate	   Sigma-­‐Aldrich,	  Taufkirchen	  	  
Dulbecco´s	   Modified	   Eagle	   Medium	  
(DMEM)	  
Life	  Technologies,	  Darmstadt	  
Dimethylsulfoxid	  DMSO	  D6	   Sigma-­‐Aldrich,	  Taufkirchen	  
dNTPs	   Fermentas,	  St.	  Leon-­‐Roth	  
Dithiothreitol	  DTT	   Sigma-­‐Aldrich,	  Taufkirchen	  
Ethylenediaminetetraacetic	  acid	  EDTA	   Roth,	  Karlsruhe	  
Ethanol	  p.a.	   Merck,	  Darmstadt	  
Ethidiumbromide	  	   Roth,	  Karlsruhe	  
Fetal	  calf	  serum	  (FCS)	   Life	  Technologies,	  Darmstadt	  
Ficoll	  400	   Roth,	  Karlsruhe	  
Glucose	  a-­‐Monohydrat	   Roth,	  Karlsruhe	  
Glutathione,	  reduced	   Sigma-­‐Aldrich,	  Taufkirchen	  
Glutathione	  Sepharose	  4B	   VWR,	  Darmstadt	  
Glutathione	  Sepharose	  4	  fast	  flow	   VWR,	  Darmstadt	  	  
Glycerin	   Roth,	  Karlsruhe	  
HEPES	   Roth,	  Karlsruhe	  
Hoechst33342	   Life	  Technologies,	  Darmstadt	  
Human	  TNFα	   Biomol,	  Hamburg	  
IRAK1/4	  inhibitor	  I5409	   Sigma-­‐Aldrich,	  Taufkirchen	  
Isopropyl-­‐β-­‐D-­‐thiogalactoside	  (IPTG)	   Fermentas,	  St.	  Leon-­‐Roth	  
Isopropanol	  p.a.	  	   Merck,	  Darmstadt	  
LB-­‐agar	   Roth,	  Karlsruhe	  
LB-­‐medium	   Roth,	  Karlsruhe	  
Lipopolysaccharide	   Sigma-­‐Aldrich,	  Taufkirchen	  
Lithiumacetate	   Roth,	  Karlsruhe	  	  
Magnesium	  chloride	   Roth,	  Karlsruhe	  
Magnesiumsulfate	  Heptahydrate	   Sigma-­‐Aldrich,	  Taufkirchen	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Mangan(II)Chloride-­‐Tetrahydrate	  	   Roth,	  Karlsruhe	  	  
Mitotracker	  Deep	  Red	  FM	   Life	  Technologies,	  Darmstadt	  
Murine	  IL-­‐1β	   Pepro-­‐Tech,	  Hamburg	  
NP-­‐40	  (Nonidet	  P40	  Substitute)	   Sigma-­‐Aldrich,	  Taufkirchen	  
Penicillin	  Streptomycin	   Life	  Technologies,	  Darmstadt	  
Phosphate	  buffered	  saline	  PBS	  10x	   Applichem,	  Darmstadt	  
Potassium	  chloride	   Roth,	  Karlsruhe	  
Potassium	   hydrogen	   phosphate	  
(KH2PO4)	  
Roth,	  Karlsruhe	  
Poly-­‐(d(I-­‐C))	   Roche	  Diagnostics,	  Mannheim	  
Protease/Phosphatase-­‐inhibitor	  
RocheComplete	  
Roche	  Diagnostics,	  Mannheim	  
Prestained	   Protein	   Marker	   (Page	  
Ruler)	  
Fermentas,	  St.	  Leon-­‐Roth	  
Protein-­‐G-­‐Sepharose	  4	  fast	  flow	   GE	  Healthcare,	  Munich	  
Roswell	  Park	  Memorial	  Institute	  RPMI	   Life	  Technologies,	  Darmstadt	  
Roti-­‐load	  4xSDS	  loading	  buffer	   Roth,	  Karlsruhe	  
Rotisolon	  B	   Roth,	  Karlsruhe	  
SOC	  outgrowth	  medium	   New	  England	  Biolabs,	  Frankfurt	  	  
Sodium	  citrate	  	   Roth,	  Karlsruhe	  
Sodium	  chloride	  NaCl	   Roth,	  Karlsruhe	  
Disodium	   phosphate	   (Na2HPO4-­‐
Dihydrate)	  
Roth,	  Karlsruhe	  
Sodium	  dodecyl	  sulfate	  SDS	   Roth,	  Karlsruhe	  
Sodium	  fluoride	  NaF	   Sigma-­‐Aldrich,	  Taufkirchen	  
Sodium	  hydroxide	  NaOH	   Roth,	  Karlsruhe	  
Sodium	  (meta)	  vanadate	   Sigma-­‐Aldrich,	  Taufkirchen	  
Strep	  Elution	  buffer	   IBA,	  Goettingen	  
Tetramethylethylenediamine	  TEMED	   BioRad,	  Munich	  
Thrombin	  protease	   GE	  Healthcare,	  Munich	  
Thiamine	  Hydrochloride	   Sigma-­‐Aldrich,	  Taufkirchen	  
Tris	   Roth,	  Karlsruhe	  
Triton-­‐X100	   Roth,	  Karlsruhe	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Trypsin/EDTA	   Life	  technologies,	  Darmstadt	  
Tween-­‐20	   Roth,	  Karlsruhe	  
Tween-­‐80	   Sigma-­‐Aldrich,	  Taufkirchen	  
Yeast	  nitrogen	  base	  (Difco)	   Roth,	  Karlsruhe	  
Zinc	  chloride	  ZnCl2	   Sigma-­‐Aldrich,	  Taufkirchen	  
2-­‐log	  DNA	  ladder	   New	  England	  Biolabs,	  Frankfurt	  
	  
7.1.3	  Antibodies	  
Primary	  Antibody	   Dilution	  in	  Western	  Blot	   Company	  
β-­‐Actin	  I-­‐19	   1:1	  000	   Santa	  Cruz,	  Heidelberg	  
Flag	  M2	   immunoprecipitation	   Sigma,	  Taufkirchen	  
IκBα	  C21	   1:1	  000	   Santa	  Cruz,	  Heidelberg	  
p-­‐IκBα	   Ser32/36	  
5A5	  
1:1	  000	   Cell	   Signaling,	   Leiden	   in	  
Belgium	  
IKKγ	  FL419	   immunoprecipitation	   Santa	  Cruz,	  Heidelberg	  
IKKγ	  1.T.26	   1:500	   Santa	  Cruz,	  Heidelberg	  
p65	  C-­‐20	   immunofluorescence	  1:250	   Santa	  Cruz,	  Heidelberg	  
TRAF6	  EP591Y	   1:2	  000	   Abcam,	   Cambridge	   in	  
England	  
Ubc13	  4919	   1:1	  000	   Cell	  Signaling	  
Ubiquitin	  P4D1	   1:1	  000	   Santa	  Cruz,	  Heidelberg	  
Secondary	  antibody	   Dilution	  in	  Western	  Blot	   Company	  
Anti-­‐Goat	   1:7	  500	   Dianova,	  Hamburg	  
Anti-­‐Mouse	   1:7	  500	   Dianova,	  Hamburg	  
Anti-­‐Rabbit	   1:7	  500	   Dianova,	  Hamburg	  
Anti-­‐Rat	   1:7	  500	   Dianova,	  Hamburg	  
Fluorescein	   Goat	  
Anti	  Rabbit	  
1:400	   Life	   Technologies,	  
Darmstadt	  
	  
7.1.4	  Enzymes	  and	  Kits	  
Enzyme	  /	  Kit	   Company	  
Alkaline	  Phosphatase	  CIP	   New	  England	  Biolabs,	  Frankfurt	  	  
ALPHAScreen	  Protein	  A	  IgG	  Kit	   Perkin	  Elmer,	  Wiesbaden	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Material	  and	  Methods	  
	   100	  
Bradford	  reagent	   BioRad,	  Munich	  
CellTiter-­‐Blue	  Kit	   Promega,	  Mannheim	  
Expand-­‐High-­‐Fidelity	  Kit	   Roche	  Diagnostics,	  Mannheim	  
Gel	  extraction	  Kit	   Qiagen,	  Hilden	  
Glutathione	  ALPHA	  Donor	  beads	   Perkin	  Elmer,	  Wiesbaden	  
Klenow	  fragment	  5,000U/mL	   Fermentas,	  St.	  Leon-­‐Roth	  
LumiGlo	  reagent	  20x	   Cell	  signaling,	  Frankfurt	  
KAPA	  SYBR	  Fast	  qPCR	  Kit	  (optimized	  for	  
LC480)	  
VWR,	  Darmstadt	  	  
Nickel-­‐Chelate	  ALPHA	  Acceptor	  beads	   Perkin	  Elmer,	  Wiesbaden	  
Nucleo	  Spin	  Plasmid	  Kit	   Macherey-­‐Nagel,	  Düren	  
p-­‐IκBα	  (Ser32/36)	  ALPHASurefire	  Kit	   Perkin	  Elmer,	  Wiesbaden	  
QiaQuick	  Nucleotide	  removal	  kit	   Qiagen,	  Hilden	  
Silver	  Stain	  Kit	   Pierce,	  Rockford	  in	  USA	  
Rapid	  DNA	  ligation	  Kit	   Roche	  Diagnostics,	  Mannheim	  
RNeasy	  Kit	   Qiagen,	  Hilden	  
RQ1	  RNase-­‐free	  DNaseI	   Promega,	  Mannheim	  
Shredder	  Kit	   Qiagen,	  Hilden	  
SuperScript	   III	   First	   Strand	   cDNA	  
Synthesis	  System	  for	  RT-­‐PCR	  
Life	  Technologies,	  Darmstadt	  
Strep-­‐Tactin®	  ALPHA	  Donor	  bead	   Perkin	  Elmer,	  Wiesbaden	  
Total	  IκBα	  ALPHASurefire	  Kit	   Perkin	  Elmer,	  Wiesbaden	  
TRIzol®	  reagent	   Life	  Technologies,	  Darmstadt	  
Restriction	   endonucleases	   (BamHI,	  
EcoRI,	  NcoI,	  NotI,	  PstI,	  SacII)	  	  
New	  England	  Biolabs,	  Frankfurt	  
	  
7.1.5	  Bacteria	  strains	  
BL21	  Codon	  Plus(DE3)	  RIPL	   strain	   for	   protein	   production	   from	   Agilent	   Technologies,	  
Waldbronn	  
TOP10	  E.coli	  	   	   	   	   	  	  	  	  (F-­‐mcrA	  (∆	  mrr-­‐hsdRMS-­‐mcrBC)	  Φ80lacZ	  ∆M15	  ∆lacX74	  
nupG	  recA1	  araD139	  ∆(ara-­‐leu)7697	  galE15	  galK16	  rpsL	  
(strR)end	  A1λ-­‐);	  Research	  Unit	  Cellular	  Signal	  Integration,	  
Prof.	  Krappmann,	  Helmholtz	  Zentrum	  München	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7.1.6	  Eukaryotic	  cell	  lines	  
MEF	  	   	   	   	   	   Mouse	  Embryonic	  fibroblast	  cells	  
MEF	  TRAF6-­‐/-­‐	   	   	   	   TRAF6	  knockout	  MEF	  cells,	  obtained	  from	  Claus	  	  
Scheidereit	  at	  the	  Max-­‐Delbrück-­‐Centrum,	  Berlin	  
HeLa	   Henriette	  Lacks	  cells,	  derived	  from	  cervical	  cancer	  	  
HepG2	  	   	   	   	   human	  liver	  carcinoma	  cell	  line	  
	  
7.1.7	  Mouse	  strains	  
C57BL/6	  J	   a	  laboratory	  mice	  strain,	  mice	  were	  fed	  an	  high-­‐fat-­‐diet	  to	  
generate	  diet-­‐induced	  obesity	  mice	  	  
	  
7.1.8	  Recombinant	  proteins	  
Recombinant	  protein	   Company	  
E1-­‐activating	  enzyme	  (UBC1)	   Boston	  Biochem,	  Chambridge	  in	  USA	  
E2-­‐conjugating	   enzyme	   complex	  
(rhHis6-­‐Ubc13/Uev1a)	  
Boston	  Biochem,	  Chambridge	  in	  USA	  
GST-­‐IκBα	  (AA	  1-­‐73)	   Affinity-­‐purified	   from	   E.coli	   from	   Krappmann	  
Group	  
Inorganic	  pyrophosphatase	  E.coli	   RayBiotech,	  Norcross	  in	  USA	  
Creatine	  phosphokinase	   Sigma-­‐Aldrich,	  Taufkirchen	  
Human	  recombinant	  Ubiquitin	   Boston	  Biochem,	  Cambridge	  in	  USA	  
	  
7.1.9	  Vectors	  and	  generated	  plasmids	  	  
Empty	  vector	   Description	  
pASK-­‐IBA3plus	   Bacterial	   protein	   expression	   vector	   tagging	   the	  
protein	   with	   a	   C-­‐terminal	   StrepII-­‐tag;	   restriction	  
sites	  NcoI	  and	  SacII	  were	  used	  for	  cloning;	  vector	  
provided	  by	  IBA	  GmbH,	  Göttingen	  
pGex	  4T1	   Bacterial	   vector	   for	   expression	   of	   GST-­‐fusion	  
proteins	  with	  thrombin	  site;	  DNA	  sequences	  were	  
introduced	   via	   the	   restriction	   sites	   BamHI	   and	  
NotI;	  empty	  vector	  from	  GE	  Healthcare,	  Munich	  
pGAD-­‐C(x)	   Yeast-­‐two-­‐hybrid	  “prey”	  vector	   for	   fusing	  a	  gene	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to	   the	   GAL4	   activation	   domain,	   EcoRI	   and	   PstI	  
restriction	  sites	  were	  used	  for	  cloning	  
pGBD-­‐C(x)	   Yeast-­‐two-­‐hybrid	   “bait”	   vector	   for	   fusing	   a	   gene	  
to	   the	   GAL4	   binding	   domain;	   for	   cloning,	   EcoRI	  
and	  PstI	  restriction	  sited	  were	  used	  	  
Generated	  plasmids	   	  
TRAF6WTStrepII	  	   in	  pASK-­‐IBA	  3	  plus	  vector	  
TRAF6C70AStrepII	   in	  pASK-­‐IBA	  3	  plus	  vector	  
TRAF6D57KStrepII	   in	  pASK-­‐IBA	  3	  plus	  vector	  
TRAF6I72FStrepII	   in	  pASK-­‐IBA	  3	  plus	  vector	  
GST-­‐TRAF6WT	   in	  pGex	  4T1	  vector	  
Ubc13FlagHis	   in	   pGex	   4T1	   vector,	   generated	   by	   Dr.	   Kenji	  
Schorpp	  
GST-­‐OTUB1	   in	   pGex	   4T1	   vector,	   generated	   by	   Dr.	   Kenji	  
Schorpp	  
GST-­‐RNF8	   in	   pGex	   4T1	   vector,	   generated	   by	   Elisabeth	  
Weber	  
TRAF6	  fulllength	   in	  pGAD-­‐C1	  vector	  
TRAF6	   RING-­‐Zincfinger1	   (RZ1)	  
WT	  
in	  pGAD-­‐C1	  vector	  
TRAF6	  RZ1	  C70A	   in	  pGAD-­‐C1	  vector	  
TRAF6	  RZ1	  D57K	   in	  pGAD-­‐C1	  vector	  
TRAF6	  RZ1	  I72F	   in	  pGAD-­‐C1	  vector	  
TRAF6	  Coiled	  Coil	   in	  pGAD-­‐C1	  vector	  
TRAF6	  Coiled-­‐Coil	  –	  MATH	   in	  pGAD-­‐C1	  vector	  








5´	  GCT	  CAA	  CTG	  GTG	  TCG	  TGA	  AG	  3´	  
5´	  ATG	  AGG	  CAG	  TTT	  CCA	  TCA	  CC	  3´	  
β-­‐Actin	  for	   5ʹ′	  CCT	  CTA	  TGC	  CAA	  CAC	  AGT	  GC	  3ʹ′	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β-­‐Actin	  rev	   5ʹ′	  GTA	  CTC	  CTG	  CTT	  GCT	  GAT	  CC	  3ʹ′	  
ICAM-­‐1	  for	  
ICAM-­‐1	  rev	  
5´	  CGC	  TCA	  GAA	  GAA	  CCA	  CCT	  TC	  3´	  
5´	  GGA	  GAC	  GCA	  GAG	  GAC	  CTT	  AAC	  3´	  
IκBα	  for	  
IκBα	  rev	  
5ʹ′	  TTG	  CTG	  AGG	  CAC	  TTC	  TGA	  AAG	  3ʹ′	  
5ʹ′	  TCT	  GCG	  TCA	  AGA	  CTG	  CTA	  CAC	  T	  3ʹ′	  
IL-­‐1β	  for	  
IL-­‐1β	  rev	  
5`	  TCA	  GCA	  CCT	  CAC	  AAG	  CAG	  AG	  3`	  
5`GCC	  CAT	  ACT	  TTA	  GGA	  AGA	  CAC	  G	  3	  
IL-­‐2	  for	  
IL-­‐2	  rev	  
5ʹ′	  GAG	  TGC	  CAA	  TTC	  GAT	  GAT	  GAG	  3ʹ′	  
5ʹ′	  AGG	  GCT	  TGT	  TGA	  GAT	  GAT	  GC	  3ʹ′	  
IL-­‐6	  for	  
IL-­‐6	  rev	  
5ʹ′	  ACC	  ACG	  GCC	  TTC	  CCT	  ACT	  TC	  3ʹ′	  
5ʹ′	  CTC	  ATT	  TCC	  ACG	  ATT	  TCC	  CAG	  3ʹ′	  
TNFα	  for	  
TNFα	  rev	  
5`CCA	  CCA	  TCA	  AGG	  ACT	  CAA	  ATG	  3`	  
5`GAG	  ACA	  GAG	  GCA	  ACC	  TGA	  CC	  3`	  
VCAM	  for	  
VCAM	  rev	  
5´	  CCC	  CTC	  ATT	  CCT	  TAC	  CAC	  CC	  3´	  




NF-­‐κB	   5`GAT	  CCA	  GGG	  CTG	  GGG	  ATT	  CCC	  CAT	  CTC	  CAC	  AGG	  3`	  
5`GAT	  CCC	  TGT	  GGA	  GAT	  GGG	  GAA	  TCC	  CCA	  GCC	  CTG	  3`	  
Oct-­‐1	  	   5`GAT	  CTG	  TCG	  AAT	  GCA	  AAT	  CAC	  TAG	  AA	  3`	  
5`GAT	  CTT	  CTA	  GTG	  ATT	  TGC	  ATT	  CGA	  CA	  3`	  
	  
7.1.11	  Buffers	  
Buffer	   Composition	  
ALPHAScreen	  buffer	  	   1xPBS;	  0.5%	  BSA,	  0.01%	  Tween-­‐20	  
Blocking	  buffer	   3%	  BSA	  (PAA)	  in	  PBS-­‐Tween20	  (0.1%)	  
10x	  Blotting	  buffer	   48mM	   Tris;	   39mM	   Glycine;	   0.037%	   SDS;	   20%	  
Methanol	  
CoIP-­‐wash	  buffer	   150mM	  NaCl;	  25mM	  Hepes	  (pH	  7.5);	  0.2%	  NP-­‐40;	  
1mM	  Glycerol	  
CoIP-­‐lysis	  buffer	   CoIP-­‐wash	   buffer;	   10mM	   NaF;	   8mM	   β-­‐
Glycerophosphat;	   1mM	   DTT;	   300µM	   Sodium-­‐
vanadate;	  complete	  protease	  inhibitor	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1%	  SDS-­‐CoIP-­‐lysis	  buffer	   CoIP-­‐lysis	  buffer;	  1%	  SDS	  
EMSA-­‐annealing	  buffer	   50mM	  Tris-­‐HCl,	  pH	  8;	  70mM	  NaCl;	  5mM	  dNTP-­‐A;	  
EMSA-­‐2xshift	  buffer	   40mM	  HEPES	  pH7.9;	  120mM	  KCl;	  8%	  Ficoll;	  	  
High-­‐salt-­‐lysis	  buffer	   20mM	  HEPES	   PH7.9;	   350mM	  NaCl;	   1mM	  MgCl2;	  
0.5mM	   EDTA;	   0.1mM	   EGTA;	   20%	   Glycerol;	   1%	  
NP-­‐40;	   10mM	   NaF;	   8mM	   β-­‐Glycerophosphate;	  
1mM	   DTT;	   300µM	   Sodium-­‐vanadate;	   Complete	  
protease	  inhibitor	  
Kinase	  buffer	  	   20µM	   HEPES	   pH7.9;	   10mM	   MgCl2;	   20µM	   ATP;	  
20mM	   β-­‐Glycerophosphat;	   200µM	   Sodium-­‐
Vanadate;	  1mM	  DTT	  
10x	  K63	  assay	  buffer	   	  
	  
250nM	   Tris-­‐HCl	   pH	   7.6;	   25mM	   MgCL2;	   50mM	  
creatine	   phosphate;	   3U/mL	   inorganic	  
pyrophosphatase;	  3U/mL	  creatine	  phosphokinase	  
15N-­‐labeled	   M9	   mineral	  
medium	  
1x15N-­‐labeled	   M9	   salt	   solution;	   0.40%	   Glucose;	  
1mM	   MgCl2;	   0.3mM	   CaCl2;	   1µg/mL	   Biotin;	  
1µg/mL	  Thiamine,	  1x	  Trace	  element	  solution	  	  
15N-­‐labeled	   M9	   salt	   solution	  
(10x)	  
337mN	  Na2HPO4*2H2O;	  220mM	  KH2PO4;	  85.5mM	  
NaCl;	  935	  15NH4Cl	  	  
GST-­‐Wash	  buffer	   1xPBS;	  400mM	  NaCl;	  1mM	  DTT	  
Pulldown	  buffer	   1xPBS;	  5%	  Glycerin;	  1%	  Triton-­‐X100	  
PEG	  medium	  for	  S.	  cerevisiae	   100mM	   Lithiumacetate;	   10mM	   Tris-­‐HCl,	   pH	   8.0;	  
1mM	  EDTA,	  pH	  8.0;	  40%	  (w/v)	  PEG-­‐3350	  
RIPA	  buffer	   150mM	   NaCl;	   1%	   NP-­‐40;	   0.5%	   Sodium-­‐
deoxycholate;	   0.1%	   SDS;	   50mM	   Tris-­‐HCl	   pH	   8.0;	  
Complete	  protease	  inhibitor	  
S.	  cerevisiae	  plates	  	   0.67%	  yeast	  nitrogen	  base	  (Difco);	  0.2%	  drop	  out	  
amino	  acid	  mix,	  2%	  glucose;	  2%	  agar	  
Drop	   out	   amino	   acid	   mix:	   20mg	   Try,	   His;	   30mg	  
Leu;	   50mg	   Phe;	   100mg	   Glu,	   Asp;	   150mg	   Val:	  
200mg	  Thr;	  400mg	  Ser;	  	  
10x	  SDS	  buffer	   250mM	  Tris;	  2M	  Glycine;	  1%	  SDS	  
Separation	  gel	  buffer	  (5x)	   1.88mM	  Tris-­‐HCl	  (pH	  8.8)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Material	  and	  Methods	  
	   105	  
Separation	  gel	  	   375mM	   Tris-­‐HCl	   pH	   8.8;	   10-­‐12.5%	   Acrylamide;	  
0.1%	  SDS;	  0.075%	  APS;	  0.05%	  TEMED	  
Stacking	  gel	  buffer	  (4x)	   0.5M	  Tris-­‐HCl	  pH	  6.8	  
Stacking	  gel	   125mM	   Tris-­‐HCl	   pH	   6.8;	   5%	   Acrylamide;	   0.1%	  
SDS,	  0.1%	  APS;	  0.1%	  TEMED	  
TRAF6-­‐wash	  buffer	   100mM	  Tris-­‐HCl	  pH8.0;	  20mM	  NaCl	  
Stripping	  buffer	   200mM	  Glycine;	  0.1%	  SDS;	  1%	  Tween-­‐20;	  pH	  2.2	  
20x	  TBE	  buffer	  	   1M	  Tris;	  1M	  Boric	  Acid;	  20mM	  EDTA;	  pH	  8.3	  
Trace	  Element	  solution	  (100x)	   13.4mM	   EDTA;	   3.1mM	   FeCl3*6H2O;	   0.62mM	  
ZnCl2;	   76µM	   CuCl2*2xH2O;	   42µM	   CoCl2*6xH2O;	  
162µM	  H3BO3;	  8.1µM	  MnCl2*4H20;	  
TRAF6	  storage	  buffer	   20mM	  Tris-­‐HCl	  pH	  8.0;	  20mM	  NaCl;	  100µM	  ZnCl2;	  
5ml	  DTT	  




Software	   Company	  
Adobe	  software	  CS5	   Adobe	  Systems	  incorporated,	  San	  Jose`	  in	  USA	  
CLC	  sequence	  viewer	   Qiagen,	  Hilden	  
Gene	  construction	  kit	   Textco	  BioSoftware,	  Raleigh	  in	  USA	  
Harmony	   Perkin	  Elmer,	  	  
LabImage	  1D	   Kapelan,	  Leipzig	  
Microsoft	  office	  2011	   Microsoft,	  Redmond	  in	  USA	  
Nanodrop	  2000	  Software	   Thermo	  Scientific,	  Rockford	  in	  USA	  
PRISM	  6	   GraphPad	  Software,	  La	  Jolla	  in	  USA	  
	  
7.1.13	  Screening	  libraries	  and	  small	  molecules	  
For	  High-­‐Throughput-­‐Screening,	  a	  chemoinformatic	  expert	  at	  the	  Helmholtz	  Zentrum	  München	  
designed	  three	  diversity	  libraries.	  Selection	  criteria	  for	  each	  compound	  were:	  	  
i) a	  molecular	  weight	  less	  than	  600g/mol,	  	  
ii) suitable	  logS/logP	  values	  for	  good	  solubility,	  
iii) meeting	  the	  criteria	  of	  the	  Lipinski´s	  rule	  of	  five,	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a. not	  more	  than	  five	  hydrogen	  bond	  donors	  	  
b. not	  more	  than	  10	  hydrogen	  bond	  acceptors	  
c. the	  molecular	  weight	  should	  not	  exceed	  500g/mol	  
d. 	  LogP	  value	  is	  less	  than	  five	  	  	  
iv) over	  90%	  purity,	  	  
v) pass	  the	  filters	  to	  exclude	  compounds	  	  
a. that	  exhibit	  reactive,	  unstable	  and	  toxic	  chemical	  groups,	  
b. which	  chemotypes	  cause	  acute	  or	  chronic	  toxicity	  
c. that	  are	  trivial	  compounds	  and	  already	  present	  in	  commercial	  available	  libraries	  
The	   goal	   was	   to	   have	   diverse	   chemical	   structures	   within	   one	   library	   and	   among	   the	   three	  
libraries.	  Three	   in-­‐house	   libraries	  were	  designed	  considering	  the	   listed	  criteria	  and	  ordered	  at	  
the	  respective	  company:	  ChemDIV	  (10,000	  compounds),	  Enamine	  (10,000	  small	  molecules)	  and	  
ChemBridge	  (5,000	  compounds).	  	  
For	  reordering	  the	  hit	  compounds,	  compounds	  were	  reordered	  from	  the	  respective	  companies:	  	  
	  
Compound	  number	   Library	  
Compounds	  1-­‐11	   ChemBridge	  
Compounds	  12-­‐19	   ENAMINE	  
Compounds	  20-­‐27	   ChemDIV	  
	  
Compounds	  were	  reordered	  at	  a	  powder	  stock	  and	  were	  dissolved	  to	  a	  concentration	  of	  20mM	  
in	   DMSO	   D6.	   If	   necessary,	   the	   compound	   solution	   was	   ultrasonic-­‐treated	   for	   30	   seconds.	  
Aliquots	  were	  frozen	  at	  -­‐20°C.	  
ADME	  studies	  for	  C27	  and	  C25-­‐0140	  were	  conducted	  by	  Bienta,	  ENAMINE	  Ltd.	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7.2	  Methods	  
	  
7.2.1	  Molecular	  biological	  methods	  
7.2.1.1	  Polymerase	  chain	  reaction	  (PCR)	  
For	  cloning	  genes	  into	  various	  vectors,	  the	  DNA	  sequences	  of	  TRAF6,	  Ubc13,	  OTUB1	  and	  RNF8	  
were	   amplified	   from	   complementary	   DNA	   (cDNA)	   (synthesis	   see	   7.2.1.8)	   using	   Polymerase	  
chain	  reaction	  (PCR).	  Therefore,	  PCR	  was	  performed	  using	  the	  Expand	  High	  Fidelity	  Kit	  (Roche)	  
including:	  
5µL	  10x	  Expand	  High	  Fidelity	  buffer	  
1µL	  dNTPs	  (10mM	  each)	  
1µL	  of	  forward	  and	  reverse	  primer	  (20µM	  each)	  
100ng	  cDNA	  
1µL	  DNA	  polymerase	  (Expand	  High	  Fidelity	  Mix)	  
ad	  50µL	  H2O	  	  
The	  following	  PCR-­‐program	  was	  set	  up:	  
Step	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   95°C	   5min	   1	  
Denaturation	   95°C	   30sec	   30	  
Annealing	   65°C	   30sec	   30	  
Elongation	   72°C	   30sec-­‐3mins	  (30sec	  per	  500basepairs)	   30	  
Final	  elongation	   72°C	   7mins	   1	  
Cooling	   4°C	   ∞	   1	  
	  	  	  	  	  Table	  7.1:	  PCR-­‐program	  to	  generate	  PCR	  amplificates	  for	  cloning	  
For	   mutagenesis,	   primer	   carrying	   the	   mutation	   were	   applied	   to	   the	   PCR	   mix	   and	   thereby	  
introduced	  the	  mutation	  to	  the	  new	  PCR	  product.	  	  
	  
7.2.1.2	  Agarose	  Gel	  Electrophoresis	  and	  DNA	  extraction	  from	  gel	  
For	  the	  separation	  of	  linearized	  DNA,	  samples	  (PCR	  product	  or	  restriction	  digest	  probes)	  were	  
mixed	  with	  6x	  loading	  dye	  and	  loaded	  on	  an	  agarose	  gel	  (1.5%	  agarose	  dissolved	  in	  1xTBE	  and	  
0.2µg/mL	  Ethidiumbromide).	   For	   size	   control,	   the	  2-­‐Log	  DNA	   ladder	  was	   loaded	  as	  well.	  Gels	  
were	   run	   in	   1xTBE	  buffer	   applying	   8	  V/cm	  gel.	   PCR	   fragments	   stained	  with	   Ethidiumbromide	  
were	  visualized	  by	  UV-­‐excitation	  and	  cut	  out	  with	  a	  scalpel.	  The	  extraction	  of	  the	  DNA	  from	  the	  
gel	   was	   performed	   according	   to	   the	   Qiagen	   Gel	   Extraction	   Kit	   protocol	   and	   eluted	   in	   50µL	  
autoclaved	  H2O.	  The	  purified	  DNA	  was	  further	  used	  for	  restriction	  digest	  followed	  by	  ligation.	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7.2.1.3	  Restriction	  digest	  
PCR	   products	   as	   well	   as	   plasmids	   were	   digested	   using	   restriction	   enzymes	   and	   buffers	   from	  
New	  England	  Biolabs.	   After	   2	   hours	   at	   the	   appropriate	   incubation	   temperature,	   1µL	   CIP	  was	  
added	  to	  the	  vector	  samples	  for	  30	  min	  at	  37°C	  to	  dephosphorylate	  the	  vector	  ends	  to	  prevent	  
re-­‐ligation.	  Samples	  were	  separated	  by	  agarose	  gel	  electrophoresis	  and	  purified	  from	  the	  gel.	  	  
	  
7.2.1.4	  Ligation	  
The	   purified	   and	   restricted	   DNA	   samples	   were	   ligated	   using	   the	   Rapid	   DNA	   Ligation	   Kit	  
following	   the	  manufacturer´s	  protocol.	  A	   ratio	  of	   vector:	   insert	  =	  1:3	  was	   chosen	   for	  optimal	  
ligation	  results.	  	  
	  
7.2.1.5	  Transformation	  of	  bacteria	  cells	  
For	  transformation,	  the	  entire	  ligation	  mix	  or	  up	  to	  500ng	  plasmid	  were	  added	  to	  the	  respective	  
bacteria	   strain	   and	   incubated	   on	   ice	   for	   30mins.	   Heat-­‐shock	   was	   performed	   at	   42°C	   for	   45	  
seconds	  followed	  by	  cooling	  the	  cells	  on	  ice	  for	  2	  minutes.	  After	  adding	  800µL	  SOC-­‐medium	  to	  
the	   cells,	   the	   suspension	   was	   incubated	   at	   37°C	   for	   1	   hour	   at	   900rpm.	   Subsequently,	   the	  
bacteria	  were	  plated	  on	  LB-­‐agar	  plates	  containing	  the	  respective	  antibiotics	  and	  incubated	  for	  
18	  hours	  at	  37°C.	  
	  
7.2.1.6	  Plasmid	  preparation	  
For	  analytical	  plasmids	  preparation,	  a	  single	  bacteria	  colony	  was	  inoculated	  in	  5mL	  LB-­‐medium	  
containing	  the	  respective	  antibiotics	  and	  grown	  for	  16	  hours	  at	  37°C	  and	  180rpm.	  Plasmid	  DNA	  
was	  isolated	  following	  the	  NucleoSpin	  Plasmid	  Kit.	  
	  	  
7.2.1.7	  RNA	  extraction	  	  
To	   obtain	   cDNA	   as	   a	   template	   for	   cloning,	   1*106	   HeLa	   cells	  were	   pelleted	   and	   subsequently	  
lysed	   according	   to	   the	  Qiashredder	   protocol.	   For	   quantitative	   Realtime	   PCR	   experiments,	   all	  
cells	  of	  one	  sample	  were	  lysed.	  RNA	  was	  isolated	  according	  to	  the	  manufacturer´s	  protocol	  of	  
the	  Qiagen	  RNeasy	  Kit.	  The	  isolation	  of	  RNA	  from	  epidermal	  white	  adipose	  tissue	  from	  DIO	  mice	  
was	   performed	   using	   TRIzol®	   Reagent	   according	   to	   manufacturer´s	   instruction.	   To	   clear	   the	  
isolated	  RNA	  from	  genomic	  DNA,	  samples	  (up	  to	  5µg	  RNA)	  were	  treated	  with	  DNaseI	  (Promega)	  
for	  30	  minutes	  at	  37°C.	  This	  reaction	  was	  inactivated	  at	  65°C	  for	  15	  minutes.	  The	  RNA	  probes	  
were	  stored	  at	  -­‐80°C.	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7.2.1.8	  cDNA	  synthesis	  and	  Quantitative	  Realtime	  PCR	  
For	   the	   reverse	   transcription	   of	   RNA	   into	   cDNA,	   the	   DNaseI	   digested	   RNA	   samples	   were	  
processed	   using	   the	   SuperScript	   III	   First	   Strand	   cDNA	   Synthesis	   System	   following	   the	  
manufacturer´s	  protocol.	  Thereby,	  random	  hexamers	  provided	  in	  the	  kit	  were	  used	  for	  reverse	  
transcription.	  cDNA	  samples	  were	  stored	  at	  -­‐20°C.	  In	  order	  to	  quantify	  the	  amount	  of	  cDNA	  in	  
the	  samples,	  the	  LightCylcer480	  (LC480)	  system	  and	  the	  KAPA	  SYBR	  FAST	  qPCR	  Kit	  were	  used.	  
Thereby,	  each	  primer	  pair	  was	  designed	   for	   sequence	  specific	  amplification	  of	  a	   single	   target	  
gene.	  For	  each	  primer	  pair	  the	  following	  reaction	  mix	  was	  prepared	  per	  sample	  and	  pipetted	  in	  
a	  96-­‐well	  plate:	  
1µL	  of	  each	  primer	  (20µM)	  
10µL	  2x	  KAPA	  SYBRGreen	  master	  mix	  
6µL	  H2O	  	  
2µL	  cDNA	  
After	   sealing	   and	   centrifuging	   the	   plate	   at	   200xg,	   the	   PCR	   was	   performed	   using	   the	   LC480	  
system	  with	  the	  following	  program:	  
	  
Step	   Temperature	   Time	   Cycles	  
Initial	  denaturation	   95°C	   10min	   1	  
Denaturation	   95°C	   10sec	   35	  
Annealing	   60°C	   10sec	   35	  
Elongation	   72°C	   10sec	   35	  
Generation	  of	  melting	  curves	   65-­‐95°C	   15sec	   1	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  7.2:	  PCR-­‐program	  to	  generate	  PCR	  amplificates	  for	  qualitative	  realtime	  PCR	  
	  
Melting	   curves	   were	   analyzed	   to	   ensure	   amplification	   of	   only	   one	   specific	   PCR	   product.	   For	  
determining	  the	  amount	  of	  mRNA	  transcripts	   in	  the	   initial	  sample,	  the	  house	  keeping	  gene	  β-­‐
Actin	  was	  included	  to	  normalize	  the	  samples.	  For	  the	  relative	  quantification,	  the	  ΔΔCp	  method	  
first	  described	  by	  Pfaffl	  (Pfaffl,	  2001)	  was	  applied.	  The	  Cp	  value	  of	  the	  target	  was	  related	  to	  the	  
Cp	   value	  of	   the	  house	   keeping	   gene.	   For	   amplification	   efficiencies,	   a	   value	  of	   2	  was	   applied.	  
DMSO-­‐treated	  samples	  were	  normalized	  to	  1	  and	  compound-­‐treated	  samples	  were	  referred	  to	  
these	   samples.	   qPCR	   experiments	   were	   performed	   at	   least	   three	   times	   and	   are	   depicted	   as	  
mean	  ±	  standard	  deviation	  of	  the	  mean.	  For	  statistical	  analysis	  the	  two-­‐tailed	  Unpaired	  t-­‐test	  
was	  applied	  and	  statistical	  significance	  was	  determined	  by	  a	  p-­‐value	  <	  0.05/p-­‐value	  <	  0.1.	  *	  =	  p-­‐
value	  <	  0.05;	  **	  =	  p-­‐value	  <	  0.01;	  ***	  =	  p-­‐value	  <	  0.001	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7.2.2	  Cell	  biological	  methods	  
7.2.2.1	  Cultivation	  of	  eukaryotic	  cells	  
For	   cultivation	   of	   eukaryotic	   cells,	   cells	   were	   grown	   in	  medium	   containing	   10%	   fetal	   bovine	  
serum	   and	   1%	   antibiotics.	   MEF	   and	   HeLa	   cells	   were	   cultured	   in	   Dulbecco´s	   Modified	   Eagle	  
Medium	  (DMEM)	  whereas	  HepG2	  cells	  were	  grown	  in	  Roswell	  Park	  Memorial	  Institute	  (RPMI)	  
medium.	   All	   cell	   lines	   are	   adherent	   cells	   and	   were	   therefore	   grown	   in	   cell	   culture	   flasks	   to	  
ensure	  attachment	  of	  the	  cells.	  Upon	  90%	  cell	  density,	  cells	  were	  splitted.	  Thereby,	  the	  medium	  
was	  removed,	  cells	  were	  washed	  with	  PBS	  and	  detached	  with	  trypsin/EDTA.	  To	   inactivate	  the	  
trypsin,	  cells	  were	  suspended	  in	  a	  five-­‐time	  excess	  of	  culture	  medium,	  diluted	  as	  required	  and	  
seeded	  in	  the	  cell	  culture	  flask.	  	  
	  
7.2.2.2	  Compound	  treatment	  and	  stimulation	  of	  MEF	  cells	  
For	  compound	  treatment,	  MEF	  cells	  were	  seeded	  the	  day	  before	  treatment.	  Depending	  on	  the	  
assay	  that	  was	  performed	  after	  compound	  treatment,	  cell	  number	  and	  well-­‐format	  differed.	  An	  
overview	  is	  given	  in	  the	  following	  table:	  
	  
Assay	   Number	  of	  cells	   Well-­‐format	   Volume	  [mL]	  
EMSA	  /	  quantitative	  RT-­‐PCR	   1.2*105	   6	   3	  
ALPHASurefire	   1*104	   96	   0.25	  
Endogenous	  TRAF6	  ubiquitination	   2.5*106	   15cm	  dish	   30	  
IKK	  kinase	  assay	   5.5*105	   10cm	  dish	   15	  
p65	  translocation	  assay	  	   3*103	   384	   0.1	  
Table	  7.3:	  Overview	  of	  number	  of	  seeded	  cell,	  well-­‐format	  and	  volume	  depending	  on	  the	  performed	  assay	  
	  
The	  cells	  were	  treated	  with	  the	  respective	  amount	  of	  compound	  and	  stocked	  up	  with	  DMSO	  to	  
ensure	  equivalent	  DMSO	  concentrations	  in	  all	  samples.	  After	  six	  hours	  of	  incubation,	  cells	  were	  
stimulated.	   Depending	   on	   the	   assay,	   different	   stimulation	   amounts	   and	   time	   points	   were	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Assay	   Amount	  [ng/mL]	   Volume	  [mL]	   Time	  [min]	  
EMSA	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  IL-­‐1β 	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  TNFα 	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ALPHASurefire	   1	   0.1	   7	  
Endogenous	  TRAF6	  ubiquitination	   3.5	   20	   10	  
IKK	  kinase	  assay	   1	   10	   8	  
p65	  translocation	  assay	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  IL-­‐1β 	  










Table	  7.4:	  	  Various	  stimulation	  procedures	  depending	  on	  the	  performed	  assay	  
	  
After	  stimulation,	  cells	  were	  put	  on	  ice,	  medium	  was	  removed	  and	  cells	  were	  washed	  with	  ice-­‐
cold	   PBS.	   After	   completely	   removing	   the	   PBS,	   cells	   were	   disrupted	   with	   the	   respective	   lysis	  
buffer.	  
	  
7.2.2.3	  Toxicity	  assays	  
For	   CellTiter-­‐Blue	   stainings	   as	   well	   double-­‐staining	   of	   Hoechst33342	   and	   Mitotracker,	   MEF	  
(1.2*103/well)	  and	  HepG2	  (4*103cells/well)	  cells	  were	  seeded	  in	  two	  µclear	  384	  well	  plates	   in	  
100µL	  medium.	  After	  18	  hours	  of	   incubation,	   compounds	  were	   transferred	   to	   the	   cells	  using	  
the	   Sciclone	  G3	   automation	   system.	   After	   24	   hours,	   stainings	  were	   performed.	   For	   CellTiter-­‐
Blue	   stainings,	   10µL	   of	   the	   CellTiter-­‐Blue	  reagent	   was	   added	   to	   cells	   in	   50µL	  medium.	   After	  
40minutes,	   the	   fluorescence	   (560Ex/590EM)	   was	   recorded	   using	   the	   Envision	   plate	   reader.	  
Thereby,	  metabolically	  active	  cells	  are	  capable	  of	  converting	  the	  non-­‐fluorescent	  dye	  Resazurin	  
into	  the	  fluorescent	  Resorufin.	  For	  double	  staining	  of	  Hoechst33342	  and	  Mitotracker,	  both	  dyes	  
were	   diluted	   in	   medium	   (final	   concentrations:	   Hoechst33342	   =	   0.5µg/mL;	   Mitotracker	   =	  
0.12µM).	  25µL	  of	  the	  medium	  containing	  the	  dyes	  were	  applied	  to	  the	  compound-­‐treated	  cells	  
in	  50µL	  medium.	  After	  45	  minutes	  incubation	  at	  37°C,	  the	  stainings	  were	  imaged	  and	  evaluated	  
in	   the	  Operetta	   system	  using	   the	  Harmony	  software.	   	  Hoechst33342	   is	  a	   cell-­‐permeable	  blue	  
fluorescent	  dye	  staining	  nuclear	  acids	  and	  is	  used	  for	  determination	  of	  the	  nucleus	  area	  in	  this	  
experiment.	  A	  decrease	  in	  nucleus	  area	   is	   indicative	  for	  condensed	  and	  fragmented	  apoptotic	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nuclei	  as	  the	  apoptotic	  process	  causes	  nuclear	  condensation	  and	  DNA	  fragmentation	  (Hua	  and	  
Xu,	   2000).	  Mitotracker	   is	   a	   red	   fluorescent	   dye	   that	   incorporates	   into	  mitochondria	   of	   living	  
cells	   and	   is	   used	   to	   analyze	   the	   mitochondrial	   mass	   in	   this	   experiment.	   Depending	   on	   the	  
compound	   targeting	   the	   mitochondria,	   the	   mitochondrial	   mass	   could	   either	   be	   reduced	   or	  
increased.	  
	  
7.2.2.4	  Storage	  of	  eukaryotic	  cells	  
For	   long-­‐time	   storage	   in	   liquid	   nitrogen,	   cells	   were	   detached	   from	   the	   cell	   culture	   flask	   as	  
described	  in	  7.2.2.1.	  1*106	  cells	  were	  pelleted,	  resuspended	  in	  1mL	  storage	  medium	  containing	  
20%	  FBS,	  1%	  penicillin-­‐streptomycin	  and	  10%	  DMSO	  and	  transferred	   into	  a	  cryo	  vial.	  The	  vial	  
was	  stored	  over	  night	  at	  -­‐80°C	  in	  a	  freezing	  container	  and	  then	  transferred	  into	  liquid	  nitrogen.	  	  
	  
7.2.2.5	  p65	  translocation	  assay	  
In	   order	   to	   analyze	   nuclear	   translocation	   of	   p65	   after	   compound	   treatment,	  MEF	   cells	   were	  
seeded	  in	  µclear	  plates,	  treated	  and	  stimulated	  as	  described	  in	  7.2.2.2.	  Cells	  were	  washed	  with	  
PBS	   and	   fixed	  with	   2%	  PFA	   for	   30	  min.	   After	  washing	  with	   PBS,	   cells	  were	   permeabilized	   by	  
adding	  0.2%	  Triton-­‐X100	   in	  PBS	  for	  30	  min	  and	  subsequently	  washed	  three	  times	   in	  PBS.	  The	  
primary	   antibody	   p65	   (C-­‐20)	   was	   1:250	   diluted	   in	   2%	   BSA	   and	   0.1%	   Triton-­‐X100	   in	   PBS	   and	  
incubated	   for	   two	   hours.	   After	   washing	   for	   three	   times	   in	   PBS,	   the	   fluorescently	   labeled	  
secondary	  antibody	  was	  diluted	  (1:400)	  in	  2%	  BSA	  and	  0.1%	  Triton-­‐X100	  in	  PBS	  and	  incubated	  
in	   subdued	   light	   for	   one	   hour.	   The	   cells	   were	   washed	   three	   times	   in	   PBS	   and	   stained	   with	  
Hoechst33342	  (1:10,000	  in	  PBS)	  for	  5	  min.	  After	  washing	  the	  cells	  with	  PBS,	  images	  were	  	  
	  
7.2.2.6	  Yeast-­‐Two-­‐Hybrid-­‐	  (Y2H)	  assay	  
In	  order	  to	  test	  the	  interaction	  of	  TRAF6	  and	  Ubc13,	  various	  constructs	  were	  cloned	  in	  pGAD-­‐
C(x)	  and	  pGBD-­‐C(x)	  vectors	  using	  the	  EcoRI	  and	  PstI	  restriction	  sites	  for	  the	  performance	  of	  an	  
Y2H-­‐assay.	   For	   transforming	  yeast	   cells,	   1µL	  of	  a	  plasmid	  was	  added	   to	  a	  10µL	  yeast	  aliquot.	  
Subsequently,	   360µL	   of	   PEG	  medium	  were	   added	   to	   the	   yeast	   cells.	   After	   incubation	   for	   30	  
minutes	   at	   room	   temperature,	   40µL	   of	   DMSO	   was	   added	   to	   the	   cells	   and	   heat	   shock	   was	  
performed	   for	   15	  minutes	   at	   42°C.	   Cells	  were	   centrifuged	   at	   200xg	   for	   five	  minutes	   at	   room	  
temperature	   and	   the	   pellet	   resuspended	   in	   100µL	   and	   plated	   on	   S.	   cerevisiae	   (SC)	   selection	  
plates	   lacking	   Leucin	   and	   Tryptophan.	   Yeast	   cells	   were	   grown	   for	   three	   days	   at	   30°C.	   For	  
spotting	  the	  yeast	  colonies,	  several	  yeast	  colonies	  were	  resuspended	  in	  1mL	  autoclaved	  water.	  
Optical	  dense	  (OD600)	  was	  measured	  from	  a	  1:10	  dilution.	  After	  adjusting	  an	  OD600=1,	  5µL	  were	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spotted	  on	  a	  SC-­‐Leu/Tryp/His	  plate	  and	  grown	  for	  three	  days	  at	  30°C.	  A	  grown	  spot	  revealed	  an	  
interaction	  of	  TRAF6	  and	  Ubc13.	  
	  
7.2.3	  Biochemical	  and	  immunological	  methods	  
	  
7.2.3.1	  Recombinant	  protein	  purification	  
7.2.3.1.1	  Purification	  of	  TRAF6StrepII	  
The	   cDNA	   sequences	   of	   the	   RING-­‐Zincfinger1	   domain	   of	   wildtype	   TRAF6	   and	   Ubc13	   binding	  
mutants	  (C70A,	  D57K	  and	  I72F)	  were	  cloned	  into	  the	  pASK-­‐IBA3+	  vector	  via	  the	  restriction	  sites	  
SacII	   and	  NcoI.	   This	  marks	  TRAF6	  RING-­‐Zincfinger1	  proteins	  with	  a	  C-­‐terminal	   StrepII-­‐tag.	   For	  
protein	  purification,	  the	  plasmids	  were	  transformed	  into	  BL21	  codon	  plus	  RIPL	  cells	  and	  spread	  
on	   a	   LB-­‐agar	   plate	   containing	   the	   antibiotics	   Ampicillin	   and	   Chloramphenicol.	   Bacteria	   cells	  
were	  grown	  for	  18	  hours	  at	  37°C.	  One	  colony	  was	  transferred	  into	  5mL	  LB-­‐medium	  containing	  
Ampicillin	   and	   Chloramphenicol	   and	   incubated	   at	   37°C	   for	   18	   hours.	   350µL	   of	   the	   bacteria	  
suspension	  were	   further	  expanded	   in	  20mL	  LB-­‐medium	  with	  Ampicillin	  and	  Chloramphenicol.	  
For	  protein	  purification,	  the	  20mL	  bacteria	  suspension	  was	  added	  to	  1L	  LB-­‐medium	  containing	  
both	   antibiotics.	   Protein	   production	   was	   induced	   at	   an	   OD600=	   0.6-­‐0-­‐8	   by	   adding	   200µg	  
anhydrotetracycline,	  0.5mM	  Isopropyl-­‐β-­‐D-­‐thiogalactopyranosid	  (IPTG)	  and	  100µM	  ZnCl2.	  Cells	  
were	   incubated	   at	   18°C	   for	   16	   hours.	   Afterwards,	   cells	   were	   centrifuged	   at	   2,600xg	   for	  
20minutes	   at	   4°C.	   The	   pellet	   was	   resuspended	   in	   10ml	   TRAF6-­‐washbuffer	   including	   1	   pill	   of	  
protease	  inhibitor	  Complete	  mini.	  The	  suspension	  was	  sonified	  (8x30seconds)	  and	  subsequently	  
centrifuged	  at	  53,000xg	  for	  2x30minutes.	  For	  the	  purification	  of	  the	  StrepII-­‐tagged	  proteins,	  the	  
protein	  solution	  was	  applied	  to	  StrepTrap	  columns	  using	  the	  ÄKTA	  purifier.	  After	  washing,	  the	  
StrepII-­‐protein	   was	   eluted	   from	   the	   column	   using	   the	   Strep-­‐elution	   buffer	   containing	  
desthiobiotin.	  The	  eluted	  protein	  was	  concentrated	  using	  Amicons	  (cut	  off	  3kDa)	  down	  to	  1mL.	  
Using	   the	   ÄKTA	   purifier	   and	   a	   HiTrap	   Desalting	   5ml	   column,	   the	   protein	   was	   desalted	   and	  
exchanged	  to	  storage	  buffer.	  The	  protein	  was	  concentrated	  in	  Amicons	  up	  to	  2µg/µL	  and	  stored	  
in	  small	  aliquots	  at	  -­‐80°C.	  	  
	  
7.2.3.1.2	  Purification	  of	  untagged	  TRAF6	  protein	  	  
The	  cDNA	  sequences	  of	   the	  TRAF6	  RING-­‐Zincfinger1	  domain	  wildtype	  and	  D57K	  mutant	  were	  
cloned	  into	  the	  pGex	  4T1	  vector	  via	  the	  BamHI	  and	  NotI	  restriction	  sites.	  This	  marks	  the	  TRAF6	  
protein	  with	  a	  N-­‐terminal	  GST-­‐tag.	  For	  the	  purification	  of	  the	  15N	  -­‐labeled	  TRAF6,	  the	  bacteria	  
suspension	   was	   grown	   as	   described	   in	   7.2.3.1.1	   in	   1L	   15N	   medium.	   For	   purifying	   unlabeled	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TRAF6,	  the	  15NH4	  was	  replaced	  with	  regular	  NH4.	  For	  protein	  production,	  1mM	  IPTG	  and	  100µM	  
ZnCl2	  was	  added	  at	  an	  OD600=	  0.6-­‐0-­‐7.	  After	  16	  hours	  at	  18°C,	  the	  cells	  were	  centrifuged	  and	  the	  
pellet	  resuspended	  in	  10ml	  TRAF6-­‐washbuffer	  including	  1	  Complete	  mini	  pill.	  After	  sonification	  
(8x30seconds)	   and	   centrifugation	   (2x30minutes	   at	   53,000xg),	   the	   protein	   suspension	   was	  
incubated	  with	  1mL	  pre-­‐washed	  Glutathione	  Sepharose	  4	   fast	   flow	  beads	   for	  2	  hours	  at	  4°C.	  
Subsequently,	   beads	   were	   washed	   with	   100mL	   Strep-­‐washbuffer	   and	   then	   incubated	   with	  
50Units	  Thrombin	   in	  2mL	  washbuffer	   for	  3	  hours	  at	   roomtemperature	   to	   cut	  off	   the	  GST-­‐tag	  
from	  TRAF7.	  The	  TRAF6	  protein	  was	  eluted	   in	  5mL	  washbuffer	  and	  again	   incubated	  with	  1mL	  
Glutathione	   Sepharose	   4	   fast	   flow	   beads	   for	   1	   hour	   at	   4°C.	   Afterwards,	   the	   solution	   was	  
centrifugated	   for	   5minutes	   at	   200xg	   and	   the	   supernatant	   transferred	   into	   an	   Amicon	   for	  
concentration	  followed	  by	  centrifugation	  at	  20,000xg	  for	  30minutes.	  The	  supernatant	  was	  then	  
applied	   to	   a	  HiLoad	   Superdex75	   column	  using	   the	  ÄKTA	  purifier	   for	   separating	   the	   untagged	  
TRAF6	   protein	   from	   uncleaved	   protein	   as	   well	   as	   buffer	   exchange	   in	   desalting	   buffer.	   After	  
concentration	  in	  an	  Amicon	  column	  to	  2µg/µL,	  the	  protein	  aliquots	  were	  stored	  at	  -­‐80°C.	  	  
	  
7.2.3.1.3	  Purification	  of	  Ubc13FH	  
The	  cDNA	  sequence	  for	  Ubc13	  fulllength	  and	  the	  Ubc13SPD	  mutant	  and	  the	  Flag-­‐His-­‐tag	  were	  
cloned	   into	   the	  pgex	   4T1	   vector	   using	   the	   restriction	   sites	   BamHI	   and	  NotI.	   This	   cloning	  was	  
performed	  by	  Dr.	  Kenji	  Schorpp.	  Bacteria	   transformed	  with	   the	  plasmid	  were	  grown	  up	  to	  1L	  
LB-­‐medium	  as	  described	  in	  7.2.3.1.1.	  Upon	  reaching	  an	  OD600=	  0.6-­‐0.8,	  protein	  production	  was	  
induced	   by	   adding	   1mM	   IPTG.	   After	   18	   hours	   at	   21°C,	   cells	   were	   harvested	   and	   the	   pellet	  
resuspended	   in	   GST-­‐washbuffer	   containing	   1	   Complete	   mini	   pill.	   After	   sonification	  
(12x30seconds)	  and	  centrifugation	  (2x30minutes),	  the	  protein	  solution	  was	  incubated	  with	  1mL	  
pre-­‐washed	   Glutathione	   Sepharose	   4	   fast	   flow	   beads	   for	   2	   hours	   at	   4°C.	   After	   washing	   the	  
beads	  with	  100mL	  GST-­‐washbuffer,	   the	  beads	  were	   incubated	  with	  50Units	  Thrombin	   in	  2mL	  
washbuffer	  over	  night.	  The	  Ubc13	  protein	  was	  eluted	   in	  5mL	  washbuffer	  and	   incubated	  with	  
1mL	  Glutathione	  Sepharose	  4	  fast	  flow	  beads	  for	  1	  hours	  at	  4°C.	  After	  centrifugation	  at	  200xg	  
for	   2minutes,	   the	   supernatant	   was	   concentrated	   to	   1ml	   and	   centrifuged	   at	   20,000xg	   for	  
30minutes.	  The	  protein	  was	  applied	  to	  Superdex75	  column	  using	  the	  ÄKTA	  purifier	  to	  desalted	  
the	   Ubc13FH	   protein	   in	   PBS	   and	   to	   clear	   it	   from	   uncleaved	   protein.	   The	   protein	   again	   was	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7.2.3.1.4	  Purification	  of	  GST-­‐tagged	  TRAF6,	  OTUB1	  and	  RNF8	  proteins	  
The	   cDNA	   sequences	   of	   TRAF6WT	   (RING-­‐Zincfinger1),	   OTUB1	   (fulllength)	   and	   RNF8	   (RING	  
domain)	  were	  cloned	  into	  the	  pGex	  4T1	  vector	  via	  the	  BamHI	  and	  NotI	  restriction	  sites.	  Cloning	  
of	  the	  OTUB1	  and	  RNF8	  constructs	  was	  conducted	  by	  Dr.	  Kenji	  Schorpp.	  Bacteria	  solutions	  were	  
grown	  up	  to	  1L	  LB-­‐medium	  as	  described	  in	  7.2.3.1.1.	  Protein	  production	  was	  induced	  by	  adding	  
1mM	  IPTG	  (and	  100µM	  ZnCl2	   in	  case	  of	  TRAF6WT)	  at	  an	  OD600=	  0.6-­‐0.7.	  Processing	  of	  bacteria	  
cells	   was	   performed	   as	   described	   in	   7.2.3.1.3.	   Thereby,	   TRAF6WT	  was	   resuspended	   in	   Strep-­‐
washbuffer	  and	  sonified	  for	  8x30	  seconds.	  After	  incubating	  the	  beads	  and	  protein	  solution,	  the	  
beads	  were	  washed	  with	   the	   respective	  washbuffer.	   The	  GST-­‐proteins	  were	  eluted	  with	  5mL	  
50mM	   Glutathione	   and	   concentrated	   in	   Amicons	   to	   1mL	   volume.	   The	   eluted	   proteins	   were	  
desalted	  using	  HiTrap	  Desalting	  columns	  and	  the	  ÄKTA	  purifier	  system.	  While	  GST-­‐OTUB1	  and	  
GST-­‐RNF8	   were	   desalted	   in	   PBS,	   GST-­‐TRAF6WT	   was	   desalted	   in	   TRAF6	   storage	   buffer.	   After	  
concentration,	  the	  aliquots	  were	  stored	  at	  -­‐80°C.	  	  
	  
7.2.3.2	  Sodium-­‐Dodecyl-­‐Sulfate-­‐Polyacrylamid-­‐Gelectrophoresis	  (SDS-­‐PAGE)	  
For	  analytical	  separation	  of	  proteins,	  a	  discontinuous	  SDS-­‐PAGE	  under	  reducing	  conditions	  was	  
performed.	   Thereby,	   the	   pore	   size	   of	   the	   separation	   gel	   (10	   or	   12.5%)	   was	   determined	   by	  
different	  amounts	  of	  acrylamid.	  For	  polymerization	  of	  the	  separation	  buffer,	  the	  crosslinker	  APS	  
(ammonium	   persulfate)	   and	   radical	   starter	   TEMED	   (tetramethylethylendiamin)	   were	   added.	  
While	  polymerizing,	  the	  gel	  was	  covered	  with	  isopropanol.	  After	  polymerization	  and	  removal	  of	  
the	  isopropanol,	  the	  5%	  stacking	  gel	  was	  added.	  After	  loading	  the	  samples,	  120V	  was	  applied	  to	  
the	   gel	   in	   1x	   SDS	   electrophoresis	   buffer	   for	   90	  minutes.	   For	   size	   control,	   the	   protein	  marker	  
PageRuler	  Plus	  Prestained	  Protein	  Ladder	  was	  loaded	  on	  the	  gel	  as	  well.	  	  
	  
7.2.3.3	  Coomassie	  and	  Silverstain	  
In	  order	   to	   check	   the	  purity	  of	   recombinant	  proteins,	   the	  proteins	  were	   loaded	  on	  a	   SDS-­‐gel	  
(separation	  gel:	  12.5%).	  After	  SDS-­‐PAGE,	  the	  gel	  was	  washed	  in	  bidest	  H2O.	  For	  Coomassie	  blue	  
staining,	  the	  Coomassie	  blue	  solution	  was	  added	  to	  the	  gel	  and	  incubated	  for	  18	  hours	  at	  room	  
temperature	  to	  allow	  staining	  of	  the	  protein.	  Thereby,	  the	  sulfonic	  acid	  groups	  of	  the	  dye	  bind	  
to	  the	  positive	  protein	  amine	  groups.	  The	  stained	  gel	  was	  washed	  in	  bidest	  H2O	  to	  visualize	  the	  
proteins.	  In	  case,	  the	  Coomassie	  blue	  staining	  was	  not	  sensitive	  enough	  to	  detect	  the	  proteins,	  
a	   Silverstaining	   was	   performed	   using	   the	   Pierce	   Silver	   Stain	   Kit	   according	   to	   manufacturer´s	  
instructions.	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7.2.3.4	  Western	  Blot	  and	  Immunodetection	  
To	   visualize	   protein	   after	   SDS-­‐PAGE	   by	   immuno-­‐detection,	   the	   separated	   proteins	   were	  
transferred	   to	   a	   PVDF-­‐membrane	   via	   semi-­‐dry-­‐blotting.	   Thereby,	   PVDF	   membranes	   were	  
activated	  in	  methanol	  and	  together	  with	  the	  SDS-­‐gel	  placed	  in	  the	  blotting	  apparatus	  between	  
whatman	  papers	   that	  were	   soaked	   in	  blotting	  buffer.	   The	  protein	   transfer	  occurred	  at	  80mA	  
per	   gel	   for	   60	   -­‐	   90	  minutes.	   Subsequently,	   the	  membrane	  was	   blocked	  with	   3%	  BSA	   in	   PBS-­‐
Tween20	  (PBS-­‐T)	  for	  60	  minutes	  to	  cover	  unspecific	  binding	  sites.	  After	  washing	  the	  membrane	  
in	  PBS-­‐T	  (3x10	  minutes),	  the	  specific	  primary	  antibody,	  diluted	  in	  1.5%	  BSA,	  was	  added	  to	  the	  
membrane	  and	   incubated	  over	  night	  at	  4°C.	  Afterwards,	   the	  membrane	  was	  washed	   in	  PBS-­‐T	  
and	   the	   horseradish-­‐peroxidase	   conjugated	   secondary	   antibody,	   diluted	   in	   0.75%	   BSA,	   was	  
applied	   to	   the	  membrane	   for	  one	  hour	  at	   room	  temperature.	  The	  membrane	  was	  washed	   in	  
PBS-­‐T	   and	   Enhanced	   chemiluminescence	   (ECL)	   substrate	   was	   added.	   The	   horseradish-­‐
peroxidase	  produces	  chemiluminescence	  that	  is	  detected	  by	  exposure	  to	  x-­‐ray	  films	  for	  various	  
time	  points	  and	  developed.	  To	  detect	  another	  protein	  on	  the	  same	  membrane,	  the	  membrane	  
was	   incubated	  with	   stripping	  buffer	   for	  60	  minutes,	  afterwards	  washed	   in	  PBS-­‐T	  and	  blocked	  
with	  3%	  BSA	  before	  adding	  the	  next	  primary	  antibody.	  
	  
7.2.3.5	  Gel-­‐filtration	  assay	  
The	  direct	  interaction	  of	  the	  recombinantly	  purified	  proteins	  TRAF6WTStrepII	  and	  Ubc13FH	  was	  
verified	   by	   gel-­‐filtration	   assays.	   First,	   50µg	   of	   TRAF6WTStrepII	   protein	   was	   applied	   to	   the	  
Superdex	  75	  100/300GL	  column	  in	  PBS	  to	  obtain	  the	  absorption	  spectra	  (A280)	  for	  TRAF6	  alone.	  
Next,	   equimolar	   amounts	   of	   Ubc13FH	   (60µg)	   in	   PBS	   were	   loaded	   to	   obtain	   the	   absorption	  
spectra	  of	  Ubc13FH.	  For	  the	  interaction	  study,	  equimolar	  amounts	  of	  both	  proteins	  were	  pre-­‐
incubated	  in	  PBS	  for	  30	  minutes	  at	  room	  temperature	  followed	  by	  absorption	  spectra	  analysis.	  	  
	  
7.2.3.6	  In	  vitro	  Ubiquitination	  assay	  
The	   ability	   of	   TRAF6	   to	   form	   K63-­‐linked	   polyubiquitin	   chains	   in	   conjunction	   with	   Ubc13	   is	  
analyzed	   after	   compound	   treatment.	   Therefore,	   untagged	   TRAF6WT	   and	   TRAF6D57K	   were	  
recombinantly	  purified.	  0.125µM	  TRAF6	  protein	  were	  pre-­‐incubated	  with	  DMSO/compound	  in	  
a	  total	  volume	  of	  100µL	  in	  K63	  assay	  buffer	  for	  30	  minutes	  at	  room	  temperature.	  An	  aliquot	  of	  
input	  samples	  were	  transferred	  to	  a	  new	  tube	  and	  denaturated	  by	  adding	  4x	  SDS	  loading	  buffer	  
and	  heating	  the	  samples	  (95°C).	  A	  master	  mix	  containing	  0.01µM	  E1-­‐activating	  enzyme	  (UBE1),	  
0.2µM	   E2-­‐conjugating	   enzyme	   complex	   (Ubc13/Uev1a),	   1mM	   ZnCl2,	   2mM	   ATP	   und	   4µM	  
monoubiquitin	   was	   added	   to	   the	   protein	   and	   the	   reaction	   mixture	   was	   incubated	   for	   120	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minutes	  at	  37°C.	  The	  reaction	  was	  stopped	  by	  adding	  4xSDS	  loading	  buffer	  and	  heating	  up	  the	  
samples	  to	  95°C	  for	  5	  minutes.	  The	  input	  sample	  were	  loaded	  on	  a	  12.5%	  SDS	  gel	  and	  stained	  
with	   the	   Pierce	   Silver	   Stain	   Kit.	   The	   ubiquitination	   samples	   were	   loaded	   on	   a	   10%	   SDS	   gel,	  
blotted	  and	  stained	  for	  Ubiquitin	  and	  TRAF6	  in	  Western	  Blot	  analysis.	  	  
	  
7.2.3.7	  Pulldown	  assay	  
To	  analyze	  the	  effect	  of	  the	  compounds	  on	  the	  GST-­‐TRAF6WT	  -­‐	  Ubc13FH	  interaction,	  500ng	  GST-­‐
TRAF6WT	  protein	  was	  incubated	  with	  the	  respective	  amounts	  of	  compound	  in	  pulldown	  buffer	  
for	  30	  minutes	  at	  room	  temperature	  followed	  by	  addition	  of	  1µg	  Ubc13FH	  for	  2	  hours	  at	  4°C.	  
Next,	  Ubc13FH	  was	   immunoprecipitated	  by	   adding	  1µL	   Flag	  M2	  antibody	   for	   2	   hours	   at	   4°C.	  
After	  incubation	  with	  10µL	  pre-­‐washed	  Protein-­‐G-­‐Sepharose	  beads	  for	  2	  hours,	  the	  beads	  were	  
washed	  eight	  times	  with	  pulldown	  buffer.	  The	  proteins	  were	  eluted	  by	  adding	  2x	  SDS	   loading	  
buffer	  and	  heating	  of	  the	  samples	  (95°C).	  Samples	  were	  loaded	  on	  a	  12.5%	  gel	  and	  stained	  for	  
TRAF6	  and	  Ubc13	  in	  Western	  Blot	  experiments.	  
	  
7.2.3.8	  Saturation-­‐Transfer-­‐Difference-­‐Nuclear-­‐Magnetic-­‐Resonance	  (STD-­‐NMR)	  
STD-­‐NMR	  was	   performed	   by	   Dr.	   Grzegorz	   Popowicz	   from	   the	   Institute	   of	   Structural	   Biology,	  
Helmholtz	  Zentrum	  München.	  For	  protein-­‐base	  experiments	   15N-­‐labeled	  and	  untagged	  TRAF6	  
RING-­‐Zincfinger1	   protein	   was	   recombinantly	   purified	   as	   described	   in	   7.2.3.1.2	   in	   a	   minimal	  
media	  with	  15N-­‐Ammoniumchloride	  as	  a	  sole	  nitrogen	  source	  and	  concentrated	  to	  c=	  120µM.	  
Protein	  and	   compound	  were	   incubated	  at	   a	   ratio	  of	  1:5	   in	   a	  3mm	  NMR	   tube	   for	  10	  minutes	  
before	   the	   spectra	   acquisition.	   To	   observe	   chemical	   shift	   perturbations	   upon	   the	   compound	  
addition,	   two	   dimensional	   SOFAST-­‐HMQC	   spectra	   were	   acquired.	   All	   measurements	   were	  
performed	  using	  Bruker	  Avance	  600	  MHz	  spectrometer.	  
	  
7.2.3.9	  ALPHAScreen	  assay	  
The	   ALPHAScreen	   technology	   was	   chosen	   for	   High-­‐Throughput-­‐Screening	   of	   the	  
TRAF6WTStrepII-­‐Ubc13FH	   interaction.	   This	   method	   is	   a	   bead-­‐based	   assay	   technology	   for	  
studying	  biomolecular	  interactions	  in	  a	  microplate	  format.	  The	  system	  requires	  two	  bead	  types	  
binding	   to	  either	  of	   the	  proteins:	  Donor	  and	  Acceptor	  bead.	  Upon	   illumination	  at	  680nm	  the	  
Donor	  bead	  releases	  a	  singlet	  oxygen	  by	  converting	  ambient	  oxygen	  through	  its	  photosensitizer	  
phthalocyanine.	   If	   an	  Acceptor	  bead	   is	   in	   close	  proximity,	   the	  energy	   is	   transferred	   from	   the	  
singlet	  oxygen	  to	  thioxene	  derivatives	  within	  the	  Acceptor	  beads	  emitting	  a	  light	  signal	  at	  520-­‐
620nm.	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Conducting	  a	  benchtop	  ALPHAScreen	  experiment	  starts	  with	  adding	  the	  protein	  that	  is	  targeted	  
by	  Donor	  beads	  to	  the	  384-­‐well-­‐opti-­‐plate	  (concentrations	  and	  volumes	  as	  indicated	  below)	  and	  
is	  followed	  by	  mixing	  in	  Ubc13FH.	  After	  one	  hour	  of	  incubation	  at	  room	  temperature,	  10µL	  of	  
both	  Donor	  and	  Acceptor	  beads	  were	  added	  to	  the	  reaction	  mix	   in	  subdued	  light	  followed	  by	  
one	  of	  incubation	  und	  subsequently	  read-­‐out	  at	  the	  Envision	  plate	  reader.	  	  




Beads	  required	   Bead	  amount	  
[µg]	  
TRAF6StrepII	   100nM	   30	   StrepTactin	  Donor	   4	  
Ubc13FH	   75nM	   10	   Nickel-­‐Chelate	  Acceptor	   4	  
	  




Beads	  required	   Bead	  amount	  
[µg]	  
GST-­‐OTUB1	   30nM	   30	   Glutathione	  Donor	   3	  
GST-­‐RNF8	   30nM	   30	   Glutathione	  Donor	   3	  
Ubc13FH	   20nM	   10	   Nickel-­‐Chelate	  Acceptor	   3	  
	  	  	  	  	  	  	  	  Table	  7.5:	  	  Experimental	  set-­‐up	  of	  the	  different	  combinations	  of	  ALPHAScreen	  assays	  
	  
7.2.3.10	  High-­‐Throughput-­‐Screening	  
In	   order	   to	   identify	   small	   molecules	   that	   specifically	   target	   the	   RING-­‐Zincfinger1	   domain	   of	  
TRAF6	  to	  prevent	   its	  binding	  to	  Ubc13	  a	  total	  of	  25,000	  compounds	  were	  screened.	  Thereby,	  
three	   in-­‐house	   libraries	   were	   available	   for	   HTS.	   In	   the	   initial	   HTS	   campaign,	   a	   compound	  
concentration	  of	  10µM	  was	  tested.	  Therefore,	  the	  compound	  plates	  from	  the	  different	  libaries	  
were	  prediluted	  in	  ALPHAScreen	  buffer	  to	  60µM	  and	  a	  volume	  of	  0.6µL	  of	  the	  compound	  was	  
transferred	  to	  the	  assay	  plate	  during	  the	  HTS	  campaign.	  	  
For	  performance	  of	  an	  automated	  ALPHAScreen	  assay,	   the	  TRAF6	  protein	   (concentration	  and	  
volume	  as	   indicated	   in	  7.2.3.9)	  was	  applied	  to	  the	  384-­‐well-­‐opti-­‐plates	   involving	  the	  FlexDrop	  
system	  and	  is	  followed	  by	  transfer	  of	  the	  compound	  via	  the	  Sciclone	  G3	  transfer	  station.	  After	  
adding	   Ubc13FH	  with	   the	   FlexDrop	   and	   incubation	   for	   one	   hour	   at	   room	   temperature,	   both	  
beads	  were	  mixed	   in	  using	   the	  FlexDrop	  as	  well	  but	   in	   subdued	   light.	  Read-­‐out	  of	   the	  plates	  
occurred	   after	   another	   hour	   of	   incubation	   at	   room	   temperature.	   Statistical	   parameters	  
including	  the	  Coefficient	  of	  Variation,	  Z´factor	  and	  Signal	  Window	  were	  calculated	  to	  determine	  
the	  quality	  of	  the	  HTS	  campaign.	  In	  order	  to	  determine	  the	  quality	  of	  a	  HTS	  campaign,	  several	  
statistical	  parameters	  were	  calculated:	  the	  average	  of	  the	  positive	  and	  negative	  controls	  as	  well	  
the	   standard	   deviations,	   coefficient	   of	   variation,	   the	   Z´	   factor	   and	   the	   Signal	   window.	   The	  
coefficient	  of	  variation	  (CV)	  gives	  the	  standard	  deviation	  as	  a	  percentage	  of	  the	  mean	  of	  a	  data	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set	  and	  should	  not	  exceed	  20%	  for	  an	  optimal	  assay	  (Lilly	  et	  al.,	  2007).	  The	  Z´	  factor	  compares	  
the	  mean	  of	  the	  positive	  signal	  to	  the	  mean	  of	  the	  negative	  control	  and	  will	  have	  a	  high	  value	  
when	   further	   apart.	   Z´	   factors	   between	   a	   value	   of	   0.5	   and	   1	   indicate	   for	   an	   excellent	   assay	  
(Zhang	  et	  al.,	  1999).	  The	  signal	  window	  (SW)	  provides	  the	  degree	  of	  separation	  of	  the	  signals	  
between	   positive	   and	   negative	   controls	   and	   should	   exceed	   a	   value	   of	   2	   (Sittampalam	   et	   al.,	  
1997).	  	  
To	  evaluate	  the	  efficiency	  of	  the	  compounds,	  ALPHAScreen	  units	  of	  compound-­‐treated	  samples	  
were	   calculated	   to	   DMSO	   treated	   samples.	   Thereby,	   the	   TRAF6D57K	   mutant	   served	   as	   the	  
control	  for	  maximum	  inhibition	  and	  was	   included	  in	  every	  plate	  of	  the	  screening.	  Compounds	  
that	   inhibited	   TRAF6WTStrepII-­‐Ubc13FH	   by	   more	   than	   25%	   were	   considered	   to	   be	   active	  
(n=500).	  After	  elimination	  of	   frequent	  hitters	  and	  His-­‐hitters	   (Schorpp	  et	  al.,	  2014)	  as	  well	  as	  
small	   molecules	   interfering	   with	   the	   GST-­‐OTUB1-­‐Ubc13FH	   interaction,	   178	   compounds	   were	  
defined	  as	  primary	  hits	  and	  were	  subsequently	  tested	  in	  nine-­‐point	  serial	  dilution	  assays	  (2.5-­‐
40µM)	   in	   TRAF6WTStrepII-­‐Ubc13FH,	   GST-­‐OTUB1-­‐Ubc13FH	   and	   GST-­‐RNF8-­‐Ubc13FH	  
ALPHAScreen	   experiments.	   Only	   compounds	   with	   serial	   dilution	   effects	   on	   TRAF6WTStrepII-­‐
Ubc13FH,	   but	   no	   effects	   on	   GST-­‐OTUB1-­‐Ubc13FH	   and	   GST-­‐RNF8-­‐Ubc13FH	   were	   taken	   for	  
further	  research	  (n=32).	  	  
	  
7.2.3.11	  Electro-­‐Mobility-­‐Shift-­‐Assay	  (EMSA)	  
In	   order	   to	   analyze	   the	   effects	   of	   the	   compounds	   on	   activation	   of	   NF-­‐κB,	   MEF	   cells	   were	  
seeded,	   treated	   and	   stimulated	   as	   described	   in	   7.2.2.2.	   70µL	   of	   High-­‐Salt-­‐Lysis-­‐Buffer	   was	  
added	  to	  the	  cells	  and	  cells	  were	  scraped	  from	  the	  plate.	  The	  solution	  was	  incubated	  at	  4°C	  for	  
30	  minutes	  rotating	  to	  allow	  lysis	  of	  the	  cells.	  After	  centrifuging	  the	   lysates	  for	  40	  minutes	  at	  
20,000xg	  and	  4°C,	  the	  supernatant	  was	  transferred	  into	  a	  new	  tube	  and	  samples	  were	  stored	  at	  
-­‐80°C.	  	  
For	  preparation	  of	  the	  radioactive	  NF-­‐κB	  and	  Oct-­‐1	  probes,	  the	  oligonucleotides	  were	  labeled	  
with	   32P-­‐α-­‐dATP.	   5µg	   of	   each	   Oligonucleotide	  was	   annealed	   in	   50µL	   annealing	   buffer	   for	   10	  
minutes	  at	  90°C	  and	  cooled	  down	  over	  night	  in	  the	  thermocycler.	  For	  radioactive	  labeling	  of	  the	  
oligonucleotides,	  the	  following	  reaction	  was	  prepared:	  
Annealed	  Oligonucleotide	  	  	  	  	  	  	  	  	  	  	  1µL	  (=	  400ng)	  
10x	  Kleenow	  buffer	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.5µL	  
dNTPs-­‐A	  (5mM	  each)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.8µL	  
	  32P-­‐α-­‐dATP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3µL	  
DNA	  Polymerase	  I	  (Kleenow)	  	  	  	  	  	  1µL	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H2O	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ad	  25µL	  
The	   reaction	  mix	  was	   incubated	   at	   37°C	   for	   30	  minutes	   and	   subsequently	   purified	   using	   the	  
QiaQuick	  Nucleotide	  Removal	  Kit.	  The	  labeled	  probes	  were	  stored	  at	  -­‐20°C.	  
For	  the	  shift	  reaction	  the	  following	  reaction	  mix	  was	  prepared:	  
2x	  shift	  buffer	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10µL	  
BSA	  (10µg/µL)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1µL	  
DTT	  (100mM)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1µL	  
Poly	  d(I-­‐C)	  2µg/µL	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1µL	  
Lysate	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4µg	  
Radioactive	  labeled	  probe	  	  	  	  10,000-­‐20,000	  counts	  per	  minute	  
H2O	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ad	  20µL	  
The	   mix	   was	   incubated	   at	   room	   temperature	   for	   30	   minutes	   and	   then	   loaded	   on	   a	   native	  
polyacrylamide	  gel	  (5%).	  The	  samples	  were	  separated	  at	  26mA	  per	  gel	  in	  1x	  TBE	  running	  buffer.	  
Subsequently,	  the	  gel	  was	  dried	  on	  whatman	  paper	  in	  vacuum	  for	  one	  hour.	  Radioactivity	  was	  
determined	  via	  exposure	  to	  an	  x-­‐ray	  film	  at	  -­‐80°C	  and	  developing	  the	  film.	  
In	   order	   to	   quantify	   the	   radioactive	   intensity,	   the	   x-­‐ray	   film	   for	   the	   NF-­‐κB	   as	   well	   as	   Oct-­‐1	  
activation	  were	   digitalized	   by	   scanning.	  Using	   the	   LabImage1D	   software,	   the	   intensity	   of	   the	  
radioactive	  bands	  was	  quantified.	  Therefore,	  one	  area	  covering	  the	  radioactive	  band	  (NF-­‐κB	  as	  
well	   as	   Oct-­‐1)	   and	   another	   area	   for	   the	   background	   was	   defined.	   Intensity	   and	   size	   of	   the	  
defined	  areas	  were	  calculated.	  To	  calculate	  the	  intensity	  of	  a	  single	  band,	  the	  intensity	  of	  each	  
area	  was	  normalized	  to	  its	  size.	  Next,	  the	  intensity	  of	  the	  background	  was	  subtracted	  from	  the	  
intensity	  of	  the	  band.	  After	  that,	  the	  normalized	  NF-­‐κB	  intensity	  was	  related	  to	  the	  normalized	  
Oct-­‐1	   intensity	   for	   the	   final	   NF-­‐κB	   activation.	   DMSO-­‐treated	   samples	   were	   set	   to	   100%	   and	  
compound-­‐treated	  probes	  were	  related	  to	  that.	  	  
	  
7.2.3.12	  Immunoprecipitation	  of	  TRAF6	  for	  endogenous	  ubiquitination	  
Cells	  were	  seeded,	  compound	  treated	  and	  stimulated	  with	  IL-­‐1β	  as	  indicated	  in	  7.2.2.2.	  For	  cell	  
lysis,	   500µL	  Co-­‐IP	   lysis	  buffer	   containing	  1%	  SDS	  was	  applied	   to	   the	   cells.	   Subsequently,	   cells	  
were	  scraped	   from	  the	  plate	  and	   the	  cells	  were	  disrupted	  by	   repeatedly	  passing	   the	  solution	  
through	   a	   syringe	   (26G).	   After	   incubation	   of	   the	   lysate	   at	   4°C	   for	   30	   minutes	   rotating,	   the	  
solution	  was	  centrifuged	  for	  30	  minutes	  at	  4°C	  and	  20,000xg.	  The	  supernatant	  was	  transferred	  
to	  a	  new	  tube	  and	   lysate	  samples	  were	   taken.	  Afterwards,	   the	  samples	  were	  diluted	   to	  0.1%	  
SDS	   and	   incubated	  with	   5µL	   TRAF6	   antibody	   EP591Y	   for	   two	   hours	   at	   4°C.	   20µL	   pre-­‐washed	  
Protein-­‐G-­‐Sepharose	  beads	  were	  added	  and	   the	   reaction	  mix	   further	   incubated	  over	  night	  at	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4°C.	  Beads	  were	  washed	  three	  times	   in	  Co-­‐IP	  buffer	  and	  the	  protein	  was	  eluted	  using	  2x	  SDS	  
loading	   buffer	   and	   heating	   up	   the	   sample.	   The	   proteins	   were	   separated	   by	   SDS-­‐PAGE	   (10%	  
separation	  gel)	  and	  stained	  for	  Ubiquitin	  and	  TRAF6	  in	  Western	  Blot	  analysis.	  	  
	  
7.2.3.13	  IKK	  kinase	  assay	  
MEF	   cells	  were	   seeded,	   compound	   treated	   and	   stimulated	  with	   IL-­‐1β	   as	   depicted	   in	   7.2.2.2.	  
Cells	  were	  lysed	  in	  500µL	  CoIP	  lysis	  buffer,	  incubated	  at	  4°C	  for	  30	  minutes	  and	  centrifuged	  at	  
4°C	   and	   20,000xg	   for	   30	  minutes.	   After	   taking	   input	   samples,	   the	   supernatant	  was	   then	  mix	  
with	   6µL	   IKKγ	   antibody	   FL-­‐419	   and	   incubated	   for	   two	   hours	   at	   4°C.	   After	   adding	   20µL	   pre-­‐
washed	   Protein-­‐G-­‐Sepharose	   beads,	   the	   sample	  was	   incubated	   over	   night	   at	   4°C.	   The	   beads	  
were	  washed	  three	  times	  with	  CoIP	  buffer	  followed	  by	  one	  washing	  step	  in	  kinase	  buffer.	  The	  
beads	  were	  incubated	  with	  20µL	  kinase	  buffer,	  1.5mg	  GST-­‐IκBα	  (1-­‐53)	  and	  0.5µL	  32P-­‐γ-­‐ATP	  for	  
30	  minutes	   at	   37°C.	   The	   reaction	  was	   stopped	   by	   adding	   10µL	   of	   4x	   SDS	   loading	   buffer	   and	  
proteins	  were	  separated	  by	  SDS-­‐Page	  (12.5	  %	  separation	  gel)	  and	  analyzed	  by	  autoradiography	  
as	  well	  as	  Western	  Blot.	  	  
	  
7.2.3.14	  ALPHASurefire	  
ALPHASurefire	   is	  a	  bead-­‐based	  ALPHA	  technology	  provided	  by	  Perkin	  Elmer	  to	  analyze	  protein	  
levels	  of	  phosphorylated	  cellular	  proteins.	  The	  phosphorylated	  protein	   is	  detected	  by	  using	  2	  
antibodies:	   one	   targets	   the	   specific	   phospho-­‐epitope	   of	   the	   protein,	   while	   the	   other	   one	   is	  
directed	   against	   a	   non-­‐phospho-­‐epitope	   at	   the	   distal	   end	   of	   this	   protein.	   The	   antibodies	   are	  
then	  selectively	  bound	  by	  either	  Donor	  or	  Acceptor	  beads	  analog	  to	  the	  ALPHAScreen	  system.	  
Upon	  phosphorylation	  both	  beads	  are	  brought	  together	  generating	  a	  signal.	  In	  order	  to	  detect	  
protein	   levels	   of	   p-­‐IκBα	   (Ser32/36)	   as	  well	   as	   total	   IκBα,	  MEF	   cells	  were	   seeded,	   compound	  
treated	   and	   stimulated	   as	   described	   in	   7.2.2.2.	   The	   protein	   levels	   were	   analyzed	   using	   the	  
ALPHASurefire	   kits	   following	   manufacturer´s	   instruction.	   The	   general	   2-­‐plate	   protocol	   was	  
performed.	  Therefore,	  the	  lysates	  were	  transferred	  from	  the	  96-­‐well	  assay	  plate	  to	  a	  384	  well-­‐
plate	  before	  adding	  the	  Acceptor	  mix.	  Experiments	  were	  performed	  at	  least	  three	  times	  and	  are	  
depicted	  as	  mean	  ±	  standard	  deviation	  of	  the	  mean.	  For	  statistical	  analysis,	  the	  Unpaired	  t-­‐test	  
was	  applied	  and	  statistical	  significance	  was	  determined	  by	  a	  p-­‐value	  <	  0.05.	  *	  =	  p-­‐value	  <	  0.05;	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7.2.4	  Diet-­‐Induced-­‐Obesity	  (DIO)	  mouse	  study	  
7.2.4.1	  Treatment	  of	  DIO-­‐mice	  
Observation	  of	  mice,	  compound-­‐treatment	  and	  measurements	  were	  carried	  out	  by	  members	  of	  
the	  Institute	  of	  Diabetes,	  Helmholtz	  Zentrum	  München.	  Mice	  were	  fed	  a	  high-­‐fat-­‐diet	  until	  they	  
reached	  a	  body	  weight	  of	  at	  least	  40g	  and	  developed	  diabetes-­‐induced-­‐obesity.	  The	  mice	  were	  
separated	   in	   control	   group	  and	  a	  group	   for	  C25-­‐0140	   injection.	  Mice	  were	   treated	  every	  day	  
with	  14µmol/kg	  (=7.4mg/kg)	  C25-­‐0140	   intra	  peritoneal	   for	  a	  period	  of	  20	  days.	  Thereby,	  C25-­‐
0140	  was	  dissolved	  in	  2.9%	  DMSO,	  1.5%	  Tween-­‐80	  and	  1xPBS.	  Every	  day	  before	  injection,	  the	  
body	  weight	  and	  food	  intake	  were	  measured.	  On	  day	  20,	  mice	  were	  sacrificed	  two	  hours	  after	  
compound	   injection	   and	   epidermal	  white	   adipose	   tissue	   from	  both	   body	   sites	  was	   removed,	  
frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  To	  determine	  the	  statistical	  significance	  of	  the	  loss	  
of	  bodyweight	  in	  the	  DIO-­‐mouse-­‐study,	  a	  two-­‐way-­‐Anova	  test	  was	  applied.	  	  
	  
7.2.4.2	  Glucose	  Tolerance	  Test	  (GTT)	  
On	  day	  18,	   a	  GTT	  was	  performed.	  Therefore,	  mice	  were	   starved	   for	   six	  hours	  and	   two	  hours	  
after	  compound	  injection	  challenged	  with	  1.5g	  glucose	  per	  kg	  body	  weight.	  	  Before,	  15,	  30,	  60	  
and	  120	  minutes	  after	   glucose	   injection,	  blood	  glucose	   levels	  were	  measured	  using	   Freestyle	  
Life	   Test	   strips.	   For	   statistical	   analysis,	   the	   Unpaired	   t-­‐test	   was	   applied	   and	   statistical	  
significance	  was	  determined	  by	  a	  p-­‐value	  <	  0.05.	  
	  
7.2.4.3	  Isolation	  of	  protein	  from	  epidermal	  white	  adipose	  tissue	  of	  DIO	  mice	  
A	   small	   piece	   of	   the	   epidermal	   white	   adipose	   tissue	   (ewat)	   was	   lysed	   in	   200µL	   RIPA-­‐buffer	  
containing	  protease-­‐phosphatase-­‐inhibitors	   and	   incubated	   at	   4°C	   rotating	   for	   two	  hours.	   The	  
solution	  was	   then	  centrifuged	  at	  20,000xg	   for	  30	  minutes	  and	  the	  soluble	   fraction	  containing	  
the	  proteins	  was	  transferred	  into	  a	  new	  tube.	  This	  step	  was	  repeated	  until	  the	  protein	  fraction	  
was	   completely	   free	   of	   fat.	   The	   protein	   concentration	   was	   determined	   using	   the	   Bradford	  
assay.	  For	  ALPHASurefire	  experiments,	  4mg	  protein	  of	  each	  sample	  were	  analyzed.	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9	  Abbreviations	  
Å	   	   	   Angström	  
AD	   	   	   Activation	  Domain	  	  
ADME	   	   	   absorption-­‐distribution-­‐metabolism-­‐excretion	  
ALPHAScreen	  	   	   Amplified	  Luminescence	  Proximity	  Homogeneous	  Assay	  
APC	  	   	   	   antigen	  presenting	  cells	  
APPL1	  	   adaptor	  protein,	  phosphotyrosine	  interaction,	  PH	  (pleckstrin	  homology)	  
domain	  and	  leucine	  zipper	  containing	  1	  
ARD	  	  	   	   	   ankyrin	  repeat-­‐containing	  domain	  
ATM	  	   	   	   Ataxia	  telangiectasia	  mutated	  
ATP	   	   	   adenosine-­‐tri-­‐phosphate	  
BAFF-­‐R	  	   	   B	  cell	  activating	  factor	  belonging	  to	  the	  TNF	  family	  
Bcl-­‐Xl	   	   	   B	  cell	  lymphoma	  extra	  large	  
BCL10	   	   	   B	  cell	  chronic	  lymphocytic	  leukemia/lymphoma	  associated	  10	  
BCR	  	   	   	   B	  cell	  receptor	  	  
BD	   	   	   Binding	  Domain	  
C25	   	   	   Compound	  25	  
Caco-­‐2	  	   	   human	  colon	  adenocarcinoma	  cell	  
CARMA	   	   CARD	  containing	  MAGUK	  protein	  1	  
cDNA	  	   	   	   complementary	  DNA	  
CD40/80/86	   	   Cluster	  of	  Differentiation	  
cIAP	   	   	   cellular	  inhibitor	  apoptosis	  protein	  
Cl	   	   	   Chloride	  
Clint	   	   	   intrinsic	  clearance	  constant	  
cpm	   	   	   counts	  per	  minute	  
C-­‐terminal	   	   carboxy-­‐terminal	  
CV	  	   	   	   Coefficient	  of	  Variation	  	  
CYLD	   	   	   Cylindromatosis	  
CYP	  	   	   	   Cytochrom	  
Cys	   	   	   cysteine	  
D/DMSO	   	   Dimethylsulfoxide	  
DELFIA	  	   	   Dissociation-­‐Enhanced	  Lanthanide	  Fluorescence	  Immunoassay	  	  
DIO	   	   	   diet-­‐induced	  obesity	  
DNA	   	   	   Desoxyribonucleic	  acid	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dsRNA	  	   	   double	  stranded	  RNA	  
DUB	   	   	   deubiquitinase	  
ELISA	   	   	   Enyzme	  Linked	  Immunosorbent	  Assay	  
EMSA	   	   	   Electrophoretic	  Mobility	  Shift	  Assay	  
ERAD	   	   	   endoplasmatic	  reticulum-­‐associated	  degradation	  
eWAT	  	   	   	   epidermal	  white	  adipose	  tissue	  
F	   	   	   Fluor	  
FADD	  	   	   	   Fas-­‐associated	  death	  domain	  protein	  
FATCAT	  	   flexible	  structure	  alignment	  by	  chaining	  aligned	  fragment	  pairs	  allowing	  
twists	  F-­‐box	  
FDA	  	   	   	   Food	  and	  Drug	  Administration	  
FetA	   	   	   FetuinA	  
FFA	  	   	   	   free	  fatty	  acids	  
FH	   	   	   frequent	  hitters	  
Fig.	   	   	   Figure	  
for	   	   	   forward	  
g/kg	   	   	   gram/kilogram	  
G6Pase	  	   	   Glucose-­‐6-­‐phosphatase	  
GSK3β   Glycogen	  Synthase	  Kinase	  3β	  
GST	   	   	   Glutathione-­‐S-­‐Transferase	  
GTT	  	   	   	   Glucose	  Tolerance	  Test	  
HECT	  	   	   	   homology	  to	  E6AP	  C	  terminus	  
HepG2	  	   	   human	  hepatoma	  cells	  
hERG	  	   	   	   human	  Ether-­‐a-­‐go-­‐go	  related	  gene	  
HFD	   	   	   High-­‐fat-­‐diet	   	  
HIF1α   hypoxia-­‐inducible	  factor	  1α	  
His	   	   	   Histidine	  
HOIL-­‐1	  	   	   Heme-­‐Oxidized	  IRP2	  ubiquitin	  ligase	  1	  
HOIP	   	   	   HOIL-­‐1	  interacting	  protein	  
HTS	   	   	   High-­‐Throughput-­‐Screening	  
IAP	   	   	   inhibitor	  apoptosis	  protein	  
IBM	  	   	   	   IAP-­‐binding	  motif	  
ICAM-­‐1	   	   Intracellular	  Adhesion	  Molecule	  1	  	  
IC50	   	   	   inhibitory	  concentration	  50	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IDO	  	   	   	   Institute	  of	  Diabetes	  and	  Obesity	  
IκB	   	   	   Inhibitor	  of	  kappa	  B	  
IFN	   	   	   Interferon	  
IGF-­‐1	   	   	   insulin-­‐like	  growth	  factor-­‐1	  
IKK	   	   	   IκB	  kinase	  complex	  
IL-­‐	   	   	   Interleukin-­‐	  
IL-­‐1R	  	   	   	   Interleukin-­‐1	  receptors	  
IRAK	   	   	   Interleukin-­‐1	  receptor	  associated	  kinase	  
JAMM	   	   	   JAB1/MPN/MOV34	  family	  
K63	   	   	   Lysine	  83	  
Kd	   	   	   dissociation	  constant	  
kel	  	   	   	   elimination	  constant	  	  
LogD	  	   	   	   distribution	  coefficient	  
LogP	   	   	   partition	  coefficient	  
LPS	   	   	   lipopolysaccharide	  
LUBAC	  	   	   linear	  ubiquitin	  assembly	  complex	  
Lys	   	   	   Lysine	  
MALT1	  	   	   Mucosa	  associated	  lymphoid	  tissue1	  
MAPK	  	  	   	   mitogen-­‐activated	  protein	  kinases	  
MAPKKK	   	   MAPK-­‐kinase-­‐kinase	  
MDM2	  	   	   Mouse	  double	  minute	  2	  homolog	  
MEF	   	   	   Mouse	  Embryonic	  Fibroblast	  
Me/CH3	   	   methyl-­‐	  
MeO	   	   	   Methyl-­‐oxide	  
Met	   	   	   Methionine	  
min	   	   	   minute	  
miR	   	   	   MicroRNA	  
mRNA	   	   	   messenger	  RNA	  
µM/mM	   	   Micro-­‐/Mili-­‐molar	  
µL/mL	   	   	   Micro-­‐/Mili-­‐litre	  
MST	  	   	   	   Microscale	  Thermophoresis	  
MyD88	  	   	   Myeloid	  Differentiation	  primary	  response	  gene	  88	  
15N	   	   	   15nitrogen	  
NAE	  	   	   	   NEDD8	  activating	  enzyme	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neg.	   	   	   negative	  
NEMO	   	   	   NF-­‐κB	  essential	  modifier	  
NF-­‐κB	   	   	   nuclear	  factor	  “kappa-­‐light-­‐chain-­‐enhancer”	  of	  activated	  B	  cells	  
NIK	  	   	   	   NF-­‐κB	  inducing	  kinase	  
nM	   	   	   Nanomolar	  
NMR	  	   	   	   Nuclear	  Magnetic	  Resonance	  
NLR	  	   	   	   Nucleotide-­‐binding	  Oligomerization	  Domain-­‐like	  receptors	  
NLS	  	  	   	   	   Nuclear	  Localization	  Signal	  
ns	   	   	   not	  significant	  
N-­‐terminal	   	   amino-­‐terminal	  
OTU	   	   	   Ovarian	  Tumor	  Proteases	  
OTUB1	  	   	   OTU	  deubiquitinase,	  ubiquitin	  aldehyde	  binding	  1	  
OTULIN	   	   OTU	  DUB	  with	  linear	  linkage	  specificity	  
PAMP	  	  	   	   pathogen	  associated	  molecular	  pattern	  
PDB	  	   	   	   Protein	  Data	  Bank	  
32P	   	   	   32Phosphorus	  
p-­‐	   	   	   phospho-­‐	  
PAINS	  	   	   	   pan-­‐assay-­‐interference-­‐compounds	  
PEPCK	  	  	   	   Phosphoenolpyruvate-­‐carboxykinase	  	  
pM	   	   	   pico-­‐molar	  
pos.	   	   	   positive	  
PPI	  	   	   	   protein-­‐protein	  interactions	  
qPCR	  	   	   	   quantitative	  realtime	  polymerase	  chain	  reaction	  	  
R1/R2/R3	   	   residue	  1/2/3	  
RA	   	   	   rheumatoid	  arthritis	  
RANK	   	   	   Receptor	  Activator	  of	  NF-­‐κB	  
RBR	   	   	   RING-­‐between-­‐RING	  
rev	   	   	   reverse	  	  
RHR	  	   	   	   Rel	  homology	  region	  	  
RING	  	   	   	   really	  interesting	  new	  gene	  
RIP1	   	   	   Receptor-­‐Interacting	  Protein	  1	  
RLR	   	   	   RIG-­‐I-­‐like	  receptors	  
RNA	   	   	   Ribonucleic	  acid	  
RNF8	   	   	   RING	  finger	  protein	  8	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RZ1	   	   	   RING-­‐Zincfinger1	  domain	  
SAR	   	   	   structure	  activity	  relationship	  
SLE	  	   	   	   systemic	  lupus	  erythematosus	  
SDS-­‐PAGE	   	   Sodium-­‐Duodecyl-­‐Sulfate-­‐Polyacrylamid-­‐Gelectrophoresis	  
SNP	  	   	   	   single	  nucleotide	  polymorphisms	  
SOFAST	  HMQC	   Band-­‐Selective	  Optimized	  Flip	  Angle	  Short	  Transient	  Heteronuclear	  Multiple	  
Quantum	  Coherence	  
ssRNA	   	   	   single	  stranded	  RNA	  
StDEV	   	   	   Standard	  Deviation	  
StrepII	   	   	   Strep-­‐TagII	  
SW	   	   	   Signal	  Window	  
T1/2	   	   	   half-­‐time	  
T2DM	   	   	   Type	  2	  diabetes	  mellitus	  
TAD	  	   	   	   C-­‐terminal	  transactivation	  domain	  
TAB	   	   	   TGFβ-­‐activated	  kinase	  1	  binding	  protein	  
TAK1	   	   	   TGFβ-­‐activated	  kinase	  1	  
TCR	  	   	   	   T	  cell	  receptors	  
TIR	  	   	   	   Toll/IL-­‐1R	  domain	  
TGFβ	  	   	   	   Transforming	  Growth	  Factor	  β	  
TLR	  	   	   	   Toll-­‐like	  receptor	  	  
TNFα	   	   	   Tumor	  Necrosis	  Factor	  α	  
TNFR1	   	   	   Tumor	  Necrosis	  Factor	  Receptor	  1	  
TRADD	  	   	   TNFR1-­‐associated	  death	  domain	  proteins	  	  
TRAF	   	   	   TNFR	  associated	  Factor	  
TR-­‐FRET	  	   	   time	  resolved	  Förster	  resonance	  energy	  transfer	  	  	  
Ubc13	   	   	   Ubiquitin-­‐conjugating	  enzyme	  13	  
Ubc13FH	   	   Ubc13-­‐Flag-­‐His	  
UCHs	  	   	   	   Ubiquitin	  COOH-­‐terminal	  hydrolases	  
Uev1a	   	   	   Ubiquitin-­‐conjugating	  E2	  variant	  1a	  
UPS	   	   	   Ubiquitin	  Proteasom	  System	  
USP	   	   	   Ubiquitin	  specific	  proteases	  
VCAM	  	  	   	   Vascular	  Adhesion	  Molecule	  
WT	   	   	   Wildtype	  
Y2H	   	   	   Yeast-­‐Two-­‐Hybrid	  assay	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10	  Supplement	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Supplement	  10.1:	  ALPHAScreen	  data	  of	   the	   reordered	  primary	  hit	   compounds	  1-­‐8.	  All	  compounds	  impair	  the	  
TRAF6WTStrepII-­‐Ubc13FH	  interaction	  (displayed	  in	  red),	  whereas	  the	  interactions	  of	  GST-­‐OTUB1	  and	  GST-­‐RNF8	  to	  























































IC50: 19.7 ± 4.3  µMIC50: 0.24 ± 0.1 µM
compound 3









































































IC50: 68.4 ± 11.2 µMIC50: 48.7 ± 10.5 µM
0.1
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Supplement	  10.2:	  ALPHAScreen	  data	  of	  the	  reordered	  primary	  hit	  compounds	  9-­‐16.	  All	  compounds	  impair	  the	  
TRAF6WTStrepII-­‐Ubc13FH	  interaction	  (displayed	  in	  red),	  whereas	  the	  interactions	  of	  GST-­‐OTUB1	  and	  GST-­‐RNF8	  to	  































IC50: 23.7 ± 4.3  µMIC50: 53.1 ± 10.5 µM
compound 11

































































IC50: 74.8 ± 17.0 µMIC50 < 0.1 µM
0.1
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Supplement	  10.3:	  ALPHAScreen	  data	  of	  the	  reordered	  primary	  hit	  compounds	  17-­‐24.	  All	  small	  molecules	  except	  
compound	   20	   impair	   the	   TRAF6WTStrepII-­‐Ubc13FH	   interaction	   (displayed	   in	   red),	   whereas	   the	   interactions	   of	  































IC50: 4.3 ± 0.9  µMIC50: 18.3 ± 2.6 µM
compound 19

































































IC50: 0.9 ± 0.3 µMIC50: 0.6 ± 0.2 µM
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Supplement	  10.4:	  ALPHAScreen	  data	  of	   the	   reordered	  primary	  hit	   compounds	  25,	  26	  and	  27.	  All	  compounds	  
impair	   the	  TRAF6WTStrepII-­‐Ubc13FH	   interaction	   (displayed	   in	   red),	  whereas	   the	   interactions	  of	  GST-­‐OTUB1	  and	  















































IC50 <  0.1  µMIC50: 1.1 ± 0.2 µM
compound 27





IC50 < 0.1 µM
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Supplement	   10.5:	  
Quantification	   of	   NF-­‐κB	  
activation	   in	   EMSA	  
experiment	   of	   all	   primary	  
hit	   compounds	   after	   IL-­‐1β 	  
and	   TNFα 	   stimulation.	  
Displayed	   are	   all	   single	  
quantified	   EMSA	  
experiments	   after	   IL-­‐1κ	   and	  
TNFκ	   stimulation.	   Values	  
represent	   %	   NF-­‐κB	  
activation	   and	   are	  
normalized	  to	  DMSO	  treated	  
control	   MEF	   cells.	  
Compounds	   marked	   in	   light	  
grey	  exhibit	  an	   IL-­‐1β	  specific	  
effect	  on	  NF-­‐κB	  activation.	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Supplement	   10.6:	   Compound	   structures,	   IC50	   and	   solubility	   data	   of	   the	   SAR	   analysis	   of	   C25	   in	  ALPHAScreen	  
experiments.	   IIC50	   values	   represent	   the	   effect	   of	   each	   compound	   on	   TRAF6WTStrepII-­‐Ubc13FH	   interaction.	  
Bindings	  of	  GST-­‐OTUB1	  and	  GST-­‐RNF8	  to	  Ubc13FH	  remain	  unaffected	  (except	  for	  25-­‐0212).	  	  
compound 
25-0196


























IC50: 3.3 ± 0.76 µM
compound 
25-0174












not soluble not soluble
compound 
25-0029
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Supplement	   10.7:	   Compound	   structures,	   IC50	   and	   solubility	   data	   of	   the	   SAR	   analysis	   of	   C25	   in	  ALPHAScreen	  
experiments.	   IIC50	   values	   represent	   the	   effect	   of	   each	   compound	   on	   TRAF6WTStrepII-­‐Ubc13FH	   interaction.	  
Bindings	  of	  GST-­‐OTUB1	  and	  GST-­‐RNF8	  to	  Ubc13FH	  remain	  unaffected.	  	  
compound 
25-0002


























































































































































IC50: 40.4 ± 24.58 µM
compound 
25-0265  
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Supplement	   10.8:	   Compound	   structures	   and	   solubility	   data	   of	   the	   SAR	   analysis	   of	   C25	   in	   ALPHAScreen	  
experiments.	   Depicted	   compounds	   did	   not	   show	   inhibitory	   effects	   on	   TRAF6WTStrepII-­‐Ubc13FH	   interaction.	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Supplement	   10.9:	   Compound	   structures	   and	   solubility	   data	   of	   the	   SAR	   analysis	   of	   C25	   in	   ALPHAScreen	  
experiments.	   Depicted	   compounds	   did	   not	   show	   inhibitory	   effects	   on	   TRAF6WTStrepII-­‐Ubc13FH	   interaction.	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Supplement	   10.10:	   Structural	   alignment	   of	   the	   RING	   domains	   of	   TRAF6	   and	   cIAP2.	   TRAF6	   (PDB:	   2jmd)	   and	  
cIAP2	  (PDB:	  3eb5)	  were	  aligned	  using	  the	  FATCAT	  software	  provided	  by	  the	  Godzik	  laboratory.	  (A)	  Calculations	  of	  
parameters	   to	   define	   the	   similarity	   between	   the	   RING	   domains	   of	   TRAF6	   and	   cIAP2.	   opt-­‐rmsd	   =	   root	   mean	  
square	  deviation	  with	   structural	   rearrangements;	   chain-­‐rmsd	  =	   root	  mean	   square	  deviation	  without	   structural	  




Supplement	  10.11:	  Structural	  alignment	  of	  the	  RING	  domains	  of	  TRAF6	  and	  RNF8.	  TRAF6	  (PDB:	  2jmd)	  and	  RNF8	  
(PDB:	   4ayc)	   were	   aligned	   using	   the	   FATCAT	   software	   provided	   by	   the	   Godzik	   laboratory.	   (A)	   Calculations	   of	  
parameters	  to	  define	  the	  similarity	  between	  the	  RING	  domains	  of	  TRAF6	  and	  RNF8.	  opt-­‐rmsd	  =	  root	  mean	  square	  
deviation	   with	   structural	   rearrangements;	   chain-­‐rmsd	   =	   root	   mean	   square	   deviation	   without	   structural	  
rearrangements.	  (B)	  Superposition	  of	  TRAF6	  and	  RNF8	  RING	  domains	  in	  two	  different	  views.	  
Alignment 
TRAF6 RING 
(2jmd_.pdb 63 amino acids) 
with cIAP2 RING 
(3eb5_.pdb 65 amino acids)
alignment-length 63 
Twists    0 
equivalent positions 55 
opt-rmsd   3.15 
chain-rmsd   1.77 






(2jmd_.pdb 63 amino acids) 
with RNF8 RING 
(4ayc_.pdb 136 amino acids)
alignment-length  62
Twists    0 
equivalent positions 59 
opt-rmsd   3.05 
chain-rmsd   1.55 
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